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Preface to ”Natural Products for Cancer Prevention
and Therapy”
Natural products represent an important source for the discovery and development of drugs for 
cancer prevention and therapy. Approximately 80% of all drugs approved by the United States 
Food and Drug Administration during the last three decades for cancer therapy are either natural 
products, per se, or are based on, or mimic, natural products. With the introduction and refinement 
of new technologies, including genetic tools for the production of secondary plant metabolites, 
combinatorial synthesis, and high-throughput assays, it is likely that novel compounds from natural 
sources, including medicinal plants and marine organisms, will be identified and developed as cancer 
preventive and anticancer drugs, with an acceptable toxicity. In this Special Issue book, contributions 
from eminent cancer researchers around the world present recent advances on our knowledge of 
natural products in cancer prevention and therapy.
This Special Issue book contains contributions from researchers working in the field of natural 
products in cancer prevention and therapy. We are working in the field of natural products and 
cancer. Several years ago, according to our experiences, we decided to organize an international 
conference series regarding the use of natural products for cancer prevention and treatment. Our aim 
was to gather researchers working in this field from all around the world, as many natural products 
are being used traditionally, and are also being prescribed as alternative medicines by physicians. 
Our first meeting was held in Istanbul between 31 August and 2 September 2015, along with the 
contributions of our invited speakers and the participants working in this field. With the success of 
our first meeting, we then organized our second meeting in Kayseri, between 8 and 11 
November 2017. The abstracts of all of the presentations at our meeting were published in 
Proceedings, and the report of the meeting was published in Nutrients. Subsequently, we edited the 
Special Issue with the same topic, to include several full-length papers based on the presentations at 
the meeting, as well as on contributions from other scientists. We are indebted to those who have 
contributed to our Special Issue with their manuscripts, the reviewers, and the MDPI publishing 
group. We hope our Special Issue book will be considered a valuable source of new information on 
natural products in the cancer research field.
Anupam Bishayee and Mukerrem Betul Yerer-Aycan
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1. Preface
Scientific experts from eight countries gathered to share their views and experience on the
latest research on natural products for cancer prevention and therapy. The traditionally used herbal
medicines, medicinal plants, plant extracts, fractions, and phytochemicals for cancer prevention and
therapy were discussed throughout the meeting. The scientific program comprised of 12 plenary
lectures, 23 oral presentations, and 72 posters, providing an opportunity for more than 130 natural
product scientists to present their research in three days. Abstracts for plenary talks, oral presentations,
and posters were published as proceedings of the meeting in the special issue of Proceedings, Volume 1
and Issue 10 (http://www.mdpi.com/2504-3900/1/10). The aim of this biannual meeting was to foster
discussion and disseminate the results of the research on natural products that are used for cancer
prevention and therapy. During the meeting, the scientific committee members of the meeting who
attended the conference had been selected as judges to evaluate all of the oral and poster presentations
and the three best oral and poster presentation awards have been granted to the young scientists.
The participants were able to network and engage in discussion for potential collaboration to advance
our knowledge on utility of natural products for prevention and treatment of cancer.
2. Summary of the Scientific Presentations
2.1. Plenary Lectures
The meeting was successfully focused on the natural products being investigated for their
efficiency in several cancer types and for their potency in cancer prevention. Only the plenary lectures
have been summarized here in this manuscript, and all of the other oral and poster presentations have
been listed where the abstracts can be reached from http://www.mdpi.com/2504-3900/1/10.
2.1.1. Growth Factors Responsible from the Cancer Progress: Role of Natural Products
Mükerrem Betül Yerer
Growth factors are one of the main factors responsible from the uncontrolled cell progress in cancer.
Up to date many scientists have focused on these factors either as the marker or as the targets in several
cancer types. Yerer has presented a plenary lecture on the natural products targeting these factors
(Nerve growth factor (NGF), epidermal growth factor (EGF), hepatocyte growth factors (HGF), fibroblast
growth factors (FGF), vascular endothelial growth factors (VEGF), platelet derived growth factor (PDGF),
and transforming growth factor (TGF-β) (http://www.mdpi.com/2504-3900/1/10/979) [1].
Nutrients 2018, 10, 8; doi:10.3390/nu10010008 www.mdpi.com/journal/nutrients1
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2.1.2. Natural Products for Cancer Prevention and Therapy: Progress, Pitfalls and Promise
Anupam Bishayee
The presentation of Bishayee highlighted studies on cancer preventive and therapeutic attributes
of various naturally occurring agents and underlying mechanisms of action, with special emphasis
on results reported from our laboratory. Current limitations, challenges, and future directions of
research for successful cancer drug development based on natural products will also be discussed
(http://www.mdpi.com/2504-3900/1/10/982) [2].
2.1.3. Novel Anticancer Capacities of Saffron
Amr Amin
Amr Amin has presented a plenary lecture on the anticancer effects of the saffron’s main active
ingredient “safranal” against HCC using in vitro, in silico, and network analyses. In their studies, in
addition to the unique and differential cell cycle arrest, safranal showed pro-apoptotic effect through
activation of both intrinsic and extrinsic initiator caspases implicating ER stress-mediated apoptosis
(http://www.mdpi.com/2504-3900/1/10/834) [3].
2.1.4. Cardiac Glycosides as Novel Modulators of Cancer Cell Survival
Marc Diederich
This plenary lecture focused on Cardiac Glycosides (GCs) can be considered as pharmacological
agents, allowing for cancer cells to switch from one cell death modality to another. All the findings
encourage to further explore a potential for CGs in general as cancer cell death modulators alone or in
combination with other targeted treatments (http://www.mdpi.com/2504-3900/1/10/972) [4].
2.1.5. Ins and Outs of Flavonoids in Cancer Prevention vs. Cancer Therapy: A Lesson from Quercetin
in Leukemia
Gian Luigi Russo, Maria Russo, Carmela Spagnuolo, Idolo Tedesco, Stefania Moccia
Russo et al. has critically reviewed the clinical and pre-clinical studies on the concept that
polyphenols, being antioxidant compounds, can fight cancer. They suggest that a clear distinction
must be done between the use of polyphenols, such as flavonoids, in cancer treatment versus cancer
prevention, starting from adequate and specifically selected cellular models. As an example, he has
present data on the potential application of quercetin against chronic lymphocytic leukemia (CLL)
(http://www.mdpi.com/2504-3900/1/10/977) [5].
2.1.6. Anticancer Potential of Flavones
Randolph RJ Arroo, Didem Şöhretoğlu, Demetrios A Spandidos, Vasilis P Androutsopoulos
Flavones are abundantly present in common fruits and vegetables, many of which have been
associated with cancer prevention. Taking into account that no flavonoid based drugs are clinically
used in cancer therapy, Randolph has focused on the flavones—which constitute a subgroup of the
flavonoids—show some structural analogy with estrogen, and are known to interact with human
estrogen receptors, either as agonist or as antagonist. Thus, whereas epidemiological and pre-clinical
data seem to indicate a high potential for flavonoids, from the point of view of the pharmaceutical
industry and drug developers, they are considered poor candidates (http://www.mdpi.com/2504-
3900/1/10/975) [6].
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2.1.7. Resveratrol in Cancer Prevention and Treatment: Focusing on Molecular Targets and Mechanism
of Action
Adriano Borriello
The relevance of these mechanisms and their translation in clinical therapy has been discussed
in Borelli’s plenary lecture. Resveratrol and its mechanism of action has been emphasized by her in
cancer cells and in experimental models of senescence, inflammation, obesity, and metabolic diseases.
Its molecular targets act at different levels: (1) specific molecular pathways (like p53, NF-kappaB,
PKC, PI3K, MDM2, LATS1, STK3 and several others); (2) epigenetic control of gene transcription
through sirtuin activation; (3) cell division cycle and differentiation; (4) apoptosis and autophagy; and,
(5) cellular redox homeostasis (http://www.mdpi.com/2504-3900/1/10/976) [7].
2.1.8. Cynaropicrin: A Promising Natural Agent with Antitumor and Antiviral Activities
Mahmoud F. Elsebai, Jukka Hakkola, Mohamed Mehiri, Juana Diez
Human infection with HCV is currently recognized as the leading cause of hepatocellular
carcinoma (HCC), which demands liver transplantation, which was estimated to result in ∼10,000 deaths
in the US only in the year 2011. Elsebai has presented a plenary lecture on cynaropicrin as a potential
agent for treatment and prevention of HCC by indirect way through inhibition of HCV and in a direct
way evidenced by the many antitumor activities in literature (http://www.mdpi.com/2504-3900/1/
10/974) [8].
2.1.9. Relationship between Structure of Phenolics and Anticancer Activity
Müberra Koşar
Many phenolic compounds have been investigated for their potential use as cancer
chemopreventive agents. Phenolic compounds consist of one or more hydroxyl substitution on
the aromatic ring system. Koşar has emphasized that Cinnamic acid esters, such as caffeic acid
phenethyl and benzyl esters, display selective antiproliferative activity against some types of cancer
cells. Flavonoids consist of a large group of polyphenolic compounds having a benzo-γ-pyrone
structure, and are ubiquitously present in plants. This structure can be responsible from the anticancer
acitvities of these compounds (http://www.mdpi.com/2504-3900/1/10/978) [9].
2.1.10. Pristimerin is a Promising Natural Product against Breast Cancer In Vitro and In Vivo through
Apoptosis and the Blockage of Autophagic Flux
Buse Cevatemre, Konstantinos Dimas, Bruno Botta and Engin Ulukaya
Ulukaya has given a lecture on the pristimerin’s cytotoxic potential on particularly cancer stem
cells (CSCs) should be much more important due to the CSCs’ recent role in recurrence of cancer.
He has presented their studies on Pristimerin that has been shown to suppress the proliferation of
various cancer cell lines at relatively lower concentrations, of which, the IC50 values are around
0.5–4 μM (http://www.mdpi.com/2504-3900/1/10/973) [10].
2.1.11. Can Curcumin Be Employed to Promote the Integration of Oncology and Natural Products?
Mutlu Demiray and Fatemeh Bahadori
Curcumin is multi-targeted molecule with pleotropic nature, which inhibits NF-κB and related
proteins promoting effectiveness of tyrosine kinase inhibitors (TKIs). Demiray has presented their
clinical studies with curcumin on adenoid cystic carcinoma where they have treated patients for
72 months by oral curcumin and eight months by i.v curcumin. Disease control rate was 89.3% (15/17),
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and no any grade III-IV toxicities was observed related to curcumin reflecting the clinical use of
curcumin on adenoid cystic carcinoma patients (http://www.mdpi.com/2504-3900/1/10/980) [11].
2.1.12. Therapeutic Potential of Black Pepper Compound for BRaf Resistant Melanoma
Neel M. Fofaria, Sharavan Ramachandran, and Sanjay K. Srivastava
Srivastava’s presentation mainly focused on the combination of BRAF inhibitors with Mcl-1
inhibitor such as piperlongumine may have therapeutic advantage to melanoma patients with acquired
resistance to BRAF inhibitors alone or in combination with MEK1/2 inhibitors (http://www.mdpi.
com/2504-3900/1/10/981) [12].
2.2. Oral and Poster Presentations
Oral Presentations
Title Authors Link
Effect of Pomegranate Extract and
Tangeretin on Specific Pathways in the
Rat Breast Cancer Model Induced
with DMBA [13].
H. Fatih Gul et al. http://www.mdpi.com/2504-3900/1/10/983
Synergistic Cytotoxic Effects of
Resveratrol in Combination with
Ceramide Metabolizing Enzymes in
Ph + Acute Lymphoblastic
Leukemia [14].
Osman Oğuz et al. http://www.mdpi.com/2504-3900/1/10/984
Characterization of cycloartane-type
sapogenol derivatives for prostate
cancer chemoprevention [15].
Bilge Debelec-Butuner et al. http://www.mdpi.com/2504-3900/1/10/985
Epibrassinolide treatment caused
autophagy or apoptosis decision in a
time-dependent manner through ER
stress in colon cancer cells [16].
Pınar Obakan-Yerlikaya et al. http://www.mdpi.com/2504-3900/1/10/986
Determination of Silymarin molecule
activity in colon cancer by AgNOR
technique [17].
Merve Alpay et al. http://www.mdpi.com/2504-3900/1/10/987
The cytotoxic effect of Lysimachia
savranii on the neuroblastoma
cells [18].
Gonca Dönmez et al. http://www.mdpi.com/2504-3900/1/10/988
Autocrine Growth Hormone-triggered
curcumin resistance abolished by
NF-κB signaling pathway dependent
on inflammatory cytokines and active
polyamine catabolic machinery in
MCF-7, MDA-MB-453 and
MDA-MB-231 breast cancer cells [19].
Ajda Çoker Gürkan et al. http://www.mdpi.com/2504-3900/1/10/989
The effect of Lysimachia savranii on the
migration of the breast cancer
cells [20].
Işıl Aydemir et al. http://www.mdpi.com/2504-3900/1/10/990
Investigation of cytotoxic effect of
Origanum minutiflorum on cancer
cells [21].
Oktay Özkan et al. http://www.mdpi.com/2504-3900/1/10/991
Celastrol modulates lipid synthesis
via PI3K/Akt/mTOR signaling axis to
finalize cell death response in prostate
cancer cells [22].
Elif Damla Arisan et al. http://www.mdpi.com/2504-3900/1/10/992
4
Nutrients 2018, 10, 8
Oral Presentations
Title Authors Link
Investigation of the Effect of Paclitaxel
and Pycnogenol on Mitochondrial
Dynamics in Breast Cancer
Therapy [23].
Suna Sayğılı et al. http://www.mdpi.com/2504-3900/1/10/993
Effects of curcumin on lipid
peroxidation and antioxidant enzymes
in kidney, liver, brain and testis of
mice bearing Ehrlich Solid Tumor [24].
Mustafa Nisari et al. http://www.mdpi.com/2504-3900/1/10/994
Curcumin enhances the efficacy of
5-FU in Colo205 cell lines [25].
Ebru Öztürk et al. http://www.mdpi.com/2504-3900/1/10/995
Effect of a New Sapogenol Derivative
(AG-07) on Cell Death via
Necrosis [26].
Yalcin Erzurumlu et al. http://www.mdpi.com/2504-3900/1/10/996
Cytotoxic and Antiinflammatory
Activity Guided Studies on Plantago
holosteum Scop [27].
Yasin Genc et al. http://www.mdpi.com/2504-3900/1/10/997
Continuously monitoring the
cytotoxicity of API-1, α-chaconine and
α-solanine on human lung carcinoma
A549 [28].
Ebru Öztürk et al. http://www.mdpi.com/2504-3900/1/10/998
The effects of α-chaconine on ER-α
positive endometrium cancer
cells [29].
Ayşe Kübra Karaboğa Arslan et al. http://www.mdpi.com/2504-3900/1/10/999
Investigation of apoptotic effect of
sinapic acid in Hep3B and HepG2
human hepatocellular carcinoma
cells [30].
Canan Eroğlu et al. http://www.mdpi.com/2504-3900/1/10/1000
Cytotoxic and Antioxidant Activity of
four Cousinia Species of Stenocephalae
Bunge. Section [31].
Leyla Paşayeva et al. http://www.mdpi.com/2504-3900/1/10/1001
Apoptotic effect of Ginnalin A on
MDA-MB-231 and MCF7 human
breast cancer cell lines [32].
Ebru Avcı et al. http://www.mdpi.com/2504-3900/1/10/1002
Cytotoxic effects of coumarin
compounds imperatorin and osthole,
alone and in combination with
5-fluorouracil in colon carcinoma
cells [33].
Ayşe Eken et al. http://www.mdpi.com/2504-3900/1/10/1003
Screening of some Apiaceae and
Asteraceae plants for their cytotoxic
potential [34].
Perihan Gürbüz et al. http://www.mdpi.com/2504-3900/1/10/1004
Cyclodextrine Based Nanogels and
Phase Solubility Studies of
Flurbiprofen as a Chemopreventive
Agent [35].
Ayşe Nur Oktay et al. http://www.mdpi.com/2504-3900/1/10/1005
Poster Presentations
Effect of a synthesized compound
against cancerous cell line and
synthesis of copper ion incorporated
1-(3,4-diaminophenyl) ethanone-based
hybrid nanoflowers [36].
Burcu Somtürk Yılmaz et al. http://www.mdpi.com/2504-3900/1/10/1006
Development of effective anticancer
drug candidates against breast and
colon cancers [37].
Senem Akkoç et al. http://www.mdpi.com/2504-3900/1/10/1007
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Poster Presentations
Title Authors Link
Synthesis of copper ion incorporated
aminoguanidine derivatives-based
hybrid nanoflowers [38].
Sevtap Çağlar Yavuz et al. http://www.mdpi.com/2504-3900/1/10/1008
Evaluation of anti-proliferative and
cytotoxic properties of chlorogenic
acid against breast cancer cell lines by
real time monitoring [39].
Onur Bender et al. http://www.mdpi.com/2504-3900/1/10/1009
Investigation of Apoptotic Effects of
Usnic Acid on Hepatocellular
Carcinoma [40].
Beste Yurdacan et al. http://www.mdpi.com/2504-3900/1/10/1010
In vitro Cytotoxic Effect Evaluation of
Dioscorea communis (L.) Caddick &
Wilkin Rhizome and Stem Extracts on
Hepatocellular Carcinoma Cells [41].
Ünal Egeli et al. http://www.mdpi.com/2504-3900/1/10/1011
The Effect of Herbal Medicine on
Neuroblastoma Cell Line in
Culture [42].
Büşra Şen et al. http://www.mdpi.com/2504-3900/1/10/1012
The foods containing miR-193b may
inhibit the growth of breast cancer
cells [43].
Dilek Asci Celik et al. http://www.mdpi.com/2504-3900/1/10/1013
Is the dietary miR-193b a novel cell
cycle arresting source for breast
carcinoma? [44].
Nilgun Gurbuz et al. http://www.mdpi.com/2504-3900/1/10/1014
The effects of Wortmannin and EGCG
and combined treatments on
MDA-MB-231 breast cancer cell lines
via inactivation of PI3K signaling
pathway [45].
Elgin Turkoz Uluer et al. http://www.mdpi.com/2504-3900/1/10/1015
The effects of Paclitaxel and
Metformin and combined treatments
on TLR signaling pathway on
MDA-MB-231 breast cancer cell
lines [46].
Melike Ozgul et al. http://www.mdpi.com/2504-3900/1/10/1016
Inhibition of telomerase activity by
cucurbitacin I in colon cancer cell line,
LS174T [47].
Emir Tosun et al. http://www.mdpi.com/2504-3900/1/10/1017
Effect of cucurbitacin I on
proliferation and migration in
colorectal cancer cell line, LS174T [48].
Emir Tosun et al. http://www.mdpi.com/2504-3900/1/10/1018
In vitro anticancer and cytotoxic
activities of some plant extracts on
HeLa and Vero cell lines [49].
Fulya Tugba Artun et al. http://www.mdpi.com/2504-3900/1/10/1019
Anticancer Effects of Oleocanthal and
Pinus Pinaster on Breast Cancer Cell in
Culture [50].
Mahmud Özkut et al. http://www.mdpi.com/2504-3900/1/10/1020
Antiproliferative and Apoptotic
Effects of the Medicinal Plants on
Breast Cancer Cell Lines [51].
Pınar Kılıçaslan Sönmez et al. http://www.mdpi.com/2504-3900/1/10/1021
The role of trophoblastic stem cells
conditioned media on JAR cell
culture [52].
Hilal Kabadayı et al. http://www.mdpi.com/2504-3900/1/10/1022
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• Selen İlgün, Faculty of Pharmacy, Department of Pharmaceutical Botany, Erciyes University,
Kayseri, Turkey
• Selim Demir, Department of Nutrition and Dietetics, Faculty of Health Sciences, Karadeniz
Technical University, Trabzon, Turkey
• Sema Misir, Department of Biochemistry, Faculty of Pharmacy, Cumhuriyet University,
Sivas, Turkey
• Senem Akkoç, Department of Chemistry, Faculty of Sciences, Erciyes University, Kayseri, Turkey
• Serap Yalcin, Department of Molecular Biology and Genetics, Ahi Evran University,
Kırşehir, Turkey
• Serap Yalın, Department of Biochemistry, Faculty of Pharmacy, Mersin University, Mersin, Turkey
• Sevil Albayrak, Biology Department, Science Faculty, Erciyes University, Kayseri, Turkey
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• Yeşim Aktaş, Erciyes University Faculty of Pharmacy Department of Pharmaceutical Technology
• Yuksel Aliyazicioglu, Medicinal Plants, Traditional Medicine Practice and Research Center,
Gumushane University, Gumushane, Turkey
• Yüksel Öğünç, Department of Biochemistry, Faculty of Pharmacy, Anadolu University,
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56. Sari, İ.; Dönmez, G.; Kırık, F.E.; Aydemir, I.; Özkan, O.; Savran, A.; Vural, K.; Tuğlu, M.İ. The Neurotoxic
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65. Şirin, S.; Aslım, B. Determination of Antioxidant Capacity, Phenolic Acid Composition and Antiproliferative
Effect Associated with Phenylalanine Ammonia Lyase (PAL) Activity in Some Plants Naturally Growing
under Salt Stress. Proceedings 2017, 1, 1035. [CrossRef]
66. Ünal, S.; Yücel, Ç.; Çelik Tekeli, M.; Şeker Karatoprak, G.; Aktaş, Y.; Bilensoy, E. Development and
Characterization of Paclitaxel-Loaded PLGA Nanoparticles and Cytotoxicity Assessment By MTT Assay on
A549 Cell Line. Proceedings 2017, 1, 1036. [CrossRef]
67. Kavurmacı, R.; Yalcin, S. Evaluation of In Vitro Anti-Proliferative Activity of St. John’s Wort (Hypericum
perforatum Linn.) Plant Extract on Cervix Adenocarcinoma. Proceedings 2017, 1, 1037. [CrossRef]
68. Kavurmacı, R.; Yalcin, S. The Cytotoxic Effect of Annona muricata Leaf Extract on Triple Negative Breast
Cancer Cell Line. Proceedings 2017, 1, 1038. [CrossRef]
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Abstract: One of the deadliest cancers among women is a breast cancer. Research has shown that two
natural substances occurring in propolis, caffeic acid (CA) and caffeic acid phenethyl ester (CAPE),
have significant anticancer effects. The purpose of our in vitro study was to compare cytotoxic activity
and migration rate inhibition using CA and CAPE (doses of 50 and 100 μm) against triple-negative,
MDA-MB-231 breast adenocarcinoma line cells, drawn from Caucasian women. Viability was
measured by XTT-NR-SRB assay (Tetrazolium hydroxide-Neutral Red-Sulforhodamine B) for 24 h
and 48 h periods. Cell migration for wound healing assay was taken for 0 h, 8 h, 16 h, and 24 h
periods. CAPE displayed more than two times higher cytotoxicity against MDA-MB-231 cells. IC50
values for the XTT assay were as follows: CA for 24 h and 48 h were 150.94 μM and 108.42 μM,
respectively, while CAPE was 68.82 μM for 24 h and 55.79 μM for 48 h. For the NR assay: CA was
135.85 μM at 24 h and 103.23 μM at 48 h, while CAPE was 64.04 μM at 24 h and 53.25 μM at 48 h.
For the SRB assay: CA at 24 h was 139.80 μM and at 48 h 103.98 μM, while CAPE was 66.86 μM at 24 h
and 47.73 μM at 48 h. Both agents suspended the migration rate; however, CAPE displayed better
activity. Notably, for the 100 μM CAPE dose, motility of the tested breast carcinoma cells was halted.
Keywords: caffeic acid; CAPE; migration; wound healing; breast cancer; propolis
1. Introduction
Properly-fortified diets, especially those enriched with compounds such as polyphenols or
phenolic acids, are found to counter the development of many diseases [1–3].
Propolis is one of many natural substances which are becoming increasingly popular for study
by cancer research projects. Propolis is an amorphous, viscous substance, of a resin-like consistency,
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produced by honey bees (Apis mellifera) from collected plant pollen, which bees supplement with bee’s
wax or bee bread. The composition of propolis is extremely complex and varies depending on the
locale, season, weather conditions, and plant species from which it is gathered [4–7].
Numerous scientific studies have shown that propolis has antiviral, antimicrobial, antifungal,
and antiparasitic properties, as well as being known to have anti-inflammatory and antioxidant
effects. Additionally, active, cardio-, and hepatoprotective effects have been measured using propolis.
There are also research reports of propolis being used as a local anesthetic. Some authors report
this compound has antitumor properties due to the antiproliferative, cytotoxic, and proapoptotic
properties of propolis compounds. The high concentration of these substances in propolis determine its
anti-inflammatory, anti-microbial, regenerative, immunomodulatory, hepatoprotective, antioxidative,
and therefore antitumor activity [4–18].
There are hundreds of substances occurring in propolis. Two of these are caffeic acid (CA)
and the caffeic acid phenethyl ester (CAPE). Some of their properties reported in research include:
antioxidative, antibacterial, antiviral, anti-inflammatory, antiplatelet, antitumor, and antineoplastic
effects [19–25].
In vitro research studies have clearly shown the cytotoxic properties of CAPE against: cells
of pulmonary carcinoma, gastric carcinoma, colorectal carcinoma, malignant melanoma, hepatic
carcinoma, pancreatic carcinoma, as well as cervical carcinoma [26–33].
Our earlier research showed that CA inhibits the viability and migration process of oral carcinoma
SCC-25 cells and head and neck squamous carcinoma cells, while CAPE was directly reported as
a growth inhibitor of breast cancer cells [34,35].
CAPE’s antitumor activity was also reported. CAPE inhibits activity of cancer cells by using
the significant nuclear transcription factor NF-κB. NF-κB inhibits apoptosis, induces proliferation,
and intensifies angiogenesis. Evidence shows that NF-κB could be one of the most important factors in
the process of oncogenesis and cancer progression. Moreover, it was shown that CAPE aggregates the
Fas death-inducing receptors through a Fas-L-independent mechanism [36–38].
Research studies of breast cancer have shown CAPE is an inhibitor of FGF-2 (fibroblasts growth
factor type 2), which is a factor of tumor growth. CAPE performance was evaluated positively, both for
in vitro and in vivo research of MCF-7 and MDA-231 breast cancer cells. It is worth noting that CAPE
did not affect healthy cells [23,39]. It was also shown that CAPE reduces expression of the mdr-1
gene, which causes increased sensitivity of tumor cells to chemotherapy. Also, after treatment with
CAPE, the decreased vascular endothelial growth factor (VEGF) inhibited angiogenesis and tumor
growth [40,41].
Breast cancer is one of the deadliest cancers among women. It is well known that genetic changes
are conducive to the development of cancer. For instance, activation of oncogenes and alteration of
tumor suppressor gene pathways leads to the development of tumor cells. Eventually, tumor cells
lose complete control from highly regulated cell growth signals, leading to abnormal proliferation and
avoiding apoptosis [42].
Breast cancer is a heterogeneous disease with many biological subtypes. One is triple negative
breast cancer (TNBC). TNBC is much more aggressive than breast cancer of other molecular subtypes
and known for its frequency of recurrence. As a result, the mortality rate of patients with TNBC is
significantly higher than among patients with other types of breast cancer (estrogen receptor α and
progesterone receptor positive) [43].
The treatment of a triple negative breast carcinoma depends on the severity of the disease.
The choice of therapy is affected by the presence of metastases, the size of the primary tumor, and the
result of detailed pathological tests, such as the degree of malignancy of the tumor, which determines
the rate of division of tumor cells. Surgical methods, radiotherapy, and chemotherapy are used in the
treatment of triple negative breast cancer. In the treatment of patients with TNBC, it is important to
inhibit a formation of blood vessels providing nutrients to tumor tissues, the angiogenesis. However,
the therapeutic options are very small here, but neither hormone therapy nor HER2 drugs works.
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Therefore, the average survival time in this group is still less than in patients with other types of breast
cancer. The biological characterization of the tumor cell is the method used to determine the type
of tumor and to obtain valuable information on the factors influencing its growth. Triple negative
breast cancer is diagnosed in patients under the age of 50. Factors that promote TNBC are: early
menopause, obesity at menopausal age, and breast cancer in the family. The disease is characterized
by an aggressive course, rapid tumor growth, and rapid onset of distal metastases (especially to the
brain and lungs, and to a lesser extent bone and liver) and early relapse (within 1–3 years of diagnosis).
A large number of patients with this type of cancer have a poor prognosis due to low remission
during adjuvant therapy, and in the case of metastases a short survival time and high resistance to
chemotherapy [44–48].
The response rate among patients with metastatic breast cancer is gradually decreasing, possibly
due to the tumor’s resistance to a wide range of cancer therapies [43,49–51]. Unfortunately, it must be
mentioned that metastatic breast cancer’s resistance to all forms of systemic treatments (hormonal,
chemotherapy, and targeted) results in an estimated 90% or more of patients with metastatic disease
developing tumors which will prove lethal [52].
The aims of decreasing toxicity levels of standard breast cancer treatment and increasing patients’
survival chances have led researchers to test natural substances and their varying compounds. Such
studies have yielded highly positive and encouraging results for breast cancer treatment. Taking into
consideration the above facts, we compare in vitro effects of CAPE and CA (viability and migration)
on MDA-MB-231 human breast cancer cells, which to the best of our knowledge is a new approach.
2. Materials and Methods
2.1. Cell Lines and Reagents
2.1.1. Breast Cancer Cell Line MDA-MB-231
In this research, the MDA-MB-231 line (human breast adenocarcinoma TNBC, No. 92020424
SIGMA from Sigma-Aldrich, Poznań, Poland) was used, as it is a model of human triple-negative
breast cancer. The manufacturer’s recommendations for preparations were all carefully followed.
The MDA-MB-231 cells were cultured with Leibovitz’s L-15 medium, with 10% of inactivated fetal
bovine serum (FBS, Sigma-Aldrich, Poznań, Poland), and kept at 37 ◦C, without CO2.
All cultured cells were supplemented with antibiotics of the following concentrations:
penicillin—100 U·mL−1, streptomycin—100 μg·mL−1 and fungistatic amphotericin B with
a concentration of 0.25 μg·mL−1. The medium was changed every 2–3 days, with the passage carried
out with a confluence of 80% to 90%.
2.1.2. CA and CAPE
Both caffeic acid (CA, Sigma: C0625) and caffeic acid phenethyl ester (CAPE, Sigma: C8221)
were purchased from Sigma-Aldrich, Poznań, Poland and were collected, stored, and used specifically
according to the manufacturer’s instructions.
2.2. Microscopic Evaluation of Carcinoma Cells Morphology. Hematoxylin and Eosin Staining Protocol
Initially, the MDA-MB-231 cells were inoculated into 2-chamber microscopic culture vessels
(Lab-Tek, Waltham, MA, USA) at a count of 1000 cells/well. Depending on the time of the experiment,
we added proper concentrations of the studied compounds to the media and left them for 24 and 48 h.
This was followed by leaving the cultures for 24 h to obtain the cells’ growth rate. They were then fixed
for 12 h in 96% ethanol. The cells were then hydrated in the following series of dilutions: 99.6%, 96%,
90%, 80%, 70%, and 50% and stained with hematoxylin for 7 min (standard H&E staining protocol).
Next, the plates were washed with PBS solution for approximately 30 min to blue up and were then
incubated for 30 s with eosin. PBS solution was used again to wash the plates, and they were then
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dehydrated with ethanol of increasing concentrations of 50%, 70%, 80%, 90%, 96%, and 99.6%. Finally,
the plates were immersed in the ethanol and xylene mixture (50:50) for 1 min and then in pure xylene.
The plates were then mounted and analyzed under a microscope.
2.3. Cell Viability by Mitochondrial Activity, XTT Test Assay
Viable cells depend on an intact mitochondrial respiratory chain and an intact mitochondrial
membrane. Activity of the measured compounds was determined using mitochondrial
dehydrogenases from the viable cells. XTT (2,3-bis[2methoxy-4-nitro-5-sulfopheny]-2H-tetrazolium
-5-carboxyanilide inner salt) is a tetrazolium salt that cleaves to formazan by the succinate
dehydrogenase system, which belongs to the mitochondrial respiratory chain. This is significant,
as it is only active in viable cells. Mitochondrial succinate dehydrogenase reduces yellow tetrazolium
salt into a soluble orange formazan in the presence of an electron coupling reagent. The number of
originating formazan is proportional to the amount of living cells [53]. We measured the enzyme
activity at 480 nm, which is in line with the manufacturer’s recommendation. The XTT assay was
obtained from Xenometrix AG, Allschwil, Switzerland.
To measure cytotoxicity, the cells were inoculated on 96-well plates, at an amount of 104 cells/well.
A fresh medium was added and left for 72 h to obtain the rate of cell growth. After the medium was
decanted, separate culture mediums were added which contained 50 μM and 100 μM of either CA or
CAPE, which had been prepared during a series of dilutions in the culture medium. A measure of
0.1 mL of medium with the defined concentrations of the substances was added to each well and left
for 24 h/48 h in a CO2 incubator at 37 ◦C. The test procedure was performed exactly in accordance
with the instructions and protocol of the manufacturer.
2.4. Cytotoxicity by Lyzosomal Activity, NR Test Assay
Cell survival and viability can also be measured by using the ability of viable cells to incorporate
and bind to neutral red (NR), which is best performed on adherent cells. Neutral red is a weak
cationic dye that readily penetrates the cell membrane and accumulates intracellularly in lysosomes
(lysosomal pH < cytoplasmic pH), where it binds to anionic sites of the lysosomal matrix. Lysosomal
fragility and other effects, which gradually became irreversible, are caused by changes of the cell
surface and the sensitivity of the lysosomal membrane. Such alterations, induced by the action of
xenobiotics, result in decreased uptake and binding of NR. Therefore, it is possible to distinguish
between viable, damaged, or dead cells [54]. The NR test was obtained from Xenometrix AG, Allschwil,
Switzerland. We used CA and CAPE at concentrations of 50 μM and 100 μM, with 24 h and 48 h of
incubation. The quantity of dye incorporated into cells was measured by spectrometry at 540 nm,
which is directly proportional to the number of cells of the intact membrane. Test procedures were
performed exactly following the instructions and protocol of the manufacturer.
2.5. Cell Proliferation by SRB Test Assay
Cell proliferation, measured as total protein synthesis, is a very sensitive toxicology marker.
Sulforhodamine B (SRB, Acid Red 52) is an anionic dye that binds electrostatically to cellular proteins.
SRB binds stoichiometrically to cellular proteins (when mild acidic conditions are guaranteed) and
can then be extracted under basic conditions. The total amount of bound dye can be used as a proxy
for cell mass, which is directly proportional to cell proliferation [55,56]. A fixed dye was solubilized
and measured photometrically at OD 540 nm, with a reference filter of 690 nm. The OD values were
correlated with total protein content and therefore with cell number. Concentrations of CA and CAPE
of 50 μM and 100 μM were used to make the experiments for 24 h and 48 h of incubation. The SRB
test was obtained from Xenometrix AG, Allschwil, Switzerland. Procedure of the test was performed
exactly in accordance to the instructions and protocol of the manufacturer.
28
Nutrients 2017, 9, 1144
2.6. Migration—Cell Wound Closure Assay
Carcinoma cell migration is the result of variable biological processes, with a specific characteristic
seen in their coordination. Wound-healing assays are standard and commonly used methods for
investigation of cell migration. CA’s and CAPE’s ability to modify cell motility using the scratch
wound healing assay was then analyzed [57,58]. This method was implemented to evaluate the
migration activity rate of MDA-MB-231 cells exposed to CA and CAPE.
Briefly, the MDA-MB-231 cells (4 × 106 cells/well) were plated in 6-well plates for 48 h to
a confluence of about 80%, then wounded by scratching with a p200 pipette tip. Thereafter, the debris
was removed and we washed the cells once with 1 mL of the growth medium to assure the edges of the
scratch were smoothed by washing. We took utmost care to make the wounds of the same dimensions,
both for the experimental and control cells to minimize any possible variety resulting from a difference
in scratch width.
The cells were then incubated with DMEM medium containing 0.5% FBS and treated with
CA/CAPE doses of 50 μM and 100 μM, respectively. The control sample contained the cells and
a standard medium without any active agents. The MDA-MB-231 cell migration was assessed by
monolayer gap closure migration assay, embedded by free ImageJ software (version 1.50i, National
Institute of Health, Bethesda, MD, USA), with a wound healing tool macro (Montpellier RIO Imaging,
CNRS, Montpellier, France). The area of the initial wound was measured, followed by gap area
measurements after 8 h, 16 h, and 24 h. The migration factor was presented as the gap area value over
the initial scratch area.
2.7. Statistical Analysis
All results are expressed as means ± SD and were obtained from three separate experiments and
performed in quadruplicates (n = 12). The results were performed with independent sample t-tests.
The experimental means were compared to the means of untreated cells harvested in a parallel manner.
Differences between 24 h/48 h and control samples were tested for significance using the one- and
multiple-way Friedman ANOVA test. A p-value less than 0.05 was considered statistically significant.
3. Results
To obtain the quantitative assessment of breast cancer cells’ viability, the XTT-NR-SRB
(Tetrazolium hydroxide-Neutral Red-Sulforhodamine B) assay was used. IN a parallel fashion,
the effects of selected times/concentrations of CA and CAPE on breast cancer cell motility and
migration were evaluated. Figure 1 shows MDA-MB-231 carcinoma cells’ morphology features
as well as the impact of CA and CAPE on these cells. Examined cells were as phenotypical as
the spindle shaped cells, with a visible hyperchromasia. Cell nuclei shapes were irregular. Small
cells clustered around the large ones. The large, irregular nuclei contained several nucleoli in the
nucleus. A pleomorphism of size and shape, as well as a coloration of nuclei, were visible. In the
optical microscope, morphological characteristics of the apoptotic cells were visible, after the CA
and CAPE treatment. Namely, we observed a cytoplasm density and changes in nuclear chromatin.
The cytoplasmic shapes were changed. A fragmentation of a cytoplasm was visible. The cells were
separated from each other.
For years, tetrazolium salts have been widely used as detection reagents in histochemical
localization studies and cell biology assays. Like the MTT assay (reducing tetrazolium dye:
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to formazan), XTT measures cell viability
based on the activity of enzymes in mitochondria of live cells, which reduces XTT and becomes inactive
shortly after cell death. The data obtained in the experiment were normalized and presented as the
percentage of control values (Figure 2).
When CA was used for treatment of MDA-MB-231, cell viability decreased as the dose increased,
dropping from 93.1% for a dose of 10 μM, 89.8% for 25 μM, 77.9% for 50 μM, and a value of 66.4%
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was reached with a dose of 100 μM after 24 h (Figure 2a,d). Simultaneously, when CAPE activity was
compared to that of CA against MDA-MB-231 cells (Figure 2a,d), CAPE cell viability values for a dose
of 10 μM were similar to CA (at 24 h, CA was 93.1%, while CAPE was 92.4%; after 48 h, CA was 92.4%
and CAPE was 90.4%). The smallest doses of these two polyphenols had a similar cytotoxic effect
on the examined cells. The effect increased in a dose-dependent manner for both agents. For CAPE,
the values reached 68.4%, 51.9%, and 37.5% for respective doses of 25, 50, and 100 μM (Figure 2a,c),
meaning that a stronger cytotoxic effect was achieved with CAPE at 24 h. After 48 h of incubation
(Figure 2b), for both CAPE and CA, cell viability showed a dose-dependent effect and the values were
as follows: for a 10 μM dose CAPE was 90.4% and CA 92.4%, for a dose of 25 μM CAPE was 53.5%
and CA 79.5%, for 50 μM CAPE was 45.3% and CA 68.5%, and finally, for 100 μM CAPE was 31.6%
and CA 55.5%.
Figure 1. Cytomorphological view of MDA-MB-231 breast cancer cells without any treatment (a–d) as
well as after 24 h of caffeic acid (CA) (e,f) and 24 h of caffeic acid phenethyl ester (CAPE) treatment (g,h),
both with a 50 μM dose. To prepare the samples a hematoxylin and eosin staining was used. Exposition:
optical magnification ×100 (a,e,g), ×400 (c,d,f,h), ×600 (b). Main features: (a) phenotypically as
spindle-shaped cells (caudate, tadpole), hyperchromasia; (b) irregular nuclear shapes, small clusters of
cells around the large ones; (c) large nuclei with irregular shape and several nucleoli in the nucleus;
(d) pleomorphism of size, shape, and coloration of nuclei and whole cells; (e) karyopyknosis; (f) lower
cell-cell contact; (g) karyopyknosis, cytoplasm density; (h) cytoplasm density and a shape change,
cytoplasm fragmentation.
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Comparing CAPE activity to that of CA, viability was again lower for CAPE at the same dosage
after 48 h. This showed a dependent trend for the dose and time domain (smaller impact) for both
examined substances (Figure 2c,d).
Figure 2. Cytotoxic effects of caffeic acid phenethyl ester (CAPE) and caffeic acid (CA) were both tested
using concentrations of from 10 to 100 μM with 24 h and 48 h incubation times on the breast cancer cell
line MDA-MB-231 using XTT (2,3-bis[2methoxy-4-nitro-5-sulfopheny]-2H-tetrazolium-5-carboxyanilide
inner salt) Cell Proliferation Assay. Both polyphenols caused visible dose-dependent effects. Stronger
activity was observed for CAPE than CA starting with a dose of 25 μM of each agent following
24 h (a) and 48 h (b) incubation times. A CAPE treatment of 48 h gave slightly stronger cytotoxic
effect compared to 24 h (except a 10 μM dose) and was exclusively stronger for the 25 μM dose (c);
however, succeeding dose increases of CAPE (50 and 100 μM) didn’t yield symptomatic difference in
viability, with both times reaching a low level. The experiment times (c,d) had only a small impact on
cytotoxic activity. The results were presented as a mean and standard deviation of three independent
experiments, with 12 wells each (p < 0.05; Friedman ANOVA test; *—significant difference vs. control,
#—significant difference 48 h vs. 24 h).
The key component of the next viability test performed was the vital dye, neutral red (NR). Viable
cells take up the dye by active transport and incorporate the dye into lysosomes, whereas non-viable
cells do not take up the dye. The data obtained in the experiment were normalized and presented as %
of viability over controls (Figure 3).
Using CA against MDA-MB-231 cells, the cell mortality increased in a dose-dependent manner.
The viability values dropped from 93.26% for a dose of 10 μM, to 89.56% for 25 μM, 71.39% for 50 μM,
and 64.54% with a dose of 100 μM of CA after 24 h (Figure 3a,d). Comparing CAPE’s cytotoxic activity
to that of CA against MDA-MB-231 cells (Figure 3a,b), cell viability values for a dose of 10 μM were
similar: at 24 h CA was 93.26% and CAPE was 91.96%, while at 48 h CA was 91.08% and CAPE
90.36%. A dosage of 10 μM of both polyphenols had a similar cytotoxic effect on the examined cells
(independent of time). Using CAPE against the examined cells, at 24 h the values reached 66.30%,
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47.40%, and 35.12% for doses of 25, 50, and 100 μM, respectively (Figure 3a,c). The results sustain that
CAPE achieved a stronger cytotoxic effect at 24 h.
For both substances, cell viability manifested a dose-dependent effect after 48 h of incubation
(Figure 3b). The values were: at 10 μM CAPE was 90.36% and CA 91.08%, at 25 μM CAPE was 55.02%
and CA 78.25%, for 50 μM CAPE was 41.38% and CA 65.80%, and finally, for 100 μM, CAPE was
29.46% and CA: 53.86%. Therefore, CAPE induces greater cell mortality than CA at the same dosage.
Both CA and CAPE showed a dependent trend for the dose and time domain, but again a smaller
impact (Figure 3c,d).
Figure 3. Cytotoxic effects of caffeic acid phenethyl ester (CAPE) and caffeic acid (CA) were tested
using concentrations of from 10 to 100 μM with 24 h and 48 h incubation times on the breast cancer
cell line MDA-MB-231 using neutral red (NR) Assay. Both polyphenols caused visible dose-dependent
effects. A higher mortality factor was observed with CAPE than CA, starting from a dose of 25 μM of
the tested compounds (a,b) for both 24 h and 48 h periods. In (c), using a dose of 10 μM of CAPE, the
48 h experiment did not produce any significant cytotoxic effects when compared to 24 h; nevertheless,
a conspicuously stronger effect for 25 μM was observed. The succeeding dosage increases of CAPE
(50 and 100 μM) displayed only a slight difference in viability factor, with both reaching a very low level.
The cytotoxic activity of both substances showed no spectacular difference over time (c,d). The results
were presented as mean and standard deviation of three independent experiments, with 12 wells each
(p < 0.05; Friedman ANOVA test; *—significant difference vs. control, #—significant difference 48 h vs.
24 h).
The key component of the last cytotoxicity test performed was the dye, Sulforhodamine B
(Acid Red 52). An increase or decrease in the number of cells causes an associated change in the
amount of dye incorporated by the cells in the culture. This indicates the specific degree of cytotoxicity
caused by the test material. Data received during the experiment were normalized and presented as %
of viability over controls (Figure 4).
Testing CA against MDA-MB-231 cells, cell viability declined in a dose-dependent manner, falling
after 24 h from 93.13% for a dose of 10 μM, to 92.78% for 25 μM, 67.46% for 50 μM, and to a value
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of 66.89% using a dose of 100 μM CA (Figure 4a,d). When CAPE cytotoxic activity was compared
to CA against MDA-MB-231 cells (Figure 4a,b), cell viability values for a dose of 10 μM were again
close to those of CA. At 24 h, CA was 93.19% and CAPE 92.21%, and at 48 h, CA was 91.99% while
CAPE was 86.90% (where a slight difference was finally observed). At a dosage of 10 μM, both
polyphenols had a similar cytotoxic effect on the examined cells, which was also observed in viability
tests performed earlier for this study. The viability was dependent for the dose and time domain.
For CAPE at 24 h, the values reached 68.85%, 50.05%, and 36.13% for doses of 25, 50, and 100 μM,
respectively (Figure 4a,c). Again, CAPE’s stronger cytotoxic effect than CA’s was confirmed after 24 h.
After 48 h of incubation (Figure 4b) for both CAPE and CA, cell viability revealed
a dose-dependent effect, with values as follows: for 10 μM CAPE was 86.90% and CA 91.99%, for 25 μM
CAPE was 56.08% and CA 77.69%, for 50 μM CAPE was 37.80% and CA 64.22%, and finally, 100 μM
CAPE reached 22.98% and CA 54.88%. Comparing CAPE to CA after 48 h, cell mortality was again
higher for CAPE than CA at the same dosage. Dependent trends in the dose and time domain (greater
impact than by XTT and NR) for both CA and CAPE were confirmed (Figure 4c,d).
Figure 4. Viability results of the SRB (Sulforhodamine B) assay of caffeic acid phenethyl
ester (CAPE) and caffeic acid (CA) at concentrations of from 10 to 100 μM for 24 h
and 48 h incubation times on the breast cancer cell line MDA-MB-231. Like the XTT
(2,3-bis[2methoxy-4-nitro-5-sulfopheny]-2H-tetrazolium-5-carboxyanilide inner salt) and NR (neutral
red) tests, there was a visible dose-dependent effect for both polyphenols. Interestingly, for the 24 h
experiment, CA (a) expressed ‘two levels’—a first for 10 and 25 μM and a second (d), for 50 and 100 μM;
this phenomenon could be explained by nonlinear absorbance; however, within a 48 h experiment it
does not exist. Greater cancer cell mortality using CAPE rather than CA started again (just as with XTT
and NR) from a dose of 25 μM of each tested compound for both 24 h (a) and 48 h (b) incubation times.
After 48 h (c), CAPE treatment showed a stronger cytotoxic effect in comparison to the 24 h period
(except the 10 μM dose). The experiment time had only slight impact on the cytotoxic activity of the
tested compounds (c,d), which wasn’t in opposition to the XTT and NR test assay. The results were
presented as mean and standard deviation of three independent experiments 12 wells each (p < 0.05;
Friedman ANOVA test; *—significant difference vs. control, #—significant difference 48 h vs. 24 h).
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For both substances (CA and CAPE) used for the MDA-MB-231 breast cancer line, the half
maximal inhibitory concentration (IC50) was calculated by all three methods during the experiment.
It is significant that the 50%-mortality of breast cancer cells (MDA-MB-231) were ca. twice as low for
CAPE than CA for all methods. This showed that CAPE has a stronger cytotoxic effect on MDA-MB-231
cells than CA during 24 h and 48 h experiments. The IC50 results are shown in Table 1.
Table 1. IC50 (μM) values of caffeic acid (CA) and caffeic acid phenethyl ester (CAPE) in
relation to breast cancer MDA-MB-231 for 24 h and 48 h, using different methods (XTT, NR,
SRB, respectively: 2,3-bis[2methoxy-4-nitro-5-sulfopheny]-2H-tetrazolium-5-carboxyanilide inner salt,
neutral red, Sulforhodamine B). All data demonstrated that lower doses of CAPE (ca. twice as low as
CA) are needed to receive a similar mortality effect on MDA-MB-231 cells.
Method Compound
Time of Incubation Time of Incubation
24 h 48 h
XTT CA 150.94 108.42
CAPE 68.82 55.79
NR CA 135.85 103.23
CAPE 64.04 53.25
SRB CA 139.80 103.98
CAPE 66.86 47.73
Considering the cytotoxic effect of CA and CAPE (measured in this study by three methods), we
clearly see that these two substances are active against MDA-MB-231 breast cancer cells, with CAPE
displaying IC50 values more than twice as low as CA.
The next stage was an analysis of CA and CAPE’s influence on migration of MDA-MB-231 cells.
This was measured by wound healing, which is the complex, dynamic process of movement and
replacement of missing cells. Observation of live cells’ motility is an effective method to measure the
rate of migration into the space created by the original wound. The desired situation is when the
wound closes as little as possible, so the gap area value over the area of the original wound remains
as great as possible, preferably for a prolonged period; this means the examined agent inhibits the
migration of the carcinoma cells.
The results of the wound healing assay are presented in Figure 5. In the control group, cell
migration was very dynamic, achieving a value of 16% after only 8 h. As seen, the wound’s closure
was practically complete, reaching a rate value of 1% after 16 h. There was no evidence of the wound
after 24 h. Using a 50 μM dose of CA, the motility of the MDA-MB-231 cells was inhibited. The rate
increased to 30% after 8 h, 11% after 16 h and 6% after 24 h. The wound closure was not complete
following the CA treatment. Increasing the CA dose to 100 μM resulted in better closure rates and
therefore promoted migration inhibition of the MDA-MB-231 cells. The wound area value was 49% in
relation to the original scratch after 8 h. A value of 16% was achieved after 16 h, and, finally, 9% after
24 h. Inhibition of the cell migration showed a dose-dependent trend.
Using CAPE for wound healing resulted in deeper inhibition of cell migration when compared to
CA. For a CAPE dose of 50 μM, the gap area factor was 66% for 8 h. The gap remained at 50% at 16 h
and achieved a value of 28% after 24 h. Increasing the CAPE dose to 100 μM displayed better results,
as was expected. CAPE stopped the MDA-MB-231 cells from migrating at 75%, after 8 h. The size of
the gap remained stable, with a value of 72% after 16 h, to reach a minimal value of 68% after 24 h.
CA and CAPE both inhibited migration of MDA-MB-231 cells in a dose-dependent manner. The CAPE
treatment displayed better results, particularly for the 100 μM dose, where the motility of tested breast
carcinoma cells was practically halted.
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Figure 5. Caffeic acid (CA) and caffeic acid phenethyl ester (CAPE) at concentrations of 50 μM
and 100 μM promote an inhibitory migration effect on MDA-MB-231 cells. There was a visible
dose-dependent effect. The gap did not reach full closure for either agent. Comparison of these two
substances shows CAPE has a greater influence on cell migration inhibition in MDA-MB-231 than
CA. CAPE treatment with a dose of 100 μM demonstrated that the wound area basically remained
unchanged over time. CAPE created a 'barrier’ that was practically impassable and impenetrable by
the MDA-MB-231 cells. The cell migration factor was performed by monolayer gap closure migration
assay and embedded by free ImageJ software. The results are presented as the gap area in relation to
the area value of the initial scratch, after 8 h, 16 h, and 24 h of observation.
4. Discussion
Research targeting finding new anticancer therapies is prompted by cancers’ high mortality rate.
Bioactive compounds have taken their place in the research arena as new, effective medicines [59,60].
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Phytochemicals such as flavonoids, polyphenols, and phenolic acids are of great interest to scientists,
due to their specific, active, anticancer effect on cancer cells [61,62].
Among patients diagnosed with breast cancer, complementary and targeted therapies using
alternative natural substances are often employed. Between 63% to 80% of all breast cancer patients
use at least one type of alternative medicine, while herbal or vitamin therapies are used by some 25%
to 63% of the same patient group [63–67].
Simonetti et al. showed that CA is bioavailable and it may be correlated with the antioxidant
potential of plasma, by intake of red wine [68].
The presence of the estrogen receptor is one of the priority classification factors of breast cancer
cells [18,69]. For breast cancer, proliferation and survival of the cells is dependent on estrogen receptor
signaling [22,70].
TNBC can be perfectly modeled using the MDA-MB-231 line because there are no estrogen
receptors α and expression of estrogen receptor β is minimal [71,72]. It was initially classified as a basal
line of breast cancer cells because of the lack of ER and PR expression, as well as HER2 amplification.
At present, it is considered to belong to the claudin-low molecular subtype because the line displays
a down-regulation of claudin-3 and claudinin-4, as well as low expression of the Ki-67 proliferative
marker and an enrichment of markers associated with an epithelial-mesenchymal transition and
an expression of traits associated with breast cancer stem cells (CSC), such as CD44+/CD24−/low
phenotype. The cells of this line are distinguished by invasive phenotype [72]. In a bone metastasis
researches, the MDA-MD-231 cell line was widely used [73]. Also, the MDA-MB-231 cell subclones
have been isolated. They displayed easy bone, brain, and lung metastases, after intraventricular
injection into a mice organism. It allowed for the identification of genes and pathways that are
potential mediators of metastasis to the specific sites when using this cell line [69,74–77].
For this research, we used MDA-MB-231 cell line as a model of TNBC. Considering the above,
this comparative study of CA and CAPE substances, which occur naturally in propolis, shows much
promise for breast cancer research.
The estrogenic effect of CAPE was not fully investigated, however; its ability to bind estrogen
receptors has been previously shown. CAPE modulates the estrogen receptor selectively and it is more
likely related to the estrogen receptor β than α [22,69]. This may indicate that the estrogen-related
compounds act better on estrogen-positive neoplastic cells [25,78].
Khoram et al. [79] showed that CAPE stimulated radiosensitivity in breast cancer cells.
Clonogenicity was inhibited and radiation-induced DNA damage was maintained in two cell lines,
particularly in T47D cells.
Chen et al. [28] and Lin et al. [80] observed that CAPE’s anticancer activity was due to cell growth
inhibition and a viability decline, both in a time and a dose-dependent manner. In another study,
CAPE reduced the colony formation ability of PC-3 prostate cancer cells [26].
In an in vivo study, Wu et al. [27] showed CAPE’s ability to reduce the volume of breast cancer
tumors, respectively, by 40% and 60% for MDA-231 and MCF-7 xenografts. Interestingly, the lower
dose of CAPE (10 μM) was more effective to inhibit the growth of MDA-231 xenografts than 50 μM for
the MCF-7 xenografts.
In earlier research, we compared the in vitro cytotoxic activity of ethanol extract of propolis and
CAPE against two cell lines, MDA-MB-231 and Hs578T, using MTT and lactate dehydrogenase (LDH)
assays. IC50 values obtained for CAPE (both assays) were definitely lower than for ethanol extract of
propolis [39].
Watabe et al. showed that CAPE inhibits nuclear factor NFκB. They also examined CAPE to
confirm that death-inducing receptors clustered. They found that Fas death-inducing receptors were
aggregated through a Fas-L independent mechanism in the MCF-7 cells. Consequently, it was shown
that CAPE induced apoptosis. The aggregation of death receptors was executed through two pathways;
FADD/caspase-8 and JNK/p38 [38].
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Beauregard et al. tested CAPE and its 18 derivatives against breast cancer MCF-7 cells. Induction
of caspase 3/7 resulted in apoptosis in five of eighteen CAPE-derivatives, which was even better than
CAPE alone. Inhibition of NFκB was similar for all tested analogs and CAPE itself. They found that
activation of the p53 pathway was realized by all CAPE derivatives [81].
Rosendahl et al. [82] tested caffeine and CA against breast cancer cells MCF-7, T47D,
and MDA-MB-231. Their results showed that CA inhibited the proliferation of breast cancer
cells, reducing the growth of breast cancer cells through modulating ER and IGFIR levels, thereby
influencing downstream effectors and cell-cycle progression, but better CA activity in the MCF-7 cells
(estrogen-positive) was observed. Their results displayed that CA suppressed the proliferation of
breast cancer cells. They also tested an influence of coffee intake on a breast cancer disease. A higher
coffee intake was correlated with a smaller invasion of primary tumors. On the other hand, it was
reported by Wu [23] that CAPE inhibits MCF-7 and MDA-231 cells growth. In both cell lines, CAPE
induced apoptosis and cell cycle arrest, and inhibited NF-κB as well as down-regulated the mdr-1
gene. VEGF formation was also suppressed by MDA-MB-231 cells. We can assume that activity of CA
is closely related to the expression of estrogen, while CAPE acts independently of estrogen.
Our results showed that CAPE has a better cytotoxic effect than CA, which is in line with other
research. However, our comparison of these two agents is novel, as it uses a triple cytotoxic assay.
Breast cancer metastasis is one of the primary reasons for its high mortality rate; therefore,
migration and invasion research, as well as their mechanism, are part of the new era of breast
cancer studies.
Wadhwa et al. used a free form of CAPE, as well as CAPE in a complex with gamma cyclodextrin
(γCD) (equivalent doses), for cell viability studies of breast cancer lines MCF-7 and MDA-MB-231.
They showed that CAPE displayed short-term toxicity, while CAPE-γCD complex caused permanent
growth inhibition or apoptosis, which suggested that CAPE-γCD complex was characterized by
a stronger effect. They also found that CAPE causes upregulation of p53 function by targeting
mortalin-p53-interaction. The scratch and invasion studies on MCF-7 and MDA-MB-231 cells and their
metastatic samples have shown that both CAPE-γCD complex and CAPE alone exhibit anti-migration
activity [83].
Bonuccelli et al. showed that CAPE treatment significantly reduced wound closure (about 70%
vs control) on breast cancer MCF-7 cells. In the 24 h period, CAPE acted as a natural mitochondrial
OXPHOS inhibitor, which preventively targeted stem-like cancer cells. They also suggested that CAPE
blocks formation of the mammosphere [84].
Recent research is being conducted to find a mechanism of the breast cancer cells migration.
Interesting results were proposed by Buchegger et al. [85]. They suggested potential mechanism
of migration of MDA-MB-231 cells. They expressed Reprimo (RPRM) ectopically in MDA-MB-231
cells. RPRM is located at 2q23 and encodes a highly glycosylated protein that shows four bands
(16, 21, 23, and 40 kDa) found predominantly in the cytoplasm. They found that RPRM overexpression
suppressed migration and invasion of MDA-MB-231 cells. Another study on a mechanism of the
migration was done by Bhat et al. [86]. Growth-regulated oncogene α (GROα) is a chemokine that
plays a role not only in inflammation, but also in tumorigenesis. They found that MDA-MB-231
cells without GROα exhibited a significant migration decrease and invasion properties reduction.
Liu et al. [87] showed that CD74 is involved in breast carcinoma metastasis. CD74 protein is the
invariant chain of major histocompatibility complex (MHC) class II. Their results showed that this
factor was highly expressed in MDA-MB-231 cells; furthermore, a downregulation of CD74 inhibited
both migration and invasion of MDA-MB-231 cells. Wang et al. [88] reported that TBC1D3 oncogene
promotes the migration of breast cancer cells, and its interaction with calmodulin enhances the effects
of TBC1D3.
CAPE is known as a specific inhibitor of activation of nuclear transcription factor NF-κB in breast
cancer cells [38,89]. Also, Wang et al. [90] found that an activation of NF-κB is required for the cell
migration and TBC1D3-induced expression of OLR1, an oxidized low-density lipoprotein receptor 1,
37
Nutrients 2017, 9, 1144
also known as lectin-like oxidized low-density lipoprotein (oxLDL) receptor-1. Our results showed
a motility inhibition of human breast cancer cells by CAPE. It appears that CAPE addition inhibited
the ability of the oncogene TBC1D3 to stimulate OLR1 expression in MDA-MB-231 cells. The tumor
cells migration might be induced by TBC1D3, therefore an inhibition of NF-κB could result in the
migration suppression thanks to CAPE addition.
CAPE influence on the migration of lung cancer A549 cells was tested by Shigeoka et al. They
found that CAPE suppressed the motility promoted by TGF-beta-induced Akt phosphorylation [89].
Today, natural resources are being used more often. Also, a synthesis of analogues from natural
remedies is proving to be an interesting source of substances that exhibit favorable activity for breast
cancer treatment [90,91].
In earlier studies, we investigated the effect of CA on wound scratch on human squamous cell
carcinoma cell line SCC-25. For ethanol treatment, approximately 5% of the wound was visible,
while there was no closure if CA or a CA/ethanol mixture were used after 12 h. Total or nearly
complete closure occurred after a treatment with 50 and 100 mmol/L of ethanol after 30 h, while with
CA, a dose of 50 μM significantly inhibited migration of the cancer cells, leaving from 30% to 40% of
wound closure after 30 h. The biggest gap (approx. 80%) was observed for pure CA treatment with
a dose of 50 μM after 48 h [34].
We also compared the cytotoxic properties (by MTT) of CA and CAPE apoptosis induction and
cell cycle arrest capabilities against MDA-MB-231 cells and found better activity of CAPE, with the
same dosage and time of experiment [92].
Our novel comparative study confirms that CA and CAPE suspended migration rate of breast
cancer MDA-MB-231 cells; however, much better results were obtained by the CAPE treatment.
5. Conclusions
In this limited in vitro study, we showed a comparison of CA and CAPE, two bioactive substances
isolated from bee propolis. An XTT-NR-SRB assay and migration evaluation by wound healing assay
were performed. We strongly believe, based on our results and other reports, that CA and CAPE can
be used for chemoprevention. Nevertheless, more advanced studies are needed, particularly clinical
trials. The mechanism of CA and CAPE’s anticancer activity is becoming more well understood and
documented; however, it remains a field in need of further investigation. Hopefully, this new approach
of testing natural agents for breast cancer research will carefully explore the anti-cancer properties of
all polyphenols. Our comparison of the effect of CA and CAPE on MDA-MB-231 cells clearly showed
better results for CAPE-producing anticancer properties using the same dosages and experiment times.
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Abstract: The formation of reactive oxygen species (ROS) during metabolism is a normal process
usually compensated for by the antioxidant defense system of an organism. However, ROS can cause
oxidative damage and have been proposed to be the main cause of age-related clinical complications
and diseases such as cancer. In recent decades, the relationship between diet and cancer has
been more studied, especially with foods containing antioxidant compounds. Eugenol is a natural
compound widely found in many aromatic plant species, spices and foods and is used in cosmetics
and pharmaceutical products. Eugenol has a dual effect on oxidative stress, which can action as
an antioxidant or prooxidant agent. In addition, it has anti-carcinogenic, cytotoxic and antitumor
properties. Considering the importance of eugenol in the area of food and human health, in this
review, we discuss the role of eugenol on redox status and its potential use in the treatment and
prevention of cancer.
Keywords: reactive oxygen species; metabolism; antitumor activity; antioxidant activity;
phenylpropanoid; natural products; essential oils; clove; Syzygium aromaticum
1. Introduction
Reactive oxygen species (ROS) are a heterogeneous group of molecules that are, along with
endogenous antioxidants, ubiquitously present in all organisms. They are implicated in various
diseases including malignant transformations [1]. The term “oxidative stress” refers to an imbalance
in which pro-oxidants overwhelm the capacity of antioxidant defense systems [2]; it has been shown
to contribute to the development of some types of cancer [3].
The report of anticancer potential of aromatic compounds found in foods and plants have
increased in the recent decades [4–8] and there are advanced studies of mechanisms of action and
clinical approaches in progress. This chemical class of natural products show interesting potential
as health promoting agents and, consequently, with application to improving the quality of life.
These include the polyphenols that are important components of human diet. Interestingly, some of
these compounds may act as either antioxidants or pro-oxidants to exert protective effects against
cancer [9–11]. Eugenol (4-allyl-2-methoxyphenol) (Figure 1) is an aromatic phenylpropanoid phenol
contained in clove (Syzygium aromaticum, Myrtaceae), which is well-known for its culinary uses.
Eugenol also occurs in soybeans, mung beans [12], coffee [13], bananas [14] and in herbs such as
nutmeg (Myristica fragrans, Myristicaceae), cinnamon (Cinnamomum verum, Lauraceae) and basil
(Ocimum basilicum, Lamiaceae); however, Syzygium aromaticum can be considered the principal natural
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source of this compound (45% or 90% of the total oil) [15]. Clove has been used for a long time by
civilizations because of its flavor and its properties make it important for culinary and medicinal
uses. Eugenol has been included as a spicy flavoring in whisky, ice cream, baked goods and candy
in restricted concentrations [16–18]. Eugenol has dual effect on the oxidative stress, which can action
as an antioxidant or prooxidant agent. In addition, it has anti-carcinogenic, cytotoxic and antitumor
properties. Considering the importance of eugenol in the area of food and human health, in this review,
we discuss the role of eugenol on redox status and its potential use in the treatment and prevention of
cancer. Searches were performed in the scientific literature database PubMed comprising all papers
in English published until September 2017 using the following key words: eugenol with oxidant;
antioxidant; cancer; cytotoxic; or antitumor. No exclusion criteria were performed.
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Figure 1. Chemical structure of eugenol.
2. Anti-Carcinogenic/Chemopreventive Effect of Eugenol and Its Relation to the Inhibition of
Oxidative Stress
The ability to inhibit oxidative stress has been described as a protective effect against cancer
formation (carcinogenesis or tumorigenesis); on the other hand, once a cancer has already formed,
the antioxidant effect can contribute to the cancer’s development, while the pro-oxidant effect can
induce cancer cell death by several signaling pathways [19]. Interestingly, eugenol has been described
as an agent with a double effect, antioxidant and pro-oxidant, presenting beneficial effects in the
prevention of cancer formation and in cancer treatment (Figure 2). Despite some contradictory studies,
there are many articles evaluating these biochemical and pharmacologic aspects.
Figure 2. The dual effect of eugenol in the oxidative stress and its action in cancer development
and treatment.
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The anti-carcinogenic effect of eugenol had been investigated in several models [20–28].
The anti-carcinogenic effect of eugenol against skin carcinogenesis was investigated by Kaur et al. [20].
Skin cancer was initiated by applying 160 nmol 7,12-dimethylbenz[a]anthracene (DMBA) and
promoted by twice weekly applications of 8.5 nmol 12-otetradecanoylphorbol-13-acetate (TPA) for
28 weeks and was followed by eugenol treatment. DMBA is a polycyclic aromatic hydrocarbon
pro-carcinogen that requires metabolic conversion to its ultimate carcinogenic diol epoxide metabolites
by oxidation, which is carried out through cytochrome P450 family 1 subfamily A member 1 (CYP1A1)
and cytochrome P450 family 1 subfamily B member 1 (CYP1B1). Therefore, the carcinogenic effect
of DMBA depends on the level of the oxidative metabolism of cytochrome P450 family 1. Two
protocols were established: an anti-initiation protocol (topical application of 200 μL eugenol at
15% v/v in acetone one week before, one hour prior and two times after DMBA application);
and an anti-promotion protocol (topical application of 30 μL eugenol at 15% v/v in acetone, 30 min
prior to every TPA application). The treatment with eugenol did not prevent tumor formation but
led to a reduction in tumor size. The control group presented tumor size of 9.7 g, and eugenol
treatment showed tumor size of 5.6 g in the anti-initiation protocol and 2.8 g in the anti-promotion
protocol. In addition, topical application of eugenol prior to TPA exposure led to the development of
papillomatous keratoacanthoma with minimal cell proliferation but without squamous cell carcinoma.
The anti-carcinogenic effect of eugenol was attributed to its anti-inflammatory activity, because some
markers of inflammation, including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2
(COX-2) expression and the levels of pro-inflammatory cytokines interleukin-6 (IL-6), tumor necrosis
factor alpha (TNF-α) and prostaglandin E2 (PGE2), were reduced in DMBA/TPA-exposed animals
after treatment with eugenol. Furthermore, eugenol was found to suppress the activation of nuclear
factor kappa B (NF-κB) in mouse skin with TPA-induced inflammation [20].
Additionally, eugenol treatment (~100 mg/kg) inhibited the tumor formation in mouse skin model
induced by application of DMBA as initiator and croton oil as promotor via radical scavenging activity
of eugenol, downregulation of Myc (proto-oncogene), H-ras (harvey rat sarcoma virus oncogene) and
Bcl-2 (B-cell lymphoma 2, apoptosis regulator) expression along with upregulation of p53, Bax (BCL2
associated X, apoptosis regulator) and active caspase-3 expression in the skin lesions [21,22]. Topical
administration of eugenol also partially inhibited the benzo[a]pyrene-induced skin carcinogenesis
in Swiss mice [23]. However, topical application of eugenol had minimal protection in reducing
DMBA-induced skin carcinogenesis in Swiss mice [24].
The chemopreventive effect of eugenol on N-methyl-N′-nitro-N-nitrosoguanidine
(MNNG)-induced gastric carcinogenesis in Wistar rats was also performed [25,26]. MNNG
(150 mg/kg) was administered by intragastric intubation three times with a gap of two weeks in
between the treatments and eugenol (100 mg/kg) was administered by intragastric route, three times
per week starting on the day following the first exposure to MNNG and continued until the end of the
experimental period. The incidence of gastric tumors in MNNG-treated rats was 100% with a mean
tumor burden of 274.38 mm3 and eugenol treatment decreased the tumor incidence to 16.66% with
a tumor burden of 14.78 mm3. Administration of eugenol induced apoptosis via the mitochondrial
pathway by modulating the Bcl-2 family proteins, apoptotic protease activating factor 1 (Apaf-1),
cytochrome c and caspases and inhibiting of invasion and angiogenesis as evidenced by changes
in the activities of matrix metalloproteinases (MMP) and the expression of MMP-2 and -9, vascular
endothelial growth factor (VEGF), vascular endothelial growth factor receptor 1 (VEGFR1), tissue
inhibitor of metalloproteinase-2 (TIMP-2) and reversion-inducing-cysteine-rich protein with kazal
motifs (RECK). Moreover, reduction in the NF-κB activation along with increasing of its inhibitor
family members, IκB kinase α (IκBα) and inhibitor of kappa B (IKKβ), reduction of cyclin D1, cyclin B
and proliferating cell nuclear antigen (PCNA) and increasing of p53, p21waf1 and growth arrest and
DNA damage-inducible 45 (Gadd45) were observed in eugenol-treated animals [25,26].
Using MCF 10A breast epithelial cells and H-ras transfected MCF 10A (MCF 10A-ras) as a model
of cancer progression, eugenol exhibited cytotoxicity in μM range to MCF 10A-ras cells but not
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in MCF 10A cells [27]. In addition, eugenol reduced the ATP generation and inhibited oxidative
phosphorylation and fatty acid oxidation via downregulating of c-Myc/PGC-1β/ERRα signaling
pathway and inhibiting ROS production in H-ras transfected MCF 10A breast epithelial cells, indicating
that eugenol can prevent breast cancer progression by regulation of cellular energy metabolism [27].
On the other hand, eugenol treatment does not exert modifying effects on lung carcinogenesis induced
by urethane [28]. No significant differences in the incidences and multiplicities of lung lesions were
observed between eugenol and control groups. In this model of lung carcinogenesis, transgenic mice
with the human prototype c-Ha-ras gene received a single intraperitoneal injection of 250 mg/kg
urethane, followed by a diet containing 6000 ppm eugenol or basal diet for 26 weeks [28]. The Table 1
summarize the anti-carcinogenic effect of eugenol.







Skin carcinogenesis DMBA + TPA Topical
Reduction in tumor incidence and
size; and/or development of
papillomatous keratoacanthoma with
minimal cell proliferation but without
squamous cell carcinoma
[20]
Skin carcinogenesis DMBA + croton oil Topical Inhibition of tumor formation ~60% [21,22]
Skin carcinogenesis benzo[a]pyrene Topical Inhibition of tumor formation ~50% [23]
Skin Carcinogenesis DMBA Topical Minimal protection [24]
Gastric carcinogenesis MNNG Intragastric Inhibition of tumor formation ~75% [25,26]
Lung carcinogenesis Urethane Oral No protection [28]
DMBA: 7,12-dimethylbenz[a]anthracene; TPA: 12-otetradecanoylphorbol-13-acetate; MNNG: N-methyl-N′-
nitro-N-nitrosoguanidine.
The anti-carcinogenic effect of eugenol can also be attributed to its antioxidant property. Eugenol
has been reported to have antioxidant activity, as assessed by diverse models [12,29–35]. Eugenol
reacts with 2,2-diphenyl-1-picrylhydrazyl (DPPH) and shows high DPPH free radical-scavenging
activity [29–33]. The concentration of eugenol required for 50% DPPH scavenging (IC50: half maximal
inhibitory concentration) activity ranged from 98 to 138 μM [31,35]. Eugenol also exhibits effective
antioxidant activity in the linoleic acid emulsion system by inhibiting lipid peroxidation at 91 μM.
In addition, eugenol has ferric ion (Fe3+) reducing ability and electron donor properties for neutralizing
free radicals by forming stable products [31]. Eugenol inhibits malonaldehyde (MA) formation from
cod liver oil by 91% at ~1 mM [12]. Furthermore, eugenol inhibits microsomal lipid peroxidation (IC50
about 80 μM) as well as iron and OH radical-initiated lipid peroxidation in rat liver mitochondria,
with IC50 values of 10 and 14 μM, respectively. The antioxidant effect was determined by the inhibition
of thiobarbituric acid-reactive substances (TBARS) formation [29,30].
The effect of eugenol on in vivo lipid peroxidation mediated by carbon tetrachloride (CCl4) has
also been evaluated [30]. The CCl4 model has been used for many years to investigate the effect
of antioxidants in the liver xenobiotic metabolism. When eugenol was given at 5 mg/kg orally
at three different times—i.e., prior to (−1 h), along with (0 h), or after (+3 h)—in relation to the
time of CCl4 dosing (i.p. administration of 0.4 mg/kg), it prevented significantly the rise in serum
glutamic-oxaloacetic transaminase (SGOT) activity, lipid peroxidation and liver necrosis. However,
eugenol failed to prevent a decrease in glucose-6-phosphatase activity, suggesting that the damage to
endoplasmic reticulum (ER) is not protected by eugenol. Thus, the protective action of eugenol can be
explained by the interception of secondary radicals derived from ER lipids rather than interference
with the primary radicals of CCl4 (•CCl3/CCl3OO•) [30]. In addition, the in vivo antioxidant effect
of eugenol on liver danger induced by thioacetamide (TA) was also performed [36]. TA is frequently
used to produce liver danger in animals due to generation of ROS and instigation of oxidative stress,
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which causes liver damage. Adult male Wistar rats were treated with eugenol (10.7 mg/kg/day) orally
for 15 days. TA was administered (300 mg/kg, i.p.) for the last two days at 24 h intervals and the rats
were sacrificed on the 16th day. Pretreatment with eugenol controlled the levels of lipid peroxidation
and protein oxidation products with consequent reduction of TBARS, lipid hydroperoxides and
protein carbonyl formation in plasma and the liver. Increased expression of the COX-2 gene as well as
increases in pro-inflammatory cytokine TNF-α and IL-6 plasma levels induced by TA was also partially
reverted by eugenol pretreatment. The protective effect of eugenol can be attributed to the reduction
of cytochrome P450 family 2 subfamily E member 1 (CYP2E1) activity, the main enzyme responsible
for TA-induced hepatotoxicity and oxidative stress [36].
Genotoxicity and mutagenicity of xenobiotics are also involved in the carcinogenic process
and may occur as a result of oxidative stress. Interestingly, the antimutagenic and anti-genotoxic
effects of eugenol has been also reported. Eugenol suppressed the mutagenicity induced by
furylfuramide, 4-nitroquinoline 1-oxide, aflatoxin B in Salmonella typhimurium [37]. Eugenol also
inhibits detoxification enzymes and prevents DMBA-induced DNA damage in MCF-7 (human breast
adenocarcinoma) cell line [38,39]. Eugenol at dose of 50–500 mg/kg administered by gavage prevents
the genotoxicity-induced by cyclophosphamide, procarbazine, N-methyl-N′-nitro-N-nitrosoguanidine
and urethane [40]. In addition, the mutagenicity of benzo[a]pyrene but not DMBA and aflatoxin B1,
in the S. typhimurium mutagenicity assay was reduced in liver S-9 fractions prepared from rats treated
orally with eugenol (1000 mg/kg) [41]. In contrast, eugenol causes intrachromosomal recombination
in yeast Saccharomyces cerevisiae in logarithmic phase cultures [42] and although eugenol induces no
mutagenesis in Ames test, it causes chromosomal aberrations and increased the incidence of sister
chromatid exchanges in Chinese hamster ovary cells [43,44]. At μM range, eugenol is not able to
prevent the DNA lesions induced by hydrogen peroxide (H2O2) [33]. However, eugenol protected the
supercoiled pBR322 plasmid DNA oxidative damage induced by Fe2+ and H2O2 at mM range [35].
Moreover, eugenol, at concentrations above 50 μM, inhibited the DNA oxidative damage induced by
hydroxyl radicals produced by Fenton reactions using Fe2+ and H2O2 [32].
3. Cytotoxic and Antitumor Effects of Eugenol and Its Relation to the Induction of Oxidative Stress
Controversial results have been found for the cytotoxic activity of eugenol. Some studies have
shown that eugenol is capable of inducing cytotoxicity at concentrations in the μM range, whereas
other studies show that eugenol is capable of inducing cytotoxic effects only at concentrations in the
mM range. Nevertheless, eugenol is able to induce cytotoxicity to cancer cell lines with different
histological types, including skin, breast, colon, prostate, cervical, hepatocellular, lung, oral squamous
cells and leukemia. In addition, the ability to induce oxidative stress has been also ascribed to eugenol
in cell-based assays.
Eugenol in the μM range inhibits the growth of melanoma cells—Sbcl2 (primary melanoma),
WM3211 (primary radial growth phase), WM98-1 (primary vertical growth phase) and WM1205Lu
(metastatic melanoma)—accompanied by cell cycle arrest at the S phase, followed by apoptosis [45].
Using cDNA array analysis, it was demonstrated that eugenol modulates expression of E2F
family members. In addition, eugenol was able to inhibit the E2F1 transcriptional activity and,
as overexpression of E2F1 restores melanoma cell proliferation, this indicates that eugenol targets E2F
functions in melanoma cells [45]. In addition, eugenol in the μM range inhibits the growth of HL-60
(human promyelocytic leukemia), U-937 (human histiocytic lymphoma), HepG2 (human hepatocellular
carcinoma), 3LL (Lewis mouse lung carcinoma) and SNU-C5 (human colon carcinoma) lines [46].
Eugenol-treated HL-60 cells display DNA fragmentation, ROS production, loss of mitochondrial
transmembrane potential, bax translocation, Bcl-2 reduction, cytochrome c release and caspase-9 and -3
activation, suggesting that eugenol causes apoptotic cell death. Moreover, pretreatment of HL-60 cells
with N-acetyl-L-cysteine (an antioxidant), Z-VAD-FMK (a pan caspase inhibitor) and Z-DEVD-FMK
(a caspase-3 inhibitor) decreases the eugenol-induced apoptosis, indicating that eugenol activates the
caspase- and ROS-mediated apoptosis pathways [46]. Moreover, treatment of HL-60 cells with eugenol,
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produced formation of three DNA adducts and incubation of HL-60 cells with the combination of
100 μM eugenol and 100 μM H2O2 potentiated the levels of DNA adduct in HL-60 cells. Oxidative base
damage was also observed. The DNA adducts formed were inhibited by the addition of either ascorbic
acid or glutathione [47]. Eugenol in the μM range is also cytotoxic to DU-145 (androgen-insensitive
prostate cancer cells) and KB (oral squamous carcinoma cells) [48].
Using LNCaP (androgen responsive human prostate carcinoma) and PC-3 (androgen independent
human prostate carcinoma) cell lines, eugenol induces cytotoxicity in the μM range and causes
an increase in G2/M phase [49]. Apoptotic cell death was not detected at the concentrations
used; however, eugenol in combination with 2-methoxyestradiol causes apoptosis along with
a reduction of the expression of anti-apoptotic protein Bcl-2 and enhancement of the expression
of the pro-apoptotic protein Bax. The apoptosis induced by this combination is not affected in PC-3
cells with overexpression or lack of Bcl-2 but is associated with the loss of mitochondrial membrane
potential [49]. Eugenol in μM concentrations causes cytotoxicity to MCF-7, T47-D (human breast
carcinoma) and MDA-MB-231 (human breast adenocarcinoma) cells through down-regulation of E2F1
and its downstream anti-apoptosis target, surviving independently of the status of p53 and ERα [50].
Eugenol inhibits the breast cancer related oncogenes, NF-κB and cyclin D1 and up-regulates the
cyclin-dependent kinase inhibitor p21WAF1 protein; On the other hand, eugenol was also cytotoxic to
non-cancer cell line MCF 10A (human breast epithelial) with IC50 value of 2.2 μM [50]. Júnior et al. [51]
also assessed the cytotoxicity of eugenol in the μM range on MDA-MB-231, MCF-7, SIHA (human cervix
carcinoma), SK-Mel-28 (human melanoma) and A2058 (human melanoma) cells; it was accompanied
by ROS production, causing G2/M phase block and, consequently, clastogenesis. Eugenol also
induced downregulation of PCNA (proliferation cell nuclear antigen), decreased the mitochondria
transmembrane potential and upregulated Bax [51].
Controversially, some studies have indicated that eugenol has no cytotoxic activity or has
cytotoxicity only when present in the mM range [52–73]. In studies with HSG (human submandibular
gland adenocarcinoma) and HSC-2 (human oral squamous cell carcinoma) cells, eugenol caused
cytotoxicity when in the mM range but no ROS induction was observed [58,59]. On the other
hand, Atsumi et al. [60] stated that eugenol caused a biphasic ROS production that was enhanced at
5–10 μM and decreased at 500 μM in HSG, treated with H2O2 plus horseradish peroxidase or with
visible light irradiation. In HL-60 cells, eugenol presents IC50 of 0.38 mM that is accompanied by
internucleosomal DNA fragmentation. The expression of the mRNAs and the activity of manganese
superoxide dismutase and copper- and zinc-containing superoxide dismutase are inhibited by eugenol,
suggesting that eugenol targets the oxidative stress in cancer cells. In contrast, eugenol-induced
cytotoxicity is enhanced by N-acetyl-L-cysteine or glutathione treatment [58,61]. On the other hand,
eugenol induces cytotoxicity and ROS generation in HSG cells in which glutathione or cysteine are
protecting from damage [62,63].
Pisano et al. [64] demonstrated that eugenol has no cytotoxic effect at 100 μM in malignant
melanoma cell lines WM266-4, SK-Mel-28, LCP-Mel, LCM-Mel, PNP-Mel, CN-MelA, 13443 and
GR-Mel. In human melanoma G361 cells, eugenol in the mM range inhibits the viability of G361
cells. Eugenol-treated G361 cells present caspase-3 and -6 cleavage and activation. The caspase-3
substrates poly(ADP-ribose)polymerase (PARP) and DNA fragmentation factor 45 (DFF45) are cleaved
in eugenol-induced apoptosis, suggesting induction of caspase-dependent apoptosis [65]. Interestingly,
similar results were found in human osteosarcoma HOS cells, suggesting that eugenol can also induce
caspase-dependent apoptosis pathways in HOS cells [66].
In a study with human cervical carcinoma cell line (HeLa), eugenol presented cytotoxicity in
the mM range and in a synergistic combination with sulforaphane, downregulated the expression of
Bcl-2, COX-2 and IL-β. It also produced a synergistic effect when combined with gemcitabine, causing
downregulation of the expression of Bcl-2, COX-2 and IL-β [67,68]. Also, in the mM range, eugenol
was cytotoxic and induced apoptosis to colon carcinoma cell lines HCT-15 and HT-29. The loss of the
membrane mitochondrial potential and generation of ROS were accompanied in the eugenol-induced
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apoptosis. Augmented ROS generation resulted in the DNA fragmentation and activation of PARP,
p53 and caspase-3 [69]. Eugenol in the mM range also inhibits the growth of human breast carcinoma
MCF-7 cells, accompanied by cell shrinkage and an increase in the percentage of apoptotic cells
and DNA fragments. A depleted level of intracellular glutathione and increased level of lipid
peroxidation are also observed [70]. In another study with MCF-7 cells, eugenol presented an IC50
value of 0.9 mM, increased the ROS production, decreased the ATP level and induced the loss of the
mitochondrial membrane potential and release of the cytochrome c and lactate. Cell viability and
ROS production were restored by pretreatment with the antioxidants. On the other hand, the eugenol
effect was not affected in MCF-7 cells with overexpression of Bcl-2 [71]. Human oral squamous cell
carcinoma cell line HSC-2 treated with a concentration of eugenol in the mM range presented metabolic
changes including reduction of ATP utilization, oxidative stress and an increase in the polyamines and
glycolytic metabolites [72]. In HepG2 and Caco-2 (human colon carcinoma) cells, the treatment with
eugenol-loaded nanoemulsions and free eugenol caused increasing in the cell death by apoptosis and
ROS generation [73]. The Table 2 summarize the in vitro cytotoxic effect of eugenol.
Table 2. Summary of in vitro cytotoxic effects of eugenol against cancer and non-cancer cell lines.
Cell Lines Histological Type Origin IC50 (μM) References
Cancer cells
Sbcl2 Primary melanoma Human ~0.5 [45]
WM3211 Primary melanoma Human ~0.5 [45]
WM98-1 Primary melanoma Human ~0.5 [45]
WM1205Lu Metastatic melanoma Human ~0.5 [45]
SK-Mel-28 Melanoma Human 7.2 [51]
A2058 Melanoma Human 12.2 [51]
WM266-4 Melanoma Human >100 [64]
SK-Mel-28 Melanoma Human >100 [64]
LCP-Mel Melanoma Human >100 [64]
LCM-Mel Melanoma Human >100 [64]
PNP-Mel Melanoma Human >100 [64]
CN-MelA Melanoma Human >100 [64]
13443 Melanoma Human >100 [64]






T47-D Breast carcinoma Human 0.9 [50]
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Table 2. Cont.
Cell Lines Histological Type Origin IC50 (μM) References
HCT-15 Colon adenocarcinoma Human 300 [69]
HT-29 Colon adenocarcinoma Human 500 [69]
Caco-2 Colon carcinoma Human ~750 [73]
SNU-C5 Colon carcinoma Human 129.4 [46]
LNCaP Prostate adenocarcinoma Human ~550 [49]
PC-3 Prostate carcinoma Human ~180 [49]
DU-145 Prostate carcinoma Human 30.4 [48]
SIHA Cervical carcinoma Human 18.3 [51]
HeLa Cervical carcinoma Human 500 [72]
HepG2 Hepatocellular carcinoma Human
118.6 [46]
~500 [73]
3LL Lewis lung carcinoma Mouse 89.6 [46]
KB Oral squamous cell carcinoma Human 28.5 [48]
HSC-2 Oral squamous cell carcinoma Human ~700 [72]
HOS Osteosarcoma Human 1500 [66]
HL-60 Promyelocytic leukemia Human
23.7 [46]
380 [61]
U-937 Histocytic lymphoma Human 39.4 [46]
Non-cancer cells
MCF 10A Breast epithelial Human 2.2 [50]
IC50: half maximal inhibitory concentration.
In vivo antitumor effects of eugenol have been also investigated [45,50,74]. Using B6D2F1 mice
bearing B16 melanoma, eugenol treatment (125 mg/kg/i.p. of body weight twice a week) caused the
in vivo antitumor effect [45]. On day 15, the size of tumors in the eugenol-treated group was 62%
less than the control group, with an increase of 19% in the survival rate. At the end of the treatment,
50% of the animals in the control group presented metastases but no eugenol-treated animals showed
any signs of invasion or metastasis [45]. Moreover, eugenol (100 mg/kg/i.p.) was able to inhibit the
growth of the Ehrlich ascites model by 28.88% and inhibited 24.35% tumor growth in the Ehrlich solid
tumor model [74].
In mice engrafted with human breast adenocarcinoma MDA-MB-231 cells subcutaneously, eugenol
treatment with a dose of 100 mg/kg every two days for four weeks inhibited tumor growth [50].
Moreover, eugenol downregulated E2F1, survivin, NF-κB and cyclin D1 and increased the levels of
p21WAF1, Bax, cleaved PARP-1 and the active form of caspase-9 in tumor xenografts [50]. The Table 3
summarize the in vivo antitumor effect of eugenol. Regarding the antimetastatic potential of eugenol,
it exerts inhibitory effects on matrix metallopeptidase 9 (MMP-9) via inhibition of extracellular
signal-regulated kinase (ERK) phosphorylation in human fibrosarcoma HT1080 cells [32].
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B16 Melanoma Mouse 125 Twice a week i.p. 62 [45]
Ehrlich
(ascites model) Carcinoma Mouse 100
Every two days
for four weeks i.p. 28.9 [74]
Ehrlich
(solid model) Carcinoma Mouse 100
Every two days
for four weeks i.p. 24.4 [74]
MDA-MB-231 Breastadenocarcinoma Human 100
Every two days
for four weeks i.p. ~66 [50]
i.p.: intraperitoneal.
Although there are a large number of papers on the cytotoxic properties of eugenol, controversial
results delay the completion of preclinical efficacy and safety studies as well as clinical trials. However,
the ability of eugenol to induce oxidative stress, as observed in cell-based assays, appears to be related
to its cytotoxic and antitumor effect. Other compounds with dual antioxidant and prooxidant effect
have a dose/concentration-response relationship, for example, at low doses/concentrations present
antioxidant effect and at high doses/concentrations show prooxidant effect [75–78]; however, we do
not find this relationship with the data published with eugenol. Problems related to the degree of
purity of the compound, its evaporation (for volatile compounds for example) during the experiments,
the methods used to quantify these data (since different cellular and animal models may present
divergent results and interpretations) and some laboratory and interpretation errors (including the use
of cell lines contaminated with Mycoplasma sp., errors in cell line authentication, etc.) may contribute
to explain these controversial results.
In relation to the structure-activity relationship of eugenol, the cytotoxicity of eugenol-related
compounds has been associated with the activity of the production of phenoxyl radicals, their stability
of the subsequent quinonemethide and the hydrophobicity [79]. In relation to the antioxidant activity,
the number of hydroxyl groups in the phenol ring of eugenol enhanced it antioxidant action [31,80].
Moreover, the presence of bromine substituent in ortho-position to the OH-group increases its
antioxidant activity [81].
4. Conclusions
The studies presented in this review reveal the therapeutic potential of eugenol in cancer
prevention and treatment and the relationship with its antioxidant and pro-oxidant activities.
The Figure 3 summarize the molecular mechanisms of eugenol. Therefore, the consumption of
vegetables containing this compound in significant quantities might well be useful in inhibiting the
free radicals responsible for tumor development. In addition, the data reported are in accordance with
the scientific understanding that a better quality of life and increased longevity may be obtained via
healthy food, with the health promoting effects of its bioactive constituents.
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Figure 3. Molecular mechanisms of eugenol. ↑: upregulation; ↓: downregulation; Apaf-1: apoptotic
protease activating factor 1; Bax: BCL2 associated X, apoptosis regulator; Bcl-2: B-cell lymphoma 2,
apopstosis regulator; COX-2: cycloxygenase-2; Cu/ZnSOD: copper- and zinc-containing superoxide
dismutase; ERRα: estrogen-related receptor alpha; Gadd45: growth arrest and DNA damage-inducible
45: IKKβ: IκB kinase α; IL-6: interleukin 6; iNOS: inducible nitric oxide synthase; IκBα: inhibitor of
kappa B; MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; MnSOD: manganese
superoxide dismutase; NF-κB: nuclear factor-kappa B; PCNA: proliferating cell nuclear antigen;
PGC-1β: peroxisome proliferator-activated receptor gamma coactivator 1-beta; PGE2: prostaglandin
E2; RECK: reversion-inducing-cysteine-rich protein with kazal motifs; ROS: reactive oxygen species;
TIMP-2: tissue inhibitor of metalloproteinase-2; TNF-α: tumor necrosis factor alpha; VEGF: vascular
endothelial growth factor; VEGFR1: vascular endothelial growth factor receptor 1.
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Abbreviations
Apaf-1 Apoptotic protease activating factor 1
Bax BCL2 associated X, apoptosis regulator
Bcl-2 B-cell lymphoma 2, apopstosis regulator
COX-2 Cyclooxygenase-2
CYP 1A1 Cytochrome P450 family 1 subfamily A member 1
CYP1B1 Cytochrome P450 family 1 subfamily B member 1





Gadd45 Growth arrest and DNA damage-inducible 45
IC50 Half maximal inhibitory concentration
IKKβ Inhibitor of kappa B
IL-6 Interleukin-6
iNOS Inducible nitric oxide synthase
IκBα IκB Kinase α
MA Malonaldehyde
MCF 10A-ras H-ras transfected MCF 10A
MMP Matrix metalloproteinases
MNNG N-Methyl-N′-nitro-N-nitrosoguanidine
NF-κB Nuclear factor kappa B
PARP Poly(ADP-ribose)polymerase
PCNA Proliferating cell nuclear antigen
PGE2 Prostaglandin E2
RECK Reversion-inducing-cysteine-rich protein with kazal motifs
ROS Reactive Oxygen Species
SGOT Serum glutamic-oxaloacetic transaminase
TA Thioacetamide
TBARS Thiobarbituric acid-reactive substances
TIMP-2 Tissue inhibitor of metalloproteinase-2
TNF-α Tumor necrosis factor alpha
TPA 12-otetradecanoylphorbol-13-acetate
VEGF Vascular endothelial growth factor
VEGFR1 Vascular endothelial growth factor receptor 1
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Abstract: Pyrroloquinoline and guanidine-derived alkaloids present distinct groups of marine
secondary metabolites with structural diversity that displayed potentialities in biological research.
A considerable number of these molecular architectures had been recorded from marine sponges
belonging to different marine genera, including Batzella, Crambe, Monanchora, Clathria, Ptilocaulis and
New Caledonian starfishes Fromia monilis and Celerina heffernani. In this review, we aim to
comprehensively cover the chemodiversity and the bioactivities landmarks centered around the
chemical constituents exclusively isolated from these three marine genera including Batzella,
Crambe and Monanchora over the period 1981–2017, paying a special attention to the polycyclic
guanidinic compounds and their proposed biomimetic landmarks. It is concluded that these marine
sponge genera represent a rich source of novel compounds with potential applications for cancer and
other therapeutic areas.
Keywords: marine sponges; Poecilosclerida; Batzella; Crambe; Monanchora; guanidine alkaloids;
pyrroloquinoline alkaloids; bioactivities; biomimetic synthesis
1. Introduction
As a result of the rise of many current medical challenges, including hepatitis, parasitic infection,
lifestyle-induced diseases, such as diabetes, hypertension, many forms of cancer, multi-drug resistance
pathogens and other diseases, searching for new bioactive compounds with novel modes of action
is necessary. Marine natural products represent potent, promising and sustainable sources for
biomedications [1]. Up to present time, eight marine-derived drugs were approved for market
pipelines for the treatment of some of these current medical challenges [2,3]. Marine sponges
(phylum Porifera), even though they are the most primitive class within the animal kingdom,
are considered renewable powerful suppliers for bioactives. The marine genera belonging to the
Nutrients 2018, 10, 33; doi:10.3390/nu10010033 www.mdpi.com/journal/nutrients59
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order Poecilosclerida, Batzella (family Chondropsidae), Crambe and Monanchora (family Crambeidae),
are rich in the production of highly physiologically active pyrroloquinoline and guanidine-derived
alkaloids [4–6], with a vast scope of biological potentialities including cytotoxic and antiviral [7–12],
HIV-1 inhibitors [13,14], enzyme inhibitors [15], receptor antagonist [16], Ca2+ channel blocker [17],
antifungal [18] and antimicrobial [19–21]. These interesting compounds are considered taxonomic
markers in particular for some Poecilosclerida and Axinellida marine sponge genera [5]. Their complex
molecular architectures and potent biological activities have made them for years ideal target
molecules for synthetic applications [22–28]. Beside the production of guanidine-derived architectures,
some deep-water species of Batzella produced pyrroloquinoline-derived alkaloids, which raises
a chemotaxonomic question about the systematic relatedness of this genus (family Chondropsidae) to
other genera like Crambe and Monanchora (family Crambeidae). A chemosystematic exploration has
revealed that Batzella sponges containing cyclic guanidine alkaloids are chemically and taxonomically
similar, and perhaps synonymous with, Monanchora and Crambe. However, the deep-water Batzella
sponges produced pyrroloquinoline alkaloids is taxonomically unrelated to the Batzella previously
mentioned. Chemically, it is almost similar to the Zyzzya and Latrunculia marine sponges but their
phylogenetic relationship is still undetermined [29]. Systematically, the World Porifera Database
accepts nine valid species of Batzella [30], nine valid species in the genus Crambe [31] and fourteen
valid species currently in the genus Monanchora [32]. To the best of our knowledge, previous chemical
investigations of Batzella was centered on only a single unidentified species from Madagascar [33],
for the genus Crambe only one identified species, the type species Crambe crambe from the
Mediterranean [34] and finally five identified Monanchora species including Monanchora ungiculata [35],
Monanchora dianchora [36], Monanchora pulchra [37], Monanchora arbuscula [38] and Monanchora
unguifera [35] in addition to one unidentified species of Monanchora n. sp. [39].
2. Chemistry and Biology of Natural Products Isolated from Batzella, Crambe and Monanchora
In this review, we provide comprehensive insights on the previous chemical and biological reports
for the metabolites of the three marine genera. To facilitate the handling of this survey, the isolated
natural compounds are classified by their polycyclic skeleton coupled with their recorded biological
potentialities whenever applicable.
2.1. Piperidine Iminosugars Alkaloids
(+)-Batzellasides A–C (1–3), three alkylated piperidine iminosugars were isolated from
a Madagascar sponge, Batzella sp. and represented the first naturally occurring marine iminosugars.
These compounds demonstrated inhibition of the growth of Staphylococcus epidermidis with MICs
(Minimum Inhibitory Concentration) that were under 6.3 μM [33] (Figure 1).
 
Figure 1. Isolated iminosugars 1–3 from Batzella sp.
2.2. Bicyclic Guanidine Alkaloids
Eleven bicyclic guanidine metabolites including five bearing crambescin type A (4–8),
three bearing crambescin type B (9–11) and further three possessing crambescin type C (12–14)
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were recorded from the Mediterranean sponge Crambe crambe. Their structures were established
using NMR and careful HRMS/MS data analyses for the complete assignment of the alkyl chain
lengths. These compounds demonstrated cytotoxic activity against neuronal cell lines in micromolar
range [34,40,41]. Additional homologue crambescin A (15), the only known bicyclic compound
reported from the Caribbean sponge Batzella sp. Compound 15 displayed potent cytotoxicity against
proliferating Vero cells and HIV gp120-human CD4 binding inhibition activity with IC50 > 100 μM [14].
Further bicyclic compounds including dehydrocrambine A (16) recorded from Monanchora sp.
that inhibits HIV-1 fusion [42]. Monanchorin (17), a guanidine alkaloid with unusual bicyclic skeleton
from Monanchora ungiculata showed very weak cytotoxic activity with IC50 = 11.3 μM against IC2
murine mast cell lines [35]. The simple pyrimidine monalidine A (18), an anti-parasitic bicyclic
guanidine alkaloid, was recently recorded from Monanchora arbuscula [43]. Urupocidins A (19) and
B (20), bisguanidine alkaloids possessing unusual N-alkyl-N-hydroxyguanidine motif, were isolated
from Monanchora pulchra. Urupocidin A (19) increases nitric oxide production in murine macrophages
via inducing iNOS expression [44]. Recently, seven cytotoxic guanidine alkaloids were described
from a French Polynesian Monanchora n. sp. including three bicyclic architectures possessing a free
carboxylic acid group monanchoradins A–C (21–23) and four bicyclic compounds bearing crambescin
A2 type skeleton with a short butyl-guanidine side chain including dehydrocrambescin A2 418 (24),
(−)-crambescin A2 392 (25), (−)-crambescin A2 406 (26) and (−)-crambescin A2 420 (27) along with
monalidine A (18). Most of these compounds showed antiproliferative and cytotoxic activities against
several cancer cell lines including KB, HCT-116, HL-60, MRC-5 and B16-F10, with IC50 values in
the micromolar range. The bicyclic analogue monanchoradin A (21) that bearing a carboxylic acid
functionality was found to be less potent, however, it is still in the nanomolar range. On the other
hand, the bicyclic compounds 24–27 bearing the butyl-guanidine terminus were found more potent,
in particular (−)-crambescin A2 420 (27) that was found to be the most active with IC50 = 0.03 μM
against KB cancer cell lines [39]. Moreover, the simple compound 18 showed potent antiproliferative
and cytotoxic activities against KB, HCT-116, MDA-435, HL-60 and MRC-5 with an IC50 values
0.2/0.4, 0.84/0.74, 0.32/0.86, 1.3/1.3, 0.55/0.60 μM respectively. It is worth noting that the bicyclic
(−)-crambescin compounds 25–27 are enantiomers for the antipodal bicyclic (+)-crambescins, recently
isolated from the marine sponge Pseudaxinella reticulata (now known as Dragmacidon reticulatum, family
Axinellidae) and their recording draws important insights about chirality and its dependence on the
species of sponge [45] (Figure 2).
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Figure 2. Isolated bicyclic guanidine alkaloids 4–27.
2.3. Tricyclic Guanidine Alkaloids Bearing Ptilocaulin
Four tricyclic compounds including 8a,8b-dehydroptilocaulin (28), 8a,8b-dehydro-8-
hydroxyptilocaulin (29), 1,8a;8b,3a-didehydro-8-hydroxyptilocaulin (30) and mirabilin B (31) were
recorded from the Bahamas marine sponge, Batzella sp. [46]. (+)-Ptilocaulin (32), an antimicrobial and
cytotoxic tricyclic guanidine alkaloid, in addition to isoptilocaulin (33) and (+)-8-hydroxyptilocaulin (34),
were obtained from Monanchora arbuscula [38,47]. Moreover, (+)-ptilocaulin (32), exhibited antimicrobial
activity against an oxacillin-resistant strain of Staphylococcus aureus with IC50 = 1.3 μM [48]. Further three
tricyclic guanidine alkaloids, including 1, 8a; 8b, 3a-didehydro-8β-hydroxyptilocaulin (35), 1,
8a; 8b, 3a-didehydro-8α hydroxyptilocaulin (36) and mirabilin B (31), were described from
Monanchora unguifera [49]. The mixture of 35 and 36 was active against the malaria parasite
Plasmodium falciparum with an IC50 = 3.8 μM. Furthermore, mirabilin B (31) exhibited antifungal
activity against Cryptococcus neoformans with an IC50 = 7.0 μM and antiprotozoal activity against
Leishmania donovani with an IC50 = 17 μM [49]. The tricyclic guanidines 31–36 were identified from
a Brazilian specimen of Monanchora arbuscula and were tested for their cytotoxicity against four cancer
cell lines including HL-60, MDA-MB-435, HCT-8 and SF-295. The two compounds (+)-ptilocaulin (32)
and (+)-8-hydroxyptilocaulin (34) displayed cytotoxicity with IC50 values ranging from 5.8–40.0 and
7.9–61.5 μM respectively. However, the other compounds 31, 35 and 36 exhibited no activity. Additionally,
compounds 32 and 34 were tested for their hemolytic activity against potential damage of mouse
erythrocytes plasma membrane, where they displayed effective concentrations with EC50 values of 577.95
and 352.91 μM respectively [50]. Further anti-parasitic tricyclic guanidine alkaloid arbusculidine A (37)
was reported recently from Monanchora arbuscula [43] (Figure 3).
62
Nutrients 2018, 10, 33
 
Figure 3. Isolated tricyclic guanidine alkaloids 28–37.
2.4. Tricyclic Pyrroloquinoline Alkaloids
Seven highly functionalized pyrroloquinoline alkaloids including three compounds named
batzellines A–C (38–40) and four compounds named isobatzellines A–D (41–44) were isolated from the
deep-water Bahama’s sponge Batzella sp. The isobatzellines A–D (41–44) showed in vitro cytotoxicity
against P388 leukemia cell with IC50 values 0.42, 2.6, 12.6 and 20 μM and moderate antifungal activity
against Candida albicans with IC50 3.1, 25, 50 and 25 μM respectively [7,51,52]. Further brominated
compounds incorporating the pyrroloiminoquinone moiety, trivially named discorhabdins P, S, T and
U (45–48) were obtained from a deep-water marine sponge of the genus Batzella. Discorhabdin P (45)
inhibited CaN and CPP32 with IC50 values of 0.55 and 0.37 μM respectively. It also showed in vitro
cytotoxicity against the cultured murine P-388 tumor cell line and human lung carcinoma A-549 cell
line, with IC50 values of 0.025 and 0.41 μM, respectively [53]. Compounds 46–48 displayed in vitro
cytotoxicity against cultured murine P-388 tumor cells, with IC50 values of 3.08, >5 and 0.17 μM,
respectively. Further cytotoxicity was also observed for A-549 human lung adeno-carcinoma cells,
with IC50 values of >5, >5 and 0.17 μM and for PANC-1 human pancreatic cells with IC50 values of 2.6,
0.7 and 0.069 μM, respectively [54]. A comprehensive review on their therapeutic applications has been
reported [55]. Additionally, secobatzellines A–B (49–50), two simple pyrroloiminoquinone enzyme
inhibitors were recorded from a deep-water marine sponge of the genus Batzella. Secobatzelline B (50) is
an artifact compound that was obtained during the purification process. Secobatzelline A (49) inhibited
calcineurin (CaN) and CPP32 with IC50 values of 0.55 and 0.02 μM. Moreover, secobatzelline B (50)
inhibited calcineurin (CaN) IC50 values of 2.21 μM. Furthermore, compounds 49 and 50 displayed
cytotoxicity in vitro against the cultured murine P-388 tumor cell line, with IC50 values 0.06, 1.22 μM
and against human lung carcinoma A-549 cell line, with IC50 values of 0.04, 2.86 μM [56]. A huge
number of synthetic aminoiminoquinone and aminoquinones analogues were prepared and tested
as capase inhibitors [57]. Furthermore, a comprehensive evaluation for the cytotoxic activity of
compounds 38–39, 41–44 and 49–50 were determined against four different pancreatic cell lines
Panc-1, AsPC-1, BxPC-3 and MIA-PaCa2 as well as in the Vero cell line, an epithelial cell line from the
kidney tissue of an African green monkey [58] (Figure 4).
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Figure 4. Isolated pyrroloquinoline alkaloids 38–50 from Batzella sp.
2.5. Polycyclic Alkaloids Bearing Batzelladine
Batzelladines represent a distinct class of particular guanidine-derived alkaloids that usually
contain two main guanidinic moieties. Chemically, they are esters compounds that bear a principle
tricyclic ring system named clathriadic acid that acting as an acidic portion bonded to another
clathriadic acid molecule or crambescin A bicyclic system as an alcoholic part. Such a unique
class of marine alkaloids is assumed to be synthesized biomimetically from different modes of
cyclization between a polyketide-derived chain and a putative guanidine precursor affording
these structurally complex metabolites [59]. These natural compounds are known for their
potent bioactivities [13,14]. A considerable number of bioactive batzelladines were recorded from
Batzella sponges. Batzelladines A–E (51–55), five potential inhibitors of HIV gpl20-human CD4
binding were recorded from the Caribbean sponge Batzella sp. [13,14]. Batzelladines F–I (56–59),
four inducers of p56lck-CD4 dissociation, were isolated from Batzella sp. collected from Jamaica [60].
Batzelladine J (60) was isolated from the Caribbean Monanchora unguifera [61]. A further six
guanidines—including batzelladines K–N (61–64), batzelladine C (53) and dehydrobatzelladine
C (65)—were discovered from Jamaican Monanchora unguifera with activities against several
cancer cell lines, protozoa, HIV-1 and AIDS [14,62,63]. Batzelladine C (53) displayed anti-HIV-1
activity at an EC50 of 7.7 μM [63]. Four batzelladines 66–69 containing crambescin A bicyclic
system in addition to dihomodehydrobatzelladine (70) were reported from the Caribbean
Monanchora arbuscula. These compounds displayed mild antitumor activity with GI50 (3–7 μM)
against three cancer cell lines, lung carcinoma A549, colon carcinoma HT-29 and breast MDA-MB-231,
in addition to antimalarial activity against protozoa [64]. Norbatzelladine L (71) was isolated from
unidentified species, Monanchora sp. that displayed MNTC (maximum non-toxic concentration) at
2.5 μg mL−1 against HSV-1, with 97% of inhibition in the viral adsorption phase. Furthermore,
it displayed cytotoxicity against several human cancer cell lines including leukemia, colorectal,
breast, melanoma and glioblastoma [65,66]. Two anti-infective tricyclic members with unique
stereochemical features—named merobatzelladines A–B (72–73)—were isolated from Monanchora sp.
Merobatzelladines A–B exhibited moderate antimicrobial activity against Vibrio anguillarum with
inhibitory zones of 9–10 mm on application of 50 μg of a sample to a paper disk of 6 mm diameter.
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Moreover, 72–73 also inhibited Tripanosoma bruceibrucei (GUT at 3.1) with IC50 = 0.24 μg mL−1 each.
Furthermore, they display moderate inhibitory activity against the K1 strain of Plasmodium falciparum
with an IC50 = 0.48 μM and 0.97 μM, respectively [67]. Four anti-parasitic batzelladines (74–77) against
Trypanosoma cruzi and Leishmania infantum were recently recorded from Monanchora arbuscula [43,68].
Numerous synthetic batzelladines and their derivatives showed potent activities against HIV-1
and AIDS opportunistic infectious pathogens, inhibition of HIV-1 envelope-mediated fusion [69],
inhibitors of HIV-1 Nef interactions with p53, actin and p56lck [70], antimalarial, antileishmanial,
antimicrobial and antiviral (HIV-1) activities [71], inhibitors against HIV-1 reverse transcriptase




Figure 5. Isolated batzelladine alkaloids 51–64.
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Figure 6. Isolated batzelladine alkaloids 65–77.
2.6. Pentacyclic Alkaloids Bearing Crambescidin
Crambescidines are pentacyclic guanidine-derived alkaloids that represent recognizable complex
marine metabolites. Chemically, they bear a common core of (5,6,8b)-triazaperhydroacenaphthalene
in their molecules (trivially named as vessel) that coupled with a linear ω-hydroxy fatty acid
(spermidine or hydroxyspermidine). These compounds vary from one to another in the length
of the internal polymethylene chain and the oxidation degree of the two-spiro rings within the
pentacyclic core. This group of compounds covers the major secondary metabolites recorded from
these three genera. Since the discovery of the parent antiviral and cytotoxic marine metabolite
ptilomycalin A (78) by Kashman and co-workers [74] from Ptilocaulis spiculifer (family Axinellidae) and
Hemimycale sp. (family Hymedesmiidae) collected from the Red Sea coast in 1989, renewable efforts
led to the discovery of further crambescidin analogues. Crambescidin 800 (79), crambescidin 816
(80), crambescidin 830 (81) and crambescidin 844 (82) were recorded from the Mediterranean marine
sponge Crambe crambe [75]. These compounds demonstrated antiviral and cytotoxic activity against
Herpes simplex virus, type1 (HSV-l) and cytotoxic activity against L1210 murine leukemia cells.
Compounds 79, 80 and 82 showed complete inhibition for HSV-l and 98% of L1210 cell growth at
concentration of IC50 = 0.1 μM. Furthermore, crambescidin 816 (80) displayed potent Ca2+ antagonist
activity and inhibited the acetylcholine-induced contraction of guinea pig ileum within very low
concentrations [17], however, recent novel evidence showed that compound 80 partially blocked CaV
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and NaV channels in neurons, proposes that this compound might be included in decreasing the
neurotransmitter release and synaptic transmission within the central nervous system [76]. Further,
recent study proved that crambescidin 816 (80) could be stored into specialized sponge cells where
it can be dispersed into the water affording a chemical umbrella surrounding the Crambe crambe
sponge [77]. Recently, Botana and co-workers [78] reported important insights about the mechanism
of the neurons cytotoxic activity of crambescidin 816 (80) in primary cultures of cortical neurons.
These results showed that compound 80 is responsible for the decreasing of neuronal viability
and hence provided a dose-dependent increase in cytosolic Ca2+ level that was also linked to the
presence of Ca2+ in the extracellular media. Crambescidins 78, 79 and 80 were recorded also from
Batzella sp. [14]. 13,14,15-isocrambescidin 800 (83) with trans-ring junction within the pentacyclic
core and crambidine (84) were discovered from Crambe crambe [17,79]. Surprisingly, compound 83
was found to be a less potent cytotoxic against L1210 cells compared to other crambescidines and
there was no observed antiviral activity against HSV-1. This observation could be attributed to the
enclosed ionic pocket feature found in 78 and related crambescidins and lacking in 83 [80]. Additional
crambescidin analogues with a chlorinated spermidine motif including crambescidin 818 (85),
crambescidin 834 (86), crambescidin 673 (87), crambescidin 687 (88) and 13,14,15-isocrambescidin 657
(89) without a spermidine unit were recorded from the FABMS guided isolation of Crambe crambe
extracts. The ADMET predictor revealed that ptilomycalin and crambescidin 800 (78–79) possess three
features of the Lipinski guidelines. Additionally, 78 showed low flexibility and a low tendency to
permeate into cell membranes. However, compound 79 displayed low permeability, low flexibility
and less tendency to permeate the cell membranes [81] Compounds 87, 88 and 89 exhibited in vitro
cytotoxicity against L1210 murine leukemia five times compared to compound 80. Furthermore,
they displayed antimicrobial activity against Rhodotorula glutinis [82,83]. Crambescidin 800 (79),
crambescidin 359 (90) and crambescidin 431 (91) have been isolated from Monanchora unguiculata [62].
Crambescidin 826 (92) and fromiamycalin (93) were recorded from Monanchora sp. They inhibited
HIV-1 envelope-mediated fusion in vitro with an IC50’s = 1–3 μM [14,42]. Indeed 78, 79 and 93
displayed high cytotoxic activity against CEM 4 infected by HIV-1 with CC-50 of 0.11 μg mL−1,
without cytoprotective effects, at a dose of <0.1 μM [84]. The antifungal 78 inhibits melanogenesis of
Cryptococcus neoformans in vitro through the inhibition of the biosynthesis of laccase in the melanin
biosynthetic pathway with an IC50 value of 7.3 μM [85]. Additionally, 79 induced a morphological
change with neurite outgrowth in neuro 2A cells at concentration of 0.03–0.1 μM and recorded to
induce the differentiation of K562 chronic myelogenous leukemia (CML) cells into erythroblasts
accompanied by cell cycle arrest at the S-phase as well [86]. Further pentacyclic members were
described, including crambescidin acid (94) from Monanchora ungiculata [35] and crambescidic
acid (95) from Monanchora unguifera [61]. Crambescidin 359 (90) and 16-β-hydroxycrambescidin
359 (96) were obtained from Monanchora unguifera [63]. Ptilomycalin D (97) showed cytotoxicity
against cancer cell line P-388 with IC50 = 0.1 μM in addition to 78 and 95 were reported from
Monanchora dianchora [36]. Monanchocidins A–E (98–102) are five unusual pentacyclic guanidine
alkaloids with a morpholine modified spermidine motif from Monanchora pulchra. These compounds
exhibited potent cytotoxic activities against HL-60 human leukemia cells with IC50 values of 540, 200,
110, 830 and 650 μM respectively [37]. Monanchocidin A (97) showed anti-migratory activity against
several human cancer cell lines where it is able to prevent local expansion and metastatic spread
of cancer cells [87]. Moreover, it could be a promising new compound for overcoming resistance
to standard therapies in genitourinary malignancies by the induction of autophagy and lysosomal
membrane permeabilization [88]. Monanchomycalins A–B (103–104), two pentacyclic with a modified
spiro five-membered ring, showed potent cytotoxicity against HL-60 human leukemia cells with
the IC50 values 120 and 140 nM, respectively, were isolated from Monanchora pulchra [89]. Recently,
compound 104 was recorded to inhibit of the TRPV1, TRPV2 and TRPV3 channels with EC50 values
6.02, 2.84 and 3.25 μM, respectively, however it displayed no activity against the TRPA1 receptor [90].
Moreover, monanchomycalin C (105) exhibited cytotoxicity against human breast cancer cell lines
67
Nutrients 2018, 10, 33
MAD-MB-231 with an IC50 of 8.2 μM, isolated from Monanchora pulchra [91]. Normonanchocidins A–B
and D (106–108) were isolated from Monanchora pulchra. Compound 106 and a mixture of 107
and 108 (1:1) displayed cytotoxic activities against human leukemia THP-1 cells with IC50 values
of 2.1 μM and 3.7 μM and against cervix epithelial carcinoma HeLa cells with IC50 of 3.8 μM
and 6.8 μM, respectively [92]. Recently, further three cytotoxic pentacyclic guanidine compounds
including crambescidin 786 (109), crambescidin 814 (110) and 20-norcrambescidic acid (111) along with
pentacyclic analogues 79, 90, 92 and 95 were isolated from a French Polynesian sponge Monanchora n. sp.
The isolated compounds showed potent antiproliferative and cytotoxic activities against KB, HCT-116,
HL-60, MRC-5 and B16-F10 cancer cells. Compounds 109, 110 and 111 exhibited cytotoxicity against
KB cell lines with an IC50 values 0.3 μM, 5 nM and 0.5 μM, respectively. The two crambescidin
95 and 111 where the (anchor) motif is terminated with the carboxylic acid functionality displayed
potent cytotoxic activity against KB cell lines with IC50 = 0.55 μM, however, they still less active
compared with analogues possessing spermidine terminus. Furthermore, crambescidin 800 (79)
exhibited the highest cytotoxic activity, while shorter pentacyclic homologue 109 along with the longer
one 110 were found less active. These observations might highlight the impact of the polymethylene
chain length within the (anchor) motif as a spacer for two site interactions. Crambescidin 359 (90),
possessing only a pentacyclic core, showed no activity against KB cell lines and this correlates with
the importance of the spermidine part for cytotoxicity. Regarding the B16-F10 murine melanoma
cells, crambescidins 79, 92 and 110 exhibited moderate activity with IC50 values of 0.2, 0.8 and 0.2 μM
respectively. The discovery of 20-norcrambescidic acid (111) with this new pentacyclic motif carries
some biogenesis impacts and raises some important insights about the variation in the oxidation
degree and the mode of cyclization within the pentacyclic core [39]. A further two new hybrid
pentacyclic guanidines monanchoxymycalin A–B (112–113) were obtained from the Far-Eastern marine
sponge Monanchora pulchra. They displayed cytotoxic activities against cervical epithelioid carcinoma
HeLa cells and breast adenocarcinoma MDA-MB231 cells [93]. Additionally, ptilomycalins E–H
(114–117)—with guanidinic modified spermidine—were recorded from the Madagascar marine sponge
Monanchora unguiculata. They displayed promising antimalarial activity against Plasmodium falciparum
with IC50 values 0.38, 0.30 and 0.27 μM respectively [94,95] (Figures 7 and 8).
 
Figure 7. Isolated pentacyclic crambescidin alkaloids 78–89.
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Figure 8. Isolated pentacyclic crambescidin alkaloids 90–117.
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2.7. Acyclic Guanidine Alkaloids
Small number of open chain guanidine-derived alkaloids was recorded. Pulchranin A (118),
was described as the first marine non-peptide inhibitor of TRPV-1 channels with an EC50 value
41.2 μM, in addition two other acyclic members pulchranins B–C (119–120) reported from the
Far-Eastern marine sponge Monanchora pulchra. Compounds 119 and 120 exhibited moderate
inhibition against TRPV1 with EC50 value 95 and 183 μM respectively and were even less potent
against TRPV3 and TRPA1 receptors [96,97]. Moreover, two synthetic derivatives—dihydropulchranin
A (121) and hexadecylguanidine (122)—were prepared and studied for their TRPV channel-regulating
activities. Compound 121 showed activity as an inhibitor of rTRPV1 and hTRPV3 receptors
with EC50 values of 24.3 and 59.1 μM, respectively, while compound 122 was found not active
against those receptors [98]. Additionally, recent studies revealed that pulchranin A (118) exhibited
cytotoxic properties and prevented EGF-induced neoplastic transformation in vitro [99]. Further,
acyclic analogue unguiculin A (123) with a modified bis-guanidine spermidine motif was
isolated from the Madagascar marine sponge Monanchora unguiculata. It displayed antimalarial
activity against the parasite Plasmodium falciparum with IC50 value of 6.04 μM [94,95]. Recently,
a further two acyclic bis-guanidine alkaloids—named unguiculins B-C (124–125), beside unguiculin
A (123)—were discovered from the French Polynesian Monanchora n. sp. sponge. These compounds
displayed potent cytotoxic activity against KB cell lines with IC50 values 0.19/0.22, 0.08/0.09 and
0.03/0.03 μM respectively. Such activity might be attributed to the two terminal guanidines ends.
Moreover, unguiculin C (125), the shorter homologue was found the most active. This could be
concluded of how the chain and its length can play an important role as a spacer between two sites of
interaction. Moreover, unguiculin B (124) showed further cytotoxicity against HCT-116, HL-60 and
MRC-5 cell lines with IC50 values 3.6/3.6, >10/>10 and 9.6/11.4 μM respectively [100,101] (Figure 9).
 
Figure 9. Isolated acyclic guanidine alkaloids 118–125.
2.8. Terpenoid Compounds
Marine sponges belong to Monanchora genus have also produced a small number of terpenoid
metabolites and classical sterols [102]. Nine sesterterpenoids 126–134 were isolated from the Korean
Monanchora sp. along with four phorbaketals 135–138. These compounds were investigated for their
cytotoxic activity against four human cancer cell lines—A498, ACHN, MIA-paca and PANC-1—where
some of them showed potent cytotoxicity [103]. Seven cytotoxic 5α,8α-epidioxy sterols 139–145 were
also described from Monanchora sp. These sterols showed moderate cytotoxicity against several human
carcinoma cell lines including renal (A-498), pancreatic (PANC-1 and MIAPaCa-2) and colorectal
(HCY-116) cancer cell lines [104]. Monanchosterols A–B (146–147) were identified from a South Korean
Monanchora sp. and described as the first examples of naturally occurring steroids bearing a rearranged
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bicyclo [4.3.1] A/B ring system. Moreover, Monanchosterols A–B (146–147) exhibited significant
inhibition of mRNA expression of Il-60 without notable cytotoxicity to the cells in a dose-dependent
manner [105] (Figure 10).
 
Figure 10. Isolated terpenoid and steroidal metabolites 126–147 isolated from Monanchora sp.
3. Biomimetic Landmarks of Polycyclic Guanidinium Motifs
The bio-mechanistic studies along with the structural analyses for the different polycyclic
guanidine alkaloids revealed two important insights; the first is chemical; where they are sharing the
same biogenesis routs. A second is ecological; where marine sponges that produced such metabolites
could be systematically classified under the same order. Generally, the different polycyclic guanidinic
moieties could be biomimetically synthesized by way of the double aza Michael strategy, by the
addition of free guanidine to α, β unsaturated polyketide chains (Figure 11) [59].
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Figure 11. Structural analysis of different polycyclic guanidine alkaloids.
3.1. Bicyclic Compounds Possessing Crambescins Type A, B and C
Snider and his team had several contributions towards the biomimetic synthesis of the
polycyclic guanidinic motifs. The bicyclic crambescin alkaloids possess three different cyclic
moieties—crambescin type A with tetrahydropyrrolo [1,2-c] pyrimidine nucleus, crambescin type B
possesses an oxa-6,8-diazaspiro [4.5] motif, while crambescin type C displays a tetrahydropyrimidin
fragment. Crambescins type B and C were isolated exclusively from the Mediterranean marine sponge
Crambe crambe [34,40,41]. A postulated strategy showed that these three guanidinium cores could
be constructed biomimetically through a conjugated Michael addition of guanidine to enone ester.
This strategy seems pertinent since it gathers the formation of three different atom arrangements from
one unified precursor (Figure 12) [106].
 
Figure 12. Proposed retrosynthetic analysis of the bicyclic alkaloids.
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The less basic O-methylisourea was chosen as guanidine precursor instead of free guanidines.
The condensation of O-methylisourea with previously prepared enone (148) followed by acid
hydrolysis and desilylation afforded the corresponding dihydropyrimidine intermediate (149).
In presence of methanolic ammonium acetate saturated with ammonia, 150 afforded the key compound
150, corresponding to crambescin type C. Subsequently, 150 was transformed to compound 151,
corresponding to crambescin type A by mesylation, hydrogenolysis and cyclization. Compound 152
possesses crambescin type B was obtained by cyclization of 150 under basic condition (Figure 13) [106].
 
Figure 13. a: 2 equiv. O-methylisourea and 7 equiv. NaHCO3 in DMF for 12 h at 60 ◦C, 79%;
b: hydrolysis, TBAF, THF, 12 h, rt, 90%; c: NH4OAc (1.5 equiv.), MeOH saturated with NH3 at 60 ◦C
for 2 days, 61%; d: MsCl, Et3N in DCM for 30 min, 0 ◦C, 6 h, rt; e: Et3N in CHCl3, reflux, 12 h, 90%;
f: Et3N in CHCl3, Δ, 12 h.
Based on the previous biomimetic approach, Berlinck and co-workers [43] accomplished the
biomimetic synthesis of the cytotoxic and anti-parasitic monalidine A (18). 1,3-diketone 153 was
introduced for condensation with guanidine free base to afford the corresponding pyrimidine 154
in 25% yield. Subsequently, the key intermediate 152 was cyclized using the Mitsunobu modified
protocol to afford 18 as hydrochloride salt in a 67% yield (Figure 14).
Figure 14. a: Guanidine hydrochloride, t-BuOK, CF3CH2OH, 30 min, then 154, rt, 48 h, 25%; b: Ph3P,
imidazole, I2, CH2Cl2, −18 ◦C, 6 h, 67%.
3.2. Tricyclic Possessing Ptilocaulin/Batzelladine
(±)-Ptilocaulin (32) was first synthesized biomimetically as a racemic mixture via Michael addition
strategy by addition of free guanidine to enone 155 followed by intramolecular enamine formation.
(−)-Ptilocaulin (156) was formed as a kinetic product where the guanidine was added to the less
hindered top convex face of enone 155, whereas (+)-ptilocaulin (32) was obtained as a thermodynamic
adduct as the guanidine was added to the more hindered bottom side of enone 155. This strategy
highlights and proves a unique unified biosynthetic route for ptilocaulins and related tricyclic
guanidinic analogues (Figure 15) [107–109].
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Figure 15. a: Guanidine, PH, reflux 25 h, then HNO3 (1% aq), 35%.
The tricyclic guanidinium framework of batzelladine K (61) was biomimetically synthesized
through the addition of free guanidine to a bis-enone 157 affording the pyrrolidine-dione 158, which was
subsequently introduced to cyclization followed by iminium ion formation giving rise to the full fused
tricyclic guanidinium core. A subsequent reduction afforded 61. A unified synthetic strategy was
applied to ptilocaulin (32), isoptilocaulin (33) and batzelladine K (61), which indicated that these
classes of tricyclic guanidines are subjected to the same biomimetic gate (Figure 16) [71,110,111].
 
Figure 16. a: Guanidine, DMF, 0 ◦C, then 25 ◦C, 5 h b: 0 ◦C, MeOH-H2O (2:1), NaBH4 (6 equiv.), 25 ◦C,
16 h, 25%.
3.3. Pentacyclic Possessing Ptilomycalins, Crambescidins and Monanchomycalins
Numerous total syntheses of the pentacyclic guanidinium core of ptilomycalin A (78),
crambescidin 800 (79) and crambescidin 359 (95) were biomimetically achieved [23,112,113].
A biomimetic synthesis of the methyl ester of the pentacyclic nucleus of 78 was conducted through
a conjugated condensation of O-methylisourea as protected guanidine strategy with double Michael
acceptor bis-enone 159 as α-β unsaturated polyketide framework. Subsequently, desilylation under
acidic conditions provided the first seven-membered spiroaminal ring within the intermediate 160.
Later, the second six-membered spiroaminal ring was achieved under basic conditions followed by
subsequently aminal formation affording the ptilomycalin A pentacyclic framework 161 (vessel) in one
single biomimetic step (Figure 17).
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Figure 17. a: O-methylisourea, i-Pr2EtN, DMSO, 80 ◦C, 1.5 h (52%, 4:l, H10, H13 trans: H10, H13 cis);
b: NH3, NH4OAc, t-BuOH, 60 ◦C, 40 h (72%, 1:1, H10, H13 cis β: H10, H13 cis α); c: 3:7 HF-CH3CN,
−30 ◦C, 3d; d: Et3N, MeOH, 60 ◦C, 20 h (78%).
Recently, a detailed biomimetic gate was proposed illustrating the biogenesis of different pentacyclic
guanidinium cores. The pentacyclic core of monanchomycalin A (103), suggests polyketide-like
biogenesis, followed by spermidine-spermidine condensations. Two different precursors were employed,
including either nine acetate units as in monanchomycalin B (104) and other known pentacyclic members,
or ten acetate and one propionate units as in monanchomycalin A (103). To finish the pentacyclic
guanidinium polyketide framework (vessel), a cyclization key-step developed by adding guanidine to bis-α,
β unsaturated chain followed by imine-enamine tautomerization (transformation (a)). Further conversions
including the allylic oxidation (transformation (b)) to afford putative intermediates (III and/or IV)
followed by cyclization-elimination (c) and (d) to generate monanchomycalins A–B (103–104) and related
pentacyclic analogues. Moreover, the interconversion of the presumptive intermediates III and IV
(transformation (e)) through allylic rearrangement like reactions also might be possible (Figure 18) [89].
 
Figure 18. Proposed conversions (a–e) and hypothetical biogenesis of different pentacyclic
guanidine alkaloids.
Recently, Guzii and collaborators [96] proposed biogenetic correlations linking between the acyclic
guanidine alkaloid pulchranin A (118) and the pentacyclic crambescidins and monanchomycalins
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A–B (103–104). This proposed biogenetic rout could unify the variation in the oxidation degree for the
left-hand side spiroaminal rings (Figure 19).
 
Figure 19. Pulchranin A (118), as a biosynthetic precursor for pentacyclic compounds (103–104).
4. Conclusions
In conclusion, we have presented complete and comprehensive up-to date literature survey
exclusively dedicated to the chemistry, biology and insights on the most leading biomimetic syntheses
of guanidine derived natural products isolated from marine sponges of three genera Batzella,
Crambe and Monanchora. One hundred forty-seven marine natural products were recorded with distinct
structural diversities that afforded wide scope of bioactivities. For their chemodiversity, along with
their displayed biological potentialities, they still present promising and attractive marine species that
are worth attracting the worldwide interest of natural products chemists and pharmacologists.
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Abstract: Cancer is caused by uncontrolled cell proliferation which has the potential to occur in
different tissues and spread into surrounding and distant tissues. Despite the current advances in the
field of anticancer agents, rapidly developing resistance against different chemotherapeutic drugs and
significantly higher off-target effects cause millions of deaths every year. Osthol is a natural coumarin
isolated from Apiaceaous plants which has demonstrated several pharmacological effects, such as
antineoplastic, anti-inflammatory and antioxidant properties. We have attempted to summarize
up-to-date information related to pharmacological effects and molecular mechanisms of osthol as
a lead compound in managing malignancies. Electronic databases, including PubMed, Cochrane
library, ScienceDirect and Scopus were searched for in vitro, in vivo and clinical studies on anticancer
effects of osthol. Osthol exerts remarkable anticancer properties by suppressing cancer cell growth
and induction of apoptosis. Osthol’s protective and therapeutic effects have been observed in different
cancers, including ovarian, cervical, colon and prostate cancers as well as chronic myeloid leukemia,
lung adenocarcinoma, glioma, hepatocellular, glioblastoma, renal and invasive mammary carcinoma.
A large body of evidence demonstrates that osthol regulates apoptosis, proliferation and invasion
in different types of malignant cells which are mediated by multiple signal transduction cascades.
In this review, we set spotlights on various pathways which are targeted by osthol in different cancers
to inhibit cancer development and progression.
Keywords: osthol; cancer; phytochemicals; natural product; malignancies; apoptosis
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1. Introduction
Cancer is a multifaceted and therapeutically challenging disease and rapidly emerging pre-clinical
and clinical studies have started to shed light on the molecular mechanisms which underlie cancer
development and progression [1]. Based on the United States National Cancer Institute’s categorization,
diverse types of cancer include myeloma, carcinoma, leukemia, lymphoma and central nervous system
cancer depending on cell type involved [2].
In the next couple of decades, the prevalence of cancer is predicted to rise to 70%, amounting to
22 million cases. The most common sites of cancer diagnosed in 2012 were lung, breast, prostate, colon,
stomach, cervix and liver carcinomas. One-third of cancer deaths can be attributed to five life style and
nutritive factors, such as overweight, low fresh and fiber food intake, absence of physical activity as
well as tobacco and alcohol use [1]. Moreover, malignancies affect the psychological well-being (e.g.,
depression, anxiety, distress and somatization) of patients and their caregivers [3].
The goals of cancer treatment are to destroy tumors or to markedly prolong survival and improve
a patient’s quality of life [1]. Deregulations in spatio-temporally controlled signaling mechanisms,
including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [4], activator protein-1
(Ap-1) [4,5] and mitogen-activated protein kinase (MAPK) signaling pathways, played contributory
role in carcinogenesis and drug resistance [6–8]. Additionally, microtubules have been targeted to
disrupt the normal function of the mitotic spindle [9]. Although chemotherapy and radiotherapy are
greatly efficient approaches in the treatment of cancer, malignant cells continue to develop resistance
to these treatments [4].
Natural products, containing bioactive secondary metabolites, have beneficial effects on human
health [10,11] and the active ingredients are strong candidates to be lead compounds for the
development of new drugs [12]. From 1930 to 2012, 183 drugs were approved as antitumor agents;
30% of these were obtained from natural sources, 57% were natural agents with semisynthetic
modifications and 34% had natural product mimetic pharmacophores [13]. Although targeted
therapies, such as monoclonal antibodies, have greatly improved, the perfect treatment of several
cancers, such as leukemia, gastrointestinal and breast cancers, remain to be achieved through new
therapies [10]. Natural products exert anticancer effects through various mechanisms such as
alteration of cell cycle [4,14] interference with microtubules [15], topoisomerase inhibitory activities [16],
immunomodulatory effects [17] and chemopreventive effects [18] achieved by modulation of various
oncogenic signaling molecules and pathways [19–21].
Coumarins are derivatives of 2H-1-benzopyran-2-one which can be obtained mainly from
cyclization of a C-2 oxygenated cis-cinnamic acid. These compounds are widely found in plants
in the form of free coumarins or their glycosides [22]. Coumarins naturally occurr with several
molecular structures, especially in the Apiaceae [23,24] and Rutaceae families, as well as many other
plant families, including Asteraceae, Poaceae and Rubiaceae [22]. Coumarins have various biological
properties related to their chemical structure [25–27]. Some coumarins have vasorelaxant activity
in coronary vessels and some other showed hypotensive [22], antiviral [28], antileishmanial [29]
anti-inflammatory [30] and antispasmodic [31] effects. Furanocoumarins are also widely used in the
treatment of leucoderma and psoriasis due to their photosensitivity properties [32,33]. Some hydroxy-
and methoxy-coumarins are able to absorb ultraviolet radiation and are commonly used in sunblock
creams [22].
Coumarins have prominent anticancer properties with low adverse effects based on the functional
groups in the original structure [34,35]. They can affect different cellular pathways, including
suppression of angiogenesis, several types of heat shock proteins (HSPs) and cell proliferation as well
as inhibition of the enzymes chiefly involved in the pathophysiology of cancer, such as telomerase,
monocarboxylate transporters, carbonic anhydrase, aromatase and sulfatase [35,36].
Osthol (osthole), 7-methoxy-8-(3-methyl-2-butenyl)-2H-1-benzopyran-2-one, a natural coumarin
obtained from Cnidium spp. and other Apiaceous plants [37], has been found to exert health-promoting
effects [38]. Cnidium monnieri fruits rich in osthol are popularly used in traditional Chinese medicine [39].
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Osthol is a prenylated coumarin with a wide range of pharmacological effects, such as neuroprotective [40],
spasmolytic [41] immunomodulatory [42], osteogenic [43], hepatoprotective [44], vasorelaxant [45],
antimicrobial [45], antiviral [46] and antileishmanial properties [47], many of which could be implicated in
the primary or secondary prevention of cancer. In this review, we aim to provide a critical and mechanistic
insight into the biological and pharmacological properties of osthol that are useful in the treatment of cancer.
2. Literature Search Methodology
Electronically available databases, including PubMed, Science Direct, Cochrane library and
Scopus, were searched for cellular, animal or human studies which assessed the anticancer effects
of osthol. We have followed the preferred reporting items for systematic review and meta-analysis
(PRISMA) criteria which are preferred for reporting systematic reviews. Relevant and high-quality
publications were collected for the years 1966–2017 (up to January). Unpublished results were not
included. Only English language papers were included in this review. The search terms were “osthol”
or “osthole” in title and abstract. Results from primary search were screened by two independent
investigators. Included articles were checked for verification of scientific name of source plant,
the dose of administration, type of cancer as well as type of cell line for cellular studies and the animal
model for animal studies. Results were reviewed for significant effects on proliferation, apoptosis,
pro-inflammatory cytokines, oxidative markers, antioxidant enzymes and tissue damage biomarkers.
From total 1354 results, 676 reports were excluded because of duplication and 17 were omitted as
they were review papers. Additionally, two were ruled out since they were not in English and 31 were
excluded because the subject was on other compounds rather than osthol. Among 628 retrieved
studies, 355 were excluded out as they were analytical and phytochemical aspects of osthol rather
than pharmacological effects; 273 reports on pharmacological effects of osthol were retrieved amongst
which 248 were omitted since they assessed pharmacological effects of osthol other than anticancer
properties. Twenty five reports including one in vivo and 24 in vitro studies were finally included.
Figure 1 shows a flow diagram of the selective procedure for literature included in this review.
 
Figure 1. Study selection diagram.
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3. Cellular and Molecular Mechanisms of Anticancer Effects of Osthol
A comprehensive review of the reported literature on anticancer activity of osthol indicated that
this therapeutic agent could potentially exert anticancer and antitumor activity via several mechanisms,
including cell cycle inhibition, apoptosis induction, anti-angiogenesis, inhibition of metastasis, and
suppression of cell proliferation and cell migration (Figure 2). Based on the type of cancer, the effective
dose and the mechanism of action could be different. A detailed data on the anticancer mechanism of
osthol is presented below and Table 1.
Figure 2. Molecular mechanisms underlying anticancer effect of osthol. EGFR, epidermal growth
factor receptor; Akt, AKR mouse thymoma kinase; MAPK, mitogen-activated protein kinase; RNA,
ribonucleic acid; MMP, matrix metalloprotease; HGF, hepatocyte growth factor; TGF, tumor growth
factor; NF-κB, nuclear factor-κB.
Table 1. Pharmacological mechanisms of osthol involved in its anticancer activities.




Colon 1, 3 & 10 mM In vitro(HCT116 & SW480 cells)
↓Cell motility; ↑apoptosis;
↑phosphorylation of p53 on
Ser15 (p-p53); ↑acetylation of
p53; ↑ROS; ↑JNK
[48]
Prostate 100 mM In vitro(PC3 cells)
↑Apoptosis; ↓Bcl-; ↑Bax;
↑Smac/DIABLO [49]











MDA-MB-231 & BT-20 cells)
↓c-Met signaling; ↓FASN;
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Table 1. Cont.





















Breast 20–90 mM In vitro(MDA-231BO cells)
↓Cell viability; ↓proliferation;
↑apoptosis; ↓TGF-β/Smads [54]
Brain 50, 100 & 200 mM In vitro(U87 cells)
↓proliferation;
↑apoptosis; ↑miR16; ↓MMP9 [55]
Brain 25, 50 & 100 mM In vitro(Rat glioma cells)
↓Proliferation;
↓PI3K/Akt/MAPK [56]
Brain 10–100 mM In vitro(GBM8401 cells)
↓EMT; ↓Akt and GSK3β;
↓Snail; ↓Twist; ↓I3K/Akt [57]
Brain 100 mM In vitro(SKNMC cells)
↑Apoptosis by ↑Bcl; ↑Bax;
↑Smac/DIABLO [49]
Lung 50, 100 & 150 mM In vitro(A549 cells)
↑G2/M arrest; ↑apoptosis;




Lung 20, 40, 60 mM80 mM
In vitro
(A549 cells) ↓MMP-2; ↓MMP-9 [58]






Lung 100 mM In vitro(H1299 cells)
↑Apoptosis; ↓Bcl; ↑Bax;
↑Smac/DIABLO [49]
Leukemia 5 mM 15 mM In vitro(K562/ADM cells)
↓MDR in myelogenous
leukemia [60]
Leukemia 30 mg/kg for 8 days
In vivo
(CDF1 female mice
transplanted with P-388 D1
cells)
↑Apoptosis; ↓P-388 D1 cells [61]
Cervix 77.96 mM64.94 mM
In vitro
(HeLa cells) ↑Apoptosis [61]
Ovary 20, 40, 80, 120, 160and 200
In vitro
(A2780 & OV2008 cells)
↓Cells proliferation;
↑apoptosis [62]
Ovary 5, 10, 24, 40 mM80 mM
In vitro





















Arrows (↑ and ↓) show increase and decrease in the obtained variables, respectively. H1299, human non-small cell
lung carcinoma; GSK3β, glycogen synthase kinase 3-β; EMT, epithelial-mesenchymal transition; Akt, AKR mouse
thymoma kinase; PI3K, phosphatidylinositol-3-kinase; IGF, insulin-like growth factor; EGFR, epidermal growth
factor receptor; COX-2, cyclooxygenase 2; TPK, tyrosine protein kinase; VEGF, vascular endothelial growth factor;
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; MAPK, mitogen-activated protein kinase;
ROS, reactive oxygen species; JNK, c-Jun N-terminal kinase; c-MET, cellular mesenchymal to epithelial transition
factor; mTOR, mammalian target of rapamycin; MDR, multiple drug resistance; Bax: BCL2-Associated X Protein;
TGFβRII, transforming growth factor-β receptor, type II; GMP, guanosine monophosphate.
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3.1. Colon Cancer
Epidemiological and scientific studies have considerably enhanced our understanding of the
evolutionary process underpinning colon cancer development and progression. Metastasis of primary
tumors affects the survival of patients [65]. In a study conducted by Huang et al. [48] using HCT116 and
SW480 human colon cancer cell lines, osthol demonstrated specific antitumor effect with concentrations
of 1, 3 and 10 μM (Table 1). Osthol significantly decreased cell motility in both cell lines through
activation of pro-apoptotic signaling pathways and up-regulation of p53 expression; p53 protein has
a main role in the regulation of several genes involved in growth inhibition process, apoptosis, cell cycle
arrest as well as DNA repair [66]. Apoptosis-induction capacity has been accepted as a mechanism
of action for the antitumor drugs [12]; therefore, considerable effort is being directed towards the
development of potential medicines that induce apoptosis in tumor cells.
Apoptosis can occur in two main pathways: the mitochondrial (intrinsic) pathway and the death
receptor (extrinsic) pathway [67]. In the intrinsic pathway, the mitochondria have a principle role. It is
characterized by cytochrome c release from the mitochondrial which activates a family of cysteine
protease enzymes, caspases. This process is controlled by the Bcl-2 family of proteins. This family is
an essential member of the programmed cell death process, acting to either inhibit (Bcl-2 and Bcl-xl)
or promote (Bax and Bcl-xS) cell death [68]. The elevation of the Bax/Bcl-2 ratio, which has a pivotal
contribution in apoptosis, is considered as one of the important mechanisms of osthol in the induction of
apoptosis and disturbance in permeability of mitochondrial membranes in cancer cells. Osthol exerted
apoptotic effect on colon cancer cell line via several mechanisms, including enhancement of the p53
phosphorylation on Ser15 (p-p53) and p53 acetylation on Lys379 (acetylp53). The p53 protein, acting as
a tumor suppressor, plays key roles in activating apoptosis through sensing both intrinsic and extrinsic
stresses [69]. Moreover, p53 protein has a significant participation in the regulation of cell cycle arrest,
and DNA repair, activating c-Jun N-terminal kinase (JNK) pathway, generation of ROS, modulating
PI3K/Akt signaling pathway as well as promoting G2/M arrest. Another mechanism which is
involved in pro-apoptotic activity of osthol is p53-independent apoptosis process via stimulating JNK
and reactive oxygen species (ROS) formation as summarized in Figure 2 [48].
3.2. Prostate Cancer
Genome sequencing and gene expression analyses have highlighted essential roles of epigenetic
and genetic changes in prostate carcinogenesis. Almost all prostate cancers are adenocarcinomas.
Mounting evidences have suggested that prostate cancer is found more often in African-American
men in comparison to white men [70]. In a cellular study performed by Shokoohinia et al. [18],
potential anticancer effect of osthol was assessed on PC3 human prostate cancer cell line. Results of this
investigation suggested that osthol acts as a powerful cytotoxic agent against PC3 cells. Caspase
activation through intrinsic or extrinsic pathway was significantly involved in the induction of
apoptotic cell death. Osthol could remarkably boost the expression of caspase-9 and caspase-3 in
PC3 cells. This natural coumarin also activated apoptosis by down-regulation of the antiapoptotic
agent, Bcl-2, and up-regulation of the proapoptotic gene Bax (BCL2-Associated X Protein) as well as
Smac/DIABLO, a mitochondrial protein released in response to apoptosis stimuli and suppresses the
activity apoptosis inhibitors; thus, can facilitate apoptosis [67].
It has previously been convincingly revealed that ectopic expression of miR-23a-3p in DU145 cells
induced considerable reversal of osthol-mediated reduction in invasive potential of prostate cancer
cells. Detailed mechanistic insights suggested that osthol markedly downregulated miR-23a-3p in
DU145 cells [50].
3.3. Breast Cancer
Breast cancer is a common malignancy responsible for cancer-related deaths in females around
the world, and accordingly, exploring therapeutic approaches in order to suppressing this disease is
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immediately vital [71]. In an in vitro study reported by Ye et al. [51] on MDA-MB-231 and 4T1, two
invasive mammary carcinoma cell lines, osthol at 15 μM showed inhibitory effect on cell proliferation
and invasion. Results showed that osthol in combination with platycodin D, a triterpene saponin, could
dramatically reduce tumor growth factor-β receptor II (TGFβRII), Smad2, Smad3 and Smad4 gene or
protein expressions and efficiently suppressed TGF-β-induced Smad2 and Smad3 phosphorylation.
The latter is the main mechanism of osthol in the reduction of proliferation and invasion of breast cancer
cells. Hepatocyte growth factor (HGF) is able to induce epithelial–mesenchymal passage in cancerous
cells which can result in cancer cell migration. In an in vitro study performed by Hung et al. [48],
a series of human breast cancer cells, such as MDA-MB-453, MDA-MB-23, BT-20 and MCF-7, were
treated with osthol. It has been observed that osthol significantly suppressed HGF-induced cell
distribution, invasion and migration in MCF-7 cell cultures. Abnormal stimulation of the HGF/c-Met
(cellular mesenchymal to epithelial transition factor) pathway has a remarkable role in the progression
of various models of cancers as well as advancement of tumor invasion and metastatic system.
Osthol inhibited HGF-induced c-Met phosphorylation along with a reduction in the total c-Met
protein expression in MCF-7 cells which is intervened by C75 (pharmacological inhibitor) of fatty acid
synthase (FASN).
In addition to the effects of osthol in breast cancer, this compound reduces the metastasis of this
cancer to the bone marrow. In an in vivo study [54], the researchers used a mouse model to investigate
the preventive effect of osthol against the metastasis of human breast cancer cells to the bone. Results
showed that osthol blocked breast cancer cell growth, migration and invasion, along with enhancement
of apoptosis of breast cancer cells.
Osteoprotegerin (OPG) is a soluble decoy receptor which lacks a trans-membrane domain.
It protects the skeleton from excessive bone resorption. Mechanistically, it was shown that OPG
interacted with receptor activator of nuclear factor-κB ligand (RANKL) and prevented its structural
binding with RANK. The role of osthol in prevention of bone marrow metastasis is mediated by the
regulation of OPG/RANKL cascade in the interactions between osteoblasts and breast cancer cells and
also suppressing TGF-β/Smads pathway which has a pivotal role in breast cancer bone metastasis.
However, many researchers are trying to find strategies to suppress tumor growth as well as tumor
metastasis [72].
3.4. Brain Cancer
Glioma, a highly relapsing type of tumor, represents 44.6% of central nervous system tumors
and has a high rate of morbidity [73]. In vitro investigation by Lin et al. [55] on glioma cell line U87
showed a significant inhibition of proliferation and augmentation of apoptosis at concentrations of
50, 100 and 200 μM of osthol. Mechanistically, it has been shown that osthol upregulated miR-16
in the U87 cells. These effects were mediated through up-regulation of expression miR-16 and
down-regulation of matrix metalloprotease (MMP)-9 expression [74]. MicroRNAs (miRNAs) are a class
of non-coding, small molecule RNAs and act as regulators of gene expression [55]. Ding et al. [56]
investigated the anticancer effect of osthol on C6 rat glioma cell. Results showed that osthol apparently
prevented glioma cell proliferation. This natural compound was also able to induce apoptosis by
up-regulating the expression of pro-apoptotic proteins as well as reduction of anti-apoptotic factors
expression. Furthermore, the compound could inhibit C6 cell migration and invasion. Results
showed that inhibition occurred through phosphatidylinositol-3-kinase (PI3K)/AKR mouse thymoma
kinase (Akt) and MAPK signaling pathway [75]. MAPK pathway was significantly involved in
regulation of the phospho-proteome of brain tumors. MAPK activation can also induce cell-cycle
arrest via cyclin D1 activation and reduction of apoptosis through modulation of the BCL-2-family [76].
Several proteins control cell proliferation processes, amongst which cyclin-dependent kinases (CDKs)
are the most important ones. A CDK binds a regulatory protein called cyclin. This complex (CDK-
cyclin) has a modulatory role in cell cycle progression and drive cells to enter the next phase at the
appropriate time. Increased cyclin D1 expression has been involved in several types of cancer. Osthol is
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demonstrated to reduce D1 expression. The PI3K/Akt signaling pathway is involved in regulation of
cancer development and progression mainly through triggering an increase in phosphorylated levels
of Akt [77].
Glioblastoma multiform (GBM) is a progressive type of brain tumor in adults. Recent treatment
approaches for GBM include surgical resection, radiotherapy and chemotherapy [78,79]. An in vitro
study on insulin-like growth factor (IGF)-1-induced GBM8401 cells exposed to different concentration
of osthol showed that this natural agent can reverse IGF-1-induced morphological changes, mediated
by increasing epithelial marker expression and reducing mesenchymal marker expression. It has
been found that IGF-1 can result in the conversion of GBM8401 cells to fibroblastic phenotype and in
this condition the intercellular space becomes expanded. In addition, a wound-healing experiment
indicated that osthol could suppress IGF-1-induced migration of GBM8401 cells. Suppression of
MMP-2 and MMP-9 plays a significant role in the inhibition of IGF-1-induced cell migration in
GBM8401 cells. Osthol reduced the phosphorylation of Akt and glycogen synthase kinase 3β (GSK3β)
and regained the GSK3β activity [57]. Pretreatment with IGF-1 can lead to phosphorylation of Akt and
Erk1/2 involved in expression of Snail and Twist. Osthol can remarkably suppress the IGF-1-induced
down-regulation of ZO-1 and β-catenin as well as up regulation of vimentin, N-cadherin, Snail
and Twist in a dose- and time-dependent manner. Suppressing Snail and Twist expression which
is characteristic of mesenchymal tumor areas, is one of the main mechanism of osthol in inhibiting
the induction of EMT in epithelial neoplasms [80]. One of the mechanisms by which the growth
suppressive effect of osthol suppresses the growth of the malignant cells is mediated via the effects of
osthol on the PI3K/Akt mTOR pathway. EMT is the critical step for metastatically competent brain
cancer cells to spread and invade distant sites. This process is mediated through growth factors. It is
interesting that osthol is able to inhibit IGF-1-induced EMT through PI3K/Akt pathway inhibition in
human brain cancer cells [81].
3.5. Lung Cancer
Lung cancer is the leading cause of cancer-related deaths all over the world, and non-small
cell lung cancer (NSCLC) is responsible for about 80% of all cases [82,83]. In an in vitro study by
Xu et al. [84], A549 human lung cancer cells were exposed to osthol at various concentrations. Osthol
significantly reduced cell growth and arrested the cells in G2/M phase. It has been revealed that
the osthol cellular mechanism of action includes down-regulation of cyclin B1, p-Cdc2 and Bcl-2
expressions and up-regulation of Bax expression in A549 cells. Osthol could also suppress the PI3K/Akt
signaling pathway which might be one of the molecular mechanisms by which the compound exerts
anticancer effects. In another study by Xu et al. [58], the effects of various concentration of osthol
on the migratory and invasive potential of A549 cells were evaluated. Osthol dose-dependently
exerted inhibitory effects on lung cancer cells and effectively suppressed proliferation, migration
and invasion of cancerous cells. Cellular mechanisms which are essential for these effects were
associated with the inhibition of MMP-2 and MMP-9 expression in the human lung cancer cells which
have a significant role in cell invasion and migration. Moreover, Feng et al. [59] investigated the
effect of osthol on adenocarcinomic human alveolar basal epithelial cells (A549). The cancerous cells
were treated with osthol in 5–20 mM for 48 h. Results showed that osthol extremely suppressed
TGF-β1-induced epithelial-to-mesenchymal transition (EMT), adhesion, invasion and migration in
A549 which is mediated by adjusting NF-κB and Snail signaling pathways. This molecule can interact
with cell adhesion molecules which are involved in angiogenesis. The process of angiogenesis is under
regulation of several pro-angiogenic genes as well as growth factors including epidermal growth
factor (EGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet
derived growth factors (PDGF), angiopoetin-1 and 2 and MMPs [81].
90
Nutrients 2018, 10, 36
3.6. Leukemia
Chronic myeloid leukemia (CML) is a type of hematologic malignancy [85]. Multidrug resistance
(MDR) has an important role in CML chemotherapy failure through drug resistance [86]. Wang et al. [60]
showed that osthol has a remarkable effect on CML. In this research, K562/ADM cells were treated with
osthol for 24 h. The potential of osthol to overcome MDR caused by P-glycoprotein (P-gp) was measured
by the CCK-8 assay in the K562/ADM cell line. Results demonstrated that osthol remarkably reduced P-gp
expression through suppression of the PI3K/Akt signaling pathway which is associated with modulation
of MDR mediated by P-gp in different types of leukemia. The authors concluded that the PI3K/Akt
signaling pathway is a key mechanism triggered in the reversal effect of osthol in the MDR.
Chou et al. [61] evaluated pharmacological properties of osthol against human leukemia via
in vivo and in vitro assessments. P-388 D1 murine leukemia cells were intraperitoneally administered
into CDF1 female mice (BALB/c female × DBA/2 male). CDF1 mice with leukemia received
osthol (30 mg/kg, orally) once a day for a period of nine days. Data clearly suggested that osthol
significantly prolonged lifespan of P-388 D1 tumor-bearing mice by more than 37.5% in comparison to
solvent-treated animals. Importantly, survival of one mouse of the osthol-treated group was noted to
be more than 60 days.
3.7. Cervical Cancer
A common type of malignancy in women all over the world is cervical cancer [87]. In an in vitro
study that utilized HeLa human cervical cancer cells, osthol concentration- and time-dependently
suppressed cell growth. Furthermore, cytotoxic effects were non-significant in coumarin-treated
primary cultured normal cervical fibroblasts which indicates its specific pharmacological effects on
cancer cells. It has been revealed that osthol performs its anticancer potential on cervical cancer cells
by elevating DNA fragmentation as well as activation of poly (ADP-ribose) polymerase (PARP) which
has an essential contribution in programmed cell death resulting in induction of apoptosis in HeLa
cells [61].
3.8. Ovarian Cancer
Ovarian cancer is considered as the most lethal gynecologic cancer [88] in women. Epidemiological
studies demonstrated that the proportion of ovarian cancer patients who experienced a five-year
survival rate is less than 50% post-diagnosis. The main therapeutic approach for ovarian cancer
patients is cytoreductive surgery along with paclitaxel-based chemical agents [88,89]. Clinical evidence
reported good primary response in many cases; however, there are still remarkable challenges such
as multi-chemotherapy drug resistance. In an in vitro study reported by Jiang et al. [62] uncontrolled
proliferation and migration of ovarian cancer cells, including OV2008 and A2780, were assessed.
Osthol remarkably reduced cell viability of ovarian cancer cells; whereas no toxicity was detected in
normal ovarian cells. Subsequent to treatment with osthol, migratory potential, expression levels and
functionalities of MMP-9 and MMP-2 were noted to be significantly suppressed in wound healing
and trans-well assays. This natural coumarin repressed cells proliferation via promoting G2/M phase
cell cycle arrest and activation of apoptosis process in malignant cells. It has been suggested that
other underlying mechanisms of its anticancer action were the enhancement of the apoptotic protein
caspase-3, caspase-9 and Bax/Bcl-2.
3.9. Renal Cancer
In an in vitro study, Min et al. [63] showed that osthol increased TNF-related apoptosis-inducing
ligand (TRAIL)-mediated cell death in Caki cell line. Induction of apoptotic cell death by osthol
(20–30 μM for 24 h) is mediated by regulation of the FLICE like inhibitory protein (c-FLIP) expression
in human renal carcinoma cells. c-FLIP overexpression markedly inhibited apoptosis; however,
osthol significantly reduced c-FILP levels and sensitized resistant cells to TRAIL. Also, osthol
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significantly decreased MMP levels and synergistic treatment with TRAIL induced an increase
in cytosolic accumulation of cytochrome c. These findings provided evidence that osthol worked
synergistically with TRAIL and induced apoptosis in TRAIL-resistant cell lines. Moreover, osthol blocks
the growth and invasion of bladder cancer cells by inhibiting the expression of the angiogenesis-related
proteins COX-2, VEGF, MMP-2 and NF-κB. Future studies must converge on detailed investigation of
osthol-mediated regulation of the TRAIL pathway in resistant cancer cells. We still have insufficient
information about regulation of death receptors (DR4 and DR5) by osthol in cancer cells.
3.10. Liver Cancer
In an in vitro study, Lin et al. [64] reported that osthol reduced hepatocellular carcinoma (HCC)
cell proliferation. The chemotherapeutic potential of osthol on HCC cell proliferation was mediated
through induction of DNA damage and cell cycle arrest as well as inhibition of migration of HCC
cells. It remarkably suppressed the cell cycle in the G2/M phase by blocking the expression of Cdc2.
Cyclin-dependent kinase 1 (CDK1)-cyclin B, also known as cell division control protein kinase 2
(Cdc2)-cyclin B is a member of cyclin-dependent kinases with a significant role in regulation of the cell
cycle. It has been found that down-regulation of MMP-2 and MMP-9 is involved in suppression of
migration of HCC cells by this natural agent. Finally, the authors demonstrated that osthole inhibited
EMT by increasing epithelial biomarkers E-cadherin and β-catenin and simultaneously repressing
the levels of N-cadherin and vimentin. This phytoconstituents also damaged DNA by induction of
DNA excision repair protein (ERCC) 1 expression enhancing epithelial biomarkers E-cadherin and
β-catenin, and reducing mesenchymal N-cadherin are among the main cellular factors which have
a key role in suppression of EMT by osthol [90]. These cellular pathways suggest an interesting
chemotherapeutic effect of osthol on HCC. The interaction of DNA and other coumarins have been
reported previously [91].
3.11. Protectice Effect against Toxicity of Chemotherpy
The positive effects of osthol in modulating cancer include direct anticarcinogenic activity along
with protective effects against side effects of conventional chemotherapeutic agents. One of the
chemotherapeutic drugs that are used for treatment of several types of cancers is doxorubicin [55]
which shows several adverse effects due to its inherent pro-oxidant activity. Protective effects of osthol
against doxorubicin-induced oxidative stress and apoptosis in the neuronal cell line (PC12) has been
confirmed. The protective mechanisms of osthol include enhancement of mitochondrial membrane
potential, elevation of Bax/Bcl-2 ratio, improvement in loss of cell viability, suppression of intracellular
reactive oxygen species (ROS) generation as well as increases in mitochondrial membrane potential in
PC12 cells [18,92]. Fatty acid synthase (FASN) is the only enzyme engaged in long-chain saturated
fatty acid synthesis and is implicated in cancer progression by regulating lipid raft function. Thus, one
of the molecular pathways by which osthol performs its protective action against cancer progression is
its potent inhibitory effect on FASN [53].
4. Toxicity of Osthol
Reviewing current literature can help to collect information regarding the bio-efficacy and
safety of the administration of significant phytochemicals in the prevention and management of
different malignancies and their relevant complications. Since osthol safety has been investigated,
the no-observed adverse-effect level (NOAEL) of osthol for both male and female rats is considered to
be less than 5 mg/kg [93]. We suggest to perform randomized, controlled, trials with adequate sample
size in order to validate the safety and efficacy of osthol in managing patients with malignancies.
5. Conclusions and Future Directions
Osthol is a natural coumarin isolated from Umbelliferae plants with a wide range of
pharmacological effects. The goal of the present review was to provide a summary of current
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knowledge on the anticancer effects of osthol as a lead compound in malignancy therapy along with
in-depth molecular mechanisms. This natural phytochemical suppresses the activation of different
apoptotic proteins such as caspase-3 and caspase-9, Smac/DIABLO, poly-ADP ribose polymerase and
survivin, which are associated with the intrinsic pathways of apoptosis. Osthol is demonstrated to
induce apoptosis in different carcinoma cell lines through up-regulation of p53 expression. It has also
been shown that osthol induces apoptosis through a mechanism independent of the tumor-suppressing
properties of p53. This effect of osthol seems to be promising since the compound demonstrated
antitumor effects in several types of cancers in which a p53 regulatory system is involved [94]. It also
can diminish metastasis via different molecular mechanisms such as reducing the expression of
Smad 2, 3 and 4, C75, and inhibition of the HGF/c-Met signaling pathway as well as HGF-induced
c-Met phosphorylation. Osthol also has a stimulatory effect on the extrinsic apoptotic pathway by
increasing levels of caspase-8 (unique to the extrinsic pathway). Furthermore, ability of osthol to
inhibit NF-κB-mediated cell survival pathway plays an important contribution in its pro-apoptotic
properties, as summarized in Figure 2.
Results obtained from studies evaluating anticancer potential of osthol have confirmed its
protective and therapeutic effect on various types of malignancies including ovarian cancer, cervical
cancer, chronic myeloid leukemia, lung adenocarcinoma cells, glioma as well as glioblastoma multiform
cells, invasive mammary carcinoma cells, colon cancer, and prostate cancer. Recent investigations,
mentioned previously, have suggested that osthol has a significant action in the brain by protecting
neurons. Additionally, the ability of osthol in penetrating the blood–brain barrier indicates its potential
as a future drug for chemotherapy of brain tumors.
Based on the insights gleaned from decades of research, it seems clear that a “one size fits
all” approach will not be effective in clinical settings. There has been a paradigm shift in our
understanding about the heterogeneous nature of cancer, and accordingly, researchers are now focusing
on multi-targeted approaches. Osthol has emerged as a promising phytochemical reportedly involved
in the regulation of different signaling pathways. However, we have just started to scratch the surface
of information related to the potential of osthol to target multiple proteins and signaling pathways.
We still need to have a better understanding of how osthol regulates specific signaling pathways,
such as VEGF/VEGFR, PDGF/PDGFR and SHH/GLI pathways, and exert differential modulation of
oncogenic and tumor suppressor microRNAs.
Numerous studies presented here clearly suggest that osthol possesses the potential to act in an
inhibitory role in the progression of malignancies. A large body of evidence demonstrated that osthol
regulates apoptosis, proliferation and invasion in different types of malignant cells which is mediated
by multiple cellular signaling pathways. However, the mechanisms of function of osthol toward
various cancers are not the same. As it was mentioned, osthol possesses antioxidant activity, causing
inhibition of ROS overproduction in different cells. ROS can activate several pathways involved in
metastasis and possess critical roles in invasion and invadopodia formation; moreover, ROS also
possess prominent roles on signaling cascades relating to resistance to apoptosis, neovascularization,
and proliferation. Therefore, ROS contribute in various mechanisms [95–98], and reduction of ROS
using antioxidants is a promising way to inhibit different cancers. Based on the different roles of ROS
in cancer cells and their contribution in different mechanistic pathways, the function of antioxidants
such as osthol in excretion of anticancer activity could be probably different. Regarding the remarkable
pharmacological functions of osthol in the protection and treatment of malignancies as described above,
this natural compound is becoming a significant natural structure for drug discovery. Furthermore,
mechanistic investigations for exploring precise intracellular mechanisms of osthol in defending and
fighting against cancer are recommended. Also, well-designed randomized clinical trials are important
to evaluate the safety and efficacy of osthol in patients with different types of cancers.
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Abstract: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men, accounting for
15% of all cancers in men worldwide. Asian populations consume soy foods as part of a regular diet,
which may contribute to the lower PCa incidence observed in these countries. This meta-analysis
provides a comprehensive updated analysis that builds on previously published meta-analyses,
demonstrating that soy foods and their isoflavones (genistein and daidzein) are associated with
a lower risk of prostate carcinogenesis. Thirty articles were included for analysis of the potential
impacts of soy food intake, isoflavone intake, and circulating isoflavone levels, on both primary and
advanced PCa. Total soy food (p < 0.001), genistein (p = 0.008), daidzein (p = 0.018), and unfermented
soy food (p < 0.001) intakes were significantly associated with a reduced risk of PCa. Fermented
soy food intake, total isoflavone intake, and circulating isoflavones were not associated with PCa
risk. Neither soy food intake nor circulating isoflavones were associated with advanced PCa risk,
although very few studies currently exist to examine potential associations. Combined, this evidence
from observational studies shows a statistically significant association between soy consumption
and decreased PCa risk. Further studies are required to support soy consumption as a prophylactic
dietary approach to reduce PCa carcinogenesis.
Keywords: prostate cancer; soy; isoflavones; epidemiology; cohort; case-control
1. Introduction
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men worldwide.
According to the International Agency for Research on Cancer’s GLOBOCAN database, 1.1 million
men were diagnosed with PCa in 2012, accounting for 15% of all cancers in men [1]. Incidence rates are
lowest in Asian countries, where soy foods are regularly consumed as part of a normal diet. Several
studies have reviewed the inverse association seen between soy food intake and PCa incidence in Asian
populations, proposing that soy isoflavones act as weak hormones to exert a protective physiological
effect against the development of PCa [2–5]. Indeed, the soy isoflavones, genistein and daidzein,
have been shown to accumulate in prostatic tissue [6], where they may be cytotoxic to cancer cells [7].
These effects may occur as a result of both non-hormonal and hormonal action. For example, genistein
upregulates tumor suppressor genes in PCa cells [8] and suppresses prostate carcinogenesis in an
estrogen receptor (ER) wild-type mouse model, when compared to ER knock-out mouse models [9].
This hypothesis has further been supported by four previous meta-analyses of epidemiological
studies, all of which showed a protective association between soy consumption and PCa [10–13].
However, these meta-analyses did not integrate and evaluate all available existing studies pertaining
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to both dietary soy food intake and circulating levels of isoflavones. Our current analysis broadens
the included categories of soy food and isoflavone measurements, allowing for a more complete
review of the literature. We include a larger number of studies and an in-depth analysis on the
relationship between total soy food intake, fermented and unfermented soy food intakes, individual
and combined dietary isoflavones, and circulating individual and combined isoflavones and the risk
of PCa. Furthermore, no previous meta-analysis has explored potential links between soy foods and
advanced PCa. Because soy isoflavones have also been linked to inhibiting PCa cell motility and
invasion [14] and reducing inflammatory markers in men with PCa [15], we also evaluated the impact
of soy on the risk of advanced PCa.
2. Materials and Methods
2.1. Study Selection Criteria
This meta-analysis was conducted following PRISMA and Meta-analysis of Observational Studies
in Epidemiology (MOOSE) guidelines [16,17]. Studies fitting the following criteria were included in
this meta-analysis: (a) examined the relationship between soy and PCa risk by using randomized
control trials and/or cohort, cross-sectional, retrospective, prospective and case-control studies;
(b) methodology was reported in replicable detail; (c) examined the association between soy and
PCa risk; (d) reported relative risk ratios with 95% confidence intervals for the reported exposure
categories; (e) were written in English; and (f) were peer-reviewed publications.
2.2. Literature Search
We conducted a thorough literature search of PubMed, Web of Science, and the Cochrane Library,
using a combination of the following key words and their variants: prostate cancer, prostate neoplasm,
soy, soymilk, soy milk, isoflavone, bean curd, tofu, soy protein, daidzein and genistein (up to 25 May
2017). The keyword search yielded a comprehensive list of titles and abstracts of articles that were
screened for relevance against the listed study selection criteria. These screened articles were evaluated
in full text for study inclusion. Finally, we conducted a reference list search (i.e., backward search) and
works cited search (i.e., forward search) from the articles identified as meeting the inclusion criteria.
The studies identified through this process were further assessed using the same inclusion criteria,
with this process being repeated until all relevant articles were identified. Three authors (CA, JR3
and KR) individually considered all articles obtained in full text for inclusion or exclusion, and any
discrepancies were discussed and resolved.
2.3. Data Extraction and Quality Assessment
The following information was extricated from each article: name of first author; year of
publication; location of study; study period; number of cases, controls and total number of participants
in the study; age of participants; total years of follow-up; exposure values of soy (serum/plasma
and/or intake); relative risk ratios for PCa; adjustments made for any covariates; and study type.
The term RR (relative risk) will be used in this study as a general term to denote the following: relative
odds (cumulative incidence data), rate ratio (incidence-rate data) and odds ratios (OR; case-control
data). Study quality was examined using the Newcastle–Ottawa Scale, which is a validated scale
used to assess the quality for case-control and non-randomized cohorts in a meta-analysis [18].
This scale evaluates each study based on the following three categories: selection of cases and
controls, comparability of studies, and exposure of the main variable (soy, genistein, daidzein, or total
isoflavones). We regarded scores of 1–3, 4–6 and 7–9 as low, medium and high quality, respectively.
The resulting quality score was included as a measurement of the strength of the evidence presented
in each study and was not used to determine the inclusion or exclusion of studies. The significance of
the study quality was analyzed in the subgroup analysis.
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2.4. Statistical Analysis
STATA/IC version 14.2 (StataCorp LP, College Station, TX, USA) was used to analyze the data.
Because OR is nearly equivalent to RR when considering low incidence of diseases [19], RR and 95%
confidence intervals (CI) were used as a measure of the effect size for all included studies. Heterogeneity
amongst studies was determined using the I2 statistic [20]. Fixed and random (DerSimonian–Laird)
effects models were used, depending on the I2 result, as markers of study heterogeneity [20]. An I2
value of less than 50% (I2 < 50%) signified low-to-moderate heterogeneity between studies, so a fixed
effect model was used to determine RR estimates. An I2 value of greater than or equal to 50% (I2 ≥ 50%)
signified moderate-to-substantial heterogeneity between studies, so a random effects model was used
to determine RR estimates. When results from fixed and random effects models were conflicting and
studies showed moderate heterogeneity (I2 = 30–60%), we presented the latter as it represents a more
conservative approach [21,22].
Because studies reported different exposure categories as tertiles, quartiles or quintiles, we used
the study specific RR for the highest quantile of dietary soy intake and/or circulating (serum or plasma)
isoflavone concentrations. Potential publication bias was assessed by using funnel plots [23,24], Egger’s
linear regression test [25], and Begg’s rank correlation test of asymmetry [26]. We also performed
sensitivity analyses to evaluate whether the pooled results could have been affected by excluding a
single study at a time. Subgroup analyses were performed on study type, study location, study quality,




In total, 3356 articles were identified from the library search engines. After removing
duplicates and adding articles identified from reference lists, 2531 articles remained. Of the
2531 articles that were screened by abstract, 39 articles were found to contain potentially relevant
information and were evaluated by full text review. Upon reviewing the full text articles for the
aforementioned inclusion criteria, 30 articles were included in the final analysis [27–56]. Of these
30 articles, 24 [27–34,36–43,45–49,52,53,55] included information regarding dietary soy intake and
nine [29,35,40,42,44,50,51,54,56] included information regarding circulating isoflavone levels (Figure 1).
3.2. Study Characteristics
Of the 30 articles included for analysis, fifteen [28–30,32,34,37–39,41,42,47–49,52,56]
articles were case-control studies, eight [27,31,33,36,43,45,46,53] articles were cohort studies,
and seven [35,40,44,50,51,54,55] articles were nested case-control studies (NCC). The total number
of study participants included was 266,699, and the total number of PCa cases reported was 21,612.
Twelve [27,32,35–37,39,41,42,44,47,49,56] articles reported data from Asia, ten [31,33,34,38,43,45,46,48,52,53]
articles reported data from North America, and eight [28–30,40,50,51,54,55] articles reported data from
Europe. The study characteristics are summarized in Table 1. Articles analyzing soy intake from the diet
used lifestyle questionnaires or validated food frequency questionnaires (FFQs) to collect usual dietary
intake. All articles reported results using risk estimates as RR or OR.
Quality scores were assigned to each article using the criteria outlined by the Newcastle–Ottawa
scales for case-control and cohort studies. The average score for case-control studies was 6.93 (standard
deviation = 0.7); 6 was the lowest score and 8 was the highest score given. Cohort and NCC studies
received an average score of 7.73 (standard deviation = 0.7); 6 was the lowest score and 9 was the
highest score given. Individual quality assessment scores are provided in Appendix A (Table A1).
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3.3. Soy Intake and PCa Risk
Twenty-four articles evaluated dietary soy and soy isoflavone intake and PCa risk. These articles
were further divided into groups that analyzed risk pertaining to total soy (n = 16) [27,29,31–34,36,37,39,
41,43,45–47,49,52], unfermented soy food (n = 11) [27,31,33,34,37,39,43,46,47,49,52], fermented soy food
(n = 8) [27,32,36,37,41,45–47], genistein (n = 10) [30,36–38,40–42,45,48,55], daidzein (n = 10) [30,36–38,40–
42,45,48,55], total isoflavones (n = 6) [28–30,45,53,55], tofu (n = 5) [27,37,43,46,47], miso (n = 3) [27,36,46],
soy milk (n = 2) [31,49], and natto (n = 1) [47] intakes. Funnel plots used to explore publication bias are
shown in Appendix A (Figure 1).
Figure 1. Literature search and study selection flow chart.
Articles that reported soy intake as either a combination of multiple soy food items or as a single
soy food item were classified as total soy intake. Sixteen articles reported the association between total
soy intake and PCa risk. The pooled RR for this association was 0.71 (95% CI: 0.58–0.85, p < 0.001)
(Figure 2A). Neither Begg’s correlation test (p = 0.300) nor Egger’s linear regression test (p = 0.052) for
bias were significant. Heterogeneity amongst studies was analyzed using the I2 index to show high
variation between studies (68.9%).
When selecting articles for evaluating the association between unfermented or fermented soy
food intake and PCa risk, studies had to have explicitly stated which soy food items were being
reported. Examples of commonly reported unfermented soy foods included soy milk, tofu and
soybeans; fermented soy foods included miso and natto. The pooled RR for unfermented soy foods
and risk of PCa was 0.65 (95% CI: 0.56–0.83, p < 0.001), and the pooled RR for fermented soy foods
and risk of PCa was 0.86 (95% CI: 0.66–1.13, p = 0.218) (Figure 2B,C, respectively). Neither Begg’s
correlation test (p = 0.161 and p = 0.902, respectively) nor Egger’s linear regression test (p = 0.117 and
p = 0.670, respectively) for bias were significant. The I2 index showed high heterogeneity amongst
studies included in the unfermented (60.3%) and fermented (66.6%) groups.
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Ten articles reported soy intake as a measurement based on the calculation of genistein and
daidzein present in soy foods. The pooled RR for genistein and risk of PCa was 0.90 (95% CI: 0.84–0.97,
p = 0.008), and the pooled RR for daidzein and risk of PCa was 0.84 (95% CI: 0.73–0.97, p = 0.018)
(Figure 2D,E, respectively). Begg’s correlation test was significant for genistein but was not significant
for daidzein (p = 0.049 and p = 0.210, respectively), and Egger’s linear regression test was significant for
both measurements (p = 0.009 and p = 0.039, respectively). The I2 index showed moderate heterogeneity
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Figure 2. Forest plots for (A) total soy intake and risk of prostate cancer; (B) unfermented soy intake
and risk of prostate cancer; (C) fermented soy intake and risk of prostate cancer; (D) genistein intake
and risk of prostate cancer; (E) daidzein intake and risk of prostate cancer; and (F) total isoflavone
intake and risk of prostate cancer. These associations were indicated as a relative risk (RR) estimate
with the corresponding 95% confidence interval (CI).
Six articles reported isoflavone intake without disclosing the sources of the isoflavones.
These studies were analyzed separately, so as not to interfere with measurements based solely on soy
intake because isoflavones are found in other food items, such as seed sprouts and pulses. The pooled
RR for isoflavone intake and PCa risk was 1.03 (95% CI: 0.97–1.09, p = 0.313) (Figure 2F). Neither Begg’s
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correlation test (p = 0.707) nor Egger’s linear regression test (p = 0.802) for bias were significant. The I2
index showed moderate heterogeneity between studies (44.9%). Notably, the inclusion of these studies
in the total soy analysis did not significantly change the RR of dietary soy intake and PCa risk.
Finally, articles were further stratified into specific soy food groups, which included tofu, miso and
soy milk. Few studies were available to accurately represent meta-analysis data on these points, so RR
are reported here, but not included in further subgroup analyses. The pooled RR for tofu and PCa risk
was 0.73 (95% CI: 0.57–0.94, p = 0.013), the pooled RR for miso and PCa risk was 1.01 (95% CI: 0.80–1.28,
p = 0.919), and the pooled RR for soy milk and PCa risk was 0.58 (95% CI: 0.19–1.78, p = 0.343). None
of the groups were significant for bias using Begg’s correlation test (p = 0.221, p = 0.296, and p = 1.000,
respectively) or Egger’s linear regression test (p = 0.093, p = 0.497, and p = NA, respectively). The I2
index showed low heterogeneity amongst the studies included in the tofu (4.5%) and miso (0.0%)
groups and high heterogeneity amongst studies included in the soy milk (63.1%) group.
3.4. Circulating Isoflavones and PCa Risk
Nine articles measured circulating isoflavone concentrations and their associations with PCa risk.
Specifically, these articles reported RR data for circulating genistein (n = 9) [29,35,40,42,44,50,51,54,56],
circulating daidzein (n = 7) [29,35,40,42,44,51,54], and total circulating isoflavones (n = 2) [29,54].
The pooled RR for circulating genistein and PCa risk was 0.87 (95% CI: 0.69–1.10, p = 0.236) (Figure 3A),
the pooled RR for circulating daidzein and PCa risk was 0.92 (95% CI: 0.78–1.08) (Figure 3B), and the
RR for circulating isoflavones and PCa risk was 1.01 (95% CI: 0.93–1.10, p = 0.738). None of the studies
were significant for bias using Begg’s correlation test (p = 0.175, p = 0.368, and p = 1.00, respectively)
or Egger’s linear regression test (p = 0.228, p = 0.197, and p = NA, respectively). The I2 index showed
high heterogeneity amongst the studies included in the circulating genistein (76.8%) and circulating
daidzein (58.1%) groups and low heterogeneity amongst the circulating isoflavone group (0.0%).
Funnel plots used to explore publication bias are shown in Appendix A (Figure 2).
3.5. Subgroup Analysis
Articles reporting total soy intake and PCa risk had a pooled RR of 0.61 (95% CI: 0.45–0.82,
p = 0.001) for case-control studies and a pooled RR of 0.90 (95% CI: 0.82–0.99, p = 0.022) for cohort
and NCC studies. Studies conducted in both North America (p = 0.009) and Europe (p = 0.021) were
significantly associated with a reduced PCa risk, whereas studies conducted in Asia (p = 0.064) were not.
A complete subgroup analysis can be found in Table 2. Cumulative meta-analyses first demonstrated
that soy food intake was significantly associated with the reduced risk of PCa in 1998 and has remained
significant over time, and with the inclusion of additional studies within the field (Figure 3).
Articles reporting unfermented soy food intake and PCa risk had a pooled RR of 0.55 (95% CI:
0.46–0.66, p < 0.001) for case-control studies and a pooled RR of 0.91 (95% CI: 0.76–1.08, p = 0.267)
for cohort studies. Studies were conducted in both North America (p = 0.014) and Asia (p = 0.005),
and there was a significantly reduced risk of PCa in both continents. Studies of medium quality were
significantly associated with a lower PCa risk (p < 0.001).
The pooled RR for articles reporting dietary genistein intake and PCa risk was 0.81 (95% CI:
0.68–0.96, p = 0.016) for case-control studies and a pooled RR of 0.93 (95% CI: 0.85–1.01, p = 0.077) for
cohort and NCC studies. Studies conducted in Asia (p = 0.004) showed a significantly reduced risk of
PCa, while studies conducted in North America (p = 0.145) and Europe (p = 0.419) did not. Mid quality
studies were significantly associated with a reduced risk of PCa (p = 0.007).
The pooled RR for articles reporting dietary daidzein intake and PCa risk was 0.68 (95% CI:
0.47–1.00, p = 0.052) for case-control studies and a pooled RR of 0.91 (95% CI: 0.84–1.00, p = 0.042) for
cohort and NCC studies. Studies conducted in Asia (p = 0.012) showed a significantly reduced risk
of PCa, while studies conducted in North America (p = 0.094) and Europe (p = 0.799) did not. High
quality studies were significantly associated with a reduced risk of PCa (p = 0.042).
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There was no significant association for case-control or NCC studies and risk of PCa for articles
evaluating circulating levels of genistein. Only studies conducted in Asia (p = 0.031) were significantly
associated with a decreased risk of PCa, while studies conducted in Europe (p = 0.784) showed no
significant association with circulating genistein levels and PCa risk.
Articles evaluating dietary isoflavones, fermented soy intake, and circulating levels of daidzein
showed no significant associations on risk of PCa when studies were grouped by design or by continent.
Finally, no studies significantly affected any of the pooled RRs when conducting sensitivity analyses
for each group.
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Figure 3. Forest plots for (A) circulating genistein and risk of prostate cancer; and (B) circulating
daidzein and risk of prostate cancer. These associations were indicated as a relative risk (RR) estimate
with the corresponding 95% confidence interval (CI).
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3.6. Soy and Advanced PCa Risk
Seven [34–36,43,45,50,53] studies reported the risk of advanced PCa with soy intake and
circulating isoflavone levels. Of these seven studies, four [34,43,45,53] studies were conducted in
North America, two [35,36] studies were conducted in Asia, and one [50] study was conducted in
Europe. Only one [34] was a case-control study, two [35,50] were NCC studies, and four [36,43,45,53]
were cohort studies. Five [34,36,43,45,53] studies reported a risk of advanced PCa with dietary soy
food intake and two [35,50] studies reported a risk of advanced PCa with circulating isoflavones.
For studies that reported dietary soy food intake, the pooled RR was 0.87 (95% CI: 0.74–1.06, p = 0.119)
(Figure 4A). Neither Begg’s correlation test (p = 1.00) nor Egger’s linear regression test (p = 0.548) for
bias were significant. The I2 index showed moderate heterogeneity between studies (45.7%). Funnel
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Figure 4. Forest plots for (A) total soy intake and risk of advanced prostate cancer; and (B) isoflavone
exposure and risk of advanced prostate cancer. These associations were indicated as a relative risk (RR)
estimate with the corresponding 95% confidence interval (CI).
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When stratifying groups by combining dietary and circulating measurements of isoflavones, the
pooled RR for genistein and PCa risk (n = 4) was 0.92 (95% CI: 0.77–1.11, p = 0.381), the pooled RR
for daidzein and PCa risk (n = 3) was 0.89 (95% CI: 0.74–1.10, p = 0.227), and the pooled RR for total
isoflavones and PCa risk (n = 2) was 0.91 (95% CI: 0.82–1.01, p = 0.337) (Figure 4B). The I2 index showed
moderate heterogeneity amongst studies reporting genistein and daidzein dietary and circulating
levels (33.7% and 30.7%, respectively), while there was substantially high heterogeneity between the
studies reporting total isoflavone measurements (100.0%).
4. Discussion
This updated systematic review and meta-analysis provides a thorough evaluation regarding
the association between soy food intake and PCa risk. Using the current pool of scientific literature,
our results support the existing evidence, which indicates that total soy food intake is associated
with a reduced risk of PCa (p < 0.001). This population-based evidence corroborates observations in
both in vitro and in vivo studies, which have shown that soy isoflavones inhibit PCa development
and growth [57–59]. In agreement with this, we found that both genistein and daidzein intake were
inversely associated with the risk of PCa (p = 0.008 and p = 0.018, respectively). These results support
our finding that total soy food consumption is associated with decreased PCa risk, as genistein and
daidzein are likely found in similar food products.
Soybeans and soy food products contain isoflavones—predominantly genistein and
daidzein—mainly as β-glycosides [60]. During digestion, these glycosides are hydrolyzed to their
aglycone forms by intestinal or bacterial β-glucosidases [60]. By removing the sugar molecule,
the isoflavones are smaller and more hydrophobic, allowing them to more readily diffuse into
enterocytes [61]. After absorption and first pass metabolism, aglycones are re-conjugated in
the liver to their glycosidic or other conjugated forms and distributed to tissues via systemic
circulation [61]. Once within cells, isoflavones act as weak estrogen receptor (ER) agonists or
antagonists, depending on the cell type and concentration of estrogen present [61]. Prostatic tissues
have higher concentrations of ER-β, to which genistein preferentially binds, with an affinity similar to
that of the endogenously-produced estrogen, 17β-estradiol [62]. Increased presence and activation
of ER-β is associated with reduced cell proliferation and reduced PCa histological grade [63,64].
This effect has been shown to occur, in part, by reducing the levels of prostate-specific antigen (PSA),
cyclin D1, and cyclin-dependent kinase 4 (CDK4) in an ER-dependent manner [57,58]. Interestingly,
ER-β expression is often lost during prostate carcinogenesis, so the ability of genistein to bind to ER-β
may be a key factor in the inhibition of prostate carcinogenesis. Additional mechanisms of the effects
of soy isoflavones on PCa cellular proliferation, apoptosis, and differentiation have been reviewed in
depth by Mahmoud et al. (2014) [65].
We also analyzed the potential relationship between unfermented or fermented soy food products
and risk of PCa. We found that unfermented soy food products were associated with a decreased risk
of PCa (p < 0.001), while fermented soy food products had no associations with PCa risk (p = 0.281).
More studies provided food intake data for unfermented soy food products than fermented soy food
products (11 studies versus 8 studies, respectively). While this meta-analysis failed to demonstrate a
significant association between fermented foods and the risk of PCa, it should be recognized that there
was wider variation in results reported by these studies than there was for studies using unfermented
and other soy foods. This wider variation could have impacted the risk outcomes. Some concerns have
been expressed in the literature regarding the effects of soy fermentation on the risk of developing
certain cancers, such as gastric cancer [66]. Due to this association, Yan and Spitznagel chose to
not include fermented soy foods in their 2005 meta-analysis [10]. However, during fermentation,
β-glucosidases, secreted by fermentative bacteria, cleave glycosidic linkages via a similar process
that digestive enzymes in the small intestine and gut microbiota cleave these linkages [60,61,67].
Isoflavones are present in fermented foods, such as tempeh and miso, predominantly as aglycones,
with few isoflavones retaining their side-chains. The ratio is reversed for nonfermented foods, but
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some naturally occurring plant β-glucosidase activity allows for continuous side-chain cleavage to
yield aglycones [60]. The more bioavailable aglycone form is readily absorbed from the intestines,
rendering this conversion from a glycosylated isoflavone to its aglycone counterpart essential for
maximal isoflavone absorption. These similar enzymatic processes yield common aglycone products
for intestinal absorption, regardless of whether these processes occur before digestion during the
fermentation of soy foods or during the digestion of unfermented soy foods.
Circulating levels of genistein and daidzein were not associated with the risk of PCa (p = 0.236
and p = 0.310, respectively) despite the elevation of circulating genistein and daidzein levels after
consumption of these isoflavones. However, peak circulating isoflavone levels can occur as soon as 30
min or as long as 6 h after feeding, depending on the specific isoflavones and foods consumed [61,68].
Mean half-life values vary as well; the average half-life for free genistein is 3.2 h and the average half-life
for free daidzein is 4.2 h [69]. Because isoflavones can exist with multiple side-chains (e.g., glucose,
sulfate, acetyl, or malonyl-CoA groups) and as different metabolites, accurately measuring in vivo
pharmacokinetics is challenging. Thus, the amount of time between isoflavone consumption and blood
collection may substantially affect measurement outcomes, which can impact the reliability of blood
isoflavone measurements as markers of soy food intake. Due to these factors, an association may have
been missed for these circulating isoflavones.
No association was seen when we examined six articles that did not disclose the source of
isoflavones measured from participants’ dietary intakes. For example, Bosetti et al. (2006) indicated
that isoflavones were measured from the FFQ, primarily based on consumption of soy and soy products,
but also from “vegetable or bean soups and pulses” [28]. Because isoflavones are found in other food
sources and supplements, such as clover and alfalfa seeds and sprouts, garbanzo beans, and other
pulses, we independently analyzed studies that did not explicitly indicate that measurements were
taken from soy food sources. As such, total dietary isoflavones were not significantly associated
with risk of PCa (p = 0.313). While most dietary isoflavones are consumed from soy food products,
examining the sources and types of isoflavones that were included in these analyses could provide
insight as to why no association was observed. Notably, this analysis was based on the information
found from a limited number of articles, so additional studies could strengthen these observations.
To our knowledge, this is the first meta-analysis to investigate the risk associations between soy
and advanced PCa. Advanced PCa is defined as poorly differentiated, aggressive, and metastatic
disease. Advanced PCa is often difficult to treat, as patients are typically less responsive to therapy.
It is therefore imperative to identify other ways to prevent disease progression, such as through dietary
modification. Relatively few studies have examined the relationship between diet and advanced PCa
or reported information pertaining to stage or grade of PCa. Our results do not show a significant
reduction in the risk of advanced PCa with total soy intake (p = 0.119) or dietary and circulating levels
of genistein (p = 0.381), daidzein (p = 0.227), or total isoflavones (p = 0.337), perhaps due to the lack
of studies. Two double-blinded, randomized, placebo-controlled clinical trials have supplemented
isoflavones in men awaiting radical prostatectomy. One study reported higher apoptotic activity in
tumors of men treated with isoflavones when compared to tumors of the men in the placebo group [70],
while the other study showed modulation of both cell cycle and apoptotic genes in the prostate
tissues of men in the treatment group, when compared to tissues of men in the placebo group [71].
More studies are needed to further explore this promising relationship and to identify whether soy can
protect against advanced PCa.
Few studies have analyzed individual soy foods and their relationships with PCa risk. Tofu was
the most investigated soy food found in the literature. Tofu showed a significant protective association
with PCa (p = 0.013). This result is consistent with the result shown by Hwang et al. (2009) [11]. More
studies are needed to understand the role of individual soy foods in PCa risk.
The research design of studies did not seem to bias our results, as case-control and cohort studies
both reported significant and null results. It is important to note that case-control studies are generally
considered to have a higher risk of bias than cohort studies; however, significant measurement
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error can occur for both cohort and case-control studies when evaluating a single exposure variable.
To accurately account for all reported estimates of soy exposure and PCa risk, both study designs were
included in the analysis. To this end, sensitivity analyses conducted for each subgroup showed that no
studies significantly altered results or heterogeneity within subgroups. Separating results by continent
showed that total soy intake was only associated with a decreased risk of PCa in North America
(p = 0.009) and Europe (p = 0.021), although only one study was included in the European group.
However, when looking at the individual dietary isoflavones, genistein and daidzein, Asia was the
only continent to show a significant risk reduction for PCa (p = 0.004 and p = 0.012, respectively).
Similarly, Asia was the only continent to show a significant association between circulating genistein
and risk of PCa (p = 0.031). Both North America (p = 0.014) and Asia (p = 0.005) showed a reduced risk
of PCa when only considering unfermented soy foods. The variability in these associations makes it
difficult to draw conclusions about whether ethnic differences, preparation methods, or eating patterns
exist in soy food or isoflavone consumption and PCa risk.
Because differences in overall dietary composition or other unmeasured lifestyle factors could
contribute to increased or decreased disease risk, the results from this study and others showing that
soy intake is associated with a reduced risk of PCa should be interpreted with caution. Our study was
limited in that our results relied on the reporting of the studies included in this analysis and may have
been affected by several factors. For example, studies relying on dietary recall or FFQ reporting are
subject to recall bias by participants. Soy food intake measurements could be inconsistently reported
or nutrient analyses may differ based on the amount and type of soy food or the database used to
collect nutrient information. In addition, not all studies accounted for potential confounding variables,
such as family history of prostate cancer (FHPC), body mass index (BMI), smoking, or energy intake.
The subgroup analyses in this study attempted to account for these limitations by highlighting some
of these differences between studies, to account for variability in data adjustments and selection bias
created by study design (i.e., whether the study was case-control or NCC/cohort).
In addition to attempting to address these study limitations, our analysis delved deeper into
potential confounding factors, through meta-regression, to determine whether study quality, length,
or the sample size impacted significant results of the study. None of these factors were found to
impact our results, and as such were not included in our results. We also reported both dietary intakes
and circulating levels of isoflavones to create a more comprehensive review of the existing literature.
Finally, we analyzed any associations between soy and advanced PCa, which has not previously
been reported.
As the second most commonly diagnosed cancer in men worldwide, it is important to identify
modifiable factors, such as diet, that may impact the risk of developing PCa. The current study
provides an updated systematic review and meta-analysis of the available literature describing the
associations between soy food consumption and PCa risk. Of the four meta-analyses previously
published, all showed that soy intake was associated with a reduced risk for PCa. Our study further
enhances this association by including additional studies for analysis, grouping soy foods by type
of food and by isoflavone intake, adding groups of circulating isoflavone concentrations, and by
evaluating the potential relationship between soy food intake and advanced PCa risk.
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the manuscript.
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Figure 1. Funnel plots for (A) total soy intake and risk of prostate cancer; (B) unfermented soy intake
and risk of prostate cancer; (C) fermented soy intake and risk of prostate cancer; (D) genistein intake
and risk of prostate cancer; (E) daidzein intake and risk of prostate cancer; and (F) total isoflavone
intake and risk of prostate cancer.
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Figure 2. Funnel plots for (A) circulating genistein and risk of prostate cancer and (B) circulating
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Figure 3. Forest plot for total soy intake and risk of prostate cancer by year of study publication.
These associations were indicated as a relative risk (RR) estimate with the corresponding 95% confidence
interval (CI).
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Figure 4. Funnel plot for total soy intake and risk of advanced prostate cancer.
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Abstract: Cervical cancer is one of the most common cancers in women living in developing countries.
Due to a lack of affordable effective therapy, research into alternative anticancer compounds with
low toxicity such as dietary polyphenols has continued. Our aim is to determine whether two
structurally similar plant polyphenols, resveratrol and pterostilbene, exhibit anticancer and anti-HPV
(Human papillomavirus) activity against cervical cancer cells. To determine anticancer activity,
extensive in vitro analyses were performed. Anti-HPV activity, through measuring E6 protein
levels, subsequent downstream p53 effects, and caspase-3 activation, were studied to understand
a possible mechanism of action. Both polyphenols are effective agents in targeting cervical cancer cells,
having low IC50 values in the μM range. They decrease clonogenic survival, reduce cell migration,
arrest cells at the S-phase, and reduce the number of mitotic cells. These findings were significant,
with pterostilbene often being more effective than resveratrol. Resveratrol and to a greater extent
pterostilbene downregulates the HPV oncoprotein E6, induces caspase-3 activation, and upregulates
p53 protein levels. Results point to a mechanism that may involve the downregulation of the HPV
E6 oncoprotein, activation of apoptotic pathways, and re-establishment of functional p53 protein,
with pterostilbene showing greater efficacy than resveratrol.
Keywords: cervical cancer; resveratrol; pterostilbene; HPV E6; p53; cell cycle
1. Introduction
Cervical cancer is one of the most prevalent cancers affecting women worldwide. It is the
second most common cancer in developing countries and 11th in developed countries—these regional
differences are often attributed to the lack of Pap smears, a preventative procedure often absent in
underdeveloped areas [1,2]. It is widely accepted that the etiological factor that causes cervical cancer
is chronic infection of the human papilloma virus (HPV), which is considered the most common
sexually transmitted infection [3]. Every year about 500,000 women acquire the disease and 75% are
from the developing countries [4]. Moreover, recent evidence indicates that HPV infection is on the rise
in men, leading to higher incidences of penile and oropharyngeal cancer [5]. HPVs can be clinically
classified as “low-risk” (LR-HPV) or “high-risk” (HR-HPV) depending on the relative tendency of
the HPV lesions to transform into malignancy. HPV 16 and HPV 18 are the two most important
cancer-causing, high-risk HPV [6]. HPV progression to cancer is dependent on prolonged infection
by these high risk HPV viruses. The progression of HPV lesions to a neoplastic stage is dependent
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on several co-factors. Although there are approved HPV vaccines and drugs available, a problem
is the affordability of these drugs in low income areas [7]. Two such vaccines are Cervarix® and
Gardasil® [8], which renders prophylactic actions against cervical lesions associated with the most
common oncogenic HPV types, 16/18, but effective therapeutic measures for post-infection lesions are
currently not available. The major concern for the common chemotherapeutic medicines like cisplatin
and paclitaxel are their adverse side effects [9,10]. The development of natural chemoprotective drugs
that effectively target HPV infection could drastically reduce the incidence and progression of cervical
cancer worldwide if they are not cost inhibitive and have low side effects.
Of the varied groups of naturally occurring antioxidants, polyphenols have gained increased
importance in cervical cancer since they have displayed potent antitumor properties in a number of
cancers by targeting several pathways that are involved in cancer progression [11,12]. The current
article uses cervical cancer cells to compare the tumor-inhibitory effects and mechanism of action of
two such polyphenols, resveratrol and pterostilbene. Both resveratrol and pterostilbene are stilbenes,
which is a class of natural polyphenolic compounds that have been studied for their anticarcinogenic
activities. Resveratrol (3,4,5-trihydroxy-trans-stilbene) has been isolated from grapes, red wine, purple
grape juice, peanuts, berries, and some medicinal plants [13]. Resveratrol is a widely studied stilbene
compound having very low toxicity in the human system, and it is also known to modulate several
pathways that are directly linked to cancer progression [14]. Both in vitro and in vivo cancer studies
have shown resveratrol to inhibit cell proliferation and angiogenesis along with inducing pro-apoptotic
properties [15]. The potential problem of using resveratrol as a chemoprotective agent is that it has
low systemic bioavailability, which might lower its efficacy in the human system [16]. In order
to overcome this, several efforts are being made to develop resveratrol derivatives with higher
systemic bioavailability [17]. Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a naturally
derived dimethylether analogue of resveratrol. Pterostilbene is believed to be produced in plants as
a defense mechanism against some external microbial or fungal infection and is therefore considered
a phytoalexin [18]. It has been isolated from grapevine leaves and blueberries [19]. Recently,
pterostilbene has gained much attention as a possible anticancer agent, showing no toxicity in humans
up to a dose of 250 mg/day [20].
Although the chemical structure of pterostilbene is closely related to resveratrol, the substitution
of the hydroxyl group with a methoxy group in pterostilbene is believed to make the molecule more
stable as well as increase its capacity to enter cells [21]. In addition, clinical studies have shown that the
half-life and oral bioavailability of pterostilbene are significantly greater than those of resveratrol [20].
Studies on colon cancer cell lines have shown pterostilbene to be more potent than resveratrol in
inhibiting DNA synthesis and in decreasing the expression of inflammatory genes responsible for
cancer progression [22]. Although studies in other types of carcinomas show the potential efficacy
of resveratrol and pterostilbene, there has been no study to the best of our knowledge that explores
an anticancer mechanism that is specific for HPV-positive carcinoma. An in silico docking study
has shown that resveratrol interacts with the p53 binding site of E6 residues [23]. E6 is a vital HPV
oncoprotein essential for cervical cancer progression. E6 binds to tumor suppressor protein p53 and
targets it for degradation by the ubiquitin proteasome pathway [24], thus causing uncontrolled cell
proliferation. Here, we set out to compare the relative effectiveness of resveratrol against pterostilbene
on cervical cancer cells, paying particular attention to their comparative IC50 values, changes in the
levels of the HPV oncoprotein E6 and its target p53, as well as their comparative pro-apoptotic and
anti-migratory capacities.
2. Materials and Methods
2.1. Cell Culture
Human cervical carcinoma HeLa cells were obtained from a commercial supplier (American
Type Culture Collection, Manassas, VA, USA) and were cultured in Dulbecco’s Modified Eagle
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Medium: Nutrient Mixture F-12 (DMEM/F-12) (HyClone, GE Healthcare Life Sciences, Manassas,
VA, USA), supplemented with 10% fetal calf serum (HyClone, GE Healthcare Life Sciences) and 0.1%
Penicillin-Streptomycin Solution (HyClone). Cells were incubated in a 37 ◦C incubator with 5% CO2.
2.2. Determination of IC50 Using WST-1 Assay
Seven thousand cells were plated on 96-well plates and allowed to grow for 24 h. Resveratrol
(Acros, #430075000) or pterostilbene (TCI, #P1924) was serially diluted from 10–120 μM into
DMEM/F-12 plus 1× insulin-transferrin-selenium (ITS) supplement (Invitrogen). Cells were treated
with dilutions (in triplicate) for 24 h prior to performing a WST-1 (Water Soluble Tetrazolium salt-1)
cell viability assay. The WST assay involved aspiration of the medium after treatment and rinsing
three times with equal volumes of 1×Phosphate Buffered Saline (PBS), followed by the addition of
80 μL of 10% WST-1 (Clontech, Mountain View, CA, USA) in DMEM to each well. The plate was
then incubated at 37 ◦C for 1 h and absorbance monitored at 440 nm using a plate reader. Results
obtained were analyzed using GraphPad Prism 5 software to determine the IC50 using a standardized
method [25,26].
2.3. Live Imaging
Images of untreated and treated (with resveratrol and pterostilbene) cells were taken every 10 min
for 24 h to generate video files using a Zeiss Axio Observer Z1 microscope.
2.4. Clonogenic Assay
Two hundred thousand cells were plated on 6-well plates and allowed to grow for 24 h prior to
treatment with pterostilbene (50 μM) and resveratrol (50 μM) for 24 h. After 24 h, cells were trypsinized
to single cell suspensions. After cell counting, 150 viable cells from each treatment set were plated in
one well from a 6-well plate and allowed to grow in complete DMEM/F-12 medium for 15 days. After
said period of time, cells were washed once with 1× PBS then fixed and stained with 0.5% crystal
violet in 6% glutaraldehyde for 30 min. The cells were briefly rinsed with tap water and allowed to air
dry. Images of each well was taken and colonies were counted using ImageJ (NIH, Bethesda, Rockville,
MD, USA). The plating efficiency and survival factor was calculated as determined previously [27].
2.5. Scratch Assay
Twelve thousand cells were grown on 96-well plates until a confluent monolayer was formed.
A scratch was made with a sterile p200 tip in each well through the center of the culture. The debris
was washed off with serum-free media and a marking was made on the bottom of the plate to take
images at the same location. Cells were then treated with different concentrations (5 μM and 20 μM) of
resveratrol or pterostilbene and brightfield images were taken after 48 h to allow closure of the control
scratch. The images were analyzed using ImageJ and the area of closure was measured according to
previous published methods [28].
2.6. Flow Cytometry
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated
with resveratrol or pterostilbene (5 μM, 10 μM, and 15 μM) for 18 h. Cells were trypsinized, centrifuged,
and washed with 0.1% Fetal Calf Serum (FCS) in 1× PBS solution and resuspended in 70% ethanol at
−20 ◦C, which was added dropwise while shaking the samples vigorously. Fixed samples were kept
at 4 ◦C for 1 h followed by washing twice in 1× PBS. Prior to flow cytometry, cells were incubated
with RNase (500 μg/mL) for 30 min at 37 ◦C and then stained with propidium iodide (PI; 70 μM) for
30 mins. Cells were analyzed for DNA content by measuring PI fluorescence using an Accuri C6 flow
cytometer (BD).
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2.7. Western Blot Analysis
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated
with resveratrol (10 μM, 50 μM) or pterostilbene (10 μM, 50 μM) for a period of 22 h. Extraction
of proteins from cultured cells was performed using M-PER Mammalian protein extraction reagent
(Thermo Fisher, Waltham, MA, USA) with protease and phosphatase inhibitors. The total amount
of protein in each well was quantified using the Lowry method. To resolve the proteins, 25 μg of
protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis using a 10%
acrylamide separating gel and then transferred to nitrocellulose membrane for 1 h. The membrane was
blocked at room temperature for 1 h with 5% nonfat dry milk in Tris Tween Buffered Saline (TTBS).
The nitrocellulose membrane was then incubated overnight with a p53 antibody (sc-6243) followed by
incubation at room temperature for 1 h with anti-rabbit IgG conjugated with horseradish peroxidase.
SuperSignal West Pico chemiluminescence substrate (Pierce) was used for detection following the
manufacturer’s instructions. The membranes were scanned using APHA INNOTECH Fluorchem SP
imaging system. Analysis of blots was done using ImageJ software.
2.8. Immunocytochemistry
Seven thousand HeLa cells were plated on 8-well chamber slides and allowed to grow for 48 h.
Cells were then treated with different concentrations of resveratrol (5–50 μM) or pterostilbene (5–50 μM)
for 22 h (for study of E6, p53 and cleaved caspase-3) and 18 h (for study of Phospho histone H3).
All drug treatments were performed in serum-free DMEM/F-12 containing 1% supplement (ITS;
insulin, transferrin, selenium; Gibco BRL, Grand Island, NY, USA). After treatment, cells were fixed
in 4% paraformaldehyde at room temperature, rinsed with 1× PBS, and then permeabilized and
blocked with 10% horse serum, 2% bovine serum albumin, and 0.5% Triton X-100 in PBS for 1 h.
The cells were then incubated overnight with primary antibodies in blocking buffer. Subsequent
to primary antibody treatment, the cells were washed and then incubated with the respective
Fluorescein isothiocyanate (FITC) conjugated secondary antibodies for 3 h, followed by incubation
with 4’,6-diamidino-2-phenylindole (DAPI) (10 μg/mL) and three washes with 1× PBS. The slides
were then mounted with coverslips and cell images were acquired using a Zeiss Axio Observer Z1
microscope and an AxioVision 4.6.3-AP1. Images of different, randomly chosen fields were acquired
with identical exposure times from each well for quantification. ImageJ was used to measure the
fluorescence intensity and cell counting. The fluorescence intensities of E6 and P53 antibodies were
normalized to DAPI intensity (blue).
Antibodies Used: E6 antibody (sc-460, Santa Cruz Biotechnology, Dallas, TX, USA), p53 antibody
(sc-6243), cleaved caspase-3 antibody (D175, 9661, CST), Phospho Histone H3 (Ser 10) antibody (06–570,
Millipore, Burlington, MA, USA).
2.9. Statistical Analysis
Statistical analyses were performed using Microsoft Excel® 2013 (Microsoft Corporation,
Redmond, WA, USA) and GraphPad Prism® 5 (GraphPad Software, Inc., La Jolla, CA, USA). Means
and standard deviations were calculated for each group. One-way ANOVA with Tukey test was
used to compare three or more datasets and determine the significance between the groups. ANOVA
is a test of variance and post hoc Tukey test used is for the determination of significance between
groups [29,30]. p < 0.05 was considered as significant.
3. Results
3.1. Pterostilbene Is More Potent in Eliminating HPV+ HeLa Cells Compared to Resveratrol
In order to study the comparative cytotoxicity of pterostilbene and resveratrol on HeLa tumor
cells, brightfield images (Figure 1A) and WST-1 cell viability assays (Figure 1B) were performed
24 h post-treatment. The brightfield images taken after 24 h of treatment (Figure 1A) showed that
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pterostilbene (40 μM) eliminates significantly more cells than resveratrol at the same concentration.
Live imaging of cells treated with 60 μM of the two compounds show significantly more death
and characteristic apoptotic blebbing in pterostilbene-treated cells when compared to untreated or
resveratrol-treated cells (Supplementary Videos S1–S3). The WST-1 analysis revealed that although
both pterostilbene and resveratrol eliminated HeLa cells significantly and in a dose-dependent manner,
pterostilbene displayed a 1.97-fold lower IC50 when compared to resveratrol (42.3 μM vs. 83.5 μM;
p < 0.05; Figure 1B). Additionally, both compounds, at 50 μM, significantly inhibited the clonogenicity
of post-treated cells in a 15-day clonogenic assay (Figure 1C). Pterostilbene significantly reduced
clonogenic survival by 87.5% compared to the control (p < 0.05), while resveratrol inhibited it by 63%
(p < 0.05) (Figure 1C). Moreover, the difference between the survival percentages of the two treatment
groups is significant (p < 0.05).
Figure 1. Pterostilbene is more potent in eliminating HeLa cervical cancer cells as compared to
resveratrol: (A) Brightfield analysis of HeLa cells untreated (Ai) or treated for 24 h with 40 μM of
resveratrol (Res; Aii) or 40 μM of pterostilbene (Pte; Aiii). Evidence of cell elimination was only seen
robustly in cells treated with pterostilbene at 40 μM. (B) Analysis of IC50 values, generated by a Water
Soluble Tetrazolium salt-1 (WST-1) assay after 24 h of exposure to resveratrol or pterostilbene indicates
that pterostilbene (IC50 = 42.3 μM) is a more potent cytotoxic agent than resveratrol (IC50 = 83.5 μM;
Bii). The graphs represent data from three independent experiments (mean ± S.E.M. (Standard error
mean)). (C) Clonogenic assays performed to compare the relative effect of the two polyphenols on
the clonogenicity of HeLa cells untreated (Ci) or treated with 50 μM of either resveratrol (Cii) or
pterostilbene (Ciii). Results are from 15-days post-treatment and indicate that pterostilbene is more
efficient in curbing the clonogenicity compared to resveratrol (Civ). Bar graph represents data from
three independent experiments (mean ± S.E.M.; * p < 0.05; Civ).
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3.2. Inhibition of Cell Migration of HeLa Cells Treated with Pterostilbene and Resveratrol
To determine the comparative efficacy of resveratrol and pterostilbene in inhibiting HeLa cell
migration, two different sub-lethal concentrations of each compound were used in a 48-h scratch
assay (Figure 2). Based on the WST-1 results and brightfield images (unpublished), we found that
cells treated with a concentration below 25 μM showed no signs of cellular toxicity. To avoid any
cytotoxicity, we used lower concentrations of 5 μM and 20 μM. At sub-lethal concentrations of 5 μM
and 20 μM, both resveratrol and pterostilbene significantly inhibited HeLa cell migration relative to
untreated cells (p < 0.05; Figure 2). Pterostilbene was more effective in inhibiting HeLa cell migration at
20 μM when compared to resveratrol; however, this result was not significant and no differences were
seen between the two compounds at 5 μM (Figure 2). In an effort to analyze the effects of resveratrol
and pterostilbene on cell migration, we normalized the amount of migration into the scratch (wound)
by untreated cells, to 100%. Relative to this control, resveratrol-treated cells migrated only 71.2%
(5 μM) and 63.7% (20 μM), while cells treated with pterostilbene migrated only 69.5% (5 μM) and 49.2%
(20 μM) (Figure 2).
Figure 2. Resveratrol and pterostilbene inhibit cell migration: (A) HeLa cells were monitored for cell
migration into a scratched “wound”. Cells were either untreated or treated with sub-lethal concentrations
(5 μM and 20 μM) of resveratrol (Res) or pterostilbene (Pte). The extent of migration into the scratched
area was calculated after 48 h and revealed that both resveratrol and pterostilbene significantly inhibit cell
migration, although pterostilbene had greater anti-migratory effect. (B) The graphs represents data from
triplicate sample experiments normalized to the control (mean % migrated cells ± S.E.M.; * p < 0.05).
Scale bar: 0.05 μm.
3.3. Cell Cycle Arrest at S-Phase in HeLa Cells Treated with Low Concentrations of Resveratrol
and Pterostilbene
In order to compare the effect of sub-lethal doses of either resveratrol or pterostilbene on the
cell cycle of HeLa cells, treatment was carried out with three different concentrations (5 μM, 10 μM,
and 15 μM) of the two compounds for 18 h prior to flow cytometric analysis (Figure 3A). Flow
cytometry analysis showed that the cells treated with either compound exhibited a significant
decrease in the number of cells in the G2-M phase with respect to the control cells (p < 0.05)
(Figure 3A,B, Table 1), indicating an S-phase cell cycle arrest. This effect corresponded with an
increase in the number of cells arrested at the S-phase. Pterostilbene was significantly more potent
than resveratrol in inhibiting cell cycle progression, showing effects at concentrations as low as
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5 μM (p < 0.05) (Figure 3A,B, Table 1). At this concentration, pterostilbene had these percentages
of cells in each phase: G1 = 53.4 ± 1.4, S = 34 ± 1.4, G2 =12.5 ± 0.2, while resveratrol had values of
G1 = 64.8 ± 2.0, S = 16.3 ± 1.0, G2 = 18.3 ± 2.3. At a higher concentration (15 μM) both compounds
significantly inhibited cells from entering into G2-M by arresting them in the S-phase, and difference
between the extent of the arrest at this phase induced by the two compounds was significant (p < 0.05)
(Figure 3A,B, Table 1).
To confirm the cell cycle data, which indicated that both compounds are potent inhibitors of cells
entering into G2-M, we investigated the status of the M-phase mitotic marker phospho-histone-H3
by immunocytochemistry (Figure 3C,D). At concentrations of 10 μM, both compounds significantly
suppressed the amount of cells positive for the mitotic marker phospho-histone-H3, when compared
to the untreated cells control. Although resveratrol significantly suppressed the abundance of
phospho-histone-H3 (mitotic cells) at 5 μM, when compared to the control cells, pterostilbene at
this concentration was significantly more potent than resveratrol (Figure 3D). Relative to the control,
which was set at 100%, cells treated with 5 μM pterostilbene exhibited only 13.8% mitotic cells positive
for the marker, which was significantly lower than the resveratrol-treated sample at this concentration,
which had 60% mitotic cells (Figure 3D; p < 0.05).
Figure 3. S-phase arrest in HeLa cells treated with low concentrations of resveratrol and pterostilbene:
(A) Flow-cytometric evaluation of HeLa cells untreated or treated with sub-lethal doses of resveratrol
(Res) and pterostilbene (Pte) for 18 h. Treated cells exhibited S-phase arrest and a subsequent decrease
in the number of cells in G2/M. Pterostilbene was a more potent compound than resveratrol, showing
a capacity to arrest cells at the S-phase at concentrations as low as 5 μM. (B) Graphical representation
of the dose-dependent cell cycle effects induced by resveratrol and pterostilbene at three different
concentrations (5 μM, 10 μM, and 15 μM). (B) The graph represents data from triplicate sample
experiments normalized to the control (mean % cells in each phase ± S.E.M.) (C) Immunofluorescent
images of HeLa cells probed for the M-phase marker phospho-histone-H3 (serine10). HeLa cells
were untreated or treated with 5 μM and 10 μM of resveratrol or pterostilbene. Immunofluorescent
images display a decrease of histone-H3 in cells treated with both the compounds, the effects at 5 μM
of pterostilbene is much greater than those of resveratrol (at 5 μM). (D) Graphical representation of
the percent of mitotic cells calculated from immunofluorescent images reveal that resveratrol and to
a greater extent pterostilbene are effective in decreasing the number of mitotic HeLa cells. The graph
represents data from experiments obtained from triplicate samples normalized to the control (mean %
mitotic cells ± S.E.M.;* p < 0.05).
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Table 1. Table showing the percentage of cells in each phase of the cell cycle (% ± S.E.M.) after treatment
with different concentrations of resveratrol (Res) and pterostilbene (Pte).
G1 ± S.E.M. S ± S.E.M. G2 ± S.E.M.
Control 64.1 ± 0.4 8.00 ± 2.5 27.7 ± 2.4
Res 5 μM 64.8 ± 2.0 16.3 ± 1.0 18.3 ± 2.3 ˆ
Pte 5 μM 53.4 ± 1.4 + 34.0 ± 1.4 * 12.5 ± 0.2 ˆ
Res 10 μM 58.5 ± 0.2 26.5 ± 0.2 * 14.4 ± 1.0 ˆ
Pte 10 μM 54.3 ± 0.8 + 35.6 ± 2.4 * 10.1 ± 1.5 ˆ
Res 15 μM 61.3 ± 1.9 27.1 ± 0.8 *,# 11.5 ± 1.2 ˆ
Pte 15 μM 52.3 ± 2.0 + 40.1 ± 3.4 *,# 7.7 ± 0.5 ˆ
+ p < 0.05 relative to G1 control, * p < 0.05 relative to S control, ˆ p < 0.05 relative to G2 control, # p < 0.05 relative to
each other.
3.4. Downregulation of Viral Oncoprotein E6 and Upregulation of Active-Caspase-3 in HeLa Cells Treated
with Pterostilbene and Resveratrol
In order to investigate how resveratrol and pterostilbene were affecting HeLa cell survival and
cell cycle progression, we treated cells with either of the two compounds at sub-lethal (10 μM)
and higher (50 μM) concentrations prior to analysis by immunostaining for E6, active caspase-3,
and p53 (Figure 4A–C). At 10 μM, both resveratrol and pterostilbene failed to significantly affect
levels of E6 and active caspase-3 levels relative to the control (Figure 4A,B). However, at 50 μM
both compounds significantly suppressed E6 levels and elevated cleaved caspase-3 levels in treated
cells relative to the untreated cells (Figure 3A–C). At this concentration (50 μM), pterostilbene was
significantly more potent than resveratrol at suppressing E6 levels (resveratrol = 0.77 ± 0.11: 23%
decrease vs. pterostilbene = 0.57 ± 0.06: 43% decrease; p < 0.05) and simultaneously elevating active
caspase-3. It should be noted that we were unable to detect any noticeable differences in the sub-cellular
localization of E6 in treated cells (Figure 4A).
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Figure 4. Downregulation of viral oncoprotein E6 and upregulation of active-caspase-3 in HeLa cells
treated with resveratrol or pterostilbene: (A) HeLa cells immunostained for E6 levels (green) and
counterstained with the nuclear dye 4’,6-diamidino-2-phenylindole (DAPI) (blue) after treatment with
resveratrol (Res) and pterostilbene (Pte; 10 μM and 50 μM). Loss of E6 proteins are visually evident
in cells treated with 50 μM of either resveratrol or pterostilbene. (B) Cell image analysis of the E6
fluorescent data revealed a significant 43% decrease of E6 protein levels in HeLa cells treated with
pterostilbene at 50 μM and a 23% decrease of E6 levels in cells treated with resveratrol, both relative to
the control. The graph represents data from experiments obtained from three independent experiments
normalized to the control (mean % normalized to DAPI ± S.E.M.; * p < 0.05). (C) Immunofluorescent
images probing for active-caspase-3 (green) shows a corresponding enhanced activation of this mediator
of apoptosis by both resveratrol and pterostilbene.
3.5. Upregulation of Tumor Suppressor Protein p53 in HeLa Cells Treated with Pterostilbene and Resveratrol
Concomitant with E6 suppression, 50 μM pterostilbene treatment for 22 h caused an upregulation
of p53 in HeLa cells (Figure 5A,B). When compared to the control, pterostilbene treatment elicited
a 2-fold increase in p53 levels (staining normalized to DAPI; Figure 5B; p < 0.05). In comparison to
the control, HeLa cells treated with 50 μM of resveratrol also caused an upregulation of p53 (1.75-fold
increase; Figure 5A,B; p < 0.05) at 22 h.
Total protein levels of p53 were also analyzed by Western blot in cells treated with either resveratrol
(10 μM and 50 μM) or pterostilbene (10 μM and 50 μM) for 22 h (Figure 5C,D). Both compounds
elevated p53 levels at 50 μM; however, significance was only noted in cells treated with pterostilbene
at this concentration (Figure 5C,D). Although cells treated with pterostilbene at 10 μM tended to have
elevated p53 protein levels relative to both the control cells and cells treated with 10 μM of resveratrol,
these differences were not significant based on an ANOVA test (Figure 5C,D).
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Figure 5. Upregulation of the tumor suppressor protein p53 in HeLa cells treated with resveratrol
and pterostilbene: (A) Immunoflourescent images of p53 protein (green) untreated or after treatment
with 50 μM of either resveratrol (Res) or pterostilbene (Pte) for 22 h. Levels of p53 are elevated
in cells treated with either polyphenol. (B) Image analysis of p53 immunofluorescence indicates
that pterostilbene treatment at 50 μM elicited a significant 2-fold increase in p53, while resveratrol
exposure at similar concentrations induced a significant 1.75 increase in p53. The graph represents data
from experiments obtained from three independent experiments normalized to the control (mean %
normalized to DAPI ± S.E.M. * p < 0.05). (C) Western blot analysis also revealed that the elevation of
p53 protein levels is evident in HeLa cells treated with 50 μM of resveratrol and pterostilbene; however,
significant differences relative to the control were only reached with HeLa cells treated pterostilbene at
50 μM. (D) The graph represents data from experiments obtained from three independent experiments
normalized to the control (mean % normalized to beta-actin ± S.E.M.; * p < 0.05).
4. Discussion and Conclusions
In the current study, for the first time to our knowledge, we have compared the antitumor
potency of resveratrol and pterostilbene on E6+ cervical cancer cells in vitro. We demonstrated that
pterostilbene was significantly more potent than resveratrol in eliminating and in abrogating the
clonogenicity of these cervical cancer cells (Figure 1). To assess and study the effects of the two
compounds, we used a wide range of concentrations. Sub IC50 concentrations ranging from 5–20 μM
were used to understand the action of these polyphenols at a low concentration. The results show that
at these concentrations the polyphenols can inhibit cell division and migration. To further understand
the cytotoxic mechanisms, it was imperative for us to look at supra IC50 concentrations. We used
50 μM to understand the mechanism of action. The clonogenic assay using this high concentration
elucidates the long-term effect of these polyphenols on surviving cells even after the removal of
treatment. While sub-IC50 values of both compounds inhibited the migration of E6+ cervical cancer
cells, a higher sub-lethal concentration of resveratrol (20 μM) was needed to exert any significant
inhibitory effect. Nonetheless, pterostilbene caused a more significant degree of inhibition to cell
migration, attesting its superior antitumor potency (Figure 2). It is a notion held by cancer researchers
that sub-IC50 concentrations of chemotherapeutic drugs are ineffective in curtailing tumor malignancy.
However, surprisingly, our data shows that even at a low sub-lethal concentration (5 μM), pterostilbene
is more effective than resveratrol as an antiproliferative agent against cervical cancer cells by triggering
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cell cycle arrest at the S-phase (Figure 3). In addition to being effective at sub-IC50 concentrations,
the supra-IC50 concentration of pterostilbene (50 μM) was also superior to resveratrol (at 50 μM) in
suppressing E6 while upregulating p53 and active-caspase-3 expression, thus causing a greater degree
of apoptosis-mediated cell elimination. This observed suppression of E6 and upregulation of p53 is of
paramount importance because HPV infection and cancer progression in cervical cells relies on the
expression of the viral E6 oncoprotein which targets p53 for degradation by the ubiquitination [24,31].
Thus, untreated cervical cancer cells continue to proliferate in the absence of p53, unable to respond
to cell stress and DNA damage. Our data indicates that resveratrol and pterostilbene may restore an
adequate p53 response and ultimately act as anticancer plant compounds.
A comparative study between resveratrol and pterostilbene on colon cancer cells had shown
pterostilbene to be a more potent anticancer agent compared to resveratrol [15]. Our first approach to
understand the comparative efficacy of resveratrol and pterostilbene in HeLa cells was a cytotoxicity
analysis, in addition to ascertaining the inhibitory concentration (IC50) (Figure 1 and Videos S1–S3).
The results clearly indicated that pterostilbene could eliminate HeLa cells much faster and at
a significantly lower concentration compared to resveratrol. We also further analyzed the cytotoxic
potential of these polyphenols on a second cell line, E6-positive murine TC1 cells, and found a similar
trend in IC50 results for resveratrol and pterostilbene, where pterostilbene is 2-fold more cytotoxic than
resveratrol [32]. Since cancer cells are known to have enhanced clonogenecity [27,33], our study aimed
to see the survival capability of the cells treated with supra-IC50 concentrations of either resveratrol or
pterostilbene. Clonogenic studies show the long term-term effects of these polyphenols on cervical
cancer cells after treatment for 24 h and then allowing the surviving cells to grow in normal growth
medium for 15 days. Both compounds at supra-IC50 concentrations showed a dramatic decrease in the
clonogenic capacity of the surviving cells. These results suggest that resveratrol and pterostilbene may
suppress new tumor growth often seen in high-grade metastatic cervical cancer.
The migration of cancer cells is a very important factor responsible for the metastasizing of
cancers [34]. Inhibition of migration can play a major role in checking the progression of cancer
metastasis. Our study found that sub-cytotoxic doses of both compounds exhibit anti-migratory
roles. These findings are supported by previous studies, which have shown that resveratrol shows
anti-migratory activity by suppressing phorbol 12-myristate 13-acetate (PMA)-induced migration in
cervical cancer cells [35]. Studies in hepatocellular carcinoma indicate that pterostilbene suppresses
migration by downregulating MMP-9 expression [36]. These mechanisms might possibly be
responsible for inhibiting migration in HeLa cells and remain to be determined in later studies.
Previous cell cycle arrest studies of resveratrol on HeLa cells showed that all the cells were
arrested at the S-phase and none remained in the G2/M-phase [37,38]. Pterostilbene shows cell cycle
arrest in several cancer studies [39]; however, to the best of our knowledge, no such study on cervical
cancer has been carried out. Our current study showed that pterostilbene shows markedly better
efficacy than resveratrol in arresting the cell cycle at the S-phase. To further analyze the effects of the
two compounds on cell cycle arrest, we looked at phospho-histone H3 as a marker for mitosis [40].
Our observations strengthen and confirm the results obtained from flow cytometric analysis indicating
that although both compounds are able to arrest mitosis, pterostilbene has enhanced capacity to arrest
cancer cell growth.
Although we initially used sub-lethal concentrations of the two compounds on HeLa cells to
decipher their antitumor mechanisms in the context of cell cycle arrest, it was imperative for us
to delineate the possible mechanism of elimination of HeLa cells by these compounds at higher
concentrations. Pterostilbene is known to be effective on cervical cancer cells by Endoplasmic reticulum
(ER)-mediated stress development as well as by targeting the Nrf-2 pathway [41]. In HPV+ cancer
cells, the oncoprotein E6 degrades the tumor-suppressor protein p53 by targeting it for proteasomal
ubiquitination, which has been shown to augment the tumorigenic characteristics of cancer cells [24,42].
In contrast, inhibition of E6 expression in the cancer cells would be expected to allow p53 protein to
trigger apoptosis and cell cycle arrest. Our findings support this latter statement, with resveratrol
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and pterostilbene activating caspase-3 while simultaneously downregulating E6 and upregulating
p53. Our findings are partly supported by previous studies indicating that resveratrol treatment on
cervical cancer cell lines upregulates p53 [43]. Our findings are the first to show a direct upregulation
of p53 in HeLa cells by another polyphenol, namely, pterostilbene. Importantly previous studies have
shown that p53 and simultaneous caspase-3 activation might be the key for triggering apoptosis in
HeLa cells [44]. Our experiments support this finding and ascertain that resveratrol and pterostilbene
act as robust agents capable of regulating the p53-dependent apoptotic pathway. The p53 protein,
which is usually very low in HeLa cells, was upregulated by resveratrol and pterostilbene, leading
us to hypothesize that reactivation of p53 in treated HeLa cells is a possible mechanism of action of
these compounds.
Cervical cancer is a major concern in developing countries due to lack of affordable prophylaxis
and treatment. As present modes of treatment like surgery, chemotherapy, or radiation involve
high systemic toxicity, there is an urgent need to find affordable alternative therapies. Diet-based
polyphenols like resveratrol and pterostilbene are therefore potential candidates for the effective
therapy of cervical cancer with significantly low toxicity. We found pterostilbene to be a more potent
anticancer agent than resveratrol in HeLa cells. This difference may be a function of pterostilbene
being capable of upregulating p53 and downregulating E6 significantly more than resveratrol.
As pterostilbene is non-toxic to normal cells [20], it has the potential to be a robust, cost-effective
anti-E6+ tumor drug. Others have found that that pterostilbene possess greater bioavailability and
stability [45] than resveratrol in vivo (80% vs. 20%). Resveratrol has been shown to be non-toxic to
several cells lines like glial cells and neurons, even after a treatment dose of 100 μM for 48 h [46]. Other
studies on normal fibroblasts also state the non-toxicity of resveratrol at our observed potent anticancer
concentrations [47]. Additionally, pterostilbene shows no toxicity at these concentrations in normal
skin fibroblasts and myoblasts [48]. According to clinical studies, the safe dosage for resveratrol and
pterostilbene is 5 g/day [49] and 250 mg/day [20], respectively. Our initial in vivo studies in the
laboratory using a non-toxic dosage of both resveratrol and pterostilbene has shown promising results
in inhibiting tumor growth in a model of cervical cancer [32]. Taken together, our findings support the
further evaluation of pterostilbene as a possible therapy against cervical cancer.
Here, we show that pterostilbene potently suppresses HPV E6 expression (Figure 4) and efficiently
eliminates HPV+ cells in culture by p53-mediated apoptosis (Figures 1 and 5) while suppressing
cell proliferation (Figure 3) and migration (Figure 2). We find that pterostilbene is a more promising
agent against cervical cancer when compared to resveratrol. Based on such properties, the use of
pterostilbene presents a relatively economical but highly hopeful therapeutic approach to treat HPV
infections and cervical cancers. Our future studies will include signaling studies using HPV+ murine
tumor models to confirm these observations in vivo.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/10/02/243/s1,
Video S1: Pterostilbene induces enhanced cell death compared to resveratrol: Time lapse video of cells untreated;
Video S2: Pterostilbene induces enhanced cell death compared to resveratrol: Time lapse video of cells treated
with 60 μM resveratrol; Video S3: Pterostilbene induces enhanced cell death compared to resveratrol: Time lapse
video of cells treated with 60 μM pterostilbene obtained for 24 h showing elevated blebbing and cell death in
pterostilbene treatment.
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Abstract: In order to fully understand the progresses and achievements in Chinese medicines for
the treatment of prostate cancer, we summarize all the available reports on formulas, extracts,
and compounds of Chinese medicines against prostate cancer. A number of clinical trials verified that
traditional Chinese formulas had some unique advantages in the treatment of prostate cancer. Many
Chinese medicine extracts could protect against prostate cancer, and many compounds isolated from
Chinese traditional medicines showed a clear anti-prostate cancer effect. However, Chinese medicines
are facing many problems regarding their multicomponent nature, complicated mechanisms of action,
and high doses required for therapy. Herein, we review the functions of Chinese medicines in
prostate cancer and focus on their mechanisms. The review will deepen the understanding of
Chinese medicines potential in the anti-prostate cancer field. In addition, we put forward a question
concerning the current research on Chinese medicines: in order to better illustrate that Chinese
medicines can be used in the clinical treatment of prostate cancer, should our research focus on
formulas, extracts, or compounds?
Keywords: prostate cancer; Chinese medicines; formulas; extracts; compounds
1. Introduction
Prostate cancer (PCa) is a common cancer in elderly men. The incidence of PCa is different in
different countries, and the general mortality rate of prostate cancer reaches 1–2% [1]. The mechanisms
of PCa progression have been explored, and key progresses have been made in the treatment of PCa.
Personalized therapies based on nanomedicines, Chinese medicines, and genetic factors, have become
one of the study hotspots of PCa treatment [2]. However, why are the complex Chinese medicines
increasingly concerned?
Because of their low toxicity, non-apparent side effects, and obvious curative effects in tumor
treatment, Chinese medicines have been accepted by doctors, experts, and patients [3]. Chinese
medicines can inhibit tumor growth and metastasis, prolong patients’ life span, and improve patients’
life quality [4]. Some patients, who were found to have cancers in the late stage, could not undergo
surgery, radiotherapy, and chemotherapy, and finally accepted Chinese medicines treatment, which
restrained the tumor progression, improved their quality of life, and obviously extended their
survival [4]. Herbal medicines are the traditional medicine resources in China, with unique advantages.
Medicinal plant resources are widely distributed in China. More than 50% of anticancer drugs
approved by the U.S. Food and Drug Administration (FDA) are extracted from terrestrial plants [5],
indicating that herbal medicines are important in the development of anticancer drugs.
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Traditional Chinese medicine formulas are widely used in clinical cancer treatment in Chinese
hospitals [6]. Many Chinese herbal extracts have been proved to inhibit the development of prostate
cancer. More and more compounds isolated from Chinese medicine herbs were found to inhibit the
development of prostate cancer via different pathways. A number of clinical trials have shown that
traditional Chinese medicines play a definite role in the protection against prostate cancer and will be
used in clinical treatment of prostate cancer in the future. Chinese medicines have a great potential in
PCa treatment.
Pharmacological research on the antitumor efficacy of Chinese herbal extracts and formulas
is developing promptly, and the application of Chinese medicine compounds in clinical oncology
has been widely accepted. Soiqnet et al. established arsenic trioxide as an effective therapy for
patients with relapsed acute promyelocytic leukemia and recorded high rates of 5-year disease-free
survival and 5-year overall survival after a long-term follow-up of newly diagnosed patients with
acute promyelocytic leukemia treated with a single-agent therapy based on arsenic trioxide [6,7].
The combination of Chinese medicines and other treatment methods has been widely used in China
and has achieved a good therapeutic efficacy [8–11]. Although studies on Chinese medicines in
anticancer therapy have demonstrated some achievements, there is still a long way for the wide
application of Chinese medicines in the treatment of prostate cancer. This work intends to summarize
the recent progresses in the use of Chinese medicines for PCa treatment and points out possible
future breakthroughs.
2. Chinese Medicine Formulas in the Treatment of Prostate Cancer
PC-SPES is a Chinese medicine formula containing eight herbal medicines. It was launched
into the market as a health care product in 1996 by Botanic Lab [12]. The New England Journal of
Medicine first reported the biological activity and the clinical effect of PC-SPES in 1998 [13]. A series
of reports showed that PC-SPES can significantly reduce serum testosterone and prostate-specific
antigen in patients with prostate cancer in a time- and dose-dependent manner [14–17]. However, in
2001, patients taking PC-SPES showed diffuse intravascular coagulation and bleeding tendency [18,19].
In 2002, some batches of PC-SPES were found to contain diethylstilbestrol, warfarin, and indomethacin,
which made the efficacy and side effects of PC-SPES controversial [20]. Considering the stability and
safety of Chinese herbal remedies, National Center for Complementary and Alternative Medicine
(NCCAM) suspended research on PC-SPES and its related compounds and withdrew it from the USA
market in February 2000 [21].
From 2010 to 2012, Lin et al. reported a series of clinical data on prostate cancer treated with
Chinese medicines. Firstly, they found that traditional Chinese medicine (TCM) treatment was only a
complementary treatment rather than an alternative treatment. Then, they found that TCM treatment
showed an increasing trend in popularity among prostate cancer patients in Taiwan. Later, they
confirmed that TCM treatment was popular among prostate cancer patients in Taiwan [22–25].
A retrospective nationwide cohort study of prostate cancer patients was conducted based on
data from 1998 to 2003 from the Taiwan National Health Insurance Research Database. Patients were
classified as TCM users or nonusers and monitored from the day of prostate cancer diagnosis to
death or to the end of 2012. The correlation between death risk and TCM use was determined with
cox-proportional-hazards models and Kaplan–Meier curves. The correlation analysis results showed
TCM users had a decreased mortality. A lower death risk was observed in patients with longer-term
TCM use, especially in those who used TCM for at least 200 days. TCM users with metastatic prostate
cancer had a significantly lower hazard ratio than non-TCM users [26].
PC-SPES’s entry into the US market has convinced that this Chinese medicine formula has a
definite efficacy on prostate cancer, although PC-SPES was withdrawn from the US market after 4 years.
Chinese medicine researchers realize that it is a key issue to ensure Chinese medicines’ stability and
safety. Many scientists in China today are devoted to the quality control of Chinese medicines.
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A leading cause of the prostate cancer treatment failure is chemoresistance, which often involves
multiple mechanisms. Chinese medicines usually contain multiple components, which can potentially
target many mechanisms simultaneously and may offer an advantage over single compounds.
The characteristic of Chinese medicines can be used as a strategy to avoid chemoresistance.
Chinese medicines have been applied for a long time. The mechanisms of Chinese medicines
should be further explored with advanced scientific and technological methods to control the stability
and safety of Chinese medicines for human health.
3. Chinese Medicine Extracts Inhibit Prostate Cancer
Traditional plant-derived products play a significant role in the development of potential
medicinal agents. Ganoderma lucidum (Leyss. ex Fr.) Karst. is a type of mushroom and has been
used as a home remedy for the general promotion of health and longevity in traditional Chinese
medicines [27]. Spores and unpurified fruiting bodies of G. lucidum (0.5–2.5 mg/mL) could inhibit the
invasion of breast MDA-MB-231 and prostate PC-3 cancer cells by downregulating the expression of
NF-kappaB, urokinase plasminogen activator (uPA), and uPA receptor [28]. Meanwhile, G. lucidum
(0.125–0.5 mg/mL) could induce apoptosis, inhibit cell proliferation, and suppress the migration of
highly invasive PC-3 human prostate cancer cells [29]. Furthermore, G. lucidum (0.125–0.5 mg/mL) was
reported to inhibit prostate cancer-dependent angiogenesis by modulating MAPK and Akt signaling
in PC-3 cells [30]. These results indicated that G. lucidum had a potential therapeutic efficacy for the
treatment of prostate cancer.
Litchi chinensis Sonn. (Litchi) is a subtropical fruit tree growing in south China. Litchi seed extracts
were found to possess diverse pharmacological effects including significantly inhibiting cell viability
and clonogenic growth of prostate cancer PC-3, DU145, RM-1, and C4-2B cells in a dose-dependent
manner (31.25–250 μg/mL) and inducing cell apoptosis and cell cycle G1/S phase arrest by inactivating
protein kinase B (Akt or PKB) signaling pathway [31]. In addition, the extracts significantly decreased
cell migration and invasion via a phenotypic inversion of epithelial–mesenchymal transition [31].
Remarkably, the extracts significantly decreased the size of PC3 xenograft nude mice, showing no
toxicity [31]. These findings suggested that Litchi seed extracts might be used to develop a safe
alternative therapy for prostate cancer patients.
Saussurea lappa Clarke has been applied in the treatment of inflammation, abdominal pain,
tenesmus, nausea, and cancer in China [32,33]. Hexane extracts of S. lappa inhibited the basal and
Epidermal Growth Factor (EGF)-induced migration of prostate cancer DU145 and TRAMP-C2 cells
in a dose-dependent manner (1–4 μg/mL), whereas they did not influence the viability of these
cancer cells. In addition, the extracts reduced matrix metalloproteinase (MMP)-9 and tissue inhibitor
of metalloproteinase (TIMP)-1 secretion, but increased TIMP-2 levels in the absence or presence of
EGF [34]. The results indicated that hexane extracts of S. lappa might be used as anti-metastatic agents
for the treatment of prostate cancer.
Scutellaria baicalensis Georgi is a widely used Chinese herbal medicine in anti-inflammatory
and anti-cancer therapy [35–37]. S. baicalensis (0.2–0.8 mg/mL) exerted dose- and time-dependent
growth inhibition effects on both LNCaP and PC3 cell lines and also inhibited prostate-specific antigen
production in LNCaP cells. Animal experiments of S. baicalensis showed a reduction of 50% in tumor
volume after a 7-week treatment at a dose of 200 mg/kg/day [38]. These results imply that S. baicalensis
possess anti-prostate cancer activity in vitro and in vivo.
Scutellaria barbata D. Don has been used to treat various cancers in China [39–41]. Wong et al.’s
in vivo data showed that S. barbata (32 mg/day) delayed tumor development in a transgenic
prostate adenocarcinoma mouse model ,and the complementary in vitro data indicated that S. barbata
(1 mg/mL) might exert this function by upregulating the apoptotic pathway and downregulating the
survival pathway in TRAMP-C1 and LNCaP prostate cancer cells [42]. According to these results,
S. barbata might possess chemopreventive properties for cancer treatment.
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Tripterygium wilfordii Hook F (12.5–50 μg/mL) combined with docetaxel could overcome the
chemoresistance and suppress prostate tumor growth in docetaxel-resistant PC3 and DU145 prostate
cancer cell lines by inhibiting P-glycoprotein activity and inducing a significant change in the expression
of genes related to angiogenesis, cell cycle regulation, and differentiation [43]. This findings imply that
T. wilfordii might be developed as a combined agent to prevent chemoresistance.
Wedelia chinensis (Osbeck) Merr. is a common ingredient in anti-inflammatory herbal medicines
in China [44–46]. The anti-prostate cancer effect of W. chinensis extracts is ascribed to three active
compounds: wedelolactone, luteolin, and apigenin, which inhibit the androgen receptor (AR) signaling
pathway in LNCaP and 22Rv1 cells. Oral administration of W. chinensis extracts (4 or 40 mg/kg)
impeded prostate cancer tumorigenesis [47].
On the basis of the above-mentioned results, we found that these Chinese medicines had
anti-prostate cancer activity (Table 1). These results also suggested that many potential natural
compounds with anti-prostate cancer activity might exist in Chinese herbal extracts.
Table 1. Chinese medicine extracts inhibit prostate cancer.
Scientific Name Chinese Name Plant Organs Extraction Solvents
Ganoderma lucidum (Leyss. ex Fr.) Karst. Ling Zhi Spores and unpurified fruiting bodies No solvent
Litchi chinensis Sonn. Li Zhi Seed n-butyl alcohol
Saussurea lappa Clarke Guang Mu Xiang Root n-Hexane
Scutellaria baicalensis Georgi Huang Qin Root Water
Scutellaria barbata D. Don Ban Zhi Lian Whole plant Water
Tripterygium wilfordii Hook F. Lei Gong Teng Root EtOH
Wedelia chinensis (Osbeck) Merr. Peng Qi Ju Whole plant EtOH
4. Compounds Isolated from Chinese Medicines Inhibit Prostate Cancer
4.1. Compounds Inhibiting the Growth of Prostate Cancer Cells
Andrographolide is a diterpenoid lactone derived from a traditional Chinese medicine plant
Andrographis paniculata (Burm. f.) Nees. Chun et al. demonstrated that andrographolide (1–20 μM)
could inhibit IL-6-induced signaling and induce signal transducer and activator of transcription 3
(STAT3) and the phosphorylation of extracellular signal-regulated kinases (ERK). Meanwhile, it could
inhibit cell viability and induce apoptosis of PC3 and DU145 prostate cancer cell lines. Moreover,
andrographolide suppressed tumor growth in a mouse xenograft model with castration-resistant
DU145 cell-derived human prostate tumors. These findings imply that andrographolide could be
developed as a therapeutic agent to treat prostate cancer [48].
Evodiamine is isolated from the Chinese herbal medicine Evodia rutaecarpa (Juss.) Benth. Recent
results showed that evodiamine suppressed the growth of LNCaP cells in a dose-dependent manner
(100 nM–100 μM) by arresting the cell cycle at the G2/M phase and inducing apoptosis [49].
Guttiferone F (10 μM and 20 μM) could induce apoptosis of LNCaP and PC3 prostate cancer cells
under serum starvation via JNK activation and Ca2+ elevation, respectively. Furthermore, it exerted a
significant growth inhibition on PC3 cells xenografts in vivo at a dose of 20 mg/kg [50].
Honokiol is a compound contained in the traditional Chinese herb Magnolia officinalis Rehd. et Wils.
The viability of PC-3 and LNCaP human prostate cancer cells was decreased when the cells were
treated with honokiol (20–60 μM). These results were confirmed to be correlated with G0/G1 phase
cell cycle arrest [51]. Honokiol (5–20 μM) induced apoptosis in PCa cell lines by activating caspases
3/8/9 and cleaving poly-adenosine diphosphate ribose polymerase. In addition, honokiol (100 mg/kg)
combined with docetaxel (5 mg/kg) showed growth-inhibitory, apoptotic, and antiangiogenic effects in
C4-2B tumor xenografts [52]. Moreover, the exposure of PC-3, LNCaP, and Myc-CaP cells to 20–40 μM
honokiol resulted in ROS-mediated cytoprotective autophagy [53].
Isorhapontigenin (ISO) is widely distributed in Chinese herbs, fruits, and vegetables [54–56].
Isorhapontigenin (ISO, 20–100 μM) induced cell growth inhibition and apoptosis of LNCaP and 22Rv1
by targeting EGFR and its downstream signal pathways and showed no obvious effects on normal
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prostate cells [57]. Moreover, the treatment with ISO decreased the protein level of AR by promoting
the ubiquitination and degradation of AR proteins in proteasome and inhibiting the expression of
AR gene [57]. In vivo, 50 mg/kg of ISO inhibited the growth of subcutaneously xenotransplanted
tumors in nude mice by inducing PCa cell growth inhibition and apoptosis [57]. EGFR-related signal
pathways are involved in ISO-induced cell growth inhibition and apoptosis in PCa cells, suggesting
the application potential of ISO in prostate cancer treatment.
Peperotetraphin is a novel cyclobutane-type norlignan isolated from the whole plant of
Peperomia tetraphylla [58]. Peperotetraphin (50–100 μM) inhibited the growth of PC-3 cells and induced
cancer cells to undergo G1 phase arrest and apoptosis [59].
Quercetin is a natural polyphenolic compound widely distributed in Chinese herbal
medicines [60]. A large body of evidence showed that quercetin could induce the apoptosis of prostate
cancer cells via multiple possible signaling pathways [61–65]. Liu et al. reported that 50–200 μM
quercetin might induce apoptosis by direct activation of the caspase cascade via the mitochondrial
pathway and endoplasmic reticulum stress in PC-3 cells [66].
Tetrandrine is an alkaloid from the traditional Chinese medicine Stephania tetrandra S. Moore [67].
Tetrandrine (2.5–30 μM) inhibited the growth and cell cloning of PC-3 and DU145 cells [68]. In addition,
tetrandrine induced apoptosis by inhibiting phosphoinositide 3-kinase–Akt signal pathway and by
activating the caspase cascade [68].
Triptolide is one of the main active components of Tripterygium wilfordii Hook.f [69]. Tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapy agent [70].
Although a number of prostate cancer cells exhibited high resistance to TRAIL effect [71], 50–200 nM
triptolide significantly sensitized LNCaP and PC-3M prostate cancer cells to TRAIL-mediated
cellular apoptosis by upregulating the expression of death receptor 5 and inhibiting prostate cancer
development [72].
Vitexicarpin is a polymethoxy flavone isolated from Vitex rotundifolia Linne fil. and has long been
used as an anti-inflammatory herb in China [73]. Meng et al. revealed that vitexicarpin (10–50 μM)
induced apoptosis by upregulating the proapoptotic protein Bax, downregulating the antiapoptotic
protein Bcl-2, releasing cytochrome C from mitochondria, and decreasing mitochondrial membrane
potential in PC3 cells [73].
These Chinese medicine compounds can inhibit the growth of prostate cancer cells mainly
by inducing cell apoptosis, arresting the cell cycle at different phases, activating caspase cascade,
and/or regulating the expression of apoptosis-related proteins. Moreover, AR signaling pathway
and the cytoprotective effect mediated by ROS are also involved in the inhibition effect of Chinese
Medicine compounds.
4.2. Compounds Inhibiting the Proliferation of Prostate Cancer Cells
Arsenic sulphide is a main component of realgar (As4S4), and 0.5–1 μM arsenic sulphide can
repress the overexpression of miRNA-372 in DU145 and PC3 prostate cancer cell lines [74]. An in vivo
study confirmed that repressing the overexpression of miR-372 by 2 mg/kg/day of As4S4 for 3 weeks
could inhibit the proliferation and migration of prostate cancer cells [74].
Baicalin, isolated from the dried roots of Scutellaria baicalensis Georgi, is widely used in China
for its anti-inflammatory, anti-pyretic, and anti-hypersensitivity properties [75]. Baicalin (150 μM)
could inhibit the proliferation of DU145, PC-3, LNCaP, and CA-HPV-10 prostate cancer cells, and,
particularly, of the androgen-independent DU145 cells. It was confirmed that this effect was associated
with the induction of apoptosis, although the exact mechanisms are not clear [75].
Pang et al. indicated that celastrol could inhibit prostate cancer development and angiogenesis
and that its effects were correlated with the extent of inhibition of AKT/mTOR/P70S6K signaling [76].
Celastrol (0.03–3 μM) could suppress PC-3 cell proliferation by downregulating IL-6 gene expression
through the NF-kappaB-dependent pathway [77]. In addition, Yang et al. first reported that celastrol was
a natural proteasome inhibitor with a great potential for prostate cancer prevention and treatment [78].
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Gypensapogenin H is a novel dammarane-type triterpene from Gynostemma pentaphyllum (Thunb.)
Makino [79]. Zhang et al. found that 5–60 μM Gypensapogenin H induced apoptosis in DU145 and
22RV-1 human prostate cancer cells by decreasing survival, inhibiting proliferation, and inducing cell
cycle arrest in G1 phase [80].
Scoparone, a natural compound isolated from Artemisia capillaris Thunb. has anti-allergic effects
in a mast cell-mediated allergy model [81]. Kim et al. indicated that scoparone could suppress
the transcription of STAT3 and decrease phosphorylation and nuclear accumulation of STAT3 [82].
Scoparone treatment suppressed anchorage-independent growth in soft agar at the concentration of
50–200 μM, and tumor growth of DU145 xenografts in nude mice at the concentration of 30 mg/kg
every 2−3 days for 18 days [82]. In addition, computational modeling suggested that scoparone might
bind to the SH2 domain of STAT3 [82]. According to these findings, scoparone exerted an anti-prostate
cancer effect by inhibiting STAT3 activity.
Triptolide could inhibit the proliferation of RM-1 cells in mice by decreasing the expression of
Bcl-2 and increasing the expression of caspase 3 at a dose of 10 and 20 ng/mL [83].
These compounds inhibited the proliferation of prostate cancer cells by repressing the
overexpression of miRNA-372, inhibiting inflammation pathways such as the NF-kappaB-dependent
pathway, inducing apoptosis, acting as a poroteasome inhibitor, and inhibiting STAT3 activity.
4.3. Compounds Inhibiting Metastasis of Prostate Cancer Cells
Metastasis development is still a huge challenge in prostate cancer treatment. Most of the
treatment failures of prostate cancer are generally ascribed to the formation of bone metastases [84,85].
Pretreatment with 2–8 μM celastrol significantly slowed down PC3 cell migration [86].
After celastrol administration, the number of cells penetrating a gel layer in a classical invasion
assay was significantly decreased, and their bone invasive ability was significantly undermined.
Pretreatment with celastrol inhibited the tumorigenicity of PC-3 cells, and almost no bone invasion
occurred in an in vivo mouse model [86]. Celastrol could target the VEGFR-2 signaling pathway and
inhibit the formation of blood vessel [86].
Curcumin is a well-known natural compound of curcuminoids. Yang et al. found that curcumin
could suppress prostate cancer by reducing the function of the PSA promoter and inhibiting PSA and
AR protein expression in LNCaP cells [87]. Meanwhile, 10 μM curcumin was demonstrated to inhibit
prostate cancer by upregulating miR-143 and FOXD3 and downregulating PGK1 expression in DU145
and PC3 cells [88]. Furthermore, 10–50 μM curcumin could inhibit the metastasis and survival of
DU145 and PC3 prostate cancer cells via the Notch-1 signaling pathway [89].
Hu et al. found three novel cyclotides from the leaves and root of Hedyotis Diffusa Willd, termed
Diffusa cyclotide 1 to 3 (DC1–3). DC3 was found to show potent cytotoxicity against PC3, DU145, and
LNCaP prostate cancer cell lines [90]. Furthermore, 0.05 μM DC3 inhibited cell migration and invasion
of LNCap cells and significantly inhibited tumor development in a prostate xenograft model [90].
D-pinitol inhibited the invasion and migration of PC3 and DU145 prostate cancer cells at the
noncytotoxic concentration of 3–30 μM [91]. D-pinitol metastatic activity was mediated by the
downregulation of αvβ3 integrin activity through focal adhesion kinase (FAK), c-Src, and NF-κB
pathways [91].
Dihydroisotanshinone I, a bioactive compound in Salvia miltiorrhiza Bunge. could inhibit the
migration of androgen-dependent (22Rv1 cells) and androgen-independent (PC3 and DU145 cells)
prostate cancer cells at the concentration of 5 μM–10 μM [92]. Dihydroisotanshinone I inhibited the
migration of these prostate cancer cells by interrupting the cross-talk between macrophages and
prostate cancer cells through the repression of the CCL2–STAT3 axis [92].
Shikonin is an active naphthoquinone from the Chinese medicine Lithospermum erythrorhizon
Sieb. et Zucc. Shikonin potently suppressed PC-3 and DU145 cell metastasis in a dose-dependent
manner (0.5–2 μM) and inhibited the migration and invasion of the two aggressive prostate cancer cell
lines by reducing MMP-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways [93].
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Transwell invasion assays showed that 2.5–30 μM tetrandrine significantly weakened the invasion
capacity of DU145 and PC-3 cells; in addition, this compound exhibited a strong inhibitory effect on
the proliferation of these prostate cancer cells [68]. However, the exact molecular mechanisms are
still unknown.
Some studies indicated that the tested compounds could inhibit metastasis of prostate cancer cells,
but the specific molecular mechanisms are not yet known. Some other findings showed that the tested
compounds exerted the inhibitory effect on prostate cancer cell metastasis mainly by inhibiting the
VEGFR-2 signaling pathway, regulating the Notch-1 signaling pathway, downregulating FAK, c-Src,
and NF-κB pathways, repressing the CCL2–STAT3 axis, and suppressing MMP-2/-9 expression via
AKT–mTOR and ROS–ERK1/2 pathways.
4.4. Summary
Among the above summarized compounds, Ten compounds showed inhibition of the growth
of prostate cancer cells. Six compounds were confirmed to inhibit the proliferation of prostate cells
and seven compounds inhibited metastasis of prostate cancer cells. Tetrandrine and celastrol were
the only two compounds which could inhibit both growth/proliferation and metastasis of prostate
cancer cells. Triptolide suppressed the growth or proliferation of prostate cancer cells was verified
in two different studies. Table 2 lists the compounds which can inhibit the growth or proliferation,
and metastasis of prostate cancer cells through similar or different targets. These findings suggest
that there are numerous natural small molecules which are potentially active against prostate cancer
in Chinese medicines. The discovery of these compounds will help to study the anti-prostate cancer
activity of Chinese medicines.
Table 2. Compounds isolated from Chinese medicines inhibiting prostate cancer.












Honokiol Aromatic phenol +
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Table 2. Cont.








Tetrandrine Alkaloid + +
Triptolide Heterocycle + +
Vitexicarpin Flavone +
Arsenic sulphide Metal chalcogenide +
Baicalin Flavone glycoside +
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Celastrol Pentacyclic triterpenoid + +
Gypensapogenin H Triterpene +
Scoparone coumarin +
Curcumin Diphenyl heptylhydrocarbon +
dihydroisotanshinone I Phenanthraquinone +
D-pinitol Alcohol +
Shikonin Anthraquinone +
Note: “Gro” = Growth, “Pro” = Proliferation, ”Met” = Metastasis, “+” = Has effect on it.
5. Perspectives and Outlook
In the past years, PCa has been widely studied in China. More and more extracts, formulas,
and compounds from traditional Chinese medicines have been found to have anti-prostate cancer
activity. Most of these Chinese herbal extracts with anti-prostate cancer activity also show
anti-inflammatory activities. Most of the Chinese medicine formulas with anticancer effects have the
functions of promoting positive blood flow, removing blood stasis, alleviating fever, and detoxifying.
The main compounds present in Chinese medicines with anti-prostate cancer activity are polyphenols,
alkaloids, and terpenoids. As shown in Table 3, the extracts of G. lucidum, Litchi, S. lappa and
T. wilfordii are active in the androgen-independent prostate cancer cells, and S. barbata suppresses
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androgen-dependent prostate cancer cells growth. In addition, the extracts of S. baicalensis and
W. chinensis inhibit both androgen-dependent and androgen-independent prostate cancer cells.
Moreover, 8 of the 19 compounds involved in this review, including Guttiferone F, Honokiol,
Quercetin, Triptolide, Baicalin, Gypensapogenin H, Curcumin, and dihydroisotanshinone I, inhibit
both androgen-dependent and androgen-independent prostate cancer cells. These extracts and/or
compounds may be potential anti-prostate cancer agents present in Chinese medicines and deserve
further study. The extracts and compounds of Chinese medicines mainly produce the anti-prostate
effect in the following ways. Firstly, Chinese medicines induce apoptosis, inhibit cell proliferation, and
suppress the migration of invasive human prostate cancer cells. Secondly, Chinese medicines inhibit
prostate cancer-dependent angiogenesis and impede prostate cancer tumorigenesis. Thirdly, Chinese
medicines induce apoptosis and downregulate survival pathways in prostate cancer cells. Fourthly,
Chinese medicines act as anti-metastatic agents. Fifthly, Chinese medicines suppress prostate tumor
growth and overcome cell chemoresistance. Chinese herb extracts are a mixture of many compounds at
low concentrations, and the effects of the extracts derive from the interactions of all their components.
Theompounds isolated from Chinese herbs here discussed perform well in inhibiting the growth,
proliferation, and metastasis of prostate cancer cells, and most of them act as selective androgen
receptor modulators to exert anti-prostate cancer activity.

















Name LNCaP 22Rv1 PC3 PC-3M DU145 C4-2B CA-HPV-10 TRAMP-C1 TRAMP-C2 RM-1 Myc-CaP
Ganoderma lucidum
(Leyss. ex Fr.) Karst. +
Litchi chinensis Sonn. + + + +
Saussurea lappa Clarke + +
Scutellaria baicalensis
Georgi + +
Scutellaria barbata D. Don + +
Tripterygium wilfordii
Hook F. + +
Wedelia chinensis
(Osbeck) Merr. + + +
Andrographolide + +
Evodiamine +
Guttiferone F + +
Honokiol + + +
Isorhapontigenin + +
Peperotetraphin +
Quercetin + + +
Tetrandrine + +
Triptolide + + +
Vitexicarpin +
Arsenic sulphide + +
Baicalin + + + +
Celastrol +
Gypensapogenin H + +
Scoparone +
Curcumin + + +
dihydroisotanshinone I + + +
D-pinitol + +
Shikonin + +
Note: “+” = has inhibitory effect on prostate cancer cell lines.
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In this review, we collected formulas, extracts, and compounds of Chinese medicines with
anti-prostate cancer activity and classified their mechanisms of action. We hope these findings
can guide and enlighten researchers to explore the use of Chinese medicines in the treatment of
prostate cancer.
Chinese researchers have carried out a large number of anti-prostate cancer studies on Chinese
medicines under the guidance of the theory of traditional Chinese medicine. Meanwhile, the commonly
used research ideas and methods that they have applied are consistent with those used in research for
western drugs. The difference is that formulas, extracts, and compounds characteristic of traditional
Chinese medicines are natural products. However, traditional Chinese medicines are often not a single
Chinese herb extract, but a mixture of many Chinese herbs. Therefore, it is important to note that a
Chinese medicine formula is an entirety. Although traditional Chinese medicines have been used for a
long time, their mechanism have not been fully elucidated. Therefore, researchers often explored the
mechanism of a single compound as a breakthrough point, and then gradually clarified the multi-target
and multilevel function of multicomponent Chinese medicines. Chinese scientists and clinicians now
are facing unprecedented opportunities and challenges to develop Chinese medicines. In the near
future, a research cooperation network for the study of Chinese medicines as anti-prostate cancer
agents will be established to impel the use of Chinese medicines in the treatment of prostate cancer.
6. Conclusions
This study has reviewed the progresses of Chinese medicines in the field of anti-prostate cancer
treatment. Since prostate cancer treatment with Chinese medicines is not popular in the world at
present, the available data on their adverse or toxic effects are not sufficient. We did not specifically
address the adverse or toxic effects of the formulas, extracts, and compounds discussed in this review.
The safety and stability of Chinese medicines have been widely examined, and scientists realize
that this is a vacancy to be eliminated. Another point requiring study is the administration dose of
Chinese medicines. The human dose of each Chinese medicine involved in a formula was stipulated
by the Chinese Pharmacopoeia to ensure safety. The human doses of extracts and compounds should
be verified through a series of pharmacological, pharmacokinetic, and toxicological studies. In our
research on the bioactivity of Chinese medicines, we found that the administered doses of some extracts
or compounds were high. High doses might be decreased by improving the extraction processes or
by modifying the structures of the active compounds. There is still a long way to go to discover new
anti-prostate cancer agents from Chinese medicines.
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Abstract: Pomegranate (Punica granatum L.) fruit has been demonstrated to have the inhibitory
activities to various tumors. In this study, we try to uncover the molecular mechanism underlying the
inhibitory capability of Taiwanese local pomegranate fruit to urinary bladder urothelial carcinoma.
The results collected from the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay
indicated that the ethanol extract of pomegranate peel exhibited better inhibitory activity to human
urinary bladder urothelial carcinoma T24 and J82 cells than that of pulp. Furthermore, the ethylacetate
layer of peel ethanol extract was observed to have the best inhibitory activity against urinary bladder
urothelial carcinoma cells. One of the eight fractions (PEPE2 fraction) collected from the ethylacetate
layer with Diaion HP-20 column chromatography demonstrated the highest inhibitory activity
in urinary bladder urothelial carcinoma cells. The results of the flow cytometry and apoptotic
pathway studies suggested that the inhibitory activity of PEPE2 fraction were attributed to the
UBUC cell apoptosis. To confirm the above results, our results of xenograft-induced bladder
tumor in nude mice showed that the oral consumption of the ethylacetate layer (2, 5, 10 and
100 mg/kg) could decrease the volume and weight of T24 tumors and caused the apoptosis in
the xenografted tumors, which was observed by terminal deoxynucleotidyl transferase-mediated
deoxyuridine triphosphate nick end-labeling assay. This study provided the likelihood that the
traditionally non-edible pomegranate peel waste is re-utilized to make an affordable and promising
chemopreventive product to prevent UBUC incidence or recurrence.
Keywords: apoptosis; T24 cells; death receptor pathway; mitochondrial pathway; endoplasmic
reticulum stress; pomegranate peel; urinary bladder urothelial carcinoma
1. Introduction
Bladder cancer is the most common tumor of the urinary system in the world and ranked the
9th in male cancer incidence in Taiwan in 2014 [1,2]. Urothelial carcinoma is the most encountered
lesion among various bladder tumor types, which contributes to more than 90% of the bladder
cancer cases in developed countries [1]. According to WHO classification (2004), urinary bladder
urothelial carcinoma (UBUC) cells can be classified into the low or high grades. Most of the UBUCs
are papillary/non-invasive or superficially invasive types and can be treated by curettage. However,
local recurrence can be observed in some UBUCs even followed by lethal distal spreading [3]. In terms
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of disease management, it may be beneficial that a chemopreventive product for bladder cancer can be
used by cancer patients or high-risk persons to avoid tumor recurrence or incidence.
Pomegranate (Punica granatum L.) is an edible fruit collected from a deciduous tree species.
Today, it is widely grown in Mediterranean countries, Northern India, Northern/Southern America,
Europe, and even in Taiwan, mainly as gardening trees. The pomegranate fruit is observed to
have a reddish peel and white to deep red seeds. Pomegranate pericarp (peel) is a rich resource of
phenolics, flavonoids, ellagitannins (predominantly punicalagin), and proanthocyanins compounds [4].
Pomegranate seeds are edible and have strong anti-oxidant activities attributed to the high amount of
hydrolyzable tannins and anthocyanins [4]. Pomegranate juice (PJ) squeezed from seed pulp is rich in
phenolics and flavonoids, mainly anthocyanins [4].
Many studies exploring the chemopreventive capability of pomegranate have indicated that the
pomegranate fruit demonstrates inhibitory activities to various tumors. Pomegranate fruit extract
(PFE) prepared from the edible portions (seed coats and pulp juice) of the pomegranate fruit with
70% acetone was proved to display the apoptotic impacts on human lung cancer A549 cells but
have minimal effects on normal bronchial epithelial cells [5]. PFE treatment also induces g0/G1 arrest
and inhibits not only NF-κB activities but also various MAP kinase pathways [5]. PFE administration
also ameliorates tumor growth/progression/angiogenesis of B(a)P or NTCU induced primary lung
tumors in A/J mice by dwindled activation of NF-κB, MAP kinase pathways, and mammalian target
of rapamycin (mTOR) signaling [6]. In addition to the effects on lung cancer, PFE may be a promising
chemopreventive/chemotherapeutic agent against human prostate cancer as well. Malik et al. [7]
found that apoptosis is evoked in PFE-treated highly aggressive PC3 cells, resulting in a decrease in
Bcl-2 along with an increase in Bax. Their studies showed that PFE treatment impairs various cell cycle
cyclins and p21 as well as p27. Additionally, the oral administration of 0.1% or 0.2% PFE in drinking
water (equivalent to the ingredients present in 250 or 500 mL of pomegranate juice) to TRAMP
mice can obviously inhibit prostate carcinogenesis by inhibiting IGF-1/Akt/mTOR pathways [8].
Retting et al. [9] reported that the treatment of polyphenols/ellagitannin-abundant extract (PE)
purified from pomegranate fruit peels can restrict LAPC4 androgen-independent xenograft via the
inhibition of the NF-κB signaling pathway. The clinical trial in patients with increasing prostate-specific
antigens (PSA) after surgery or radiotherapy demonstrated that daily oral consumption of 8 ounces of
pomegranate juice (PJ) significantly extends the PSA doubling time (PSADT) from 15 to 54 months
in men with prostate cancer (PCa) [10]. However, a randomized, double-blind, placebo-controlled
clinical study also showed that PFE treatment does not significantly extend the PSADT in PCa patients
with rising PSA after primary therapy, compared to the placebo-treated group [11]. Our previous
documented results demonstrated that Taiwanese local pomegranate juice (PJ) could evoke cell
apoptosis via the intrinsic mitochondrial pathway and the extrinsic death receptor signaling in PCa cells.
It also can de-regulate the expression levels of genes linked to cytoskeletal functions, anti-apoptosis,
metabolism, NF-B signaling in PJ-treated PCa cells [12]. Based on the above-documented findings,
pomegranates may be a promising chemopreventive or chemotherapeutic source against UBUC
carcinogenesis and recurrence.
In this study, we found that the ethanol extract isolated from pomegranate peels (PEP) exhibited a
better inhibitory activity comparatively to UBUC cells than that of pulps. Fractionation of PEP with
increasing polarity showed that the EtOAc fraction of PEP had the best anti-cancer efficacy. Treatment
of 1 of 8 column-fractionation parts of the EtOAc fraction, PEPE6, could evoke UBUC cell apoptosis.
Oral administration of the EtOAc fraction of PEP to UBUC xenografted nude mice caused a significant
reduction in tumor growth and evoked cell apoptosis. Taken together, our results implied that the
ingredients present in pomegranate peels demonstrated the inhibitory activity of UBUC cells.
156
Nutrients 2018, 10, 543
2. Materials and Methods
2.1. Materials
The following antibodies were used for western immunoblotting: Actin (1:5000, Millipore,
Billerica, MA, USA), Bip (1:1000, BD Biosciences, San Jose, CA, USA), Caspase-3 (1:250, Gene Tex, Irvine,
CA, USA), Caspase-8 (1:250, BD Biosciences, San Jose, CA, USA), Caspase-9 (1:1000, BD Biosciences,
San Jose, CA, USA), Caspase-12 (1:1000, Gene Tex, Irvine, CA, USA), DR4 (1:1000, Gene Tex,
Irvine, CA, USA), DR5 (1:2000, Gene Tex, Irvine, CA, USA), VCP (1:1000, Abnova, Taipei,
Taiwan, ROC), Anti-rabbit IgG (1:10,000, GE Healthcare, Mickleton, NJ, USA), and Anti-mouse IgG
(1:10,000, GE Healthcare, Mickleton, NJ, USA). Annexin V conjugated with FITC was bought from
the Strong Biotech Corporation in Tainan, Taiwan. Chemiluminescence ECL detection system was
purchased from GE Healthcare Bio-Sciences AB in Uppsala, Sweden. Dulbecco’s Modified Eagle
Medium, McCoy’s5A, and fetal bovine serum were purchased from GIBCO, Grand Island in NY, USA.
MTT was bought from Merck in Darmstadt, Germany. Propidium iodide was purchased from Sigma,
Saint Louis in MO, USA. PVDF membrane was bought from Stratagene, La Jolla in CA, USA. TUNEL
reaction mixture was purchased from Rochel in Mannheim, Germany.
2.2. Collection and Identification of Plant Materials
The fruits of the P. granatum were field collected from a farmland (22◦41′59.3267′′ N,
120◦30′45.1836′′ E) located in Jiuru, a suburban township in the Pingtung county in southern Taiwan
from August to September 2012. The plant specimens were identified by Dr. Gwo-Ing Liao from
National Chen-Kung University, Taiwan and were pressed/dried for voucher specimens (Nan-Kai Lin,
STUSTG308-001 to STUSTG308-003) deposited in the herbarium of Taiwan Forestry Research Institute
(TFRI), Taiwan.
2.3. Preparation of the Ethanol Extracts from Pulps and Peels of Pomegranates
Fresh pomegranate pulps (452 g) and peels (392 g) were extracted respectively with 95% ethanol,
three times, at a ratio of 1:3 at room temperature for 24 h. The filtrates were evaporated under
reduced pressure to yield the dark brown syrups from pulp (PEG, 51 g) and peel (PEP, 74 g) extracts
respectively. PEP was suspended in water (300 mL) and then partitioned with ethyl acetate (EtOAc)
(4 × 300 mL) and n-butanol (4 × 300 mL) successively to yield individual layers of extracts of EtOAc
(4.5 g), n-butanol (29.8 g) and water (28.7 g), respectively. The above three layers were examined
for their anticancer bioactivities. Among these three layers, the EtOAc layer exhibited the most
potent effectiveness (Figure 1). Hence, the EtOAc layer (4.5 g) was subjected directly to Diaion HP-20
column chromatography, eluted with water containing increasing proportions of ethanol to render
eight fractions labeled PEPE1 (0.1256 g), PEPE2 (0.1064 g), PEPE3 (1.712 g), PEPE4 (1.4595 g), PEPE5
(0.3758 g), PEPE6 (0.1384 g), PEPE7 (0.1731 g), and PEPE8 (0.1567 g). The eight fractions were then
evaluated for their anticancer bioactivities.
2.4. Cell Lines
Human UBUC T24 cells, identified as high grade and invasive, were purchased from the
Bioresource Collection and Research Center, Hsinchu, Taiwan and cultured at 37 ◦C in McCoy’s5A
supplemented with 10% (v/v) fetal bovine serum. Human UBUC J82 cells recognized as high grade
were provided by Dr. Chien-Feng Li from Department of Pathology, Chi-Mei Medical Center, Tainan,
Taiwan and maintained at 37 ◦C in Dulbecco’s Modified Eagle Medium supplemented with 10% (v/v)
fetal bovine serum. Human papillomavirus E7 immortalized uroepithelial cell was kindly provided by
Professor Hsiao-Sheng Liu from the department of microbiology and immunology, college of medicine,
National Cheng Kung University, Tainan, Taiwan and maintained as described previously [13].
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Figure 1. The inhibitory activities of Taiwanese local pomegranate fruit. The ethylacetate, butanol,
and water layers extracted from pomegranate peel extract (PEP) were tested for the inhibitory efficacy
to T24 (A) or J82 (B) cells using MTT assay as described in Materials and Methods. PEPE2 and PEPE3
(C) were also investigated for the inhibitory effectiveness to T24 or J82 cells. 0.1% (v/v) Dimethyl
sulfoxide (DMSO)-treated urinary bladder urothelial carcinoma (UBUC) cells were regarded as the
solvent control. Each MTT result was the typical data of at least three independent experiments.
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
2.5. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Assay
As indicated in Figure 1, 5, 10, 20, 50, and 100 μg/mL of ethanol extracts of pomegranate peels
were added to a 96-well plate seeded with 5000 human T24 cells, 6000 human J82 cells, or 3000 human
E7 cells per well. The same concentrations and protocol were also conducted with pulp ethanol extracts
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and further with EtOAc, BuOH and H2O layers from peel ethanol extracts and PEP2/PEP3 column
fractions. After incubation for the time period shown in Figure 1, 20 μL of MTT solution (5 mg/mL
PBS) was added to each well and the plate was incubated at 37 ◦C for 4 h. After medium removal,
200 μL of dimethyl sulfoxide (DMSO) was added to each well and the plate was gently shaken for 5 min.
The absorbance was measured at 540 nm. Quadruplicate wells were applied to each concentration for a
specific time period. 0.1% (v/v) DMSO (vehicle)-treated UBUC cells were recognized as the control.
2.6. Cell Cycle Analysis of PEPE2-Treated UBUC Cells
1 × 106 T24 or 7 × 105 J82 cells were first seeded on a 10-cm plate. After overnight incubation,
50 μg/mL and 20 μg/mL of PEPE2 was added to respectively T24 and J82 cells seeded on each
10-cm plate and the cells were harvested at the appropriate time duration. The collected cells of each
plate were suspended in 500 μL of ice-cold 70% ethanol at 4 ◦C overnight. After treatment, the cells
were washed with 1 mL ice-cold PBS and re-suspended in 100 μL PBS. Afterward, the cells were
incubated in 300 μL propidium iodide (PI) solution (3 μL RNase and 20 μg PI per mL) in the dark at
37 ◦C for 30 min. The stained cells were analyzed by FACSCalibur flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). 0.1% (v/v) DMSO-treated UBUC cells were regarded as the control and
analyzed as described above.
2.7. Annexin V/PI Analyses of PEPE2-Treated UBUC Cells
T24 and J82 cells were treated as indicated in the annexin V/PI analyses. The collected cells of
each plate were washed with 1 mL ice-cold PBS and re-suspended in 100 μL binding buffer. Then 2 μL
of annexin V conjugated with FITC and 2 μL of PI solution were administrated to the re-suspended
cells and incubated in the dark on ice for 15 min. After incubation, the cells were measured using a
FACSCalibur flow cytometer (Becton Dickinson). A percentage of 0.1% (v/v) DMSO-treated UBUC
cells were deemed as the control and analyzed as described above.
2.8. Western Immunoblotting
After treatment, as described in the results, T24 or J82 cells were harvested and lysed in the lysis
buffer (10 mMTris (pH 8.0), 0.32 M sucrose, 1% (v/v) Triton X-100, 5 mM EDTA, 2 mM DTT, and 1 mM
PMSF). After determining its protein concentration using Bio-Rad DC protein assay kit, equal volume of
2× sample buffer (0.1 M Tris (pH 6.8), 2% (w/v) SDS, 0.2% (v/v) β-mercaptoethanol, 10% (v/v) glycerol,
and 0.0016% (w/v) bromophenol blue) was mixed with the protein lysate. The protein lysates were
separated by SDS-PAGE at 100 V for the suitable time and further transferred onto a PVDF membrane.
After blocking for 1 h in 3% (w/v) bovine serum albumin at room temperature, the membranes were
hybridized for 2 h at room temperature with primary antibodies. Then the membranes were washed
and hybridized with correspondent secondary antibodies for 1 h at room temperature. The secondary
antibodies binding on the membrane were detected by a chemiluminescence ECL detection system using
Fujifilm LAS-4000 Luminescent Image Analyzer (Fujifilm Corporation, Tokyo, Japan). The intensity of
each protein band of interest was quantified by PDQUEST Quantity One software (Bio-Rad Laboratory,
Hercules, CA, USA) and normalized with actin protein expression level. The acquired data were
analyzed with Student’s t-Test (STATISTICA, StatSoft, Tulsa, OK, USA). The 0.1% (v/v) of DMSO-treated
UBUC cells were deemed as the control and analyzed as described above.
2.9. Xenografted Tumors of T24 Cells in Nude Mice
Relevant animal studies were performed in accordance with the guide for Laboratory Animal
Facilities and Care as promulgated by the Council of Agriculture, Executive Yuan, Taiwan. The protocol
was approved by the Animal Research Committee (permit number: MED-100-05; project code:
NSC 101-2632-B-218-001-MY3) of Southern Taiwan University of Science and Technology. Male nude
mice (BALB/cAnN-Foxn1, 9 weeks old) were purchased from the animal center of the National Science
Council in Taiwan. The animals were nurtured at 23–25 ◦C and 30–70% humidity with 12-h light/12-h
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darkness cycle. The mice intake rodent Lab Diet 5001 (Lab Supply, Fort Worth, TX, USA) and sterile
water ad libitium. The mice were quarantined for 7 days before the experiment. The mice were
subcutaneously (s.c.) inoculated on the right lower abdomen with 100 μL T24 cell/matrigel mixture
prepared by blending 1 × 107 of T24 cells with an equal volume of the gel. All efforts were made
to minimize the suffering of the mice. Dried EtOAc extract was suspended thoroughly in water and
then the suspension was used for oral gavage (o.g.). The mice were separated into 4 subgroups.
The xenografted mice were fed o.g. with water (n = 11), 2 mg/kg (n = 8), 5 mg/kg (n = 10), 10 mg/kg
(n = 10), and 100 mg/kg (n = 6) of EtOAc extract. For the extract-treated groups, after implanted
with T24 cells, the mice were fed with EtOAc extract suspension by o.g. in the next day and then
administrated with the suspension once a day until the endpoint. At the endpoint, each mouse was
euthanized by intraperitoneal (i.p.) injecting with 0.5 mL of 500 mg/mL urethane and the tumor, as well
as liver, was collected. growth of the xenografted tumors was measured by vernier calipers at 3-day
intervals. The tumor volume was calculated as V = length × width2/2 as described previously [14].
For Statistical Analysis, the results are expressed as the mean ± standard error (SE) of at least 3
independent experiments. Statistical significance was determined by Student’s t-test and one-way
ANOVA using the SigmaPlot program for Windows, version 12.0 (Systat Software Inc., San Jose,
CA, USA).
2.10. Terminal Deoxynucleotidyl Transferase-Mediated Deoxyuridine Triphosphate Nick End-Labeling
Assay (TUNEL)
Histologic specimens were prepared in the way as described for preparation of the subcutaneous
xenografts. Animal specimens were fixed in 10%-buffered formalin solution and embedded in paraffin.
For morphological analysis, the hematoxylin-eosin (H&E) staining and microscopic examination
were performed on the 3-μm-thick sections of the paraffin-embedded tumor blocks. Slides were
either stained with H&E according to the aforementioned specifications or exposed to TUNEL assay.
The sections were treated with xylene and then with ethanol. After paraffin removal and dehydration,
the sections were washed with PBS and incubated with 3% (v/v) H2O2 solution for 20 min. Then the
specimens were treated with 5 μg/mL proteinase k at room temperature for 2 min. After enzyme
incubation, the specimens were washed with 0.1 M PBS (pH 7.4) and incubated with a TUNEL reaction
mixture at 37 ◦C for 1 h. Then the treated sections were washed with distilled water and hybridized
with a horse-radish peroxidase-conjugated fluorescent antibody at room temperature for 30 min.
Lastly the sections were washed with distilled water. The TUNEL-positive cells were evaluated in at
least 6 fields per section (×200 magnification) by two persons under a blinding condition.
2.11. Statistical Analyses
Student’s t-test (STATISTICA Ver 10.0 MR1, StatSoft, Tulsa, OK, USA) were used for the statistical
analyses of MTT assay, flow cytometry, and western immunoblotting. Student’s t-test and one-way
ANOVA of the SigmaPlot program for Windows, version 12.0 (Systat Software Inc., San Jose, CA, USA)
were exploited for the statistical significance of animal studies.
3. Results
3.1. Pomegranate Fruits Exhibited the Inhibitory Impacts on UBUC Cell Proliferation
In this investigation, the pulps and peels of fresh pomegranate fruits were extracted with ethanol,
respectively, to give pulp extract (PEG) and peel extract (PEP). The results of MTT assays showed that
PEP exhibited better suppressive ability than that of PEG toward UBUC cells (Figure S1A,B). Therefore,
PEP was partitioned successively between H2O/EtOAc and between H2O/n-BuOH, respectively,
to yield three layers of EtOAc, n-BuOH, and H2O. The results of the MTT assays demonstrated that
IC50 of EtOAc, butanol, and water layers from PEP were 5, 10, and 50 μg/mL, respectively, against
the T24 cells while for the J82 cells IC50 of these three layers were 20, 50, and 50 μg/mL (Figure 1A,B).
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Taken together, the EtOAc layer had the best inhibitory activity against the UBUC cell lines. The HPLC
profile of EtOAc layer was shown in Supplementary Figure S2A.
Furthermore, the EtOAc layer was fractionated into 8 fractions by Diaion HP-20 column
chromatography as described in Materials and Methods. We first examined the toxicity of each
column fraction to normal-like urothelial E7 cell and found that IC50 of PEPE2 and PEPE3 were
>200 μg/mL, respectively, (Figure S1C) and the other PEP fractions would harm E7 cell (data not
shown). Findings in Figure 1C demonstrated that the PEPE2 fraction showed the best inhibitory effects
on human T24 and J82 cells and the least harmful impacts on normal-like human E7 urothelial cells.
The HPLC map of PEPE2 was shown in Supplementary Figure S2B.
3.2. PEPE2-Evoked Retardation of Human UBUC Cell Proliferation Attributed to Cell Apoptosis
To discover which mechanism was engaged in the inhibition of human UBUC cell proliferation,
the cell cycle analyses conducted following incubation of T24 cells with 50 μg/mL PEPE2 showed that
the PEPE2 treatment induced 20.9% on average of T24 cells in the sub-G1 phase at 72-h as compared
to 2.45% on the average DMSO-treated cells (Figure 2A), whereas treatment with 20 μg/mL PEPE2
evoked 41.78% on average of J82 cells in the subG1 phase at 72-h as compared to 4.17% on average of
DMSO-treated cells (Figure 2B). Furthermore, the annexin V/PI analysis indicated that 50 μg/mL of
PEPE2 incubation for 72 h enhanced the early apoptotic T24 cells significantly from 2.9 to 46.2% on
average as compared to the vehicle-treated cells (Figure 2C) while 20 μg/mL PEPE2 treatment for 72 h
augmented the early/late J82 apoptotic cells prominently from 6.4 to 66.3% on average as compared to
the DMSO-treated cells (Figure 2D), suggesting that the PEPE2 treatment could induce apoptosis in








Nutrients 2018, 10, 543
Figure 2. The propidium iodide (PI) and PI/annexin V analyses of UBUC cells treated with PEPE2.
The results of PI analyses were represented in (A) the T24 cells and (B) the J82 cells. The data of the
PI/annexin V measurement were shown in (C) T24 cells and (D) J82 cells. Each flow cytometry figure
was the typical result of three independent experiments. The diagram under the PI/annexin V panel
was the results of the three independent experiments. The cell cycles and apoptosis detection of the
T24 or J82 cells treated with PEPE2 were measured with PI and PI/annexin V analyses, respectively,
using flow cytometry as described in the supplementary document. The 0.1% (v/v) DMSO-treated
UBUC cells were implemented as the vehicle control. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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3.3. Molecular Mechanism of the Apoptotic Pathway Induced in PEPE2-Treated UBUC Cells
The previous results showed that the PEPE2 treatment could induce bladder cancer cell apoptosis.
However, the cytometric analysis cannot decipher whether PEPE2 resulted in the apoptosis by death
receptor signaling, the mitochondrial damage pathway, or ER stress. Caspase-3 is a key player in
mitochondrial damage, death receptor signaling, and ER stress. Meanwhile, Caspase-3 can be activated
by caspase-8 in death receptor signaling, by caspase-9 in mitochondrial damage, and by caspase-12
in endothelium reticulum (ER) stress [15]. In order to search for the molecular mechanism by which
PEPE2 evoked the apoptosis, the processing and activation of caspase-3 was measured in drug-treated
UBUC cells. The results in Figure 3A showed that the activated caspase-3 (21 and 17 kDa) amount was
increased in PEPE2-treated T24 cells in a time-dependent response, implicating that caspase-3 was
activated while the apoptosis might be initiated in PEPE2-incubated T24 cells. The data in Figure 3B
and Figure S3A also demonstrated that the expressions of DR4 as well as DR5 and activated caspase-8
were augmented, implicating that the death receptor pathway was evoked in PEPE2-treated T24 and
J82 cells. In PEPE2-incubated T24 and J82 cells, the apoptosis-activator Bax level was increased while
the anti-apoptotic Bcl-2 amount was decreased and thus, the pro-caspase-9 level dwindled, implying
that the mitochondrial pathway was related to cancer cell apoptosis (Figures 3C and S3B). Our studies
also showed that the amount of Bip and VCP (ER stress markers) was increased in PEPE2-treated T24
and J82 cells and thus, pro-caspase-12 was activated (Figures 3D and S3C), implying that the ER stress
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Figure 3. The molecular mechanisms of apoptotic pathway evoked in PEPE2-incubated UBUC cells.
T24 and J82 cells were treated with 50 and 20 μg/mL PEPE2 respectively. Then the protein levels of
(A) pro-/cleaved caspase-3; (B) pro-/cleaved caspase-8, DR4 and DR5; (C) pro-/cleaved caspase-9,
Bax and Bcl-2 and (D) Bip, VCP and pro- caspase-12 in PEPE2-treated T24 cells were measured using
western immunoblotting as described in the supporting information. The 0.1% (v/v) DMSO-treated
UBUC cells were used as the solvent control; (E) The proposed molecular apoptotic pathway provoked
in the PEPE2-treated UBUC cells. The immunoblot in each figure was the representative result of at
least three independent experiments. The diagram (ratio (mean ± standard deviation (S.D.)) under
each immunoblot indicated the ratio of the normalized protein intensity (observed protein/actin) of
PEPE2-treated cells at the indicated time interval, divided by that at the 0-h time point. * p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001.
3.4. The EtOAc Layer of PEP Could Reduce Xenografted Tumor growth in Nude Mice
In order to further confirm the UBUC-cell-line-associated inhibitory activity of pomegranate
fruits, xenografted tumors induced by implanting T24 cells into nude mice as described in Materials
and Methods were exploited to investigate the inhibitory effectiveness of the EtOAc layer of PEP
on tumor growth in vivo. The results in Figure 4A demonstrated that the oral consumption of the
EtOAc layer affected slightly the body weight of mice. The effects were more obvious in mice fed with
100 mg/kg EtOAc layer. As indicated in Figure 4B,C, the volume and weight of T24 tumors of the
EtOAc layer-treated group (2, 5, 10, and 100 mg/kg) grew at a slower rate than those of the untreated
tumors. On week 10, the tumor volumes of the control group had increased significantly to 600 mM3 on
average, which is the endpoint of the animal protocol, whereas the tumor volumes of 5 and 10 mg/kg
of EtOAc layer-fed animals had only reached 200 mM3 on average, respectively. The tumor weight
of the control group increased to 456.5 mg on average while those of 5, 10, and 100 mg/kg EtOAc
layer-fed mice decreased dramatically to 94.6, 94.9, and 39.4 mg, on average. The inhibitory effects on
the tumor volume/weight were much higher than the body weight, suggesting that the decreased
tumor volume/weight did not attribute to the body weight loss. Although EtOAc administration
might impact the body weight, hematoxylin/eosin (H/E) staining of liver specimens showed that
165
Nutrients 2018, 10, 543
EtOAc layer demonstrated no lesion to the liver. The H/E stainings of the liver specimens were
presented in Supplementary Figure S4.
To observe the impacts of the EtOAc layer on the xenografted tumors, T24 xenografted tumors,
treated with H2O (vehicle), 2 mg/kg, 5 mg/kg, or 10 mg/kg of the EtOAc layer, were dissected
from nude mice for histological examination. The hematoxylin/eosin (H/E) staining of H2O-treated
tumors revealed large neoplastic areas while the 5 and 10 mg/kg treated counterparts showed less
neoplastic areas comparatively (Figure 4B). Furthermore, the TUNEL assay was performed to evaluate
if apoptosis was induced in treated xenografted tumors. The results in Figure 4C demonstrated that the
amount of TUNEL-positive T24 cells had increased obviously in tumors treated with the EtOAc layer
(2, 5, 10, and 100 mg/kg) after 10 weeks as compared to that of the control groups, suggesting that the
apoptosis was evoked in treated xenografted tumors. The above results indicated that the apoptosis
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Figure 4. The inhibition of the xenografted UBUC growth in nude mice by the treatment of the EtOAc
layer. T24 cells were injected s.c. into nude mice and were o.g. administrated with water (control), 2, 5,
10, or 100 mg/kg EtOAc layer as described in Materials and Methods. (A) The body weights of the
extract-treated mice. *** p < 0.001, ** p < 0.005; (B) The effects of the EtOAc layer on tumor growth in
the xenografted nude mice. The volumes of tumors from the extract-fed mice were compared to those
of the water-fed mice. *** p < 0.001; (C) The tumor weight. The tumor weight was measured at the 10th
week. *** p < 0.001; (D) The typical H/E images (400×) of tumor specimens dissected from xenografted
nude mice; (E) The representative terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick end-labeling (TUNEL) images (400×) of tumor lesions from xenografted nude mice.
H&E and TUNEL assays were performed as described in Material and Methods.
4. Discussion
In this study, we found that the ethanol extract isolated from pomegranate peels exhibited
a better inhibitory activity comparatively T24 and J82 cells than that of pulps. Fractionation of
PEP with increasing polarity showed that the EtOAc layer of PEP had the best anti-cancer efficacy.
Among 8 collecting parts of PEP fractionated with the Diaion HP-20 column chromatography,
the PEPE2 fraction demonstrated the best inhibitory activity on UBUC cells along with the least
influence on normal-like urothelial E7 cells. Annexin V/PI and western immunoblotting analyses
demonstrated that PEPE2 treatment evoked UBUC cell apoptosis through stimulation of the death
receptor pathway, the mitochondrial pathway, and ER stress. The suggested apoptotic pathway
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evoked by PEPE2 was shown in Figure 3E. The mitochondrial pathway starts with the increased
permeabilization of the mitochondrial outer membrane, causing the rupturing of the outer membrane.
The outer membrane rupturing the release of cytochrome c, apoptosis-inducing factor (AIF),
endonuclease g, and Smac/DIABLO (second mitochondria-derived activator of caspases/direct
IAP-associated binding protein with low pI) [16–18]. Cytochrome c along with apoptosis protease
activating factor (APAF-1) and pro-caspase 9 form an apoptosome which activates caspase 9. Caspase
9, in turn, activates the effector caspases which orchestrates the progression of apoptosis [19]. AIF and
endonuclease g participate in DNA fragmentation and subsequent chromosomal condensation,
which is typical phenomena of apoptosis [17,18]. Smac/DIABLO can antagonize IAP (inhibitor
of apoptosis protein) to promote caspase activation [20]. In addition to our proposed apoptotic
mechanism, pomegranate peels might impair the release of cytochrome c, apoptosis-inducing
factor (AIF), endonuclease g and Smac/DIABLO to interfere with the activation effector caspases.
Taken together, our results implied that the components present in pomegranate peels demonstrated the
inhibitory activity against UBUC cells and owned much better intervention capability than those of the
pulps. The anti-cancer efficacy of PEP was further confirmed in the xenografted mice. It was observed
that oral administration of the EtOAc layer of PEP to nude mice implanted with T24 cells caused a
significant reduction in tumor growth. Besides, the TUNEL-positive cells were extensively observed in
EtOAc layer-treated T24 tumors, suggesting cell apoptosis was evoked in extract-treated tumors.
Most of the chemopreventive/chemotherapeutic cancer studies of pomegranate fruits focus on
the juice or various extracts prepared from the juice [1]. Very few documented findings emphasize the
medicinal value of the pomegranate peels. The studies carried out by Zahin et al. (2014) showed that
A549 and H1299 lung cancer cell lines demonstrate the comparable susceptibility to punicalagin and
ellagic acid, the main ingredients of pomegranate peels [21]. In addition, treatment of the methanol
extract of pomegranate pericarps (PME) results in the significant dose-responsive inhibition on cell
proliferation in MCF7 cell lines that are positive for estrogen receptors (ER) while showing no impacts
on that of ER− MDAMB-231 cells. PME also reduces the expression of estrogen-responsive genes such
as ERα, pS2, and PR in MCF7 cells. Examination on the PME estrogenicity indicated that there are
no obvious differences in the uterus weight and the proliferation of uterine endometrium between
PME- and vehicle-treated 17 β-estradiol-evoked ovariectomized mice, implying that PME is a selective
estrogen receptor modulator [22]. Consistent with the above findings, Dikmen et al. (2011) also
observed that the administration of pomegranate fruit peels (PPE) inhibits MCF7 cell proliferation and
induces cancer cell apoptosis [23].
In addition to the above cancer cells, Asmaa et al. (2015) reported that the treatment of 80%
ethanol extract of pomegranate peels (PGPE) mainly evokes g2/M cell cycle arrest to inhibit chronic
myeloid leukemia K562 cells [24]. The compounds present in pomegranate peels possess inhibitory
activities against prostate cancer. The effects of pomegranate peel extract (PoPx) on prostate cancer
cell lines examined by Deng et al. (2017) demonstrated that PoPx incubation can induce apoptosis
by the loss of mitochondrial transmembrane potential (Δym), the increased reactive oxygen species
(ROS) as well as the augmented Bax/Bcl-2. Furthermore, they reported that PoPx treatment can retard
migration/invasion likely through the down-regulation of matrix metallopeptidase (MMP) 2/MMP9
and the up-regulation of Metallopeptidase Inhibitor 2 (TIMP2) [25]. gou et al. (2016) indicated that
ellagic acid purified from pomegranate peels provokes Hela cell apoptosis by increasing the IGFBP7
expression level [26]. Song et al. (2016) found that treatment of polyphenol of pomegranate peels can
induce HepG2 cells apoptosis by increasing cytochrome c amount, p53 expression level, Bax/Bcl-2
and caspase-3/9 activities. It can also arrest HepG2 cell at S-phase [27]. Most of the above-mentioned
literature with regard to pomegranate peels focuses on the investigations of single cancer cell line.
However, in this study, two cancer cell lines and animal studies were implemented for examination.
Besides anti-cancer activities, the pomegranate peel is demonstrated to have activities for other
ailments. Due to its abundant phenolics and flavonoids, the pomegranate peel is indicated to possess
high anti-oxidant activities [28]. Morzelle et al. demonstrated that the administration of pomegranate
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peel extract (PPE) decreases amyloid plaque density, augments the expression of neurotrophin BDNF,
and reduces TNF-α production in mice infused with amyloid-β peptide. Their results imply that
treatment of PPE provides neuroprotective effectiveness to the neurodegeneration provoked by
infusion with amyloid-β peptide in mice [29]. PPE is also shown to alleviate the hepatic pathology,
body weight, liver enzymes, and retard lipogenesis. It can enhance the cellular redox status in the liver
tissues of rats with a non-alcoholic fatty liver disease to reduce oxidative damage [30]. Pomegranate
peel extract is also showed to reduce significantly fasting blood glucose in type 2 diabetic mice,
suggesting that it might be recommended for the management of type 2 diabetes [31]. Although a
variety of studies related to the therapeutic effects of pomegranate peel have been reported, there are
no clinical trial results.
Most of the UBUCs are papillary/non-invasive, or papillary/superficially invasive lesions.
The lesions are normally treated by curettage but the local recurrence is often observed in papillary
UBUCs, even followed by lethal distal spreading. The results of our studies implicated that the
pomegranate peel extract may be a potential chemopreventive product for lowering the possibility of
UBUC recurrence. Pomegranate peels cover the whole fruits and are handy to be separated from the
fruit bodies, thus, it is easier to obtain than pulps. Furthermore, our results provide the likelihood that
the traditionally non-edible pomegranate peel waste is re-utilized to make an affordable and promising
chemopreventive product.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/5/543/s1.
Supplementary document: legends for supplementary figure, Figure S1: The inhibitory activities of peel and
pulp of pomegranate fruit. T24 (A) or J82 (B) cells were used to examine the inhibitory activities. PEP2 and PEP3
fractions from the EtOAc layer were examined for the toxicity to normal-like E7 cells (C), Figure S2: The HPLC
profiles of EtOAc layer of PEP and PEPE2. (A) The HPLC profile of EtOAc layer of PEP. (B) The profile of
PEPE2, Figure S3: The molecular mechanisms of apoptotic pathway evoked in PEPE2-incubated UBUC J82 cells.
(A) pro-/cleaved caspase-8, DR4 and DR5, (B) pro-/cleaved caspase-9, Bax and Bcl-2, (C) Bip, VCP and pro-
caspase-12 in PEPE2-incubated J82 cells. The immunoblot in each figure was the representative result of at least
three independent experiments. The diagram (ratio (mean ± SD)) under each immunoblot indicated the ratio of
normalized protein intensity (observed protein/actin) of PEPE2-treated cells at indicated time interval divided by
that at 0-h time point. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, Figure S4: liver specimens collected at 10th week from
non-fed- and EtOAc layer-fed xenografted mice.
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Abstract: Over recent years, we have demonstrated that Frondoside A, a triterpenoid glycoside
isolated from an Atlantic sea cucumber, has potent in vitro and in vivo anti-cancer effects against
human pancreatic, breast, and lung cancer. We have also demonstrated that Frondoside A is able
to potentiate and/or synergize the anti-cancer effects of major classical cytotoxic agents, namely,
gemcitabine, paclitaxel, and cisplatin, in the treatment of pancreatic, breast, and lung cancer,
respectively. This study evaluates the impact of Frondoside A alone and in combination with
the standard cytotoxic drugs oxaliplatin and 5-fluorouracil (5-FU) in the treatment of colon cancer
using three human colon cancer cell lines, namely, HT-29, HCT-116, and HCT8/S11. We demonstrate
that Frondoside A, oxaliplatin, and 5-FU cause a concentration- and time-dependent reduction in the
number of HT-29 colon cancer cells. A concentration of 2.5 μM of Frondoside A led to almost 100%
inhibition of cell numbers at 72 h. A similar effect was only observed with a much higher concentration
(100 μM) of oxaliplatin or 5-FU. The reduction in cell numbers by Frondoside A, oxaliplatin, and 5-FU
was also confirmed in two other colon cancer cell lines, namely, HCT8/S11 and HCT-116, treated for
48 h. The combinations of low concentrations of these drugs for 48 h in vitro clearly demonstrated
that Frondoside A enhances the inhibition of cell numbers induced by oxaliplatin or 5-FU. Similarly,
such a combination also efficiently inhibited colony growth in vitro. Interestingly, we found that
the inhibition of ERK1/2 phosphorylation was significantly enhanced when Frondoside A was
used in combination treatments. Moreover, we show that Frondoside A and 5-FU, when used
alone, induce a concentration-dependent induction of apoptosis and that their pro-apoptotic effect is
dramatically enhanced when used in combination. We further demonstrate that apoptosis induction
upon the treatment of colon cancer cells was at least in part a result of the inhibition of phosphorylation
of the survival kinase AKT, leading to caspase-3 activation, poly (ADP-ribose) polymerase (PARP)
inactivation, and consequently DNA damage, as suggested by the increase in the level of γH2AX.
In light of these findings, we strongly suggest that Frondoside A may have a role in colon cancer
therapy when used in combination with the standard cytotoxic drugs oxaliplatin and 5-FU.
Keywords: colon cancer; Frondoside A; oxaliplatin; 5-fluorouracil; cell proliferation; apoptosis
1. Introduction
Colorectal cancer is the third leading cause of cancer death in the world and represents a serious
threat to human health [1]. Without treatment, patients with inoperable or metastatic colorectal cancer
have a median life expectancy of about 8 months. The standard cytotoxic drugs for the treatment
of metastatic colorectal cancer are 5-fluorouracil (5-FU) (combined with folinic acid), oxaliplatin,
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and irinotecan. These chemotherapeutic agents currently in use for colon cancer remain unsatisfactory
because of their associated collateral toxicity and resistance. In the last decade, the survival rate of
patients with metastatic colorectal cancer has improved with the application of targeted drugs such as
Bevacizumab. Despite these advances, patients still die, and a cure remains elusive [2].
Patients, oncologists, and scientists have for decades expressed interest in using natural compound
remedies because of the overall disappointing results and side effects of the current cytotoxic drugs
and targeted therapies. Recent studies have demonstrated that low concentrations of Frondoside A,
a triterpenoid glycoside isolated from the Atlantic cucumber Cucumaria frondosa, induces apoptosis in
human pancreatic, leukemic, breast, lung, and prostate cancer cells, leading to the inhibition of their
tumor xenograft growth in vivo [3–7]. Investigators have also demonstrated that Frondoside A was
able to synergize or to potentiate the anti-cancer effects of major classical cytotoxic agents, namely,
gemcitabine, paclitaxel, and cisplatin, in the treatment of pancreatic [8], breast [5], and lung [6] cancer
xenografts, respectively.
We know from clinical trials that single-agent treatments rarely result in clinical benefits to cancer
patients and that combination therapy is necessary for the effective treatment of tumors. This study
investigates the potential anti-cancer effects of Frondoside A alone and in combination with the
standard cytotoxic drugs oxaliplatin and 5-FU (FOLFOX protocol) in the treatment of colon cancer.
2. Materials and Methods
2.1. Cell Culture and Reagents
The human colon cancer cell lines HT-29, HCT-116, and HCT8/S11 were maintained in DMEM
(Hyclone, Cramlington, UK) supplemented with antibiotics (penicillin: 50 U/mL; streptomycin:
50 μg/mL) (Hyclone, Cramlington, UK) and with 10% fetal bovine serum (FBS; Biowest, Nouaille,
France). In all experiments, the cell viability was higher than 99% using trypan blue dye exclusion.
Frondoside A, oxaliplatin, and 5-FU were purchased from Sigma-Aldrich (Sigma-Aldrich, Saint Louis,
MO, USA). Antibodies to phospho-AKT, phospho-p44/42 MAPK (ERK1/2), cleaved caspase-3
(Asp175), and cleaved poly (ADP-ribose) polymerase (PARP) were obtained from Cell Signaling
Technology (Cell Signaling, Beverly, MA, USA). The AKT antibody was obtained from Abcam
(Abcam, Cambridge, UK). The antibody to phospho-histone H2AX was obtained from Millipore
(Millipore, Hayward, CA, USA). Antibodies to ERK2 and β-actin were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA).
2.2. Impact of Frondoside A, Oxaliplatin, 5-Fluorouracil, and Their Combinations on Colon Cancer Cell Numbers
Cells were seeded at a density of 50,000 cells per well into 6-well plates. After 24 h, the cells
were treated for another 24, 48, and 72 h with increasing concentrations of Frondoside A (0.1–5 μM),
oxaliplatin (1–100 μM), or 5-FU (1–100 μM) in triplicate. Control cultures were treated with 0.1%
DMSO (the drug vehicle). In the second set of experiments, cells were treated with a combination of
Frondoside A and oxaliplatin or Frondoside A and 5-FU. The effects of these combinations on the
cell numbers were determined at the indicated times using the Scepter 2.0 Handheld Automated Cell
Counter (Millipore, Hayward, CA, USA). Data were presented as the proportional cell numbers (%)
by comparing the drug-treated cells with the DMSO-treated cells, the cell numbers of which were
assumed to be 100%.
2.3. Impact of the Treatments on Colony Growth in Matrigel Matrix
A layer of 150 μL of matrigel was poured into the wells of a 24-well cell culture dish and allowed
to set at 37 ◦C for 30 min. A second layer (300 μL) composed of 150 μL of matrigel dissolved in 150 μL
of growth media containing 1.5 × 103 cells was placed on top of the first layer and allowed to set in the
humidified incubator at 37 ◦C for 30 min. Growth medium (0.5 mL) was added on top of the second
layer, and the cells were incubated in a humidified incubator at 37 ◦C for 14 days and then treated for
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another 7 days with Frondoside A, oxaliplatin, 5-FU, or the combinations. Control cells were exposed
to 0.1% DMSO. The medium was changed twice a week. At the end of the experiment, colonies were
stained for 1 h with 2% Giemsa stain and incubated with PBS overnight to remove excess Giemsa
stain. The colonies were photographed and scored, and the percentages of colonies larger than 100 μm
were determined. Data presented compare the drug-treated colonies with the DMSO-treated colonies.
Colonies larger than 100 μm were expressed as a percentage of the total counted colonies and were
then compared to the DMSO-treated controls.
2.4. Quantification of Apoptosis by Annexin V Labeling
Apoptosis was examined using the Annexin V Dead Cell kit (Millipore, Hayward, CA, USA)
according to the manufacturer’s instructions. Briefly, HT-29 cells were treated with or without
each compound individually or in combination for 48 h. Detached and adherent cells were
collected and incubated with Annexin V and 7-AAD, a dead cell marker, for 20 min at room
temperature in the dark. The early and late apoptotic cells were counted with the Muse Cell Analyzer
(Millipore, Hayward, CA, USA). Experiments were carried out in triplicate and were repeated three times.
2.5. Impact of Frondoside A, Oxaliplatin, 5-Fluorouracil, and Their Combinations on Pro-Apoptotic and
Anti-Proliferation Proteins’ Expression and Phosphorylation Levels
Cells were seeded in 100 mm dishes at 2 × 106 cells per dish for 24 h and were then treated
with Frondoside A (0.5 μM), oxaliplatin (10 μM), 5-FU (10 μM), a combination of Frondoside A
and oxaliplatin, or Frondoside A and 5-FU, for another 24 h. Control cultures were treated with
0.1% DMSO (the drug vehicle). In a second set of experiments, cells were treated with increasing
concentrations of Frondoside A (0.5–2.5 μM) for 2 h. Total cellular proteins were isolated using
a RIPA buffer (25 mM Tris.HCl, pH 7.6; 1% Nonidet P-40; 1% sodium deoxycholate; 0.1% SDS;
0.5% protease inhibitor cocktail; 1% PMSF; 1% phosphatase inhibitor cocktail) from the DMSO- and
drug-treated cells. The whole cell lysates were recovered by centrifugation at 14,000 rpm for 20 min
at 4 ◦C to remove insoluble material, and the protein concentrations of the lysates were determined
using a BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Proteins (30 μg) were
separated by SDS-PAGE gel to determine the expression and the phosphorylation levels of different
pro-apoptotic and anti-proliferation proteins (AKT, p-AKT, activated caspase-3, cleaved PARP, p-H2AX,
ERK-2, p-ERK, and β-actin). After electrophoresis, the proteins were transferred onto a nitrocellulose
membrane, blocked for 1 h at room temperature with 5% non-fat milk in TBST (TBS and 0.05% Tween
20), and then probed with specific primary antibodies and β-actin (1:1000) overnight at 4 ◦C. The blots
were washed, exposed to secondary antibodies, and visualized using the ECL system (Thermo Fisher
Scientific, Waltham, MA, USA). Membrane stripping was performed by incubating the membrane
in Restore Western blot stripping buffer (Thermo Fisher Scientific, Waltham, MA, USA) according to
the manufacturer’s instructions. Densitometry analysis was performed using an HP Deskjet F4180
Scanner (HP Development Company, Palo Alto, CA, USA) with ImageJ software.
2.6. Statistics
Results are expressed as means ± S.E.M. of the indicated data. The difference between the
experimental and control values was assessed by ANOVA followed by Dunnett’s post hoc multiple
comparison test (*** p < 0.001, ** p < 0.01, and * p < 0.05 indicate a significant difference).
3. Results and Discussion
3.1. Effect of Frondoside A, Oxaliplatin and 5-Fluorouracil on Cell Numbers
As shown in Figure 1, Frondoside A (0.1–5 μM), oxaliplatin (1–100 μM), and 5-FU (1–100 μM)
caused a concentration- and time-dependent decrease in HT-29 cell numbers over 24, 48, and 72 h
(Figure 1A–C). The concentration-dependent effects of Frondoside A, oxaliplatin, and 5-FU were also
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confirmed on two other colon cancer cell lines, namely, HCT-116 and HCT8/S11 (Figure 1D–F). At 48 h,
the IC50 concentration of Frondoside A was 0.5 μM in HT-29 cells and approximately 0.75 μM in both
HCT-116 and HCT8/S11 cells (Table 1). On the other hand, the IC50 concentrations of oxaliplatin
and 5-FU were found to be much higher than for Frondoside A (Table 1). Because previous work has
reported the anti-tumor activity of oxaliplatin and 5-FU in HT-29 colon cancer cells [9], we therefore
decided to pursue the rest of this study on HT-29 cells.
Figure 1. Frondoside A inhibition of colon cancer cell numbers compared to oxaliplatin and
5-fluorouracil. Exponentially growing HT-29 cells were treated with vehicle (0.1% DMSO) and the
indicated concentrations of Frondoside A (A), oxaliplatin (B), and 5-fluorouracil (C) for 24 to 72 h.
The effects of the three drugs were confirmed at 48 h in two additional colon cancer cell lines, namely,
HCT8/S11 and HCT-116 (D–F). Cell count was determined as described in Materials and Methods.
All experiments were repeated at least three times. Shapes represent means; bars represent S.E.M.
* Significantly different at p < 0.05. ** Significantly different at p < 0.01. *** Significantly different at
p < 0.001.
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Table 1. IC50 (μM) of Frondoside A compared to oxaliplatin and 5-fluorouracil at 48 h of treatment.
IC50 (μM)
Frondoside A Oxaliplatin 5-Fluorouracil
HT-29 0.5 5 2.6
HCT-116 0.75 5 2.5
HCT8/S11 0.75 2.5 0.9
3.2. Frondoside A Enhanced the Anti-Tumor Activity of Oxaliplatin and 5-Fluorouracil on HT-29 in Cell Count
and Colony Growth Assays
The treatment of HT-29 cells for 48 h using the IC50 concentration of Frondoside A (0.5 μM)
significantly enhanced the growth inhibitory effects of increasing concentrations of oxaliplatin
(1–10 μM) (Figure 2A) and 5-FU (0.5–2.5 μM) (Figure 2B). We next examined the impact of these
combinations on the growth of already formed HT-29 colonies. First, HT-29 cells were allowed
to grow and form visible colonies in the absence of any treatment. After two weeks of growth,
the colonies were treated for one more week with DMSO as the control, Frondoside A (0.5 μM),
oxaliplatin (10 μM), 5-FU (10 μM), or a combination. Although the number of colonies obtained
in each treatment seemed unchanged, we noticed, however, that the sizes of the colonies were
significantly reduced. Indeed, while large colonies represented approximately 70% of the total number
of colonies in the control, they represented only 25% and 35% of the total number of colonies exposed
to both oxaliplatin (Figure 3A) and 5-FU (Figure 3B) alone. Although Frondoside A did not lead
to significant colony growth inhibition when compared to oxaliplatin or 5-FU alone, when used
in combination, Frondoside A significantly enhanced the inhibition of colony growth mediated by
oxaliplatin (Figure 3A) or 5-FU (Figure 3B). We speculate that the effect of these drugs alone and
in combination on the size of the colony growth may be due to cell death and/or inhibition of
cellular proliferation.
It is well documented that the MAPK signaling pathway is mainly involved in regulating
cellular proliferation and that a blockade of this pathway suppresses the growth of colon tumors [10].
ERK1 and ERK2, the final effectors of the MAPK pathway, activated through phosphorylation,
lead to the activation of a variety of substrates responsible for the induction of cell proliferation.
Hence, we decided to investigate the activation of ERK1/2 in response to Frondoside A alone and in
combination with oxaliplatin and 5-FU. Interestingly, although we observed a marked inhibition of
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Figure 2. Frondoside A enhances the inhibition of HT-29 cell numbers by (A) oxaliplatin (1–10 μM),
and (B) 5-fluorouracil (0.5–2.5 μM). Cells were treated for 48 h, and all experiments were repeated
at least three times. Columns are means; bars are S.E.M. ** Significantly different at p < 0.01.
*** Significantly different at p < 0.001. ns (not significant).
 
Figure 3. Frondoside A enhances the inhibition of colonies’ growth by (A) oxaliplatin (10 μM),
and (B) 5-fluorouracil (10 μM). Data are presented as histograms of the mean percentage of large
colonies’ growth ± S.E.M. (C) The inhibition of ERK phosphorylation by oxaliplatin and 5-fluorouracil
was enhanced by Frondoside A in HT-29 colon cancer cells. (D) Densitometry analysis of p-ERK
from three different experiments. β-actin was used as an internal loading control of the protein levels,
and the normalized p-ERK bands’ densities are expressed as percentage change in comparison to
control samples considered equal to 100%. * Significantly different at p < 0.05. ** Significantly different
at p < 0.01. *** Significantly different at p < 0.001. ns (not significant).
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3.3. Combination of Frondoside A with 5-Fluorouracil or Oxaliplatin Enhances Apoptotic Cell Death in HT-29
Colon Cancer Cells
Next, we investigated whether the enhanced decrease in HT-29 cell numbers when Frondoside
A was used in combination with 5-FU or oxaliplatin was the result of increased apoptotic cell death.
Toward this aim, HT-29 colon cancer cells were incubated with Frondoside A (0.5 μM) alone or in
combination with increasing concentrations of oxaliplatin (1–10 μM) or 5-FU (0.5–10 μM), and apoptosis
was examined after 48 h using Annexin V staining. As shown in Figure 4, a combination of Frondoside
A and oxaliplatin caused no increase in the level of apoptosis in comparison with either drug alone.
On the other hand, and very interestingly, we found that a combination of Frondoside A and 5-FU led
to an increased number of apoptotic cells. Indeed, the population of apoptotic cells rose from 21% for
Frondoside A (0.5 μM) and 23% for 5-FU (10 μM) when used alone to 66% when used in combination,
suggesting a possible synergism between Frondoside A and 5-FU at these concentrations (Figure 5).
Figure 4. Impact of Frondoside A on apoptotic cell death induced by oxaliplatin in HT-29 colon cancer
cells. (A,B) Annexin V binding was carried out using Annexin V Dead Cell kit. HT-29 cells were treated
with or without Frondoside A (0.5 μM) and indicated concentrations of oxaliplatin (1, 2.5, and 10 μM)
individually and in combination for 48 h. Detached and adherent cells were collected and stained with
Annexin V and 7-AAD, and then the events for early and late apoptotic cells were counted with the
Muse Cell Analyzer as described in Materials and Methods. Data represent the mean ± S.E.M. of at
least three independent experiments. Fr represents Frondoside A and Oxa represents oxaliplatin.
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Figure 5. Frondoside A enhances apoptotic cell death induced by 5-fluorouracil in HT-29 colon cancer
cells. (A,B) Annexin V binding was carried out using Annexin V Dead Cell kit. HT-29 cells were treated
with or without Frondoside A (0.5 μM) and indicated concentrations of 5-fluorouracil (0.5, 1, and 10 μM)
individually and in combination for 48 h. Detached and adherent cells were collected and stained with
Annexin V and 7-AAD, and then the events for early and late apoptotic cells were counted with the
Muse Cell Analyzer as described in Materials and Methods. Data represent the mean ± S.E.M. of at
least three independent experiments. Fr represents Frondoside A and 5-FU represents 5-fluorouracil.
179
Nutrients 2018, 10, 560
3.4. Effects of Frondoside A, Oxaliplatin, and 5-Fluorouracil alone or in Combination on Survival and Apoptotic
Pathways and on the DNA Damage
A marked inhibition of AKT phosphorylation was noted with all three drugs when used alone;
however, no further decrease in the level of phosphorylation was observed when the drugs were used
in combination (Figure 6A). As expected, neither of the treatments carried out affected the level of
total AKT proteins (Figure 6A). It has been reported that downregulation of AKT phosphorylation
induces caspase-3-dependent apoptosis [11,12]. In line with these reports, oxaliplatin was shown to
induce dephosphorylation of AKT, leading to the accumulation of cleaved caspase-3 [13]. We and
others have previously reported that Frondoside A induced caspase-3 cleavage in pancreatic, breast,
lung, and prostate cancer cells [3,5–7]. In this context, apoptosis induced by Frondoside A alone and in
combination with oxaliplatin and 5-FU was further assessed by measuring caspase-3 activation and
consequently PARP cleavage and inactivation. Cells treated with Frondoside A (0.5 μM), oxaliplatin
(10 μM), and 5-FU (10 μM) for 24 h induced the activation of the executioner caspase-3, a key step
to induce apoptosis. This activation was further slightly enhanced when Frondoside A was used in
combination with either oxaliplatin or 5-FU (Figure 6A). Caspase-3 activation leads to the cleavage
and consequently the inactivation of the downstream PARP, a nuclear protein involved in DNA repair
and apoptosis. Similarly, downstream PARP cleavage was also observed in the single and combined
treatments of HT-29 cells. This is supported by previous reports demonstrating that Frondoside A,
oxaliplatin, and 5-FU induce PARP cleavage [3,7,14].
 
Figure 6. Western blot analysis of: (A) the effects of Frondoside A, oxaliplatin, 5-fluorouracil,
and their combinations on the phosphorylation of the survival kinase AKT and on caspase-3 activation,
Poly (ADP-ribose) polymerase (PARP) inactivation and H2AX phosphorylation. HT-29 cells were
treated for 24 h with the indicated concentrations of Frondoside A, oxaliplatin, 5-fluorouracil, and their
combinations. Densitometry analysis is from three different experiments. β-actin was used as
an internal loading control of the protein levels, and the normalized bands’ densities are expressed
as percentage change in comparison to control samples considered equal to 100%. (B) The levels of
p-AKT, p-ERK, and p-H2AX after 2 h of treatment with Frondoside A (0.5–2.5 μM).
180
Nutrients 2018, 10, 560
PARP inhibition using PARP inhibitors is known to increase the levels of DNA-damage-associated
phosphorylation of H2AX [15]. Phosphorylated H2AX histone (γH2AX) is a marker of DNA
double-strand breaks. 5-FU was previously reported to induce DNA damage in colon cancer cells [16].
To check whether the induction of cell death by Frondoside A, oxaliplatin, and 5-FU is associated
with DNA damage, HT-29 cells were exposed to the drugs either alone or in combination, and the
total proteins were evaluated for γH2AX expression. We found that cells treated with the three drugs
alone underwent DNA damage. Interestingly, when the drugs were used in combination, this further
increased the level of DNA damage in the treated cells (Figure 6A). To determine whether Frondoside
A mediates its effect through DNA damage, the inhibition of ERK1/2, AKT signaling pathways,
or a combination, we performed an experiment to measure the levels of DNA damage, p-AKT,
and p-ERK1/2 after 2 h of treatment with Frondoside A (0.5–2.5 μM). Figure 6B clearly demonstrates
that the concentration of 0.5 μM of Frondoside A used in this study had no effect on the DNA damage,
while it strongly reduced the levels of phosphorylated AKT and ERK. DNA damage occurred at
a minimal level only at a very high concentration of Frondoside A. Hence, this result strongly suggests
that the inhibition of ERK and AKT signaling is an early event that occurs in response to Frondoside
A treatment and that DNA damage is a late event that might result from excessive DNA damage as
a consequence of active apoptosis. Taken together, our results strongly suggest that Frondoside A,
when used in combination, enhances the anti-proliferative and the pro-apoptotic effects of oxaliplatin
and 5-FU.
4. Conclusions
To the best of our knowledge, the present study identifies for the first time that Frondoside
A treatment significantly inhibits proliferation and induces apoptosis in colon cancer cells.
The combinations of Frondoside A with the DNA-damaging agent oxaliplatin or with the thymidylate
synthase inhibitor 5-FU were significantly more effective in inhibiting HT-29 cell proliferation and
triggering apoptosis, leading to the inhibition of the HT-29 colonies’ growth, than either cytotoxic
agent alone.
Our data suggests that the inactivation of the proliferation (ERK) and pro-survival (AKT)
pathways along with caspase-3 activation, PARP cleavage, and consequently DNA damage account,
at least partly, for the anti-cancer effect of Frondoside A. Moreover, combination therapy either with
oxaliplatin or 5-FU enhanced these effects and further clarified the capacity of Frondoside A to
enhance the apoptosis induced mainly by 5-FU. The data also suggests that the inhibition of ERK1/2
phosphorylation with single treatments and its enhanced inhibition under the combination conditions
suggests a potential impact of the treatments on colon cancer cell proliferation.
The dual inhibitory effect of our treatments on the PI3K–AKT and the Raf–MEK–ERK
pathways is in line with the previously reported interactions between these two pathways [17].
Here, we demonstrate that the inhibition of AKT and ERK phosphorylation is crucial for the anti-tumor
activity of Frondoside A. These results are in agreement with previous reports showing that Frondoside
A inhibited AKT and ERK1/2 activation in TPA-stimulated breast cancer cells [18] and ERK1/2
activation in PGE2-stimulated breast cancer cells [19].
The current findings are in line with a study by Janakiran et al. demonstrating that Frondanol A5,
a Cucumaria frondosa extract that contains several agents, including monosulphated triterpenoid
glycoside Frondoside A, the disulphated glycoside Frondoside B, the trisulphated glycoside
Frondoside C, 12-methyltetradecanoic acid, eicosapentaenoic acid, fucosylated chondroitin sulfate,
and canthaxanthin/astaxanthin, inhibits HCT-116 colon cancer cell growth by inducing a G2 arrest
followed by the induction of apoptosis [20].
This study provides sufficient rationale to carry out in vivo studies to confirm the relevance of the
combination therapy. We believe that Frondoside A in combination with the standard cytotoxic drugs
oxaliplatin and 5-FU currently used in colon cancer treatment may improve colon cancer therapy.
181
Nutrients 2018, 10, 560
Author Contributions: S.A. conceived and designed the experiments; K.A., T.K., S.S., and R.I. performed the
experiments; S.A. and R.I. analyzed the data; S.A. and R.I. wrote the paper.
Acknowledgments: This work was supported by the CMHS Grant (31M146), was partly supported by the
Terry Fox UAE Grant (21M081) to S.A., and was partly supported by the ZCHS Research Grant (31R086) to R.I.
The funders had no role in the study design, the data collection and analysis, the decision to publish, or the
preparation of the manuscript.
Conflicts of Interest: The authors declare no conflict of interest. The authors have no other relevant affiliations or
financial involvement with any organization or entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript apart from those disclosed.
References
1. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer
J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
2. Chemotherapy of Metastatic Colorectal Cancer. Available online: https://www.ncbi.nlm.nih.gov/pubmed/
21180382 (accessed on 19 October 2010).
3. Li, X.; Roginsky, A.B.; Ding, X.Z.; Woodward, C.; Collin, P.; Newman, R.A.; Bell, R.H., Jr.; Adrian, T.E.
Review of the apoptosis pathways in pancreatic cancer and the anti-apoptotic effects of the novel sea
cucumber compound, Frondoside A. Ann. N. Y. Acad. Sci. 2008, 1138, 181–198. [CrossRef] [PubMed]
4. Jin, J.O.; Shastina, V.V.; Shin, S.W.; Xu, Q.; Park, J.I.; Rasskazov, V.A.; Avilov, S.A.; Fedorov, S.N.; Stonik, V.A.;
Kwak, J.Y. Differential effects of triterpene glycosides, frondoside A and cucumarioside A2-2 isolated from
sea cucumbers on caspase activation and apoptosis of human leukemia cells. FEBS Lett. 2009, 583, 697–702.
[CrossRef] [PubMed]
5. Al Marzouqi, N.; Iratni, R.; Nemmar, A.; Arafat, K.; Al Sultan, M.A.; Yasin, J.; Collin, P.; Mester, J.; Adrian, T.E.;
Attoub, S. Frondoside A inhibits human breast cancer cell survival, migration, invasion and the growth of
breast tumor xenografts. Eur. J. Pharmacol. 2011, 668, 25–34. [CrossRef] [PubMed]
6. Attoub, S.; Arafat, K.; Gelaude, A.; Al Sultan, M.A.; Bracke, M.; Collin, P.; Takahashi, T.; Adrian, T.E.;
De Wever, O. Frondoside a suppressive effects on lung cancer survival, tumor growth, angiogenesis, invasion,
and metastasis. PLoS ONE 2013, 8, e53087. [CrossRef] [PubMed]
7. Dyshlovoy, S.A.; Menchinskaya, E.S.; Venz, S.; Rast, S.; Amann, K.; Hauschild, J.; Otte, K.; Kalinin, V.I.;
Silchenko, A.S.; Avilov, S.A.; et al. The marine triterpene glycoside frondoside A exhibits activity in vitro
and in vivo in prostate cancer. Int. J. Cancer 2016, 138, 2450–2465. [CrossRef] [PubMed]
8. Al Shemaili, J.; Mensah-Brown, E.; Parekh, K.; Thomas, S.A.; Attoub, S.; Hellman, B.; Nyberg, F.; Adem, A.;
Collin, P.; Adrian, T.E. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic
cancer. Eur. J. Cancer 2014, 50, 1391–1398. [CrossRef] [PubMed]
9. Raymond, E.; Buquet-Fagot, C.; Djelloul, S.; Mester, J.; Cvitkovic, E.; Allain, P.; Louvet, C.; Gespach, C.
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor
AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997, 8, 876–885. [CrossRef] [PubMed]
10. Sebolt-Leopold, J.S.; Dudley, D.T.; Herrera, R.; Van Becelaere, K.; Wiland, A.; Gowan, R.C.; Tecle, H.;
Barrett, S.D.; Bridges, A.; Przybranowski, S.; et al. Blockade of the MAP kinase pathway suppresses growth
of colon tumors in vivo. Nat. Med. 1999, 5, 810–816. [CrossRef] [PubMed]
11. Moon, D.O.; Park, S.Y.; Choi, Y.H.; Kim, N.D.; Lee, C.; Kim, G.Y. Melittin induces Bcl-2 and
caspase-3-dependent apoptosis through downregulation of Akt phosphorylation in human leukemic U937
cells. Toxicon 2008, 51, 112–120. [CrossRef] [PubMed]
12. Weng, H.Y.; Hsu, M.J.; Chen, C.C.; Chen, B.C.; Hong, C.Y.; Teng, C.M.; Pan, S.L.; Chiu, W.T.; Lin, C.H.
Denbinobin induces human glioblastoma multiforme cell apoptosis through the IKKα-Akt-FKHR signaling
cascade. Eur. J. Pharmacol. 2013, 698, 103–109. [CrossRef] [PubMed]
13. Shiragami, R.; Murata, S.; Kosugi, C.; Tezuka, T.; Yamazaki, M.; Hirano, A.; Yoshimura, Y.; Suzuki, M.;
Shuto, K.; Koda, K. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon
cancer cells. Int. J. Oncol. 2013, 43, 431–438. [CrossRef] [PubMed]
14. Flis, S.; Gnyszka, A.; Misiewicz-Krzeminska, I.; Spławiński, J. Decytabine enhances cytotoxicity induced by
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Abstract: Novel and alternative options are being adopted to combat the initiation and progression
of human cancers. One of the approaches is the use of molecules isolated from traditional medicinal
herbs, edible dietary plants and seeds that play a pivotal role in the prevention/treatment of
cancer, either alone or in combination with existing chemotherapeutic agents. Compounds that
modulate these oncogenic processes are potential candidates for cancer therapy and may eventually
make it to clinical applications. Diosgenin is a naturally occurring steroidal sapogenin and is one
of the major bioactive compounds found in dietary fenugreek (Trigonella foenum-graecum) seeds.
In addition to being a lactation aid, diosgenin has been shown to be hypocholesterolemic, gastro-
and hepato-protective, anti-oxidant, anti-inflammatory, anti-diabetic, and anti-cancer. Diosgenin
has a unique structural similarity to estrogen. Several preclinical studies have reported on the
pro-apoptotic and anti-cancer properties of diosgenin against a variety of cancers, both in in vitro and
in vivo. Diosgenin has also been reported to reverse multi-drug resistance in cancer cells and sensitize
cancer cells to standard chemotherapy. Remarkably, diosgenin has also been reported to be used
by pharmaceutical companies to synthesize steroidal drugs. Several novel diosgenin analogs and
nano-formulations have been synthesized with improved anti-cancer efficacy and pharmacokinetic
profile. In this review we discuss in detail the multifaceted anti-cancer properties of diosgenin that
have found application in pharmaceutical, functional food, and cosmetic industries; and the various
intracellular molecular targets modulated by diosgenin that abrogate the oncogenic process.
Keywords: diosgenin; steroidal sapogenins; anti-cancer; apoptosis; oncogenic; metastasis
1. Introduction
Cancer is a complex and heterogeneous disease that afflicts men and women worldwide; it is
expected to increase due to human lifestyle changes and a rapidly aging population [1]. Hanahan
and Weinberg’s proposed hallmarks of cancer are widely accepted towards understanding the
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biology of cancer cells, through a multi-stage and progressive process [2–6]. These hallmarks include
sustained proliferation of cells, constitutive activation of pro-survival transcription factors, deregulated
cellular functions, evading cell death signals and growth suppressors, an increased pro-inflammatory
tumor microenvironment, camouflaging against immune cell destruction, promoting angiogenesis,
activating cell movement from the primary site and metastasis, enabling replicative immortality,
and finally, severe genome instability [2,3,5–10]. In addition, several deregulated cellular signaling
networks underlying the above hallmarks have been extensively investigated in pre-clinical and
clinical drug development [3,4,11–18]. In spite of detailed information of these semi-synthetic and
synthetic anti-cancer agents, they only provide limited therapeutic advantages to patients due to
highly toxic unwanted side effects and the development of chemoresistance [19–21]. Emerging
approaches should include the identification of novel drug targets that are very effective in inhibiting
the growth of cancer cells, while exhibiting fewer adverse effects. Natural products are a good
source of compounds with novel chemical structures that are effective and less toxic [18,22–27]. High
throughput technologies should be exploited for the screening of a large library of compounds for
their anti-cancer activities [28–30]. The mainstream of United States Food and Drug Administration
(US FDA)-approved compounds divulge that natural products and their derivatives occupy one-third
of all novel drugs [22–24,31]. These natural compounds, in general, show multi-targeted effects and
can modulate several oncogenic transcription factors that block the tumor microenvironment targets
that usually sustain tumor growth [22,27,32]. These compounds can also be classified as cytotoxic or
cytostatic compounds [30]. Therefore, many secondary metabolites and pure molecules isolated from
herbs, spices, dietary fruits and vegetables, and even marine sources have been explored [33–35].
Several novel bioactive molecules have been found in various edible cereals, pulses, roots, and
in several parts of medicinal plants. Fenugreek (Trigonella foenum-graecum) belongs to the family
Leguminosae and is considered a traditional medicinal herb that is commonly used in India, China,
Thailand, and South-East Asian countries; it is also cultivated in the Mediterranean region and Northern
Africa [36–41]. Fenugreek seeds, shoots and leaves are used in Indian curry preparation as a condiment.
Bibliometric data indicates that fenugreek extract has several pharmacological properties, such as
being hypocholesterolemic, a lactation aid, antibacterial, a gastric stimulant, anti-anorexic, antidiabetic,
galactogogic, hepatoprotective, and anti-cancer both in in vitro and in vivo studies [40–43]. Fenugreek
seed extract contains several bioactive molecules in various classes of compounds, such as saponins,
flavonoids, coumarins, and alkaloids that target several molecules involved in inflammation and cancer
cell proliferation, invasion, migration, angiogenesis, and metastasis [40]. Sapogenins are a class of
compounds that widely occur in natural products in their glycoside form and promote general healthy
living. Among these compounds, steroidal sapogenins (otherwise known as spirostans) are the most
potent bioactive compounds isolated from natural product sources [44,45]. Steroidal sapogenins exhibit
ubiquitous pharmacological properties and the majority of them demonstrate anti-cancer activity
in vitro and in pre-clinical animal models. Several clinical trials have been conducted with fenugreek
seed extract, they are either completed or ongoing; however, diosgenin anti-cancer trials are yet
to start [36,41]. Diosgenin is the most abundant steroidal sapogenin in fenugreek seeds. Fujii and
Matsukawa isolated and identified diosgenin from Dioscorea tokoro Makino in 1935 [41,46] (Figure 1).
Diosgenin is a phytosteroidal saponin and a major bioactive compound found in the seeds of T.
foenum-graecum, commonly known as fenugreek, and in the roots of wild yam (Dioscorea villosa) [36,40,
41,47,48]. Interestingly, diosgenin is also found in high levels in numerous plant species including Costus
speciosus, Smilax menispermoidea, species of Paris, Aletris and Trillum, and in species of Dioscorea [41,49,50].
The steroidal saponin, diosgenin, is biosynthesized from cholesterol. Cholesterol is formed from
lanosterol and catalysed by the cytochrome P450 system. Several other routes of synthesis have been
identified, such as from squalene-2,3-oxide in two ways: From cycloartenol through the formation
of sitosterol [51] and from lanosterol via cholesterol [52]. Several studies have demonstrated the
diverse biological activities of diosgenin, such as hypolipidemic, anti-inflammatory, anti-proliferative,
hypoglycemic activity, and as a potent anti-oxidant [44]. In addition, diosgenin inhibited cancer cell
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proliferation and induced apoptosis in a variety of cancer cell lines including colorectal, hepatocellular,
breast, osteosarcoma, and leukemia [53–55]. The primary mechanism of action of diosgenin is through
the modulation of multiple cell signaling pathways that play prominent roles in cell-cycle regulation,
differentiation, and apoptosis [56]. Remarkably, pharmaceutical companies use diosgenin as a principal
precursor compound for the manufacturing of several steroidal drugs [48]. Diosgenin is also an attractive
molecule with multifaceted properties that has found application in pharmaceutical, functional food,
and cosmetic industries. In this review we provide an in-depth evaluation of literature on diosgenin
and its pharmacodynamics and pharmacokinetics, and discuss several of its novel derivatives and
nanoformulations that increase its bioavailability and therapeutic efficacy. Diosgenin, over the years,
has provided abundant data on the prevention and treatment of various inflammation-driven diseases,
including cancers [36] (Figure 2).
Figure 1. Chemical structure of diosgenin.
Figure 2. Tumor stage-specific inhibition of molecular targets by diosgenin.
2. Fenugreek Seed Bioactive Compounds
Fenugreek contains several chemical constituents, such as alkaloids, steroidal sapogenins,
saponins, flavonoids, lipids, amino acids, and carbohydrates. Diosgenin is a major bioactive steroidal
sapogenin in the fenugreek seed, which is reported to have chemopreventive and therapeutic effects
against inflammation and chronic inflammation-driven cancers in preclinical in vitro and in vivo
models of cancer [36,57]. Table 1 illustrates the major constituents of fenugreek seeds and leaves.
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Table 1. Main phytochemical constituents of fenugreek (T. foenum-graecum).
Class of Compounds Phytochemical Constituents Reference
Steroidal sapogenins Diosgenin, Yamogenin, Smilagenin, Sarsasapogenin, Tigogenin,Neotigogenin, Gitogenin, Yuccagenin, Saponaretin [40]
Flavonoids Quercetin, Rutin, Vitexin, Isovitexin [40]
Saponins Graecunins, Fenugrin B, Fenugreekine, Trigofoenosides A–G [40]
Alkaloids Trimethylamine, Neurin, Trigonelline, Choline, Gentianine,Carpaine, and Betain [40]
Fibers Gum, Neutral detergent fiber [40]
Lipids
Lipids, Triacylglycerols, Diacylglycerols, Monoacylglycerols,
Phosphatidylcholine, Phosphatidylethanolamine,
Phosphatidylinositol, Free fatty acids
[40]
Others Coumarin, Amino acids, Vitamins, Minerals. 28% Mucilage;22% Proteins; 5% of a stronger swelling, Bitter fixed oil [40]
3. In Vitro Anti-Cancer Effects of Diosgenin
Diosgenin, the major steroidal sapogenin in the fenugreek seed, has been shown to potently
suppress constitutively-activated pro-inflammatory and pro-survival signaling pathways in a variety
of cancer cells, and induced apoptosis [58]. Some of the earlier studies by Shishodia and Aggarwal [58]
reported that diosgenin abrogated TNF-α-induced NF-κB activation and suppressed osteoclastogenesis
in RAW 264.7 macrophage cells [58]. In Her-2 positive breast cancer cells, diosgenin inhibited the
expression of AKT, mTOR, JNK and their associated pro-survival signaling pathways, and induced
apoptosis in these cells [53]. In another study by Li et al., they reported that diosgenin could inactivate
the STAT3 signaling pathway in hepatocellular carcinoma (HCC) cells, by inhibiting intracellular
signaling molecules such as c-SRC, JAK1, and JAK2 (Figure 3). Diosgenin also suppressed STAT3
transcriptional activity and the expression of its downstream gene products involved in proliferation,
invasion and metastasis. In addition, diosgenin sensitized HCC cells to doxorubicin and paclitaxel,
and synergistically augmented apoptosis, thereby suggesting that diosgenin is a potential bioactive
compound for the treatment of HCC and other cancers [54]. Diosgenin inhibited proliferation,
AKT and JNK in a dose- and time-dependent manner and induced caspase-dependent apoptosis
in A431 and Hep2 skin squamous cell carcinoma cells [59]. HT-29 colon cancer cells have been
reported to be resistant to TRAIL-induced apoptosis. Diosgenin was shown to sensitize the HT-29
colon cancer cell to TRAIL. In addition, it potently suppressed cell proliferation and induced
apoptosis by suppressing the p38/MAPK signaling pathway and the overexpression of DR5 [60].
Furthermore, Romero-Hernandez et al. [61] demonstrated that diosgenin-derived thio(seleno)ureas
and glycomimetics, bearing a 1,2,3-triazolyl tether on C-3, showed more potent anti-cancer activity
against MDA-MB-231 and MCF-7 breast cancer cells, HepG2 hepatocellular carcinoma cells, and
induced apoptosis, compared to its parent compound diosgenin [61]. In another study, diosgenin
conjugated to methotrexate was found to be more potent in inhibiting the growth of transport-resistant
breast cancer cells and dihydrofolate reductase (enzyme involved in DNA synthesis), compared to
the parent diosgenin [62]. In chronic myeloid leukemia cells, diosgenin-induced autophagy inhibited
the mTOR signaling pathway and induced apoptotic cell death [63]. Diosgenin induced cytotoxicity
and significantly inhibited the growth and proliferation of MCF-7 breast cancer cells in a dose- and
time-dependent manner. Diosgenin was also shown to inhibit N-nitroso-N-methylurea-induced breast
cancer in rats [64].
Of several factors that contribute to the sustained growth and proliferation of tumors, one important
factor is the abundant neovascularization or formation of new micro blood vessels at the tumor site,
or within the tumor. This process is also known as tumor angiogenesis. Thus, the formation of new
blood vessels in tumors actively supplies the essential nutrients and growth factors that allow tumors to
187
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acquire the ability to reject chemotherapeutic drugs and develop chemoresistance [27,65–68]. Diosgenin
is also a potent inhibitor of cancer cell invasion, migration, and tumor-associated angiogenesis [27,69].
He et al., reported that diosgenin inhibited the invasion and migration of triple-negative breast cancer
cells and was associated with the concomitant suppression of actin polymerization, phosphorylation of
Vav2, and activation of Cdc42 oncoprotein expression. These proteins have been shown to be involved
in the initiation of cancer cells’ invasive and migratory potential [70]. Similarly, diosgenin was found
to inhibit PC3 androgen-independent prostate cancer cell invasion and migration. The inhibitory
effect was mediated by the downregulation of matrix metalloproteinase (MMP)-2 and MMP-9, the key
enzymes in matrix degradation and stroma invasion. Furthermore, diosgenin also downregulated
the tissue inhibitors of metalloproteinase (TIMP)-2, vascular endothelial growth factor (VEGF),
extracellular regulated kinase (ERK), Janus kinase (JNK), phosphotidyl-inositol-3 kinase/protein
kinase B (PI3K/AKT), and NF-κB transcriptional activity [56]. In addition, diosgenin was reported
to inhibit the expression of E-cadherin, integrin 5a and 6b, invasion, migration, and angiogenesis in
hypoxia-sensitive BGC-823 gastric cancer cells [71]. Diosgenin was reported to inhibit proliferation
of ER-positive MCF-7 breast cancer cells by the upregulation of the p53 tumor suppressor gene and
activation of caspase 3, while it downregulated BCL2 in ER negative MDA-MB-231 triple-negative
breast cancer cells [72]. Diosgenin, either alone, or in combination with thymoquinone, inhibited A431
and Hep2 squamous cell carcinoma cell proliferation, increased the Bax/Bcl2 ratio, and induced caspase
3-mediated apoptosis [59] (Table 2). The potential effect of diosgenin on NF-κB and STAT3 signaling
pathways in tumor cells, is shown in Figure 3.
Figure 3. Role of diosgenin in NF-κB and STAT3 signaling pathways. Diosgenin abrogates TNF-α
-induced activation of NF-κB and IL6-induced STAT3 signaling pathways in tumor cells. Diosgenin can
hence prevent proliferation, invasion and angiogenesis; and induce apoptosis, a characteristic vastly
looked for in cancer therapy.
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4. In Vivo Anti-Cancer Effects of Diosgenin
In addition to in vitro inhibition of cancer cell proliferation by dietary fenugreek seeds and
its bioactive constituent diosgenin, several studies have provided evidence that diosgenin is
a potent inhibitor of tumor growth in vivo in rodent models of cancer. In a rat colorectal tumor
model, administration of diosgenin, given during the promotional stage, reduced azoxymethane
(AOM)-induced colonic aberrant crypt foci formation [79]. Similarly, Malisetty et al., showed
that diosgenin, at a dose of 15 mg/kg, significantly suppressed both the incidence and invasive
potential of AOM-induced rat colon adenocarcinoma mass by 60% and colon tumor multiplicity
(adenocarcinomas/rat) by 68% [80]. However, in the murine model of AOM/dextran sodium
sulfate-induced colon aberrant crypt foci, diosgenin at doses of 20, 100 and 200 mg/kg b.w. in the
diet did not reduce adenocarcinoma mass; nonetheless, a significant reduction in tumor multiplicity
was observed with all three doses tested [81]. In another study, diosgenin (at a dose of 10 mg/kg
b.w. administered intra-tumorally) significantly inhibited the growth of MCF-7 and MDA-MB-231
human breast cancer xenografts in mice [72]. In another study using inbred T739 mice, diosgenin was
shown to significantly inhibit the growth of mouse LA795 lung adenocarcinoma tumors by 33.94% [82].
Diosgenin, at a dose of 80 mg/kg administered by oral gavage, was reported to inhibit the growth
of oral tumors in a DMBA-induced hamster buccal pouch model [64]. Diosgenin, in combination
with thymoquinone, exhibited significant tumor growth inhibition in a mice xenograft model [59].
Therefore, diosgenin modulates multiple targets and suppresses tumor growth in preclinical models
of cancer. However, diosgenin’s poor solubility in organic solvents and its lack of bioavailability
greatly hinder its translational process as a therapeutic compound. Further clinical trials are required
to evaluate its potential either as a preventive or therapeutic anti-cancer agent.
5. Semisynthetic Derivatives of Diosgenin That Exhibit Anti-Cancer Activity
Diosgenin is used in the pharmaceutical industry as the main precursor in the synthesis of
steroids [83]. It has the ability to penetrate cell membranes and bind to specific receptors [84]. Steroidal
sapogenins are bioactive molecules that have shown exceptional antiproliferative activity against several
human cancer cells. By making specific changes in the steroidal structure of diosgenin, it can affect its
biological activity. In a recent report, using diosgenin as the parent molecule, the authors synthesized
two novel steroidal oxime compounds that showed significant antiproliferative activity on cervical
cancer cells and human lymphocytes. These compounds induced apoptosis and activated caspase
3 [85]. In another study Mohammad et al., reported on the anti-proliferative activity of diosgenin
and its semi-synthetic derivatives against breast (HBL-100), colon (HCT-116 and HT-19) and lung
(A549) cancer cells. A structure-activity relationship study revealed that the potent anti-proliferative
activity was mainly attributed to the analogs with the simple phenyl R moiety or electron-withdrawing
ortho-substituted R moieties attached to the parent diosgenin [86]. In another study, diosgenin was
used as a parent compound to synthesize 1α-hydroxysolasodine; it showed significant anti-cancer
activity against prostate cancer (PC3), cervical carcinoma (HeLa), and hepatocellular carcinoma
(HepG2) cells [87]. Twelve different analogs of diosgenin containing a long chain fatty acid/ester
of diosgenin-7-ketoxime exhibited anti-cancer activity when tested against a panel of cancer cell
lines. Compound 16 in this series exhibited potent anti-proliferative activity against DU145 prostate
cancer cells, which was associated to the suppression of lipopolysaccharide-induced activation of
TNF-α and IL6. The compound was also identified as safe, with a maximum tolerated dose of
300 mg/kg in Swiss albino mice [88]. In a recent article by Ghosh et al., they reported the synthesis of
diosgenin functionalized iron oxide nanoparticles that exhibited anti-breast cancer activity by inhibiting
proliferation and migration, and by inducing apoptosis [89].
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6. Conclusions and Future Perspectives
Compounds derived either from medicinal or dietary plant sources embrace distinct advantages,
such as novel bioactive structures, low toxicity, and being multi-targeted in abrogating oncogenic
processes; thereby, they may form the source of improved therapeutic options. A vast body of pre-
clinical experimental evidence suggests that diosgenin has great potential as an anti-cancer agent.
In this review we have compiled and analyzed the role of diosgenin in modulating various oncogenic
transcription factors and intracellular molecular targets that drive tumor initiation, progression and
metastasis. It is well known that the majority of cancers are a consequence of chronic inflammation,
infection, dysfunctional cell death mechanisms, and deregulation of cell cycle molecules. The ability of
diosgenin to prevent carcinogenesis by acting as an anti-oxidant and anti-inflammatory agent, and its
ability to induce apoptosis of cancer cells, suggests that it can be useful as an anti-carcinogenic agent.
Due to the complexities in the cellular processes involved, several new studies need to be conducted to
decipher the exact molecular targets that can be exploited to prevent cancer progression. Interestingly,
there are 12 reported clinical trials on fenugreek seed extract on a variety of human ailments, as
reported in www.clinicaltrials.gov. However, to date, there are no cancer-related clinical trials reported
either on diosgenin or on fenugreek seed extract. Several novel synthetic diosgenin derivatives have
been shown to improve its anti-cancer efficacy. Several nano-formulations and delivery systems of
diosgenin are also shown to improve its bioavailability. In conclusion, several challenges such as
developing novel delivery systems, pharmaceutical formulations, and semi-synthetic derivatives that
are water soluble, need to be overcome to uncover diosgenin’s benefits either as a chemopreventive or
therapeutic agent.
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Abstract: The aim of this study is to investigate the potential inhibitory effect of α-chaconine and
α-solanine on RL95-2 estrogen receptor (ER) positive human endometrial cancer cell line and to
identify the effect of these glycoalkaloids on the Akt signaling and ERα. The cell proliferation
profiles and the cytotoxicity studies were performed by Real-Time Cell Analyzer (xCELLigence) and
compared with Sulphorhodamine B (SRB) assay. The effects of α-chaconine (2.5, 5, 10 μM), α-solanine
(20, 30, 50 μM), API-1 (25 μM) and MPP (20 μM) effects on Akt (Ser473) and ERα (Ser167) expressions
evaluated by Western blot and qPCR method. Their IC50 values were as α-chaconine (4.72 μM) <
MPP (20.01 μM) < α-solanine (26.27 μM) < API-1 (56.67 μM). 10 μM α-chaconine and 20, 30 and
50 μM α-solanine were effective in decreasing p-Akt(Ser473)/Akt ratio compared to positive control
API-1. When the p-ERα/ERα ratios were evaluated, it was observed that α-chaconine (2.5, 5, 10 μM)
and α-solanine (50 μM) were as effective as the specific ERα inhibitor MPP in reducing the ratio of
p-ERα/ERα compared to the control group. In conclusion, it has been shown that the proliferation
of α-chaconine and α-solanine in human endometrial carcinoma cells reduces the expression and
activity of the Akt and ERα signaling pathway.
Keywords: α-chaconine; α-solanine; Solanum tuberosum L.; API-1; MPP dihydrochloride; RL95-2;
endometrium cancer; steroidal glycoalkaloids; Akt; ERα
1. Introduction
Glycoalkaloids, a class of nitrogen-containing steroidal glycosides, are biologically active
secondary plant metabolites, usually found in plants of the genus Solanum. These plants include many
agricultural plants, especially the plants from Solanaceae family such as Solanum tuberosum L. (potato),
Solanum lycopersicum (tomato) and Solanum melongena (eggplant) [1]. S. tuberosum L. (potato) contains
significant amount of glycoalkaloids α-chaconine and α-solanine, which are trisaccharide steroidal
glycoalkaloids [2].
S. tuberosum glycoalkaloids are naturally produced and the main glycoalkaloids are α-chaconine
and α-solanine, which make up 95% of the total glycoalkaloid content. The molecules of both
substances contain the same steroid scaffold (aglycone), but differ in the trisaccharide moiety [1].
Steroidal glycoalkaloids are produced from the cytosolic terpenoid (mevalonate) biosynthetic pathway.
Cholesterol is produced starting from acetyl-CoA. Cholesterol is modified by various glycoalkaloid
metabolism enzymes via hydroxylation, oxidation and transamination, and thus solanidine (Figure 1a)
is synthesized in S. tuberosum. Aglycone solanidine is glycosylated by solanidine glycosyltransferase
enzymes to produce α-solanine and α-chaconine [3,4]. α-Chaconine and α-solanine are derived
from the compound solanidine and include a carbohydrate side-chain; the side-chain is composed of
glucose and two rhamnose molecules and glucose, rhamnose and galactose molecules, respectively [5].
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The glycoalkaloids are found at all parts of the potato plant. The highest glycoalkaloid level is in
flowers and sprouts while the lowest glycoalkaloid level is in potato tubers. Glycoalkaloids are
concentrated in the skins and the prolonged exposure of the tubers to the light promotes the formation
of glycoalkaloids on the surface of the tuber [1]. Steroidal alkaloids and their glycosides are known to
possess a variety of biological activities including anti-tumor [6], anti-fungal [7], anti-inflammatory [8],
teratogenic [9], anti-viral [10], antimicrobial [11], antiestrogenic [12,13], antiandrogenic [14] and
anti-cancer activities [15]. There are some studies related to the evaluation of α-chaconine and
α-solanine which are naturally occurring toxic steroidal glycoalkaloids in potato sprouts effects on
different cancer cells such as lymphoma and lung [16], prostate [17], cervical [18], stomach [19],




Figure 1. Structural similarities of the potato aglycone solanidine to the estradiol: (a) The molecular
structure of solanidine; (b) The molecular structure of estradiol.
Endometrial cancer is the fifth most common gynecological malignancy in the world in 2012,
but its incidence varies between regions [24,25]. In 2012, 320,000 new cases of endometrial cancer were
diagnosed worldwide. The number of new cases is expected to increase by about 70% over the next
20 years [26]. Approximately 30% of patients diagnosed with endometrial cancer are under 54 years of
age, with 20% between 45–54 years of age and approximately 9% under the age of 44. For this reason,
it is necessary to carefully select women with fertility-protective approaches in managing endometrial
cancer [27]. Because early detection and treatment modalities have not had a major influence on
mortality and fertility, searching out and developing novel approaches for treatment of endometrial
cancer is very important.
Akt, a serine-threonine protein kinase, central signaling molecule in the PI3K pathway and plays
an important role in controlling the balance between cell survival and apoptosis [28]. Alterations in
the Akt pathway have been identified in a variety of human cancer types, including endometrial
cancer. Akt is activated by phosphorylation, on account of this Akt phosphorylation is a marker for
the activation of this enzyme. The serine/threonine kinase Akt pathway integrates both extracellular
and intracellular oncogenic signals, and therefore presents a promising new target for molecular
therapeutics [29]. The central negative regulator of the Akt signaling cascade is the tumor suppressor
gene PTEN. Mutations in PTEN result in notably increased Akt activity. PTEN mutations occur
in 50% of endometrial carcinomas. Patients with increased Akt phosphorylation as a result of loss
of PTEN expression have a poor prognosis. Consequently, targeting the Akt pathway may be an
appropriate strategy in addressing endometrial cancer [30]. Selective inhibition of Akt represents
a potential approach for the treatment of endometrium cancer. Akt/protein kinase B inhibitor,
4-amino-5,8-tetrahydro-5-oxo-8-(β-D-ribofuranosyl)pyrido[2,3-d]pyrimidine-6-carboxamide (API-1)
is a novel, small molecule and potent selective inhibitor of Akt signaling that binds to the pleckstrin
homology (PH) domain of Akt. It blocks its membrane translocation, which cause inhibition of
Akt-regulated cell growth and cell survival in vitro and in vivo [31,32].
ERα plays a role in mediating the activity of estrogen [33]. The biological effects of 17β-estradiol
(E2) (Figure 1b) are mainly mediated by ERα and estrogen receptor β (ERβ) receptors and ERα
is primarily expressed in the uterus. E2 stimulates the growth of cancer cells as well as many
type of cells [34]. Oncogenic transformation of cells in the uterus can initiate to the development
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of cancerous lesions and these lesions take advantage of E2 signaling pathways for growth [35].
Methyl-piperidino-pyrazole (MPP) is a highly selective ERα antagonist [36].
Although α-chaconine and α-solanine as being steroidal glycoalkaloid exhibit anti-carcinogenic
potential against several cancer cell lines, its effect on endometrium cancer is still unclear. The aim
of this study is to investigate the potential inhibitory effect of α-chaconine and α-solanine to clarify
the potential of inhibiting proliferation, and to explain the effect of these glycoalkaloids on the Akt
signaling and estrogen receptor α (ERα) in RL95-2, which is estrogen receptor (ER) positive human
endometrial cancer cell line.
2. Materials and Methods
2.1. Materials
α-Chaconine (Cat No: A9544) was purchased from Applichem (Darmstadt, Germany),
whereas α-solanine (Cat No: S3757) was Sigma (St. Louis, MO, USA). Chemical inhibitors API-1
(Cat No: 3897) and 1,3-Bis(4-hydroxyphenyl)-4-mtehyl-5-[4-(2-piperidiylethoxy) phenol]-1H-pyrazole
dihydrochloride (MPP dihydrochloride) (Cat No: 1991) were purchased from Tocris bioscience (Bristol,
UK). Stock solutions of α-chaconine, α-solanine and the chemical inhibitors were prepared in dimethyl
sulfoxide (DMSO). DMSO (Cat No: A3672) and phosphate-buffered saline (PBS) (Cat No: A9177) were
purchased from Applichem. Dulbecco’s modified eagle’s medium with F-12 nutrient mixture (DMEM:
F-12) (Cat No: 01-170-1A) and penicillin/streptomycin solution (Cat No: 03-031-1C) were obtained from
Biological Industries (Cromwell, CT, USA). Fetal bovine serum (FBS) (Cat No: S0115) obtained from
Biochrom (Cambridge, UK). Insulin (Cat No: I9278), RNAzol (Cat No: R4533, Sigma) and trypsin-EDTA
(T3924) were purchased from Sigma. Sulforhodamine B (SRB) sodium salt (Cat No: sc-253615A) and
radio immuneprecipitation assay (RIPA) buffer (Cat No: sc-24948) were purchased from Santa Cruz
Biotechnology (Heidelberg, Germany). Akt (Cat No: 9272), phospo-Akt (Ser473) (Cat No: 9271)
and β-actin (Cat No: 4967) antibodies, estrogen receptor α (D8H8) rabbit mAb (Cat No: 8644),
phospho-estrogen receptor α (Ser167) (D1A3) rabbit mAb (Cat No: 5587) and HRP-linked secondary
antibody (Cat No: 7074) and BCA kit (Cat No: 7780) were purchased from Cell Signaling Technology,
Inc (Leiden, The Netherlands). Reagents for electrophoresis and Western blotting were obtained from
Sigma. Polyvinylidene difluoride (PVDF) membrane obtained from (Cat No: 162-0177) Bio-Rad (Dubai,
United Arab Emirates). Chemiluminescence solution (ECL) (Cat No: 34080) obtained from Thermo
Scientific (Paisley, UK). FastStart Essential DNA Probes Master (06 402 682 001), Transcriptor High
Fidelity cDNA Synthesis Kit (05 081 955 001), RealTime ready human β-actin, Akt and ER-α catalog
assays (05 532 957 001), E-plate (05 232 368 001), Cedex Smart Slides (05 650 801 001) were purchased
from Roche (Roche, Laval, QC, Canada).
2.2. Cancer Cell Line and Culture
Human endometrial cancer cell lines RL95-2 was purchased from the American Type Cell
Collection (Cat No: CRL-1671™ ATCC, Manassas, VA, USA). The cell line was grown in DMEM:F-12
that was supplemented with 10% (v/v) FBS, 1% penicillin/streptomycin and 0.005 mg/mL insulin.
The cells were cultivated in 75 cm2 culture flasks at 37 ◦C in humidify atmosphere of 95% air and 5%
CO2. When the cells had approximately reached 80% confluence, trypsin containing 0.25% EDTA was
used to remove them from the flasks for subculture or for the corresponding experimental treatments.
An inverted microscope was used to observe the changes in cell morphology. α-Chaconine, α-solanine,
API-1 and MPP dihydrochloride were dissolved in DMSO and the final DMSO concentration in the
medium was less than 0.1%.
2.3. Cell Growth and Proliferation Assay Using xCELLigence Real-Time Cell Analysis (RTCA)
The essence of the real-time growth profile is based on measuring the change in the adhesive
properties of the cells as they are attached to the microelectrode-coated surface of special e-plates of
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xCELLigence system. Impedance measurement gives time quantitative information about the current
state of cells such as cell number, viability, morphology and movement. Measurement is possible
without using any label or chemicals. By eliminating the need for label or dye, it is possible to maximize
the acquired data physiologically. The device’s software allows real-time monitoring of the experiment
and real-time data visualization and analysis functions [37,38].
RL95-2 cells were resuspended in the culture medium and then seeded, to e-plate of xCELLigence
RTCA SP system (ACEA Biosciences Inc., San Diego, CA, USA). In this experiment, different number of
cells varying from 1.250 to 40.000 were used to obtain growth profile of RL95-2 cell line. xCELLigence
system calculates the impedances parameter called “Cell Index (CI)”. CI values of RL95-2 were used
to examine cell profile depending on proliferation and viability during 96 h. All experiments were
performed at least three times.
2.4. Cytotoxicity Assay Using xCELLigence RTCA
According to SRB assay results, novel concentrations were determined in order to evaluate its
effects on cell growth and proliferation of α-chaconine (1–10 μM), α-solanine (10–30 μM), API-1
(10–25 μM) and MPP dihydrochloride (5–50 μM). In brief, RL95-2 cells were seeded at a density of
20.000 cells per well of a 96-well E-plate (Catalog No. 05232368001; ACEA Biosciences, Inc., San Diego,
CA, USA). The compounds added to cells at their growth phase. The assay was monitored during
96 h. Effects of α-chaconine, α-solanine, API-1 and MPP dihydrochloride on cell growth curve
was assessed with the RTCA system xCELLigence. After obtaining cell profile data, another RTCA
assay was performed by using 20.000 cells/100 μL per well to monitor the cytotoxicity of α-chaconine,
α-solanine, API-1 and MPP dihydrochloride. Proliferation, spreading and cell attachment kinetics were
monitored every 15 min. IC50 values were defined as the inhibition of the cell line by the compounds
at 24 h. The RTCA software performs a curve-fitting of selected “sigmoidal dose–response equation”
to the experimental data points and calculates logarithmic half maximum effect of concentration
(log [IC50]) values at a given time point based on log of concentration producing 50% reduction of CI
value relative to solvent control CI value (100%), expresses as log IC50 [37,38]. All experiments were
performed at least three times and the results were given as the mean ± Standart Deviation (SD) of
independent experiments.
2.5. Determination of Cell Viability via Sulphorhodamine B Assay
The effect of α-chaconine, α-solanine, API-1 and MPP dihydrochloride on RL95-2 cell viability
were determined by the method of SRB assay [39,40]. The compounds were dissolved in DMSO to
a stock concentration of 50 mM. 20.000 cells/wells seeded and after 24 h incubation cells treated
with different final concentrations of α-chaconine (1 nM-100 μM), α-solanine (1 nM-100 μM), API-1
(1–100 μM) and MPP dihydrochloride (1–100 μM) for 24 h, followed by fixing the cells in 10% (v/v) of
trichloroacetic acid (TCA) for 1 h at 4 ◦C. After washing 5 times, cells were exposed to 0.5% (w/v) SRB
solution for 30 min in a dark place and subsequently washed with 1% (v/v) acetic acid. After drying,
10 mM (pH 10.5) Tris base solution was used to dissolve the SRB-stained cells using a plate-shaker
(PST-60 HL plus Biosan) and color intensity was measured at 510 nm in a microplate reader (Biotek
Synergy HT). Data are represented as a percentage of control cells. The measurement of the “half
maximal inhibitory concentration” (IC50) values was calculated with the Microsoft Excel program.
All experiments were performed at least three times and the results were given as the mean ± SD of
independent experiments.
2.6. Protein Extraction and Western Blot Analysis
1 × 106 cells were seeded in 6 well plate to be left overnight and incubated with α-chaconine (2.5; 5;
10 μM), α-solanine (20; 30; 50 μM), API-1 (25 μM) and MPP dihydrochloride (20 μM) for 24 h. The cells
were scraped using a cell scraper and centrifuged at 10.000 rpm for 10 min, after which the sample
was rinsed again with PBS. Proteins were isolated with RIPA buffer. After cell lysates sonication,
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total protein contents were determined by using a BCA kit. A 10% separating and 5% stacking gel
was prepared freshly on western blotting day. Electrophoresis was carried out at a voltage of 70 V,
which was then raised to 100 V after the specimens had reached the separation gel. PVDF membrane
was activated in 100% methanol for 10 s. The transfer was performed at 100 V for 1 h and 20 min in
cold conditions. 5% non-fat dry milk in tris buffered saline with tween (TBST) was used for blockage
for 1 h. Membranes were washed with TBST three times for 10 min. 1:1000 dilution of primary rabbit
antibodies in TBST were applied to membrane and incubated overnight at 4 ◦C. The membranes were
subsequently washed with TBST and incubated with a 1:2000 dilution of secondary antibody for 2 h at
room temperature. After washing the membrane three times for 10 min in TBST, the proteins were
visualized using ECL. Blue sensitive X-ray film was used for detection in a dark room. A Developer,
water and fixer were used for photographic process. The band intensity was analyzed using Image J
(ImageJ 1.48, ABD). β-actin was used for normalization. All experiments were performed three times
and the results were given as the mean ± SD of independent experiments.
2.7. RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
RL95-2 cells were seeded at a density of 1 × 106 cells per well of a 6-well plate and cells
were harvested for RNA isolation 24 h after the treatment with α-chaconine (2.5; 5; 10 μM),
α-solanine (20; 30; 50 μM), API-1 (25 μM) and MPP dihydrochloride (20 μM). Total RNA was
isolated using RNAzol in accordance with the manufacturer’s instructions. The RNA concentration
and purity were determined by measurement of absorbance at 260 and 280 nm using a NanoDrop
(DeNovix) and 1000 ng of each total RNA sample was used for cDNA synthesis with the Transcriptor
High Fidelity cDNA Synthesis Kit (Roche, Quebec, Canada) according to the manufacturer’s
specifications. qRT-PCR was performed using the FastStart Essential DNA Probes Master
(Roche, Quebec, Canada) with primers. The qRT-PCR primer sequences were as follows: ACTB
5′-TCCTCCCTGGAGAAGAGCTA-3′ (forward) and 5′-CGTGGATGCCACAGGACT-3′ (reverse); AKT1,
5′-GCAGCACGTGTACGAGAAGA-3′ (forward) and 5′-GGTGTCAGTCTCCGACGTG-3′ (reverse).
ESR1, 5′-TTACTGACCAACCTGGCAGA-3′ (forward) and 5′-ATCATGGAGGGTCAAATCCA-3′
(reverse). Threshold cycle (CT) values obtained from the instrument’s software were used to calculate
the fold change of the respective mRNAs. ΔΔCT for each mRNA was calculated by subtracting the CT
value of the control from the experimental value. Fold change was calculated by the formula 2−ΔΔCT.
All experiments were performed at least three times and the results were given as the mean ± SD of
independent experiments.
2.8. Statistical Analysis
All calculations from xCELLigence were obtained using the RTCA-integrated software of the
xCELLigence system. Statistical analysis was performed GraphPad Prism Software Version 7.01
(La Jolla, CA, USA) using to compare differences in values between the control and experimental
group. The results are expressed as the mean ± SD. Statistically significant values were compared
using one-way ANOVA and Dunnett’s post-hoc test, and p-values of less than 0.05 were considered
statistically significant.
3. Results
3.1. Real Time Cell Growth Profile Curve
A cell number titration experiment is necessary to assess cell growth and proliferation and to
decide the optimum cell number for further steps of the study. This approach not only helps to
determine the appropriate seeding density but also the time for compound addition [37].
The dynamic cell proliferation of the RL95-2 cells was monitored for a period of 96 h, and the
growth curves at different densities are shown in Figure 2. When we examined the growth profile
of RL95-2 cells, it was seen that the CI values were low. The factors affecting the value of CI may
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include cell dimension, morphology and cell-substrate adhesion quality [37,41]. Lack of CI fluctuation
in cell attachment and spreading stages was characteristic for RL95-2 cells. The growth curve after cell
seeding showed a linear adhesion period that was followed by a continuous increase of CI for all tested
densities. According to the growth profile of the cells, even after 96 h, it has been observed that the
20,000 cells/well did not reach the plateau and continued to proliferate at a constant rate. Densities of
10,000 cells/well and above were not considered suitable for further studies as their logarithmic phase
lasted before than 20,000 cells/well. It was decided that the optimal cell number for the surface area of
0.20 cm2/well was 20,000 cells/well. The density of 20,000 cells/well produced the most ideal growth
curve for further experiments. Approximately 24-h after seeding was selected as the ideal time for
compound addition.
Figure 2. Dynamic monitoring of cell adhesion and proliferation using the xCELLigence system. RL95-2
cell at a density of 40,000; 20,000; 10,000; 5000; 2500; 1250 cells/well in E-Plates 96 were observed
during 96 h.
3.2. Effects of the Compounds on the Cell Viability
This test is the first test elucidated the cytotoxic effect of API-1, MPP dihydrochloride, α-chaconine
and α-solanine on RL95-2 endometrium cancer cells (Figures 3, 4, 5 and 6b). The cell viabilities in the
presence of various concentrations of these compounds were analyzed by SRB assay. Seven different
concentrations (1, 3, 5, 10, 25, 50 and 100 μM) of API-1, six different concentrations (1, 5, 10, 25, 50 and
100 μM) of MPP dihydrochloride, eight different concentrations (10 and 100 nM, 1, 5, 10, 25, 50 and
100 μM) of α-chaconine and α-solanine were selected to assess the effect of the compounds on cell




Figure 3. Dose dependent cytotoxic effects of API-1 was determined by SRB assay and shown for 24 h.
(a) The molecular structure of API-1; (b) Effect of API-1 on viability of RL95-2 cell. Cells were treated
with various concentrations of API-1 for 24 h. The absorbance was determined after 1 h-incubation of
the cells with SRB. Cell viability is presented as the mean ± SD at least three independent experiments.
*** p < 0.001 compared with the untreated control.
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Figure 4. Dose dependent cytotoxic effects of MPP dihydrochloride was determined by SRB assay
and shown for 24 h: (a) The molecular of MPP dihydrochloride; (b) Effect of MPP dihydrochloride on
viability of RL95-2 cell. Cells were treated with various concentrations of MPP dihydrochloride for 24 h.
The absorbance was determined after 1 h-incubation of the cells with SRB. Cell viability is presented as
mean ± SD at least three independent experiments. *** p < 0.001 compared with the untreated control.
 
Figure 5. Dose dependent cytotoxic effects of α-chaconine was determined by SRB assay and shown
for 24 h: (a) The molecular structure of α-chaconine; (b) Effect of α-chaconine on viability of RL95-2
cell. Cells were treated with various concentrations of α-chaconine for 24 h. Cell viability is presented
as mean ± SD at least three independent experiments. ** p < 0.01 and *** p < 0.001 compared with the
untreated control.
As shown in Figure 4b, the treatment of MPP dihydrochloride with 25; 50 and 100 μM for 24 h
decreased cell viability significantly. However, cell viability was not significantly changed by MPP
dihydrochloride at concentration below 25 μM.
At 1, 3, 5 and 10 μM concentrations there was no significant decrease compared to the control,
whereas the cell viability did not change at higher than 5 μM. The next step was to work with a lower
concentration of 25 μM, as it reduced viability at the same significance compared to the control at
25 and 50 μM concentration. In addition, the RTCA viability test results show a similar profile at
concentrations of 10 and 25 μM, but supporting this, 25 μM concentration when evaluated together
with the SRB assay results.
As shown in Figure 3b, the treatment of API-1 (5; 10; 25; 50 and 100 μM) for 24 h decreased cell
viability significantly. However, cell viability was not significantly changed by API-1 at concentration
below 5 μM.
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Figure 6. Dose dependent cytotoxic effects of α-solanine was determined by SRB assay and shown
for 24 h: (a) The molecular structure of α-solanine; (b) Effect of α-solanine on viability of RL95-2 cell.
Cells were treated with various concentrations of α-solanine for 24 h. Cell viability is presented as
mean ± SD at least three independent experiments. ** p < 0.01 and *** p < 0.001 compared with the
untreated control.
As shown in Figure 5b, the treatment of α-chaconine with 5; 10; 25; 50 and 100 μM for 24 h
decreased cell viability significantly. However, cell viability was not decreased by α-chaconine at
concentrations below 5 μM.
α-Chaconine at concentrations of 5 μM and over were found to reduce viability in the same
sense of significance compared to the control. However, at concentrations of 10 μM and higher it was
considered cytotoxic since it reduced viability by more than 70% whereas α-chaconine decreased the
viability by about 50% compared to the control at the concentration of 5 μM.
As shown in Figure 6b, the treatment of α-solanine with 30; 50; 70 and 100 μM for 24 h decreased
cell viability significantly. However, cell viability did not decrease by α-solanine at concentration below
30 μM. It was found that the cytotoxicity produced by α-Solanine at 50 μM and higher concentrations
did not increase due to the dose. A significant increase in α-solanine was observed at 10 μM compared
to the control, and a decrease in viability was observed at 30 μM and over at the same concentrations.
3.3. Monitoring of Cytotoxicity in Real-Time Using xCELLigence System
To monitor and validate the reliability and accuracy of the SRB assay in evaluating the cytotoxic
effects of the compounds, the cell viability was evaluated using the xCELLigence system in parallel
with the studies above. As the cells interacted with these compounds, continuous CI alterations
resulting from changes of cell number, morphology, and adhesion on the microelectrodes were
measured by the RTCA SP instrument for approximately 72 h. A correlation was noted between
results obtained from the impedance-based detection and those from SRB assay. As shown in
Figures 3, 4, 5 and 6b, the concentration-response curves of the given time points marked with
dashed lines in Figures 7–10 corresponded well with at the same dose of the xCELLigence system.
The concentration-response curves and the viability of treated cells at the indicated time points are
exhibited in Figures 7–10. Control groups without compound treatment indicated the normal cell
growth in electronic microwells. As shown in Figure 7, the CI values of the treated cells decreased
from 5 μM in a concentration-dependent manner after an initial rise, while the CI values of the control
kept rising until the maximal value at about 72 h after the treatment. In order to compare the cytotoxic
effects of the four compounds, their 50% inhibitory concentrations (IC50) were calculated after 24-h
exposure. The IC50 values of α-chaconine, α-solanine, API-1 and MPP dihydrochloride were 4.72,
26.27, 56.67 and 20.01 μM, respectively (Table 1).
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Figure 7. Dose and time-dependent cytotoxic effect and alteration of CI of α-chaconine determined
by xCELLigence system: Effect of α-chaconine on proliferation of RL95-2 cell. Cells were
treated with various concentrations of α-chaconine for 72 h. The CI was calculated from four
repeated measurements.
Figure 8. Dose and time-dependent cytotoxic effect and alteration of CI of α-solanine determined
by xCELLigence system: Effect of α-solanine on proliferation of RL95-2 cell. Cells were treated with
various concentrations of α-solanine for 72 h. The CI was calculated from four repeated measurements.
 
Figure 9. Dose and time-dependent cytotoxic effect and alteration of CI of MPP dihydrochloride
determined by xCELLigence system: Effect of MPP dihydrochloride on proliferation of RL95-2 cell.
Cells were treated with various concentrations of MPP dihydrochloride for 72 h. The CI was calculated
from four repeated measurements.
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Figure 10. Dose and time-dependent cytotoxic effect and alteration of CI of API-1 determined by
xCELLigence system: Effect of API-1 on proliferation of RL95-2 cell. Cells were treated with various
concentrations of API-1 for 72 h. The CI was calculated from four repeated measurements.





MPP dihydrochloride 20.01 μM
1 The IC50 of the four compounds were obtained based on the dose–response curves of CI during 24 h exposure in
and calculated from repeated experiments (n = 4) with the real-time xCELLigence system.
α-Chaconine has an antiproliferative effect at concentrations of 1 and 2.5 μM; it was observed
that cell viability decreased at concentrations of 5 and 10 μM in a dose-dependent manner (Figures 7
and 11). RTCA viability assay results showed similar profiles at 10 μM concentrations (Figure 5b),
while 2.5 μM α-chaconine reduced viability by at least 70%. A decision was made to work with this
concentration since the CI value was 50% change at 5 μM and was close to IC50 (4.71 μM).
Figure 11. Correlation between cell index and the compounds effects using the xCELLigence system.
Cells were treated with various concentrations of the compounds for 24 h. The CI was calculated
from four repeated data and presented as mean ± SD. ** p < 0.01 and *** p < 0.001 compared with the
untreated control.
It was observed that 10 and 15 μM concentrations of α-solanine had an antiproliferative effect
and decreased cell viability at 25 and 30 μM concentrations (Figures 8 and 11). RTCA exhibited
similar profiles to the control at concentrations of 10 and 15 μM according to the viability test results.
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α-Solanine did not provide a 50% CI change at 25 μM concentration and was close to a value of
26.27, which was calculated as the IC50 value, therefore 30 μM concentration has been selected for
further studies.
MPP dihydrochloride showed antiproliferative activity at a concentration of 10 μM, while cell
viability decreased at concentrations of 15, 20 and 25 μM in a dose-dependent manner (Figures 9
and 11). According to RTCA and SRB results, IC50 value was calculated 20 μM for MPP dihydrochloride
and this concentration was selected for further studies.
While 5 μM concentration of API-1 showed antiproliferative activity, cell viability was reduced
at 10, 25 and 50 μM concentrations and the CI value at 25 μM concentration decreased to below 0.05
(Figures 10 and 11).
SRB and real-time xCELLigence measurements show that RL95-2 cells are more sensitive to
α-chaconine then the other tested compounds (Table 1).
3.4. α-Chaconine, α-Solanine Inhibits Phosphorylation of Akt (Ser473) and ERα
Since Akt is crucial for cancer progression, being a critical mediator and required for metastasis,
the effect of the glycoalkaloids were investigated on the activation of Akt.
Data demonstrated that API-1 reduced the phosphorylation of Akt (Figure 12a,c), while it did not
alter the phosphorylation of ERα (Figure 12b,c). MPP dihydrochloride reduced the phosphorylation
of ERα, while it did not alter the phosphorylation of Akt. The quantitative results showed that
α-chaconine significantly suppressed the phosphorylation of Akt and ERα in a dose-dependent manner
(Figure 12a–c). α-Solanine significantly suppressed the phosphorylation of Akt in a dose-depend





Figure 12. Western blot analysis of the expression of p-Akt, Akt, p-ERα and ERα proteins in the RL95-2
cell line: (a) In the bar graph the data represent the relative density of the bands p-Akt (Ser473)/Akt;
(b) In the bar graph the data represent the relative density of the bands p-ERα/ERα; (c) RL95-2 cells
were treated with the compounds. The relative intensity is presented as mean ± SD. three independent
experiments. * p < 0.1, ** p < 0.01 and *** p < 0.001 compared with the untreated control.
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3.5. Changes in the Expression of Akt and ERα Genes
Expression of genes associated with cancer progression was demonstrated by RT-qPCR
(Figure 13a,b). It is demonstrated that α-chaconine and α-solanine suppressed the expression of
Akt mRNA at concentration 5 μM and 30 μM, respectively as seen in Figure 13a. The results showed
that API-1, α-chaconine and 30 μM α-solanine markedly suppressed the mRNA expression of ERα
(Figure 13a,b).
Figure 13. Effects of α-chaconine and α-solanine on suppressing the genes expression of: (a) Akt;
(b) ERα in the RL95-2 cell line. The mRNA expressions were calculated from three repeated data and
presented as mean ± SD. * p < 0.1, ** p < 0.01 *** p < 0.001 compared with the untreated control.
4. Discussion
The most basic steroidal trisaccharide glycoalkaloids are α-chaconine and α-solanine that
are found in potato plants [16,20]. Solanidine, the aglycone of α-chaconine and α-solanine,
shows structural similarities with diosgenin, the precursor of steroidal hormones. Solanidine is
a nitrogen-containing equivalent of diosgenin (steroidal saponin) [42]. Although the potential toxicity
of α-chaconine and α-solanine is well known, studies showing that they have beneficial effects such
as anticholinesterase [43], anti-inflammatory [8], antibacterial [44], antiviral [10], antifungal [45],
antimalarial [46] and anticancer [2] depending on dosage and use conditions are included in
the literature.
α-Chaconine and α-solanine can cause toxicity in mouse and normal human liver cells in
physiological functions [18,47]. Although the steroidal glycoalkaloids are toxic to normal cell
membranes and lead to cell disruption [48], the compounds are thought to be possesses with the
potential for therapeutic treatment against cancer cells. α-Chaconine exhibits anti-carcinogenic
potential, including the ability to inhibit cell growth of various cancer cell lines in the human
colon [49], lung [50,51], prostate [17], liver [18,52], cervical [18] cancer cells. Similarly, α-solanine
exhibits anti-carcinogenic potentials, such as inhibiting cell growth of various cancer cell lines in
human melanoma [20], prostate [2,52], pancreatic [21] and mice breast [22], lung [51] cancer cells.
However, no information was available in the literature regarding whether it is effective in combatting
endometrial cancer, and the effects on endometrial cancer were investigated for the first time in
this study.
In endometrial cancer, inhibition of both extrinsic (Fas proteins) and intrinsic (Bcl-2 protein
family) apoptotic pathways, alterations in PI3K/Akt activity and p53 mutation are known resistance
mechanisms. Progressive and recurrent endometrial carcinomas continue to be a compelling tumor
group with a high rate of multi-factor chemotherapy resistance. Chemotherapy resistance resulting
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from overexpression of drug flow efficacious proteins and mutations in β-tubulin isoforms in both
primary and recurrent disease represent treatment difficulties. For this reason, the need for a less
sensitive new agent for known resistance pathways arises [53]. The development of resistance to these
drugs and the serious toxic effects of high doses lead researchers to search for different drug molecules.
When the effects of α-chaconine and α-solanine on cell viability is examined, most of the studies
have been performed on various cell culture lines and confirm our findings [16,20,50,54]. The IC50
values of α-solanine in HepG2, human gastric carcinoma (SGC-7901) and human large intestine cancer
(LS-174) cells were 14.47, >50 and >50 μg/mL, respectively, and HepG2 cells were more sensitive to
α-solanine [55]. The IC50 value of α-solanine was found to be 34 μM in mouse mammary carcinoma
cells (4T1) and 30 μM in human hepatocellular carcinoma cells (HuH-7) [22]. These findings agree with
the IC50 value of our study of α-solanine. In our study, glycoalkaloids were not combined. However,
it is shown that α-chaconine has a more acute toxicity in RL95-2 than α-solanine. According to our
findings, α-chaconine increased cell viability at concentrations of 1 μM and lower at 10 μM and
lower concentrations of α-solanine, similar to steroidal hormones [56] in the structure of solanidine,
the aglycone of these glycoalkaloids, it was evaluated that they could be responsible for this effect.
Since α-chaconine and α-solanine have decreased both cell proliferation and apoptosis-inducing
effects in different cancer types as mentioned above, we decided to investigate the effects of these
compounds with API -1 and MPP in regulation of Akt and ERα signaling in estrogen-positive
RL95-2 cells.
In this study, SRB cytotoxicity assay was chosen to give better linearity and signal-to-noise ratio
than sensitive, simple, and formazan-based experiments when measuring the effect of α-chaconine
and α-solanine on viability in RL95-2 cells [57].
Supporting the previous data with α-solanidine with MCF-7 cells, α-solanine significantly
increased the viability relative to control group up to a concentration of 10 μM [56].
We showed that α-chaconine and α-solanine reveal similar effects at different concentrations
and these differences might be their glycone group, although the aglycones are the same. It is also
possible to discover more effective molecules by synthesizing chemical derivatives. The inhibition is
related to a concentration—but not time—dependent manner. Both compounds might have an even
stronger effect than API-1 and MPP dihydrochloride, although there was no significant difference
between their IC50 values in this study. Their cytotoxic efficacy on RL95-2 cells was α-chaconine >
MPP dihydrochloride > α-solanine > API-1. Thus, more studies should be conducted to investigate
the activity of these compounds especially these steroidal glycoalkaloids. In this in vitro study, the
activity of these glycoalkaloids and the potential structure–activity relationship was shown, and further
in vivo investigation about the cellular mechanisms should be conducted in the future. As shown
in Figures 5a and 6a, all the two steroidal glycoalkaloids have same aglycone but not glycone side
chain. The cytotoxic effects of α-chaconine which contains chacotriose was significantly stronger
than α-solanine with solatriose groups. Thus, the glycone groups besides aglycone ring might be
an influencing factor for the cytotoxicity effects of potatoes steroidal glycoalkaloids on RL95-2 cells.
There is another study in the literature where this effect is seen in different cell lines supporting our
results [19].
When the effects of both glycoalkaloids on cell viability is examined, some of the studies have
been performed on various cell culture lines and confirm our findings. From the results obtained,
it can be concluded that α-chaconine can decrease phosphorylation of ERα as the same significance in
positive control MPP dihydrochloride on RL95-2 cells whereas the specific Akt inhibitor API-1 did not
show any effect on ERα phosphorylation. It has been shown for the first time that it may be related to
the steroidal aglycone solanidine structure that they might have on the estrogen-dependent pathways
on endometrium cancer cell line. This study showed for the first time the effect of α-chaconine on cell
proliferation, ERα activity and expression in RL95-2 cells.
It has been shown that α-chaconine inhibits bovine aortic endothelial cell proliferation, migration
and invasion. These effects have been shown to be mediated by JNK and PI3K/Akt signaling pathways
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and NF-κB activation by antiangiogenic activity [20]. α-Chaconine also showed anti-metastatic activity
in human lung cancer cells A549. This effect has been shown to decrease MMP-2 and MMP-9
activities [50]. In another study, α-chaconine inhibited prostate cancer cells proliferation (LNCaP
and PC-3) by increasing p27 levels and downregulating Cyclin D1, and apoptosis in these cells was
associated with caspase-dependent and independent pathways. In addition, it has been shown that
caspase-dependent apoptosis is induced via JNK activation in that study [17]. Beforehand α-solanine
has been shown to inhibit metastasis, migration and invasion in human melanoma cells (A2058)
by inhibiting JNK, PI3K, Akt phosphorylation and NF-κB activation and by decreasing MMP-2/9
activity/expression [20]. In another study, α-solanine down-regulated oncogenic microRNA-21
expression by decreasing MMP-2/9 expression via the ERK and PI3K/Akt signal pathway suppressed
by human prostate cancer cell (PC-3) invasion and upregulated of tumor suppressor microRNA-138 [2].
α-Solanine has been shown to increase expression of radio-sensitivity and chemo-sensitivity by
decreasing miR138 and focal adhesion kinase (FAK) expression in lung cancer cells (A549 and
H1299) [58]. It has been reported in the literature that α-solanine acts as an antitumor agent in
inhibition of Wnt/β-catenin, Akt/mTOR, Stat3 and NF-κB pathways in non-toxic concentrations in
healthy cells and in pancreatic cancer cells (PANC-1) [21]. Another study has shown that α-solanine
induces apoptosis by reducing the ratio of Bcl-2/Bax resulting in intracellular [Ca2+]i, which can
cause and alteration in the enzymatic activity of the caspase family in human hepatocarcinoma cells
(HepG2) [21]. In a study of the effects of α-solanine on the mitochondrial membrane potential and
intracellular [Ca2+]i in HepG2 cells, α-solanine resulted in lowering the membrane potential and
reducing the Ca2+ concentration in the organs by facilitating the opening of the permeability transition
(PT) channels in the mitochondria. This has been shown to increase the Ca2+ concentration in the cell
and thus trigger the apoptosis mechanism [59]. Therefore, α-chaconine and α-solanine are thought
to play an active role in the control of signal transduction pathways and signaling proteins and
apoptosis-dependent or independent cell proliferative functions. However, so far, the mechanism of
these steroidal glycoalkaloids actions and effects in endometrium cancer has not yet been elucidated.
In this study it is found that α-chaconine may have led to an increase in cell viability related to an
increase in mRNA overexpression of Akt compared with the control, but the level of growth factors in
the environment is increased at the 2.5 μM concentration and should be investigated with different
parameters in detail. The reason for preference for the investigation of Akt expressions of RL95-2 cells
is the presence of active Akt in mutated PTEN human endometrial cancer cells [60]. In our study, it was
found that API-1 25 μM strongly reduced p-Akt (Ser473) levels, resulting in RL95-2 cells sensitive to
API-1. However, the relative p-Akt (Ser473) protein level results at a concentration of 10 μM α-solanine
at 20, 30 and 50 μM α-chaconine were shown to be at the same level of significance as the 25 μM
reduction of API-1. Thus, at these applied concentrations, α-chaconine and α-solanine were found
to be as potent as API-1, the pure Akt inhibitor, inhibition of Akt phosphorylation. In our study, it
was observed that 10 μM α-chaconine and 20, 30 and 50 μM α-solanine were effective in decreasing
p-Akt (Ser473)/Akt ratio compared to control 25 μM API-1. At these concentrations, Akt was shown
to act by reducing phosphorylation like API-1. This effect of α-chaconine and α-solanine was shown
to be related to the dose and these findings were also confirmed in the RL95-2 cell of the α-chaconine
A549 [50] and α-solanine [21] in the PANC-1 cells.
When the p-ERα/ERα ratios were evaluated, it was observed that α-chaconine (2.5, 5 and 10 μM),
α-solanine (50 μM) and the specific ERα inhibitor was as effective as MPP dihydrochloride (20 μM) to
reduce the ratio of p-ERα/ERα compared to the control group. At these concentrations, ERα, such as
MPP dihydrochloride, was shown to be effective by reducing the phosphorylation. It has been shown
for the first time that it may be effective in estrogen-dependent pathways and may be related to the
steroidal aglycone solanidine structure. α-Chaconine showed this effect in a dose-dependent manner.
E2 stimulates the growth of many cancer cells. The mechanisms underpinning this effect include
the blockade of MAPK/ERK and PI3K/Akt pathways that inhibit E2-induced DNA synthesis [34].
Estrogen-mediated signaling pathways are classified as genomic and non-genomic, depending on
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whether ER-dependence is transcriptionally regulated or not [61,62]. Taking into account the fact that
RL95-2 cells are ER positive, we have investigated the effect of the compounds on the p-ERα/ERα
expressions in these cells. In our study, p-ERα levels were increased α-chaconine (2.5, 5 μM)
and α-solanine (20 μM) compared to the control group, and the increase in the concentration of
α-chaconine 2.5 μM was found to be significant. This result is also consistent with the results of
the RTCA and concludes that α-chaconine did not show cytotoxic effects up to 2.5 μM but may
increase ERα phosphorylation through an estrogen receptor-dependent signaling pathway. However,
contrary to protein expression, this decrease in mRNA level relative to control may be attributed to
non-transcriptional activity of α-chaconine via non-genomic pathway using ERα interaction proteins
and secondary messengers. This effect can also be caused by the estrogen-like effect of these steroidal
compounds. The fact that RL95-2 cells are also ER positive confirms these results. The mRNA levels of
Akt and ERα were decreased with α-chaconine and α-solanine at IC50 concentrations 5 and 30 μM
respectively however these alterations were not concentration-dependent.
There are also limited data regarding the combination for these glycoalkaloids revealing that
they have synergic toxic effects [63,64]. However, in our study the effects of the combination of these
compounds has not been studied.
Furthermore, bioavailability of these compounds is not well-defined and there are a limited
number of papers regarding the bioavailability of these glycoalkaloids [63,65,66]. Because of the
steroidal structure and lipid solubility of the compounds they might probably go through pre-systemic
elimination or enterohepatic cycle therefore the bioavailability of the compounds should be clarified
with further in vivo studies.
Our study shows that α-chaconine and α-solanine have cytotoxic effects in RL95-2 cells,
specifically affect cellular signaling pathways, and decrease phosphorylation of Akt and ERα. It is
clear that there is a need for other scientific studies to be able to fully elucidate which mechanisms
might be related to other effects. In addition, the scope of this study should be supported by expanded
in vitro and in vivo studies. In this respect, α-chaconine and α-solanine are thought to be potential
candidates for endometrial cancer therapy research.
5. Conclusions
In conclusion, we attributed the decrease in expression and activity of Akt and ERα by α-chaconine
and α-solanine, and such suppressive effect might contribute to the inactivation of the PI3K/Akt and
ERα signaling pathways in human endometrium cancer cells by both these steroidal glycoalkaloids.
We demonstrated with a RL95-2 endometrial carcinoma cell line that α-chaconine and α-solanine alone
seems to be as effective as both API-1 and MPP dihydrochloride. In ER positive cancers, active ER
signaling is a pharmacological target so that ERα is a clinically important target for endometrial cancer.
It is, therefore, necessary to carry out further research to explore novel candidates capable of both
anti-estrogenic and cytotoxic potential. This should lead a strong insight into endometrial cancer
therapy. In addition to this, steroidal glycoalkaloids which have anticancer potential to the estrogens,
may also give further insight into endometrial cancer therapy. These findings reveal a new therapeutic
potential for these glycoalkaloids on endometrial cancer therapy.
One of the main problems that should be taken into account while using such steroidal
glycoalkaloids is the possible hormonal effects/interferences of these compounds on the physiological
hormonal system. However, taking into account that conventional hormonal therapies are still being
used for ERα positive endometrium cancer treatment, physicians should consider the benefit/risk ratio
while treating these types of cancer, as this glycoalkaloids might be used to reduce the interference
of these conventional hormonal therapies by lowering the doses with their synergistic effect which
should be further investigated by in vivo studies.
On the other hand, it is possible to investigate whether pre- and combined estradiol administration
to these glycoalkaloids leads to a change in Akt and ER expressions, and how it affects other
endometrial cancer cell lines, Ishikawa and HEC-1A. When PI3K/Akt is thought to be one of
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the major signaling pathways in endometrial cancer, it is possible to investigate other signaling
proteins associated with this pathway. It is also important to investigate whether the effects of these
glycoalkaloids on cell migration are related to steroidal structural similarities.
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Abstract: Cancer initiation and progression are the result of genetic and/or epigenetic alterations.
Acetylation-mediated histone/non-histone protein modification plays an important role in the
epigenetic regulation of gene expression. Histone modification is controlled by the balance between
histone acetyltransferase and (HAT) and histone deacetylase (HDAC) enzymes. Imbalance between
the activities of these two enzymes is associated with various forms of cancer. Histone deacetylase
inhibitors (HDACi) regulate the activity of HDACs and are being used in cancer treatment either
alone or in combination with other chemotherapeutic drugs/radiotherapy. The Food and Drug
Administration (FDA) has already approved four compounds, namely vorinostat, romidepsin,
belinostat, and panobinostat, as HDACi for the treatment of cancer. Several other HDACi of natural
and synthetic origin are under clinical trial for the evaluation of efficiency and side-effects. Natural
compounds of plant, fungus, and actinomycetes origin, such as phenolics, polyketides, tetrapeptide,
terpenoids, alkaloids, and hydoxamic acid, have been reported to show potential HDAC-inhibitory
activity. Several HDACi of natural and dietary origin are butein, protocatechuic aldehyde, kaempferol
(grapes, green tea, tomatoes, potatoes, and onions), resveratrol (grapes, red wine, blueberries and
peanuts), sinapinic acid (wine and vinegar), diallyl disulfide (garlic), and zerumbone (ginger).
HDACi exhibit their antitumor effect by the activation of cell cycle arrest, induction of apoptosis and
autophagy, angiogenesis inhibition, increased reactive oxygen species generation causing oxidative
stress, and mitotic cell death in cancer cells. This review summarizes the HDACs classification,
their aberrant expression in cancerous tissue, structures, sources, and the anticancer mechanisms of
HDACi, as well as HDACi that are either FDA-approved or under clinical trials.
Keywords: cancer; histone deacetylases; histone deacetylase inhibitors; vorinostat; natural
HDACi; apoptosis
1. Introduction
Cancer is the second leading cause of death worldwide and caused 8.8 million deaths in 2015.
Globally, 1 out of 6 deaths is because of cancer. Low and middle-income countries are the hotspot
of cancer deaths, accounting for approximately 70% of deaths. Lung cancer is the most common
cause of cancer death worldwide. According to the National Center for Health Statistics about
1.73 million new cancer cases and 0.6 million cancer deaths are projected to occur in the United States
in 2018 [1]. Cancer results from altered cell physiology leading to self-sufficient growth potential, loss
of cell cycle control, extended angiogenesis, delay in replicative senescence, dysregulated apoptosis,
invasion, and metastasis [2,3]. Progression of the disease is not only governed by genomic and genetic
changes, such as translocation, amplification, deletion and point mutation, it also involves epigenetic
changes; i.e., alteration in the pattern of gene expression without changing underlying DNA sequence.
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Methylation of DNA, histone protein modifications and non-coding RNA-mediated gene silencing are
the major epigenetic changes, reversible in nature [4].
Chromatin is a compact and highly ordered structure comprised of DNA and histone protein.
Nucleosome, the basic unit of chromatin, is made up of 147 bp of DNA superhelix wrapped around
histone core protein containing two copies each of H2A, H2B, H3 and H4. H1 is the linker histone.
The core plays an important role in establishing interactions between the nucleosomes and within the
nucleosome particle itself. N-terminals (histone tails) of core histones are flexible and unstructured
while the rest of histone proteins are basically globular and highly ordered. Depending on the
epigenetic changes in histone tail, chromatin undergoes various conformational changes responsible for
upregulation or downregulation of respective genes [5,6]. The common posttranslational modifications
occurring in histones are acetylation, methylation, phosphorylation, sumoylation, ubiquitinylation,
and ADP ribosylation.
Acetylation of a lysine residue of histone was discovered by Vincent Allfrey and colleagues in
1964 and based on the finding it has been proposed that acetylation of ε-amino group of lysine residues
could play a role in gene expression [7,8]. Acetylation and deacetylation of N-terminal ε-amino group
of lysine residues are regulated by two enzymes, namely histone acetyltransferase (HAT) and histone
deacetylase (HDAC) (Figure 1). Acetylation neutralizes the positive charge and decreases the affinity
between the histone and DNA helix responsible for relaxation of conformation and greater accessibility
to transcription machinery [4,9]. Therefore, acetylation is generally associated with gene activation,
however, deacetylation catalyzed by HDAC induces chromatin condensation and downregulation of
gene expression. N-terminal acetylation of lysine residue also occurs in non-histone proteins, such as
cytoplasmic proteins, transcription factors responsible for alteration in gene expression and other
cellular processes [10].
Figure 1. Histone acetylation at the N-terminus lysine by histone acetyltransferases (HATs) and
deacetylation by histone deacetylases (HDACs).
Imbalance in the activities of enzymes HATs and HDACs is responsible for the development and
progression of wide variety of cancers [2]. Histone deacetylase inhibitors (HDACi) increase the level of
acetylated lysine residues of core histone which in turn restarts the expression of silenced regulatory
genes in the cancerous cell and therefore, HDACi are now emerging as anticancer agents [11].
Epidemiological studies have suggested that vegetables, fruits, whole grains, microorganism-
derived bioactive components, and fatty acids provide protection against some forms of cancer and
other diseases without detectable side effects [12–14]. Many dietary compounds that have been
identified as having HDAC-inhibitory activities implicated in therapeutic potential in the context of
a whole food [11,15]. In the present review an effort has been made to highlight the role of HDACs
in the tumor initiation and progression and their inhibitors from natural (dietary and non-dietary)
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as well as synthetic sources in the management of cancer either alone or in combination with other
chemotherapeutic drugs/radiotherapy.
2. Classification of HDACs
In humans, 18 HDACs have been identified so far and are divided into two families and four
classes based on their sequence homology to Saccharomyces cerevisiae HDACs (Figure 2) [16]. One of
the family group members are zinc-dependent, they require Zn++ as a cofactor for their deacetylase
activity and include HDAC 1 to HDAC 11. HDACs 1, 2, 3 and 8 are grouped into class 1 having
a sequence similarity with yeast reduced potassium dependency-3 (Rpd3) and class II HDACs are
subdivided into class IIA and Class IIB that include HDACs 4, 5, 6, 7, 9 and 10 which are reported to
have sequence homology with yeast histone deacetylase-1 (hda-1) while HDAC 11 of class IV share
sequence similarity with both classes of yeast deacetylase Rpd3 and hda-1.
Another group of the family requires nicotinamide adenine dinucleotide (NAD+) as a cofactor for
deacetylase activity classified as class III, has sequence similarity to yeast deacetylase silent information
regulator-2 (Sir2) and includes seven members from sirtuins (SIRTs) 1 to 7. Sirtuins are known
to regulate several cellular processes; e.g., survival, aging, stress response, and various metabolic
processes. The members of class I and IV are located in the nucleus while class IIA is mainly located
into the cytoplasm and class IIB is found shuttling between the nucleus and cytoplasm. Cellular
localization of class III HDACs are nucleus, cytoplasm, and mitochondria [11,17]. Nomenclature of
class I, II and IV HDACs are based on their chronological order of discovery; for example, both HDAC
1 and 2 were discovered in 1996 while HDAC 2 was discovered a few months after HDAC 1 [18,19].
Later on, HDAC 3 was discovered in the subsequent years [20]. While HDACs 4, 5, and 6 were first
reported in 1999, the HDAC 7 was discovered in early 2000 and so on [21,22]. Table 1 summarizes
the HDACs classification, number of amino acids, cellular and chromosomal locations, biological
functions, relevant histone/non-histone target proteins, and their expression pattern [6,23,24].
Figure 2. Classification of HDAC family.
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3. Cellular Targets of Histone/Non-Histone Protein Acetylation
The acetylation or deacetylation status of histone proteins and transcription factors modulate
the gene expression pattern. Hyperacetylation of lysine residues of histone proteins promotes
the relaxed state of chromatin and activates gene expression [25]. Besides this, acetylation of
transcription factors affects their cellular localization. For example, signal transducer and activator of
transcription 1 (STAT 1) and nuclear factor-κB (NF-κB) are internalized into the nucleus from cytosol
after the acetylation of specific lysine residues where they activate transcription of respective genes.
The activity of other transcription factors, such as p53 and FOXO, is also positively regulated by
the acetylation process. Acetylation process also affects the stability of proteins, i.e., acetylation of
p53, p73, and mothers against decapentaplegic homolog 7 (SMAD 7) prevents their ubiquitinylation
and degradation. Interestingly, cell mobility is also affected by the acetylation pattern of α-tubulin
and cortactin. It has been reported that HDAC 6 and SIRT2 cause deacetylation of α-tubulin,
which promotes microtubule depolymerization and therefore increases microtubule dynamics and cell
mobility. Acetylation also affects the activity of retinoblastoma protein (pRB) by blocking its cyclin
E-cdk2 dependent phosphorylation so acetylation-dependent hypophosphorylation causes cell cycle
arrest [26,27].
4. HDAC Mutations in Cancer
Mutations of HDACs have also been observed. HDAC2 mutation in human epithelial cancer
resulted in microsatellite instability. Interestingly, a truncating mutation of HDAC2 in human cancers
confers resistance to HDACi. These findings suggest that the HDAC2 mutational status of patients
should be assessed before therapies using HDACi [28]. HDAC3 are associated with DNA damage
control response. Inactivation of HDAC3 causes genomic instability. HDAC4 acts s transcriptional
repressor and its mutations have been identified at significant frequency in breast and colorectal cancers.
SIRT 2 acts as a tumor suppressor and mutation in its catalytic domain eliminates its enzymatic activity,
which compromises the mitotic checkpoint, contributing to genomic instability and tumorigenesis.
HDAC9 and 10 are reported to be involved in homologous recombination, and depletion in HDAC 9
and 10 resulted in inhibition of homologous recombination [11].
5. HDACs and Cancer: Expression Pattern and Function
Altered acetylation level and mutation/or aberrant expression of various HDACs have been
observed frequently in numerous human diseases including cancer, hence making them an important
drug target [2]. Fraga et al. (2005) reported that change in genome-wide patterns of acetylation may
lead to the initiation and progression of cancer by demonstrating that cancer cells undergo a loss
of acetylation at lysine 16 of H4 [29]. HDACs have various histone and non-histone protein targets
that not only regulate the chromatin activity, but also control apoptosis, cell cycle progression and
differentiation. Association of HDACs with regulatory processes reflects their involvement in cancer
phenotypes [30].
5.1. Class I HDACs
5.1.1. HDAC 1
HDAC 1 overexpression has been reported in Hodgkin’s lymphoma (HL), gastric, ovarian,
and prostate cancers [11,23]. Choi and co-workers (2001) have shown the overexpression of HDAC
1 in 60% cases compared with normal tissue [31]. This study was further validated by a recent
study including 293 gastric cancer samples showing upregulation in expression of HDACs 1, 2,
and 3 [32,33]. Elevated level of expression of HDAC 1, 2, and 3 was reported in pancreatic cancer
involving 192 samples and this overexpression was responsible for dedifferentiation and enhanced
proliferation of pancreatic cancer cell [34]. Overexpression of HDAC 1, 2, and 3 is associated
with mortality rate in colorectal cancer. Expression of HDAC 2 has emerged as an independent
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prognostic marker in colorectal cancer [35]. Furthermore, overexpression of HDAC 1 is reported in
hepatocellular carcinoma [36], lung cancer [37] and breast cancer [38]. Direct correlation between
HDAC 1, 3 expression and estrogen and progesterone receptor expression have been reported by
Krusche et al. [39].
HDAC 1 induces cell proliferation and inhibition of differentiation and apoptosis [23,38]. HDAC 1
and 3 knockdowns (KD) resulted in the inhibition of cell proliferation in Hela cells [40]. HDAC 1 KD
has been shown to result in cell cycle arrest either at the G1 phase or at the G2/M transition phase,
causing loss of mitotic cells, inhibition of cell growth, and an increase in the number of apoptotic
cells in osteosarcoma and breast cancer cells. However, HDAC 2 KD showed no such effects in these
cells [41]. HDAC1 might also be involved in multidrug resistance as they showed overexpression in
a pattern in chemotherapeutically resistant neuroblastoma cells [42].
5.1.2. HDAC 2
Overexpression of HDAC2 reported in uterine, cervical, gastric, cutaneous T cell lymphoma
(CTCL), HL, prostate and colorectal cancers [38]. Elevated expression of HDAC 2 along with HDAC 1
and 3 are associated with advance stage of disease and prognosis of gastric, colorectal, and prostate
cancers [33–35].
Knockdown of HDAC2 in cervical cancer causes increased apoptosis and the differentiated
phenotype of cells associated with increased p21Cip1/WAF1 expression that was independent of p53 [43].
In breast carcinoma cells, HDAC 2 KD results into the increased DNA binding activity of tumor
suppressor protein p53, which causes the inhibition of cell proliferation and induction of cellular
senescence [44]. HDAC 2 KD also causes decreased viability, growth arrest, and increased apoptosis in
colorectal and breast cancer cells [45].
5.1.3. HDAC 3
HDAC 3 overexpression has been reported in HL, ovarian and lung cancers, colon cancer,
and chronic lymphocyte leukemia (CLL) [11,38,46]. An upregulated expression of HDAC1 along
with HDAC3 was paradoxically related to disease-free survival in invasive breast cancer patients [24].
HDAC3 elevated expression together with HDAC 1 and 2 significantly causes poor prognosis in
gastric, colon, and prostate cancers [33–35]. Decreased expression of HDAC 3 has been observed in
liver cancer [45].
HDAC 3 KD in acute promyelocytic leukemia (APL) cells causes restoration of expression of
a retinoic acid-dependent gene whose transcription repression was caused by promyelocytic leukemia
retinoic acid receptor alpha (PML-RARα) [47]. While HDAC3 KD in colon cancer causes a decrease in
the viability of cell by increasing the rate of apoptosis [45].
5.1.4. HDAC 8
Expression of HDAC 8 has been reported to increase in childhood neuroblastoma. HDAC KD
shows reduction in proliferation of lung, colon, and cervical cancer. In childhood neuroblastoma cell
HDAC 8 KD causes cell cycle arrest, reduction in cell proliferation [48,49]. HDAC 8 has also been
reported in controlling telomerase activity [50].
5.2. Class IIA HDACs
5.2.1. HDAC4
A breast cancer sample showed overexpressed genotype of HDAC 4 [51]. However, lung and
colon cancer analysis showed downregulated expression of HDAC 4 [11].
In APL, HDAC 4 was found to repress the expression of differentiation-associated genes by
interacting with a leukemic fusion protein, PLZF-RARa [52]. HDAC 4 also regulates the activity
of hypoxia inducing factor-1α (HIF-1α). HDAC4 has also been shown to help prostate cancer cells
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overcome hypoxic conditions by stabilizing HIF-1α. The binding of HDAC4 to HIF-1α generates
a complex that regulates glycolysis and the cytotoxic stress of cell adaptation to hypoxic conditions [53].
HDAC4 KD in colon and glioblastoma cells causes an increased apoptosis rate and reduced growth
rate [54].
5.2.2. HDAC 5
HDAC 5 overexpression has been reported in medulloblastoma [55] and colon cancer [51] while
interestingly, the lung cancer sample showed a downregulated genotypic expression of HDAC5 [11].
HDAC 5 traverses from the nucleus to the cytosol upon interacting with transcription factor GATA-1
during differentiation of mouse erythroleukemia cells [56]. Knock down of HDAC 5 has been shown
to cause reduced growth and viability of medulloblastoma cells [55].
5.2.3. HDAC 7
They are highly expressed in ALP, CLL, and colon cancer [46,51] and downregulated expression is
reported in lung cancer samples [45,57]. HDAC 7 silencing in endothelial cells altered their morphology,
their migration, and their capacity to form capillary tube-like structures in vitro but did not affect
cell adhesion, proliferation, or apoptosis, suggesting that HDAC7 may represent a rational target for
anti-angiogenesis in cancer [58].
5.2.4. HDAC 9
Elevated expression of HDAC 9 was reported in ALL and medulloblastoma [59,60] and in cervical
cancer [31]. Silencing HDAC 9 results into inhibition of homologous recombination, sensitivity towards
DNA damage and decreased viability and growth of medulloblastoma [45].
5.3. Class IIB HDACs
5.3.1. HDAC 6
A significantly higher expression of HDAC 6 was reported in oral squamous cell carcinoma,
hepatocellular carcinoma, acute myeloid leukemia, CLL, breast cancer, CTCL and ovarian cancer,
whereas its expression increased in the advanced stages of cancer compared to the early stages of
cancer [5,61].
HDAC 6 overexpression causes increased migration of the fibroblast cell while the inhibition
of HDAC 6 results in decreased fibroblast cell migration [62]. HDAC 6 targeted inhibition causes
HSP 90 protein acetylation and disruption of its chaperone activity resulting in decreased viability
of K562 leukemic cell [63]. HDAC4/6 has the potential to help prostate cancer cells overcome
hypoxic conditions by stabilizing HIF-1 α [53]. HDAC 6 is also involved in metastasis, epithelial
to mesenchymal transition in lung cancer cells by compromising TGF-β SMAD 3 pathway [64].
5.3.2. HDAC 10
Osada and colleague [57] described the potential role of HDAC 10 in cancer initiation and
progression and reported the downregulated expression of HDAC 10 in non-small lung carcinoma
cells and this is related with poor prognosis in lung cancer patients. Its role in gastric cancer and CLL
is also reported [65].
HDAC 10 are shown to regulate the production of reactive oxygen species in gastric cancer
cells [66]. HDAC 10 KD causes reduced vascular endothelial growth factor of receptor 1 and 2 (VEGF 1
and 2) and increased sensitivity towards DNA damage in cancer cells [67].
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5.4. Class III HDACs
Sirtuins
Growing evidence supports the relation between cancer and sirtuins. As other HDACs they are
also both tumor suppressors as well as pro-oncogenic in nature. SIRT 1 expression was shown to be
upregulated in acute myeloid leukemia (AML), non-melanoma skin cancer and prostate cancer [68–70]
while downregulated in colorectal cancer [51]. SIRT 2 expression decreased in glioma and gastric
cancer [71]. However, a mutation in the catalytic domain of SIRT 2 has also been reported [72].
Expression pattern of SIRT 3 has been found to increase or decrease in different kinds of breast cancer
tissues [73]. SIRT 6 expression was reported to decrease in liver cancer while increased expression
pattern in CLL [46]. SIRT 7 shows an upregulated expression pattern in breast cancer [73].
SIRT 2 functions as a tumor suppressor protein and the mutation in its catalytic domain results in
compromised cell cycle checkpoints leading to genomic instability and tumorigenesis [74]. In many
cancerous cells, increased expression of SIRT 1 induces the p-glycoprotein expression responsible for
chemotherapeutically resistant cancer cells whereas siRNA-mediated SIRT 1 KD causes a reversal of
drug-resistant phenotype [75]. SIRT 3 functions both as a tumor suppressor and a tumor promoter
protein. Higher expression of SIRT 3 was responsible for preventing bladder cancer cells from
p53-mediated cell growth arrest [76]. SIRT 7 was shown to stabilize cancer cell phenotypes. SIRT 7 KD
results in the tumorigenic potential of human cancer xenograft in mice [77].
5.5. Class IV HDACs
HDAC 11
The involvement of HDAC 11 in cancer is not well understood. However aberrant expression
of HDAC 11 were reported in HL and Philadelphia-negative chronic myeloproliferative neoplasms
(CMPN) [78].
siRNA-mediated HDAC 11, KD results in an increased apoptosis rate in HL, colon, prostate,
breast, and ovarian cell lines [45,79]. Selective inhibition of HDAC 11 with histone deacetylase inhibitor
(HDACi) reduces the chance of splenomegaly and other metabolic disorders reported in CMPN affected
people [78].
6. Histone Deacetylase Inhibitors as an Anticancer Agent
The aberrant or altered expression of HDACs or their functions is frequently observed in a variety
of cancer types and is the reason for targeting HDACs in cancer therapy. The availability of HDACi
not only has accelerated our understanding of HDAC functions and its mechanism of actions but also
presented a promising new class of compounds for cancer treatment. HDACi belong to a large and
diverse family of both natural and synthetic compounds and can be categorized into four groups;
i.e., hydroximic acid, benzamides, cyclic peptides, and aliphatic fatty acids [80]. Several natural or
synthetic compounds are isolated and characterized for their potential as histone deacetylase inhibitors.
The first significant compound identified as HDACi was n-butyrate, responsible for the accumulation
of hyperacetylated histone inside the nucleus [81]. Subsequently, trichostatin A (TSA) and trapoxin A
were found to be reversible and irreversible inhibitors of HDACs, respectively [11,82]. Schreiber et al.
(1996) were first to discover and clone the human HDAC by using trapoxin A [80]. While developing
these compounds as anticancer agents, parameters like their specificity, efficiency, pharmacokinetic
and toxicological properties were analyzed [83]. Some HDACi, such as TSA, lycorine and zerumbone,
are pan-HDAC inhibitors since they act on all isoform of zinc-dependent HDAC classes, while others
are class specific.
HDCAs can reversibly modify the acetylation pattern of histone/non-histone protein resulted in
abnormal gene expression without changing the DNA sequence. HDACi can overcome this problem
and can resume the expression of tumor the suppressor genes responsible for apoptosis, cell cycle
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arrest, and the inhibition of angiogenesis and metastasis. Ungerstedt and co-workers [84] reported
that cancerous cells are more sensitive than normal cells towards HDACi-induced apoptosis.
6.1. Natural HDACi
Altogether natural compounds provide pleiotropic and potent inhibitors of all hallmarks of cancer.
Many of the HDACi discovered to date are of natural origin; for example in 1976, Tsuji et al. [85]
isolated a naturally occurring HDACi, TSA from Streptomyces hygroscopicus. FK322, a cyclic peptide
isolated from Chromobacterium violaceum selectively inhibits the activity of HDAC 1 and 2. TSA causes
differentiation of cell and arrests the cell cycle of both normal and cancerous cells, resulting in the
accumulation of acetylated histones [86]. Depudecin and trapoxin A and B are also the examples
of naturally occurring HDACi extracted from a fungus. Marine organisms are also the source of
natural HDACi, such as largazole and azumamides, and they are reported to be active even at
nanomolar concentrations [11]. Other well-characterized naturally occurring HDACi, such as butein,
kaempferol, protocatechuic aldehyde, sinapinic acid, resveratrol and zerumbone, are isolated from
plant, fruits or vegetables (Table 2). Molecular modelling studies revealed the HDACi like activity of
other dietary compounds; i.e., vitamin E, α-lipoic acid, and biotin [48]. For the first time, the clinical
validation of natural HDACi was done by Riggs and colleague [81] in 1977. They analyzed the effect
of butyrate on histone modificationin HeLa and Friend erythroleukemia cell lines [80]. Later in 1980,
McKnight et al. [87] reported the effect of propionate on histone deacetylation in chick oviduct and
showed it to have lesser activity than butyrate. Both these compounds were active at millimolar
concentrations and synthesized by colonic bacteria. Valproic acid, a longer chain aliphatic fatty acid,
also reported to have significant HDACi activity. Valproic acid inhibits HDACs activity by binding to
its active site [87]. Detailed features of other natural histone deacetylase inhibitors and their sources
are shown in Table 2.
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6.2. FDA-Approved and Under Clinical Trial HDACi
Aberrant expression of HDACs gene is reported in various cancer types. So, the scientists across
the globe are searching for a therapeutic alternative, which not only can inhibit the increased activity of
HDACs, but also reverse the malignant phenotype. The histone deacetylase inhibitors chiefly cause the
gene to be in a hyperacetylated state, which in turn restarts the gene expression, and are also involved
in chromatin stability, mitosis, and the DNA repair mechanism [23]. However, it has been reported that
both normal and cancerous cells show accumulation of acetylated histone after treatment with HDACi,
but healthy cells appear to be much less susceptible to apoptosis and growth inhibition than a cancerous
cell. Four synthetic compounds, viz., vorinostat, romidepsin, belinostat, and panobinostat have been
approved as HDACi for cancer treatment to date by the United States Food and Drug Administration
(FDA). In addition, many other HDACi are under clinical trials in patients suffering from various types of
cancer [101,102]. FDA-approved and other HDACi under clinical trials are presented in Table 3.
Vorinostat, a hydroximic acid-based drug, is also known as suberanilohydroxamic acid (SAHA)
and is marketed with different names. Zolinza was the first FDA-approved vorinostat drug for
cutaneous T cell lymphoma treatment (CTCL). It inhibits the HDACs except class III sirtuins and
was developed by Merck & Co. (Kenilworth, NJ, USA). In phase II clinical trial study (NCT00958074)
on 74 CTCL patients with a daily oral dose of vorinostat (400 mg), an objective response rate (ORR)
of 30% was observed [11]. Vorinostat is also reported to be useful in other cancer types, such as
brain metastasis, refractory colorectal, advanced solid tumors, melanoma, pancreatic, lung cancer and
multiple myeloma [6]. A combinatorial therapy of vorinostat with temozolomide and radiotherapy is
under clinical trial for the treatment of early stage of glioblastoma multiformae (NCT00731731).
Romidepsin, a cyclic tetrapeptide, was the second FDA-approved drug for treatment of CTCL
in 2009 and in 2011, for treatment of peripheral T cell lymphoma (PTCL) with the response rate of
34% and 25%, respectively. However, romidepsin treatment was associated with side effects, such as
nausea, vomiting, cardiac toxicity, and myelotoxicity [11,37]. Romidepsin has been evaluated for
treatment of T-cell lymphoma either as a single agent (NCT00426764) or in combination with other
drugs (NCT03141203) in 30 clinical trials. Romidepsin intake produced fatigue, nausea, vomiting,
diarrhea, constipation, phlebitis, headache, and dyspnea as side effects [6]. Romidepsin either singly
or in combination with paclitaxel exhibited elimination of both primary tumors and a metastatic lesion
at multiple sites formed by the SUM149 IBC cell line in the Mary-X preclinical model [103].
In 2014, belinostat was the third drug approved by the FDA for PTCL treatment. It is a hydroxamate
that inhibits the activity of class I and II HDACs. Clinical trial study (NCT00865969) on 120 PTCL
patients showed an ORR of 26% [6]. Belinostat is now being investigated in more than 15 clinical trials
for the treatment of CTCL (NCT00274651), multiple myeloma (NCT00431340), Burkitt lymphoma
(NCT00303953), and solid tumors as in fallopian tube cancer (NCT00301756) [23].
Panobinostat was approved by the FDA in 2015 for the treatment of multiple myelomas [37]. It is
a hydroxamate derivative causing the inhibition of class I, II, and IV HDACs. An ORR of 27% was
reported for panobinostat. Diarrhoea and cardio-toxicity are side effects associated with Panobinostat.
It has been used for treating other cancer types, such as CTCL (NCT00490776), AML (NCT01613976),
Hodgkin’s lymphoma (NCT00742027), MDS (NCT00594230), thyroid carcinoma (NCT01013597),
and colorectal and prostate cancers (NCT00663832) in more than 50 clinical trials [23].
In contrast to the above mentioned clinical trials and studies reporting efficacy of HDACi in the
treatment of various lymphomas, leukemia and myeloma, solid tumors have shown limited response
against HDACi. The study conducted by Paller and colleagues [104] reported that HDACi VPA
and vorinostat in combination with AMG 900, a pan-aurora kinase inhibitor, significantly enhanced
cellular senescence, polyploidy, and apoptosis in prostate cancer cell lines (DU-145, LNCaP and PC3)
as compared with a single agent treatment. Combination therapy with Janus kinase (JAK) inhibitor
INCB018424 has been shown to improve the clinical efficacy of vorinostat in triple-negative breast
cancer patients [105]. Similarly, combination therapies targeting HDACs and IκB kinase have shown
potential against ovarian cancer [106].
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7. Mechanisms of Action of HDACi
HDACi induces cell cycle arrest, differentiation, and apoptosis as well as inhibits
angiogenesis [119]. The mechanism of the anticancer effect of HDACi depends upon the cancer
type, individual, stage of cancer, dose, and some other factors [120]. The antiproliferative mechanisms
of HDACi action are described below.
7.1. Cell Cycle Arrest
Various mechanisms are involved in HDACi-mediated cell cycle arrest. One of the most
important mechanisms is the increased expression of the cyclin-dependent kinase (CDK) inhibitor
gene CDKN1A (p21, WAF1/CIP1). An interesting fact is that the HDACi-mediated overexpression
of p21 is independent of p53 [121,122]. The concentration-dependent cell cycle inhibitory effects of
HDACi have been observed. At lower concentrations HDACi predominately induces G1 arrest while
at higher concentrations induces both G1 and G2/M arrest [123]. p21 is mainly associated with G1 and
G2/M arrest, inhibits the activity of CDKs (i.e., CDK 4/6), which regulates the progression of the G1
stage of cell cycle, CDK 2 responsible for G1/S transition and cdc2/CDK 1 causes G2/M transition.
The p21 mutation abolishes the HDACi induced G1 arrest [124]. However, HDACi-mediated G1 arrest
is also observed in a cell without p21. Hitomi et al. [125] reported that TSA causes G1 arrest in human
colon p21 mutant cell by induction of p15 (INK4b), which subsequently causes inhibition of cyclin
D-dependent kinases resulting in the absence of CDK 2. Protein p53 interacts with the p21 promoter
by competing with HDAC1 and alters the expression of the p21 gene. HDAC1 is the transcriptional
repressor of p21, which gets detached from the Sp1 (promoter-specific RNA polymerase II transcription
factor) after HDACi treatment, resulting in increased p21 expression. Moreover, HDACi also causes an
increase in the half-life of protein p53 thereby improving its interaction with p21 and increased levels of
p21 inside the cell mediates cell cycle arrest and apoptosis [126]. HDACi treatment also compromises
the CDK activity, which may account for the dephosphorylation of the retinoblastoma protein (Rb),
which blocks the elongation factor, E2F function in the transcription of genes for G1 progression and
G1/S transition [118].
7.2. Induction of Apoptosis in Transformed Cell
HDACi induces the rate of apoptosis in a transformed cell by regulating both pro-apoptotic and
anti-apoptotic genes (Figure 3) and this involves the activation of both extrinsic and intrinsic apoptotic
pathways. HDACi induced extrinsic pathway initiation involves the binding of death receptor such as
Fas (Apo-1 or CD95), tumor necrosis factor (TNF) receptor-1 (TNFR-1), TNF-related apoptosis-inducing
ligand (TRAIL) receptors (DR-4 and DR-5), DR-3 (Apo3) and DR-6 to their ligand FasL, TNF, TRAIL,
and TL1A resulting into activation of caspase 8 and 10. In vitro and in vivo studies suggest that
HDACi upregulates the expression of both death receptor and their ligand in transformed cells but
no such effect is observed in normal cells [127]. Upregulated expression of Fas and FasL have been
reported in the treatment of human neuroblastoma cells with m-carboxycinnamic acid bihydroxamide,
nude mice xenograft of osteocarcinoma with FK228, acute promyelocytic leukemia model of a rat with
valproic acid, and so on [128,129]. FK228 also induces the expression of TNF α in HL 60 and K562
cells. cFLIP, an inhibitor of the activity of the death receptor has been reported to be downregulated
after HDACi treatment in cancer cells [127]. HDACi-mediated apoptosis also involves the activation
of the intrinsic apoptotic pathway, which causes the release of inter mitochondrial membrane protein,
such as cytochrome c, Smac, apoptosis-inducing factor (AIF), and the subsequent activation of caspase.
HDACi activate the intrinsic apoptotic pathways by regulating the transcription of pro-apoptotic genes;
i.e., Bid (BH3 interacting domain death agonist protein), Bad (Bcl-2 associated agonist of cell death
protein), and Bim [130]. The mechanism of HDACi-mediated intrinsic pathway activation is not well
understood, but it is suggested that HDACi causes leaking of mitochondrial intermembrane proteins,
cytochrome c, AIF and Smac. The release of cytochrome c from mitochondria in turn causes activation
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of caspase-9 [131,132]. The intrinsic apoptotic pathway is regulated by changing the HDACi-mediated
expression of factors. It can be concluded that HDACi upregulate the expression of proapoptotic genes
and pathways (BAX, Apaf1 and BAK) and downregulate the expression of the antiapoptotic Bcl-2
family proteins, Bcl-2, Bcl-XL and Mcl-1 [133].
Figure 3. Multiple anti-tumor pathways such as, cell cycle arrest, induction of autophagy and apoptosis,
DNA damage repair, ROS generation, angiogenesis inhibitor and mitotic cell death are activated by the
action of HDACi in cancer cells. Arrows (↑ and ↓) indicates the increase and decrease, respectively,
in the obtained variables. HIF, Hypoxia inducing factor; VEGF, Vascular endothelial growth factor; HR,
homologous recombination; NHEJ, Non-homologous end joining; Trx, Thioredoxin; TBP, Thioredoxin
binding protein.
7.3. Autophagic Cell Death
The role of HDACi in autophagy is not well understood. Recent findings suggest that autophagy
serves as cell death mechanism, therefore, autophagy inhibitors or knockdown of autophagy-related
gene decreases the anticancer effect of HDACi. When HeLa cell line having an Apaf-1 knockout or
Bcl-XL overexpression was cultured with vorinostat or butyrate, it undergoes autophagic cell death by
forming autophagosome inside cytoplasm [134]. Treatment of a colon carcinoma cell HCT116 with
vorinostat resulted in the inhibition of cell growth as well as senescence type phenotype [135]. SAHA
causes cell death in endometrial stromal sarcoma cell via autophagy [136]. In p53 mutant cancer cells,
SAHA induces autophagy and cell death. HDACi-mediated autophagy involves several signaling
pathways, one such pathway is the mechanistic target of the rapamycin (mTOR) pathway that is the
234
Nutrients 2018, 10, 731
main suppressor of autophagy via phosphorylation and the inactivation of the Unc51 like autophagy
activating kinase 1 (ULK1) complex. SAHA inhibits the activity of mTOR and resumes the activity
of ULK1, upstream component of autophagy pathway [137]. SAHA up-regulates the expression of
autophagy-related protein by stimulating NF-κβ activity [138]. SAHA also induces autophagy via
ROS production in leukemic and hepatocellular carcinoma cells. Romidepsin induces autophagy in
HeLa cells [139]. SAHA inhibited the growth of glioblastoma cells xenograft in nude mice by inducing
autophagy via downregulation of AKT-mTOR signaling [140]. In some cancer cells showing resistance
towards apoptosis, HDACi can induce cell death via the induction of autophagy by bypassing the
apoptosis. Hence, HDACi induced autophagy stimulation could be a promising anticancer strategy.
7.4. Inhibition of Angiogenesis
HDACi mediated inhibition of angiogenesis can interfere with the metastasis. HDAC inhibitors
downregulate proangiogenic genes, such as the vascular endothelial growth factor gene (VEGF)
and endothelial nitric oxide synthase gene [141]. The inhibition of the activity of hypoxia-inducible
factor (HIF) by HDACi can block the angiogenesis. Hypoxia is a commonly occurring condition
in tumor cells responsible for the overexpression of class I HDACs, except HDAC 8, which in
turn causes activation of HIF 1α and promotes angiogenesis [142]. Several compounds viz., TSA,
vorinostat, FK228, butyrate and LAQ824, have been reported to inhibit the angiogenesis process and
thereby decrease the expression of proangiogenic (HIF 1α and VEGF) factors. Several mechanisms
are responsible for the HDACi-mediated degradation of HIF 1α. These include the degradation of
HIF 1α by acetylation at Lys532 leading to ubiquitination, class II HDACs associate with HIF 1α
and cause siRNA-mediated degradation of HIF 1α [143,144]. HDACi also degrades HIF 1α through
compromising its transactivation potential, and also reduces the sensitivity of cancerous cells towards
the angiogenic signal generated by VEGF [145,146]. Vorinostat and TSA downregulate the expression of
VEGF receptors. Valproic acid impedes angiogenesis by increasing the production of thrombospondin-1
and activin A, the antiangiogenic proteins [147]. Use of combination therapies with VEGF inhibitors
finds support from the above reports.
7.5. ROS Generation
Oxidative stress has been implicated in cell death [148–151]. Experimental facts support the
treatment of transformed cells with HDACi, such as TSA, vorinostat, butyrate or MS275, leading to the
accumulation of reactive oxygen species (ROS) inside cells that subsequently induce cell death [152].
Ruelfi and co-workers [153] in 2001 reported that the quenching of ROS by N-acetylcysteine, a free
radical scavenger decreases HDACi induced apoptosis, suggesting the role of HDACi in cell death.
Thioredoxin (Trx), a hydrogen ion donor, is a ROS scavenger [154]. It is required in several redox
reactions and is responsible for the activity of many protein, such as ribonucleotide reductase,
which play an important role in the synthesis of DNA and the transcription factor. HDACi inhibits
the activity of Trx by inducing the expression of Trx binding protein 2 (TBP2), which binds to it and
inhibits its activity in cancer cells but not in normal cells [155]. Trx binds and inhibits the activity of
ASK1. ASK1, an apoptosis signal regulating kinase, increases the rate of apoptosis by the activation
of the SET1-JNK and MKK3/MKK6-p38 signaling pathways, and by elevating the expression of
pro-apoptotic protein Bim. Therefore, higher expression of TBP2 by HDACi prevents the activity of
Trx resulting in the increased expression of ASK1 and ultimately leading to apoptosis [156].
7.6. Mitotic Cell Death
HDACi treatment causes an abnormal acetylation pattern of histone protein in heterochromatin
and centromere region. Newly synthesized chromatin contains acetylated histones and TSA treatment
in transformed cells causes newly synthesized chromatin to remain acetylated, leading to the structural
and functional disorder of centromere and pericentric heterochromatin [157], and this structural
disturbance interferes with the phosphorylation of histone as well as disrupts the activity of mitotic
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spindle checkpoint proteins; i.e., BubR1, hBUB1, CENP-F, and CENP-E [123]. And this causes cell
division arrest at the prometaphase stage followed by abnormal mitosis, such as the disaggregation
and chromosomal loss leading to cell death either through apoptosis or mitotic cell death [2,124,158].
8. Potential Limitation and Side-Effects of HDACi
There are potential limitations to selective HDACi therapy. The effects of class I HDACi on
DNA damage and repair pathways suggest that prolonged exposure to these agents could lead to
unacceptable toxicities and secondary malignancies [159]. Class I HDACs may also play an oncogenic
role depending on the context. Sontoro et al. [160] reported that in mouse tumor model, a single
putative barrier to full transformation is surprisingly provided by HDAC 1 and HDAC2. Knock-down
of HDAC 1 resulted in the both blockade of cellular differentiation and the increased genomic instability
mediated by PML-RAR in hematopoietic progenitors. Either or both biological deregulations could be
sufficient to cooperate with the tumor-promoting activities of oncoproteins, such as PML-RAR and Myc,
and would provide a functional explanation for the observed increase in frequency of transformation to
leukemia in HDAC1-deficient cells. Epigenetic changes are important for reprogramming somatic cells
into pluripotent stem cells. Therefore, several inhibitors of epigenetic-modifying enzymes, including
HDACi, are able to reprogram somatic cells into the pluripotent stem cells by modifying a chromatin
structure and making it more permissive to transcription factors [119].
9. Conclusions
The present review summarizes the biological activities of HDAC. Further, emphasis has been
given on the structural and functional features of the natural and synthetic inhibitors of HDAC as
well as on their antitumor potential. HDACs are multisubstrate (histone and non-histone) enzyme
involved in many biological processes; i.e., cell proliferation, differentiation, apoptosis, and senescence.
According to scientific reports, histone deacetylase inhibitors have shown their efficacy as inhibitors of
cancer initiation and progression. Generally, normal cells are resistant to HDACi, which selectively
modulates gene expression in cancerous cells. Pan-HDAC inhibitors, such as vorinostat, belinostat,
and panobinostat stimulate antitumor pathways, suggesting their therapeutic potential. FDA-approved
HDACi are being used for the treatment of several types of cancers. Many HDACi are under
clinical trial stages. HDACi show their anticancer action involving various mechanisms; i.e., cell
cycle arrest, induction of apoptosis and autophagy in transformed cells, inhibition of angiogenesis,
ROS as mediators of cell death, and mitotic cell death. Several natural HDACi are present in our
diet: kaempferol (grapes, green tea, tomatoes, potatoes, and onions), resveratrol (grapes, red wine,
blueberries and peanuts), sinapinic acid (wine and vinegar), diallyl disulfide (garlic) and zerumbone
(ginger). Hence a better understanding of dietary HDACi regarding their target specificity and toxicity
may underscore potential health benefits through nutritional intervention. Combination therapy
might be another important direction to enhance the therapeutic efficacy of HDACi. Elucidation and
validation of the detailed mechanistic aspects of HDACi action will provide a bright future for the use
of HDACi as one of the important tools in the fight against cancer.
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Abstract: Polyphenols, chemically characterized by a polyhydroxylated phenolic structure, are well
known for their widespread pharmacological properties: anti-inflammatory, antibiotic, antiseptic,
antitumor, antiallergic, cardioprotective and others. Their distribution in food products is also
extensive especially in plant foods such as vegetables, cereals, legumes, fruits, nuts and certain
beverages. The latest scientific literature outlines a resilient interconnection between cancer
modulation and dietary polyphenols by sphingolipid-mediated mechanisms, usually correlated
with a modification of their metabolism. We aim to extensively survey this relationship to show
how it could be advantageous in cancer treatment or prevention by nutrients. From this analysis it
emerges that a combination of classical chemotherapy with nutrients and especially with polyphenols
dietary sources may improve efficacy and decreases negative side effects of the antineoplastic drug.
In this multifaceted scenario, sphingolipids play a pivotal role as bioactive molecules, emerging as
the mediators of cell proliferation in cancer and modulator of chemotherapeutics.
Keywords: sphingolipids; ceramide; flavonoids; resveratrol; genistein; curcumin; nutrients;
nutraceuticals; chemotherapeutics
1. Polyphenols
1.1. Polyphenols: Chemical Classification
Polyphenols are one of the biggest class of phytochemicals (more than 8000 compounds)
chemically characterized by common polyhydroxylated phenolic structures. Polyphenols are easily
found in many plant-based products [1].
They can be divided into two main classes: flavonoids and non-flavonoids (Table 1). Flavonoids
generally contain two phenolic rings (A and B rings) connected by a carbon chain or, more commonly,
by an O-ring (C ring) which is similar to a phenylbenzopyrane structure. Based on the respective
position of the B and C rings, functional groups and the presence of unsaturation in the C ring,
they have been separated into subclasses: flavones, isoflavones, flavanones, flavonols, anthocyanidins,
chalcones and flavanols, containing catechins and tannins. Hydroxylation and conjugation patterns
characterize individual compounds in each subclass. In nature polyphenols (flavanols are an
exception) exist as glycosides or other conjugates. Polyphenols can polymerize into large molecules,
such as tannins, which are able to bind and precipitate proteins. The most important subclasses
of tannins are proanthocyanidins, derived tannins and hydrolyzable tannins. Proanthocyanidins
consist of monomeric units of flavans which are linked through carbon-carbon and ether linkages.
They also may contain gallates. Relevant proanthocyanidins are procyanidins ([epi]catechin polymers),
prodelephinidins ([epi]gallocatechin polymers) and propelargonidins ([epi]afzelechin). There is a
second class of tannins which is comprised of tannins formed primarily beneath aerobic conditions
during the manipulation of plants and subsequent processing into foods such as oolong and black
teas, red wines and coffee. Important members of this subclass are theaflavins and thearubigins, easily
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found in tea. The last subclass of tannins comprises hydrolyzable tannins namely esters of gallic acid
(gallotannins) or ellagic acid (ellagitannins) with a non-aromatic polyol [2].
Table 1. Polyphenols classes and examples of more relevant compounds.
Flavonoid Polyphenols
Flavones apigenin, chrysin, diosmin, luteolin, baicalein
Isoflavones daidzein, daidzin, genistein
Flavanones hesperetin, narigenin
Flavonols kaempferol, quercetin, rutine, myricetin, morin
Anthocyanidins cyanidin, dephinidin, malvidin, pelargonidin, peonidin
Chalcones butein, curcumin, xanthohumol
Flavanols catechins, tannins
Non-Flavonoid Polyphenols
Benzoic acids vanillic acid, gallic acid, syringic acid
Cinnamic acids caffeic acid, chlorogenic acid, CAPE, tannic acid
Stilbenes resveratrol, piceatannol, isorhapontigenin, oxyresveratrol
Non-flavonoid polyphenols are divided into three main classes: phenolic acids (benzoic
acid derivatives and cinnamic acid derivatives), stilbenoids and other polyphenols. Phenolic
acids can be further divided, depending on the number of carbons, into two subclasses:
benzoic acid derivatives (7 atoms of carbon) and cinnamic acid derivatives (9 atoms of carbon).
In fruits and vegetables they are in a free-form whereas in grains and seeds they are in a
conjugated form, that could be hydrolyzed by acid, alkaline or enzyme catalysis [1]. Stilbenoids
class includes basic stilbenes, bibenzyls or dihydrostilbenes, bis(bibenzyls), phenanthrenes,
9,10-dihydrophenanthrenes and related compounds derived from the phenylpropanoid pathway.
Stilbenes are structurally identified by a 1,2-diphenylethylene nucleus. They exist as both
monomers and complex oligomers. The common monomeric skeleton consists of two aromatic
rings linked by an ethylene bridge, commonly in trans configuration. The oligomers are formed
by stilbene units (resveratrol-oxyresveratrol, resveratrol-piceatannol, resveratrol-isorhapontigenin,
oxyresveratrol-isorhapontigenin and piceatannol-isorhapontigenin) linked by either C-C or C-O-C
bonds [3]. Figure 1 shows the chemical structures of polyphenols considered in this review article.
Figure 1. Chemical structures of polyphenols that are connected with a sphingolipid-based mechanism
for cancer prevention and treatment.
1.2. Distribution of Polyphenols in Food
Many plants and herbs consumed by humans are known to contain relevant amounts of
polyphenols, which have been demonstrated to have many beneficial effects such as anti-inflammatory,
antibiotic, antiseptic, antitumor, antiallergic, cardioprotective and others. They are ubiquitous in plant
foods such as vegetables, cereals, legumes, fruits, nuts and beverage such as wine, cider, beer, tea, cocoa.
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Their levels are mainly influenced by genetic factors, environmental conditions, variety, cultivars,
processing and storage [4]. Specifically, the greatest dietary sources of flavonoids are tea (Camellia
sinensis), onions (Allium cepa), apples (Malus domestica), citrus fruits (Citrus spp.), berries (blackberry
Rubus ulmifolius, blueberry Vaccinium spp., elderberry Sambucus spp., raspberry Rubus spp., strawberry
Fragaria × ananassa), legumes (Fabaceae spp.) and red wine (Vitis vinifera). Human flavonoid intake was
estimated in the USA to be approximately 170 mg/day and in Netherlands 23 mg/day (both expressed
as aglycones) using the content of only five flavonoids (quercetin, kaempferol, myricetin, luteolin
and apigenin). Consequently, the effective intake may be much higher [5]. The dietary consumption
of polyphenols consists principally of 80% flavanols, 8% for flavonols, 6% for flavanones, 5% for
anthocyanidins, and less than 1% for isoflavones and flavones [6]. The major dietary sources of
stilbenes are grapes and red wine (Vitis vinifera). Within this family resveratrol (Res) derivatives
predominate, with several patterns of oligomerization and glycosylation [3]. For benzoic acid
derivatives, the dietary sources were especially açaí oil (obtained from the fruit of Euterpe oleracea) [7],
wine and vinegar [8]. For cinnamic acid compounds the food distribution was abundantly widespread:
cereal grains, rice (Oryza sativa), wheat bran, coffee (Coffea Arabica), sweet potato (Ipomoea batatas),
artichoke (Cynara cardunculus), cinnamon (Cinnamomum cassia), citrus fruits (Citrus spp.), grape (Vitis
vinifera), tea (Camellia sinensis), cocoa (Theobroma cacao), spinach (Spinacia oleracea), celery (Apium
graveolens), brassicas vegetables (Brassicaceae spp.), peanuts (Arachis hypogaea), basil (Ocimum basilicum)
and garlic (Allium sativum) [9].
1.3. Bioavailability, Absorption and Metabolism of Polyphenols
The absorption and metabolism of polyphenols are consequent to: their chemical structure,
the degree of glycosylation/acylation, the molecular size, the degree of polymerization and
solubility [10]. Polyphenolic compounds can be distinguished into extractable and non-extractable
according to their molecular weight and solubility: extractable polyphenols have a low-medium
molecular mass and can be extracted using different solvents, whereas non-extractable remain insoluble
due to their high molecular weight or complex phenols structures. Non-extractable polyphenols
were highly recovered in feces, confirming the lack of absorption/digestion [11]. Concerning their
metabolism, aglycones and simple monomeric polyphenols can be absorbed through the intestinal
mucosa. On the other hand, glycosides cannot be absorbed because mammals lack in the proper
β-glycosidases. However, some glycosides can be partially absorbed by the intervention of an enzyme
present in the gastrointestinal microbiota [12]. Polyphenols undergo liver-mediated metabolism:
methylation and/or conjugation with glucuronic acid or sulfate. Metabolites were secreted in the
urine or in the bile, according to their lipophilic nature. In bile, some of them can be deconjugated and
reabsorbed for many times (enterohepatic cycle) [13]. The level of absorbed polyphenols in the body
and consequently their potential physiologic effects are still not clear [11,14].
2. Sphingolipids
2.1. Sphingolipid Classification
Sphingolipids are a complex family of amino alcohols compounds sharing a common structure:
a sphingoid base backbone that is synthesized de novo from serine and acyl-CoA [15]. Sphingolipids
can be divided into several different classes: sphingoid bases, ceramides, phosphosphingolipids,
phosphonosphingolipids, neutral glycosphingolipids, acidic glycosphingolipids, including
gangliosides, basic glycosphingolipids, amphoteric glycosphingolipids, arsenosphingolipids and
others. The major sphingoid base of mammals is commonly referred to as sphingosine (Sph), that is
(2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol. Sphingoid bases found in nature could diverge in alkyl
chain length and branching, the number and positions of unsaturation, the presence of additional
hydroxyl groups and other features. These differences are mostly related to their specific role as for
example by skin phytoceramides enriched in hydroxylation. Thus, interaction with nearby molecules
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strengthens the permeability barrier of the skin. In addition, a large number of fungi and sponges
produces compounds with structural similarity to sphingoid bases some of which (such as myriocin
and the fumonisins) are potent inhibitors of the enzymes of sphingolipid metabolism. In mammals
sphingolipids are mainly represented by sphingomyelins (SM) which are formed by a polar head of
phosphocholine and a core of ceramide (Cer). The latter is formed by a sphingosine amide-linked to
fatty acids, mostly saturated or monounsaturated, bearing from 14 to 26 carbon atoms [16]. The major
sphingolipid in insects is Cer-phosphoethanolamines whereas fungi have phytoCer-phosphoinositols
and mannose-containing head groups [17]. SM is a dominant structural molecule, not only in
plasma membrane but also in ER-to-Golgi vesicles as well as in membrane buddings (endocytosis
and exocytosis). A high ratio of SM over cell lipids is present in blood cells, platelets and in the
eye lens, which exhibits a peculiar increase of dihydro-sphingomyelin [18]. Cer is the central core
of another important class named glycosphingolipids, in which Cer links one or more uncharged
sugars such as glucose, galactose and fucose or modified sugars such as N-acetylglucosamine
and N-acetylgalactosamine. Gangliosides are particular glycosphingolipids showing N-acetyl or
N-glycolyl neuraminic acid as glycol-residues. Finally, there are basic glycosphingolipids and
amphoteric glycosphingolipids. Water-living organism replace the phosphate polar group with
either phosphono-group or arsenic acid. Sphingolipids can be linked to proteins, such as the
inositol-phospho-Cers that are used by fungi to anchor membrane proteins and ω-hydroxyCers
and ω-glucosylCers that are attached to surface proteins in human epidermal cells [17].
2.2. Sphingolipid Metabolism
Sphingolipids are synthesized in eukaryotic cells in the endoplasmic reticulum (ER) through
a multiple step process whose rate is limited by serine palmitoyltransferase (SPT), an enzyme that
catalyzes the initial condensation of serine with palmitic acid, forming 3-keto-sphinganine (3-KDS) [19].
Hereditary sensory and autonomic neuropathy type 1 has been recently associated with SPT mutations
that enhance the affinity of the enzyme for alanine, instead of serine, thus forming neurotoxic
deoxysphingolipids [20]. Reduction of 3-KDS by 3-KDS reductase (KDSR) releases dihydrosphingosine
(or sphinganine, DHSph), which can be differentially acylated to form dihydroceramide (DHCer).
Acylation is catalyzed by six different Cer synthases (CerS) [21] each using specific acyl chains,
typically with saturated or mono-unsaturated fatty acids with 14 to 26 carbons. Cers are then
formed by dehydrogenation via DHCer desaturase (DHCD). The enzymes involved in the Cer
biosynthesis are included in the ER while in the Golgi occurs: (1) the synthesis of SM; (2) the
synthesis of glycosphingolipids; and (3) the unusual phosphorylation of Cer, by Cer kinase (CerK),
to Cer-1-phosphate (Cer-1P). Cer can be translocated from ER to Golgi by vesicular transport or
anchored to a protein transporter (CERT). The transport via CERT was demonstrated to be specific for
SM synthesis whereas vesicular trafficking for glycosphingolipids synthesis [22,23].
SM is synthesized through the transfer of the phosphocholine head group of phosphatidylcholine
to Cer by two enzymes: SM synthase 1 (SMS1) and 2 (SMS2). SMS1 is responsible for the
de novo synthesis of SM whereas SMS2 probably resynthesizes SM from Cer generated by the
catabolism of SM [22]. The whole production of glycosphingolipids starts from two direct derivatives
of Cer, galactosylceramide (GalCer) and glucosylceramides (GlcCer). From the latter it is produced
lactosylceramide (LacCer), that is the precursor of the neolacto-, lacto-, globo-, asialoganglio- and
ganglio- series of glycosphingolipids [23]. Sphingolipids have a rapid turnover and their levels
are constantly in change between synthesis and degradation. They are degraded in lysosomes
by glycosidases or acid sphingomyelinases (aSMase) which remove the head groups to form Cers.
Deacylation of Cer by ceramidases (CDase) is the only pathway known to generate Sph, that can be
recycled back to Cer. Sph could also be phosphorylated by Sph kinases (SphK1 and SphK2) forming
Sph-1-phosphate (Sph-1P). Sph-1P could either be dephosphorylated by phosphatases (SPPase1 and
SPPase2) or degraded by Sph-1P lyase (SPL) to ethanolamine-1-phosphate and trans-hexadecenal.
Sphingomyelinase (SMase) cleaves SM to Cer and phosphatidylcholine by a reversible reaction.
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Five types of SMase have been described and classified on their cation dependence and pH optima
of action. The more relevant are Mg-dependent neutral sphingomyelinase (nSMase) and lysosomal
aSMase [24]. An overview of sphingolipids metabolism and chemical structure of the principal ones is
shown in Figure 2.
Figure 2. Sphingolipids metabolism and their chemical structures. Lc3: GlcNAcβ1-3Galβ1-4Glcβ-Cer
for others see the abbreviation list.
2.3. Sphingolipids Modulation of Cellular Functions
The structural diversity of sphingolipids reflects a correspondent diversification in
pathophysiological functions: regulation of apoptosis [25], proliferation, differentiation, autophagy [26],
invasiveness, modification of signaling cascade and mediation of inflammatory responses by
cytokines [27,28].
Cer promotes cell-type specific apoptosis by (1) activating both protein kinases such as protein
kinase C (PKC), protein phosphatases 1-2 and proteases, including caspases and cathepsin D;
(2) formation of pores in the mitochondrial membrane; and (3) modulation of pro-apoptotic Bcl-2-family
proteins [29,30]. Also, Sph via PKC upholds apoptosis [31].
In contrast to Cer, that is predominantly pro-apoptotic, Sph-1P is mainly an anti-apoptotic messenger
by stimulating G-protein-coupled receptors activating RAS, RAC, phosphatidylinositide 3-kinases (PI3K),
protein kinase B (AKT), phospholipase C (PLC) and Rho kinase. The regulation of a signaling cascade
mediated by Sph-1P includes modulation in mitogenesis, cell migration, cytoskeletal rearrangement and
angiogenesis. Sphingolipids could also be correlated with pro-inflammatory cytokines through different
mechanisms [31,32]. Sph-1P stimulate inflammation by either upregulation of cyclooxygenase 2 (COX-2)
with overproduction of prostaglandin E2 and activation of nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB). In the same way, Cer-1P through activation of cytosolic phospholipases A2
(cPLA2) enhances the production of pro-inflammatory arachidonic acid [33].
2.4. Sphingolipids and Cancer
Sphingolipids have emerged as mediators of cell proliferation in cancer and as potential
chemotherapeutics (Table 2). In general, Cer regulates anti-cancer cellular fate whereas Sph-1P is
pro-oncogenic and pro-metastatic.
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Table 2. Roles of sphingolipids in cancer.
Sphingolipids Biological Target Effect in Cancer References
Cer PKC, I2PP2A, cathepsinD, caspases, telomerase Apoptosis, growth arrest, senescence [23,26–31,34–37]
Cer-1P cPLA2
Release of arachidonic acid and activation
of inflammatory cascade [31,33,37]
DAG (from SM) PKC Cellular proliferation [38,39]
Sph-1P NFKB, COX-2, ERK Malignant transformation, anti-apoptosis,angiogenesis, survival, metastatization [31–33,40]
Cer normally mediates antiproliferative responses such as cell growth inhibition, apoptosis
induction, senescence modulation, ER stress response and autophagy. Interestingly, recent
studies [34,35] suggest that de novo-generated Cers present an ambivalent role in the
promotion/suppression of tumors reliant to their fatty acid chain lengths, subcellular localization and
direct downstream targets. In a study [36] on head and neck squamous cell carcinoma (HNSCC)
decreased levels of C18 Cer are correlated with lymphovascular invasion and nodal metastasis.
Conversely, overexpression of CerS1 and increased levels of de novo synthesized C16 Cer show a
reduction of tumoral cell growth by inhibition of telomerase activity. Overexpression of de novo
synthesized C16 Cer was associated with tumor proliferation whereas downregulation of de novo
synthesized C16 Cer induce ER stress and apoptosis of HSNCC cells by activating the ATF6/CHOP
pathway. Furthermore, elevated levels of C16 Cer, CerS2 and CerS6 were associated with breast cancer.
Moreover, the interaction of Cer with cathepsin D, PKC, I2PP2A, caspases and telomerase leads to
apoptosis, growth suppression and senescence.
Cer-1P has been shown to induce the release of arachidonic acid in cancer cells leading to an
inflammatory condition [37].
SM contributes to release diacylglycerol from phosphatidylcholine, a well-known activator
of PKC, thus promoting cellular proliferation. GlcCer indeed leads to drug resistance.
Sph-1P induces anti-apoptosis processes engaging with Sph-1P receptors 1–5 (S1PR1–5).
In addition, elevated levels of Sph-1P have been observed in different cancer and tumor tissues [38,39].
The SphK1 expression has been found to be upregulated in a number of solid tumors. High levels
of SphK1 has been correlated with poor survival of patients who suffer from glioblastoma, gastric
and breast cancers. In accordance, anticancer regimens have been shown to down-regulate SphK1
activity in various cancer cell and animal models. This enzyme-increased transcription is proposed
to be responsible for chemo- and radio-resistance of cancer cells and to favor the progression of
hormone-refractory state. As an example, it was proved a direct correlation of SphK1 activity and
expression with prostate tumor grade as well as with the clinical outcome after prostatectomy [40].
3. Focus on Cancer: Dietary Polyphenols and Sphingolipids
3.1. Apigenin
Apigenin (4′,5,7-trihydroxyflavone) is a flavone found in fruits, vegetables and other
plants. It counteracts inflammation, oxidative stress and development of cancer [41]. Major
apigenin-containing food sources include thyme (Thymus vulgaris), cherries (Prunus avium),
tea (Camellia sinensis), olives (Olea europaea), broccoli (Brassica oleracea), celery (Apium graveolens),
and legumes (Fabaceae spp.). The most abundant sources are the leafy herb parsley (Petroselinum
cripspum) and dried flowers of chamomile (Matricaria chamomilla) [42]. Although a few contradictory
reports [43,44], apigenin exerts anti-tumoral effect influencing mitochondria activity, gene expression
and partially through targeting of the JAK/STAT pathway [45].
Moussavi et al. [46] investigated the effect of apigenin as a dietary component in colon cancer by
testing its relationship with cell death, mediated alternately by Cer and reactive oxygen species (ROS).
Apigenin was reported to elevate Cer levels and apoptosis in colon cancer cells (HCT116) in a
concentration- and time-dependent manner but independently on the de novo synthesis pathway (Figure 3A).
251
Nutrients 2018, 10, 940
Figure 3. Mechanism of modulation on sphingolipids by apigenin (A), caffeic acid (B), CAPE (C),
catechin (D) and chlorogenic acid (E). It is depicted with an asterisk (*) enzymatic pathway, with plus
(+) red-regulated pathway and with minus (−) down-regulation ones. PTK: protein tyrosine kinase.
3.2. Caffeic Acid
Caffeic acid (3,4-dihydroxycinnamic acid) is a widespread hydroxycinnamic acid, naturally found
in many plant species as a secondary metabolite of the shikimate pathway. It displays the classical
framework of phenylpropanoids (C6-C3) with a 3,4-dihydroxylated aromatic ring connected to a
carboxylic acid moiety by a trans-ethylene ether. It is the most abundant hydroxycinnamic acid and
the diet sources are argan oil (Argania spinosa), oats (Avena nuda), wheat (Triticum spp.), rice (Oryza
sativa), olive oil (Olea europaea), narrow-leaved purple coneflower (Echinacea angustifolia), and berries
(blackberry Rubus ulmifolius, blueberry Vaccinium spp., elderberry Sambucus spp., raspberry Rubus spp.,
strawberry Fragaria × ananassa). Other dietary sources include potatoes (Solanum tuberosum), carrots
(Daucus carota), artichokes (Cynara cardunculus) and obviously coffee (Coffea arabica) [47,48]. The average
phenolic acids intake in humans is in the order of 210 mg/day within a broad range, depending
on nutritional habits. Caffeic acid has been reported to account for up to 90% of total phenolic
acids intake [49]. The wide spectrum of biological effects induced by caffeic acid includes: enzyme
activity inhibition (5- and 12-lipoxygenases, glutathione S-transferase, xanthine oxidase), antitumor
activity, anti-inflammatory properties, modulation of cellular response to ROS and inhibition of HIV
replication [50–52].
Nardini et al. [50] reported that caffeic acid significantly inhibits Cer-induced activation of NF-κB
in human monocytic U937 cells, with consequent suppression of acute inflammation, septic shock,
HIV replication, acute phase response, viral replication, radiation damage, atherogenesis and possibly
some neoplastic degeneration. The NF-κB inhibition mechanisms may be different: countering
the changes of the intracellular redox status induced by Cer, inhibition of 5 and 12 lipoxygenases
activities or PKC and PKA activity arrest. Additionally, some data indicate that caffeic acid inhibits
protein tyrosine kinase activity [53,54]. This ability may be the mechanism liable for the inhibition of
Cer-induced apoptotic response rather than its antioxidant properties. This hypothesis was also in
agreement with the observation that no tested antioxidants inhibit DNA fragmentation and therefore
apoptosis. The action of caffeic acid is two-faced: it shows pro-apoptotic effects at high concentrations
(>200 μM) and antiapoptotic ones at lower levels explaining a conflicted range of activities [50].
At low concentrations, close to those expected in vivo, it mediates a double inhibition mechanism
on Cer-induced NF-κB activation and Cer-induced apoptosis by protein tyrosine kinase. Under this
perspective, caffeic acid could not be used as a coadjuvant to chemotherapy in low concentrations
since it reduces Cer-mediated apoptosis (Figure 3B).
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3.3. CAPE
Caffeic acid phenethyl ester (CAPE) or 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)acrylate is
a natural bioactive compound. It occurs in many plants and the main human source is propolis.
Propolis is a resinous substance made by honeybees mixing saliva, beeswax and exudate collected
from botanical sources. CAPE is a cinnamic acid polyphenol characterized by a hydroxyl catechol ring.
It has different biological activities on infections, oxidative stress, inflammation, cancer, diabetes,
neurodegeneration and anxiety [55].
Tseng et al. [56] demonstrated that CAPE-induced apoptosis involves nSMase activation and
accumulation of Cer in C6 glioma cells. CAPE modulates two parallel signaling pathways both leading
to activation of caspase 3 as an ultimate effector of apoptosis. On one hand CAPE increases nSMase
activity triggering the activation of ERK/NGFR/NGF/JNK pathway and on the other hand it causes
an accumulation of Cer which initiates the p38 MAPK/p53/BAX signaling path. In addition to the
apoptotic potential of CAPE in cancer cells a coherent manipulation of Cer levels may improve the
efficacy of chemotherapy agents (Figure 3C).
3.4. Catechin
The catechin family presents two benzene rings and a 3-OH-dihydropyran heterocycle with two
chiral centers on C2 and C3. Thus, it has four diastereoisomers: two in trans configuration called
catechin and two in cis configuration called epicatechin. In plants they are usually conjugated with
gallic acid.
Epigallocatechin-3-gallate (EGCG) is the most potent catechin with antioxidant properties and it is
mainly present in green tea together with its related compounds epicatechin [57]. High concentrations
of catechin can be found in fresh tea leaves (Camellia sinensis), red wine, broad beans (Vicia faba), black
grapes, apricots (Prunus armeniaca) and strawberries (Fragaria × ananassa) nevertheless epicatechin
could be found in high concentrations in apples (Malus domestica), blackberries, broad beans (Vicia faba),
cherries (Prunus cerasus), black grapes, pears (Pyrus spp.), raspberries (Rubus spp.), and chocolate
(Theobroma cacao). Catechins showed in vitro protection against degenerative diseases and a strong
inverse relationship between the intake of catechins and risk of mortality by cardiovascular heart
diseases [58]. It has been reported that catechins have antimicrobic activity (gram-positive more than
gram-negative) and inhibit carcinogenesis of the skin, lung, esophagus, stomach, liver, small intestine,
colon, bladder, prostate, and mammary glands. EGCG has been described to have many potential
targets for action against carcinogens and among them also sphingolipids [58].
Brizuela et al. [40] reported, for the first time, that green tea polyphenols (EGCG and
polyphenon E, PPE) inhibit SphK1 activity, via a novel ERK/PLD-dependent mechanism in
prostate cancer cells (C4-2B hormone-responsive and PC-3 hormone-refractory). The treatment
with ECGC and PPE in both PC-3 and C4-2B cell lineages showed a remarkable inhibition of
cell growth by altering the sphingolipid balance correlated with SphK1 inhibition and increment
of pro-apoptotic Cer. The mechanisms underlying SphK1 inhibition by green tea extract are
dependent on the down-regulation of the ERK1/2 and consequently with PLD/PA signaling
pathway [40,59]. In vivo studies, confirmed the data obtained in vitro, suggesting that animals with
SphK1 overexpressing PC-3 cells implanted in a subcutaneous district develop larger tumors and
resistance to green tea due to disruption of sphingolipid equilibrium. In conjunction, EGCG and PPE
diet is also associated with a significant metastasis reduction in the orthotopic PC-3 model. Preventive
approaches [60,61] using catechins have been shown to inhibit other cancers as the colon one. Hence,
a combination of green tea polyphenols and chemotherapeutic agents or radiation therapy would
be promising.
Another mechanism of Cer-mediated apoptosis proposed by Wu et al. [62] involves ENOX2
(tNOX) inhibition by EGCG. Inhibition of the ENOX family commonly results in an accumulation of
cytosolic NADH at the inner leaflet of the plasma membrane. Regarding sphingolipid metabolism,
NADH modulates SphK inhibition and SMase stimulation. The disruption of sphingolipid rheostat,
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which is clearly connected with apoptosis, occurs when Sph-1P levels increase and Cer levels decrease
(Figure 3D).
3.5. Chlorogenic Acid
Chlorogenic acid, a non-flavonoid polyphenol, is a quinic acid conjugate of caffeic acid found
in high levels in coffee beans (Coffea arabica). An average coffee drinker tends to consume 0.5–1 g of
chlorogenic acids daily. It could be found also in apples (Malus domestica), pears (Pyrus spp.), eggplants
(Solanum melongena), tomatoes (Solanum lycopersicum), blueberries (Vaccinium myrtillus), strawberries
(Fragaria × ananassa), bamboo (Bambuseae spp.) and potatoes (Solanum tuberosum) [63,64]. It has
various biological activities such as anti-inflammatory, anti-diabetic, anti-tumorigenic, antioxidative,
anti-gout and anti-obesity.
Lee et al. [65] demonstrated that the inhibition of Hypoxia-Inducible factor-1α (HIF-1α) by
chlorogenic acid involves the SphK-1 pathway under hypoxia in the DU145 human prostate cancer
cell line. Hypoxia is a common condition in solid tumors enhancing its rough development.
HIF-1α is a transcription factor that regulates cancer progression such as angiogenesis, metastasis,
anti-apoptosis, cell proliferations whereby it imparts resistance to chemotherapy. SphK-1 regulates
and stabilizes HIF-1α through the AKT/GSK-3 leading to his accumulation. It was shown that under
hypoxia, chlorogenic acid significantly decreases HIF-1α and SphK-1 activity. Besides, it prevents
phosphorylation of AKT and GSK-3β which are involved in stabilization of HIF-1α by SphK.
In summary, chlorogenic acid decreased cancer cell growth by (1) inhibition of SphK-1 and reduction of
HIF-1α; (2) decrement of phosphorylation of HIF-1α stabilizing agent; (3) decrease of VEGF (vascular
endothelial growth factor) and angiogenesis.
Additionally, according to Belkaid et al. [66], chlorogenic acid possesses anticancer properties
in highly invasive U-87 glioblastoma cells. The competitive inhibition of ER-glucose-6-phosphate
transport was shown causing a consequent downregulation of Sph-1P-induced cell migration and a
hindrance to Sph-1P-induced ERK phosphorylation. Sph-1P is present at high levels in brain tissue
acting as a potent mitogen for glioblastoma multiform cells, triggering intracellular signaling by MAPK
pathway and causing the release of intracellular calcium pools (Figure 3E).
3.6. Chrysin
Chrysin is a naturally occurring flavone found in human diet products such as Passiflora caerulea,
Passiflora incarnate infuse, Oroxylum indicum and mushroom, Pleurotus ostreatus [67]. Traditional Chinese
medicine uses the seed of Oroxylum indicum in the treatment of cough, acute or chronic bronchitis,
pharyngitis, pertussis and other respiratory disorders. Other parts of this small tree such as leaves,
flowers and immature boiled fruits are commonly used in the daily diet in Thailand and Laos. Baicalein,
oroxylin A and chrysin which can be isolated from its bark play an important role in cancer, as well as
viral and bacterial infections [68]. Chrysin has been shown to have a broad range of pharmacological
effects such as anti-oxidation, anti-viral, anti-inflammatory properties and anti-cancer properties on
breast cancer cells.
Hong et al. [69] evaluated the effects of chrysin treatment on human estrogen receptor
(ER)-negative breast cancer cells (MDA-MB-231). This study provides mechanistic evidence that
chrysin treatment inhibits the cancer cell growth with a direct or indirect increased expression of
PPARα mRNA. PPARs activation can result in intracellular accumulation of Cer, which mediates
downstream effects such as apoptosis. Besides, Cer accumulation is assumed to be dependent on a
modulation of arachidonic acid (Figure 4A) [70].
3.7. Curcumin
Curcumin is one of the main substances found in the rhizome of turmeric (Curcuma longa) and
other Curcuma spp. Commercially available curcumin contains about 77% in curcuminoids that include
pure curcumin, demethoxycurcumin and bis-demethoxycurcumin. [71].
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Curcumin inhibits cell proliferation and stimulates apoptosis by affecting various key targets in
signal transduction pathways, including Akt, cyclooxygenase, NF-kB, c-myc, Bcl-2, c-Jun N-terminal
kinase (JNK), and epithelial growth factor (EGF) receptor (Figure 4B).
Figure 4. Mechanism of modulation on sphingolipids by chrysin (A), curcumin (B) and genistein (C).
It is depicted with an asterisk (*) enzymatic pathway, with plus (+) red-regulated pathway and with
minus (−) down-regulation ones.
Cheng et al. [72] demonstrated that curcumin inhibits cell growth and induces apoptosis in
colon cancer cells (Caco-2 cells) affecting aSMase activity. It reduces the hydrolytic capacity of the
enzyme associated with a slight increase of cellular SM. No modification of alkaline, nSMase and
phospholipase D was found after curcumin treatment. Reduction of aSMase activity was not due to
a direct inhibitory effect of curcumin on the enzyme, but rather to an inhibition of the enzyme
biosynthesis. The up-mentioned action is particularly evident in specific cell type: stronger in
monolayer Caco-2 cells than in polarised ones. The role of aSMase in cancer is still debated and
there is evidence suggesting that this enzyme activity may affect phospholipase A2 and thus the
formation of lysophosphatidylcholine and lysophosphatidic acid which are required for colon cancer
metastasis [73,74].
In contrast, Moussavi et al. [75] found that curcumin significantly increased the Cer levels in colon
cancer HCT 116 cells without detectable changes of aSMase and nSMase. Cer generation by curcumin
occurred through de novo synthesis since cell death could be reversed by myriocin, an inhibitor of serine
palmitoyltransferase. Colon cancer cell apoptosis by curcumin was strongly related with JNK activation
mediated principally by ROS generation and to a minor extent via a parallel Cer-associated pathway.
Another study on anti-colorectal cancer effects by curcumin was conducted by Chen et al. [76].
They showed that co-administration of curcumin and perifosine, an orally bioactive alkylphospholipid,
increases colorectal cancer cell apoptosis by modulating multiple signaling pathways such as
inactivation of Akt and NF-κβ, activation of c-Jun, downregulation of Bcl-2 and cyclin D1 and
increment in intracellular levels of both ROS and Cer. Furthermore, they suggested that ROS/Cer
production after co-administration of curcumin and perifosine and ER stress response were
independent of Akt inhibition and Bcl-2/cyclin D1 downregulation.
Yu et al. [77] showed that curcumin-induced cell growth inhibition and apoptosis in
melanoma cell lines (WM-115 and B16) could be facilitated by PDMP (DL-threo-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol). PDMP is a well-known inhibitor of sphingolipid
biosynthesis especially directed to the formation of GlcCer, thus resulting in an accumulation of
its endogenous precursor. Combination of PDMP and curcumin may be used as a new therapeutic
intervention against melanoma. Curcumin induces an early increase of Cer (12 h), that melanoma
cells could remove, after long-term (24 h), by glycosylation. Upon incubation on PDMP, Cer levels
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remain elevated causing further cell death and apoptosis. In addition, exogenous cell-permeable
C6-Cer sensitizes melanoma cell lines to curcumin-induced apoptosis.
The curcumin effect was investigated in clinical trials of patients with multiforme glioblastoma,
ideally as a second line therapy after failure of radiation and temozolomide [78]. The optimal method
should be setting curcumin in combination with an established cytotoxic chemotherapy agent such as
carmustine or lomustine. A progression of this aggressive brain cancer is related to a decrease in Cer
levels: curcumin has been shown to enhance Cer production influencing CerS activity.
According to Thayyullathil et al. [79], curcumin has been shown to be a pro-autophagic drug in
malignant gliomas. Malignant glioma cells are likely responding to therapy better via autophagy than
apoptosis but, for apoptosis-resistant glioblastoma patients, a pro-autophagic drug could be extremely
advantageous. Curcumin induces autophagy by Par-4 (prostate apoptosis response-4) upregulation
and Cer generation via ROS-dependent mechanism. Cer generation was correlated to the nSMase
pathway in U87MG malignant glioma cells since GW4869, an inhibitor of nSMase, significantly blocked
curcumin-induced Cer generation and autophagy.
Hilchie et al. [80] determined the mechanism by which curcumin induces cytotoxicity in prostate
cancer cells (PC3). This treatment caused time- and dose-dependent apoptosis and depletion of
cellular reduced glutathione, Cer accumulation, activation of p38, JNK and release of different caspases
and cytochrome c. The authors conclude that apoptosis in prostate cancer is due principally to Cer
accumulation causing mitochondrial membrane integrity damage, a consequent release of cytochrome
c and apoptosis-inducing factor. By contrast, clinical trials have confirmed that curcumin is poorly
absorbed in the gastrointestinal tract owing to the efficient efflux of monoglutathionyl curcumin
conjugates from intestinal epithelial cells into the lumen. Achieving a useful plasma concentration
to trigger apoptosis is the major obstacle to the clinical application of curcumin-based therapy.
Combination of curcumin and piperine or more stable analogs of curcumin may overcome these
pharmacokinetics problems.
Kizhakkayil et al. [81] investigated more deeply the glutathione decline as a mechanism
by which curcumin acts on human leukemic cells. A decrease of intracellular glutathione
regulates caspase-dependent inhibition of SMS activity and Cer generation, and thus apoptosis.
Curcumin-induced Cer generation and apoptosis were inhibited by extracellular supplementation
of glutathione, N-acetylcysteine and caspase inhibitor z-VAD-fmk, supporting these findings.
In particular, an important role in Cer generation was found to be related to the regulation of the SMS
cycle and not to the de novo pathway.
Scharstuhl et al. [82] revealed that curcumin induces apoptosis by the formation of channels in
the outer mitochondrial membranes and the release of apoptosis-inducing factors. The formation of
channels was correlated to the combined action of Cers, VDAC and BAX and not to caspases pathways.
Nevertheless, inhibition of the de novo synthesis and inhibition of SMase did not significantly block
curcumin-induced apoptosis, indicating that Cers are partially involved.
Shakor et al. [83] examined curcumin-induced apoptosis in human leukemia HL60 cells and their
HL60/VCR multidrug-resistant counterparts. The molecular mechanism of curcumin action consists
in a biphasic Cer accumulation in the cells firstly by rapid activation of nSMase2 and then by inhibition
of SMS, accompanied in the drug-resistant cells by glucosylceramide synthase (GlcS, the enzyme
involved in GlcCer synthesis from Cer) inhibition. The intracellular increase of Cer modulates the
transcription of apoptosis-regulating genes, such as BAX, Bcl-2 and caspase-3. The glycosylation
of Cer, via GlcS, is recognized as a chemoresistance strategy and enhanced by several tumors. On the
other side, the down-regulation of this Golgi enzyme seems to be related to P-gp inhibition. P-gp,
an ATP consuming flippase, translocates GlcCer. P-gp antagonists (cyclosporine A or tamoxifen)
impair Cer clearance and enhance its cytotoxicity. Moreover, molecular modeling studies confirmed
that curcumin binds to P-gp in its substrate binding site possibly competing with GlcCer binding.
Finally, apoptosis is associated with Cer increase, glutathione depletion and ROS generation after
curcumin treatments.
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Another study by Shakor et al. [84] indicated a complex crosstalk among Bcl-2, Bcl-xL, caspases
and glutathione during curcumin-induced apoptosis. This point to the superior role of caspase-8
activity, Bcl-xL down-regulation and glutathione depletion in the pro-apoptotic cascade leading to
nSMase activation and hence generation of Cer. The signaling cascade controlling Cer-mediated
apoptosis in curcumin-treated cells was: caspase-8 activation, Bcl-xL degradation, glutathione
depletion, nSMase activation and Cer accumulation. Caspase-3 activation and Bcl-2 degradation,
both regulated by glutathione levels and reciprocally interconnected, are also co-involved in SMase
initiation. SMS degradation was indeed regulated only by caspase-3 activation.
Yang et al. [85] analyzed the impact of the SphK1 inhibitor on Cer production, particularly
as a potential curcumin chemo-sensitizer in ovarian cancer cells (CaOV3). Inhibition of SphK1,
by pharmacological tools as SKI-II (2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole) or by RNA
interference, dramatically enhanced curcumin-induced apoptosis and growth inhibition in ovarian
cancer cells via Cer production and p38 activation and Akt inhibition.
A further supplement to curcumin treatment (Qui et al. [86]) was the addition of exogenous
cell-permeable short-chain, C6-Cer. It sensitizes melanoma cells (B16 and WM-115) to curcumin-mediated
apoptosis due to the augment of the mitochondrial apoptosis pathway, especially through (1) the cleavage
of caspases 3 and 9 and (2) the downregulation of anti-apoptosis protein Bcl-xL and X-IAP.
3.8. Genistein
Genistein is essentially present in soy-derived products and the soybeans contain the compound
in ranges from 5.6 to 276 mg/100 g. In addition to genistein soy foods contain another major
isoflavone, daidzein. Daidzein differs from genistein by the lack of the hydroxyl group on position 5.
Both isoflavones may exist in their aglycone or glycoside forms. The most common glycoside forms
of genistein and daidzein are O-β-D-glucoside derivatives. Due to soy consume the average dietary
isoflavone intake in Asian countries is in the range of 25–50 mg/day, whereas in Western countries,
the intake is approximately 2 mg/day. In lower concentrations genistein and daidzein are also present
in legumes. The genus Lupinus (commonly known as lupin) represents a typical example of the legume
that is now widely cultivated for its seeds, which possess a nutritional value similar to soybean. Other
important legumes are broad beans (Vicia faba) and chickpeas (Cicer arietinum), but the flavones can be
detected also in fruit, nuts, and vegetables where their content can vary considerably, ranging being
from 0.03 to 0.2 mg/100 g [87].
This soybean isoflavone exerts many cellular effects, namely apoptosis activation,
and protein-tyrosine kinase activity and angiogenesis inhibition (Figure 4C). It is important to note
that genistein affects in a dose-dependent manner, both positively and negatively tumorigenesis.
Engel et al. [88] reported the influence of phytoestrogens, such as genistein, on the metabolome
of breast cancer cells. They compare either MCF-7, positive for ERα and ERβ, and MCF-12A,
a non-tumorigenic epithelial breast cell line. Three sphingolipids were analyzed: Sph, DHSph and
ethanolamine-phosphate. These metabolites were elevated in MCF-7 under control conditions and
genistein treatment normalizes their levels. Whereas their amounts, in MCF-12A, were not affected.
By contrast, DHSph was not normalized by genistein treatment in MCF-7 to gain the level of MCF-12A
under control conditions. Western blotting-coupled immunofluorescence experiments revealed a
significant, concentration-dependent, decrease in the amount of SphK1 and SphK2 enzyme in MCF-7
after genistein exposure. In MCF-12A phytoestrogen exposure revealed boosted SphK1 amounts and
undetectable expression of SphK2. These findings suggested that SphK1 is expressed in cancerous
as well as non-tumorigenic cells while Sphk2 is overexpressed in cancer line. SPL expression was
also investigated. MCF-7 has a weaker expression than MCF-12A but after exposure with genistein,
the SPL amount increases dramatically. Exposure to phytoestrogens in higher concentrations (10 μM
of genistein) resulted in (1) decreased tumor progression via sphingolipids pathway and (2) enhanced
the reaction of SPL causing a higher conversion of Sph-1P to phosphoethanolamine.
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Lucki et al. [89] showed that nanomolar concentrations of genistein induces aCDase transcription
in MCF-7 breast cancer cells via ERK1/2 dependent mechanism.
The proliferative properties of genistein are supposed to be related to its ability to stimulate
estrogenic pathways by binding ERα and GPR30. GPR30 is a transmembrane G-protein-coupled
receptor that binds most ER ligands triggering estrogenic signaling and proliferation. aCDase is a
lipid hydrolase, that degrades Cer to Sph and a free fatty acid, thus playing a key role in cellular
homeostasis regulation by controlling the Cer/Sph/Sph-1P balance within the cell. Activation of
this pathway promotes: (1) histone acetylation; (2) recruitment of the phospho-estrogen receptor α;
and (3) translocation of Sp1 transcription factor to the aCDase promoter. This activation culminated
in an increased enzymatic activity, which results in increased Sph-1P production. Nanomolar
concentrations of genistein stimulates the growth of ER-positive breast cancer cells by modulating
expression of aCDase. Such modulation produces two synergic but different events: (1) an increment
of Sph-1P levels, which activates proliferative pathways by binding to cell surface receptors and (2) the
modulation of cyclin B2 expression, driving mitotic progression and cell growth.
Another study by Engel et al. [90] showed that high doses of genistein promote the growth of
bone cancer cells. They explored the co-administration of genistein and calcitriol in order to inhibit
immature osteosarcoma cells MG-63. The malignant proliferation induced by 100 μM genistein could
be normalized to control levels after simultaneous exposure to 10 nM calcitriol. This synergistic effect
may be consistent with (1) an overexpression of ERβ, (2) a reduction of extracellular acidification and
respiration rates and (3) an increased ethanolamine production by the overexpression of SPL.
The use of genistein as an anti-cancer compound is usually limited because a relatively high
concentration is necessary. Ji et al. [91] counteracted this limitation by adding exogenous cell-permeable
short-chain Cers to enhance genistein activity. In this study, melanoma cell line (B16, WM451, MeWo)
were sensitized to genistein by increasing cellular level of Cers, both exogenously and endogenously.
In B16 melanoma cells, genistein caused only a moderate increase of intracellular Cers, which are
poorly related to significant cell apoptosis. Co-administration of PDMP, a Cer glycosylation inhibitor,
or SKI-II facilitated Cers accumulation and significantly enhanced genistein-induced melanoma cell
apoptosis. Moreover, adding to genistein some exogenous cell-permeable short-chain Cers (C2, C4
and C6) lead to a major anti-melanoma effect by increasing cytotoxicity and apoptosis (especially C6).
This mechanism could be explained by the JNK activation of and Akt inhibition.
Tiper et al. [92] showed that VEGF and ganglioside GD3 production by ovarian cancers suppress
NKT- mediated anti-tumor response. The growth of cancer and the development of metastases
strongly depend on the divert of the immune system response. Previous reports [93,94] showed
that the ganglioside GD3 and VEGF levels in ovarian cancer ascites (OV-CAR-3 and SK-OV-3) are
much higher than in ascites associated with other solid tumors. They proposed that VEGF and
ganglioside GD3 synthesis pathway might be linked, working in tandem to suppress immune
responses. The data proposed suggest that VEGF could modulate ganglioside GD3 expression
confirming that ovarian cancer associated GD3 is responsible for suppressing CD1d-mediated NKT
cell activation. This malignant overproduction of immunodepressive ganglioside could be reduced
after 72 h of genistein treatment.
Phenoxodiol is a sterically modified version of genistein, with a higher bioavailability, a lower
rate of metabolism and increased antitumor potency. According to Gamble et al. [95] phenoxodiol may
be an effective anticancer drug, targeting the proliferation of the tumor cells and the angiogenic and
inflammatory stimulation of the vasculature. These findings involve different enzymatic pathways,
one of them concerning sphingolipids. It inhibited SphK which has been recently correlated with
endothelial cell activation [96], angiogenesis and oncogenesis [97]. Hence, the inhibitory effect of
phenoxodiol on pro-survival signals, mediated by SphK and Sph-1P, might contribute to arrest mitosis,
to reduce angiogenesis and to promote apoptosis [95].
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3.9. Luteolin
Luteolin (3′,4′,5,7-tetrahydroxyflavone) is a naturally occurring flavone, another subtype of
flavonoid, found in food sources such as broccoli (Brassica oleracea), green chili (Capsicum spp.), onion
leaf (Allium unifolium), French bean (Phaseolus vulgaris), carrot (Daucus carota), white radish (Raphanus
sativus var. longipinnatus) and in infusion of clover blossom (Trifolium pratense) [67].
On a broad range of malignancies, luteolin displays different effects such as inhibition of cell
proliferation, angiogenesis, metastasis, induction of apoptosis and sensitization to chemotherapy.
Nevertheless, the molecular mechanisms of luteolin still remain unclear.
Hadi et al. [98] conducted an important study aimed to demonstrate a connection between
luteolin and apoptosis in colon cancer cells. First, luteolin elevated Cer levels, followed by the
apoptotic death of colon cancer cells, but not in differentiated enterocytes. Second, luteolin impaired
the vesicle-mediated transport of Cer from ER to Golgi. The consequent dysregulation of sphingolipids
equilibrium consisted of Cer elevation and significant reduction of both SM and glycosphingolipids.
This effect may be correlated with the inhibition of AKT phosphorylation which emerges as a key
mechanism affecting this vesicles route. Third, luteolin inhibited the production of Sph-1P by a SphK2
hindrance. Moreover, luteolin was proven to unbalance the sphingolipid rheostat by bending it to
apoptosis in colon cancer cells (Figure 5A).
Figure 5. Mechanism of modulation on sphingolipids by luteolin (A), morin (B) and quercetin (C). It is
depicted with an asterisk (*) enzymatic pathway, with plus (+) red-regulated pathway and with minus
(−) down-regulation ones.
3.10. Morin
Morin (3,5,7,2′,4′-pentahydroxyflavone) is a flavonoid polyphenol of the class of flavonols. It is a
yellow pigment that could be isolated from non-edible Osage orange (Maclura pomifera) and old fustic
(Maclura tinctoria). Morin is also present in dietary infusions of white mulberry leaves (Morus alba),
in figs (Ficus carica), almond (Prunus dulcis), guava (Psidium guajava) and wine [99]. Morin is a flavonol
that exhibits antiproliferative, antitumor, and anti-inflammatory effects through a mechanism that is
not well understood.
Manna et al. [100] proposed that morin mediates its effects by modulating NF-κB in the control of
cell survival, proliferation, and tumorigenesis. NF-κB is a heterodimeric protein complex of members
of the Rel protein family. NF-κB morin-mediated transcription can be promoted by a wide variety of
inflammatory stimuli, including Cer (Figure 5B).
3.11. Quercetin
Quercetin is a naturally occurring flavonol found in high concentrations in red onions (Allium cepa),
citrus fruits (Citrus spp.), apples (Malus domestica), red wine, and sour cherry seeds (Prunus cerasus) [67].
A study done by Ferrer et al. [101] showed that intravenous administration of quercetin prevented
the metastatic growth of highly malignant B16 melanoma F10 cells, by enhancing NO release from the
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vascular endothelium through an increment of eNOS expression. The rise of NO promotes a tumor
cytotoxicity and an activation of nSMase, thus increasing Cer and apoptosis.
Torres et al. [102] reported that the derivative of quercetin THDF
(5,7,3′-trihydroxy-3,4′-dimethoxyflavone) inhibits cell proliferation and induces apoptosis in
human leukemia cells (HL-60 and U937) by a disruption of tubulin polymerization and an activation
of aSMase-dependent generation of Cer correlated with cell death (Figure 5C).
3.12. Resveratrol
Res (3,5,4′-trihydroxy-trans-stilbene) is a natural stilbene found in several plants including
blueberries (Vaccinium sect. Cyanococcus), mulberries (Morus spp.), cranberries (Vaccinium subgenus
Oxycoccus), peanuts (Arachis hypogaea), grapes (Vitis spp.), rhubarb (Rheum spp.) and wine. It has been
reported to have anti-cancer, anti-inflammatory, anti-cardiovascular disease and blood-sugar lowering
properties [103,104]. It has been classified as phytoalexin for being synthesized in spermatophytes in
response to injury, UV irradiation and fungal attack. It exists in both trans, the more frequent, and cis
isomeric forms. In plants, Res is generally found in glycosylated forms, known as 3-O-β-D-glucosides,
and called piceids. Other natural Res analogs contain pterostilbene and piceatannol [105]. Anticancer
properties of Res are quite complex and composed of different mechanisms. It can affect the processes
underlying all stages of carcinogenesis, angiogenesis and metastasis. Its activity against cancer appears
to be closely associated with: mutational activation of Ras, deregulation of myc, overexpression of AP-1,
amplification of cell cycle regulator cyclins D/E and Cdks 2/4, mutation of Fas and Bax, deletion of p53,
disruption of DNA-damage response regulators Chk1/2 and ATM/ATR, overexpression of survival
kinase AKT1, mutation of cell cycle inhibitors and translocation of anti-apoptotic Bcl-2 [106]. Here we
focus on the several Res anticancer properties triggered by modulation of sphingolipid metabolism
(Figure 6C).
Signorelli et al. [107] demonstrated a strict correlation between sphingolipid metabolism, Res and
autophagy in gastric cancer cells (HCGC-27). Res inhibits DHCD and subsequently induces an
imbalanced accumulation of DHCers versus Cers thus promoting autophagy rather than apoptosis.
Shin et al. [108] established that Res leads to the accumulation of endogenous Cers and
significantly increases DHCers especially DHCer-C24:0 (containing lignoceric acid) in SNU-1 gastric
cancer cells and HT-29 colon adenocarcinoma cells. The accumulation of DHCer with different fatty
acid chain lengths (C24:0 > C16:0 > C24:1 > C22:0) was powerfully associated with Res- induced cell
cytotoxicity although the inhibition of DHCD was not found to be a critical mechanism. The effect of
Res was drastically increased by dimethylsphingosine (a non-specific SphK inhibitor) and retinamide
(4-HPR, a non-specific DHCD inhibitor) but not by GT-11 (a specific DHCD inhibitor). The Res
cytotoxic effect is cell-specific: SNU-1 and HT-29 are highly sensitive in contrast with SNU-668.
According to Lin et al. [109], Res and Cer could be used in sequence or in combination for
chemoprevention and cancer treatment due to their similarities in transduction pathways to induce
apoptosis in human ovarian cancer OVCAR-3 cells. Cer and Res uses an endocytic- and activated
ERK1/2 dependent pathway to induces apoptosis in human ovarian cancer cells. Additionally,
exposure to these compounds induces expression and nuclear accumulation of COX-2 without affecting
COX-1, Ser-15 phosphorylation of p53 and accumulation of BcL-xS. By contrast, only Cer utilizes both
p38 kinase-dependent pathway and ERK 1/2-dependent pathway whereas Res only the latter one.
However, the relationship of COX-2 protein on cancer is not easy to establish: some studies reported an
expression of COX-2 in cells associated with tumor cell growth, metastasis, enhanced cellular adhesion
and inhibition of apoptosis [110] whereas others suggested a pro-apoptotic activity [111].
Lim et al. [112] showed that Res and its dimers (ampelopsin A and balanocarpol) could perturb
SphK 1-mediated signaling in MCF-7 breast cancer cells. Ampelopsin A and balanocarpol are dimers
of Res formed by the fusion of cis- and trans-isomers and they could be extracted and isolated from
plants in the Dipterocarpaceae family. In this family Hopea dryobalanoides and Hopea odorata supply a
very limited food products. In this study, Res was found to be a competitive inhibitor of SphK1 and
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balanocarpol is about twice as potent as Res on kinase inhibition because of its binding to two catalytic
sites simultaneously. The mechanism of down-regulation of SphK1 expression might involve changes
in its protein turnover by ubiquitin-proteasomal or modification in lysosomal-cathepsin B proteolysis
or alterations in gene promoter activity.
Figure 6. Mechanism of modulation on sphingolipids by silibinin (A), xanthohumol (B) and Res (C).
It is depicted with an asterisk (*) enzymatic pathway, with plus (+) red-regulated pathway and with
minus (−) down-regulation ones.
In agreement with Lim et al. [112], Tiang et al. [113] proposed Res to be an apoptotic agent in
the myelogenous leukemia cell line K562 by modulation of SphK1 and translocation of the enzyme
from the membrane to the cytosol. The kinase activity is clearly repressed granting a restoration of
sphingolipid balance. Sph-1P level decreases whereas Cer level increases.
Cakir et al. [114] showed that Res induces apoptosis through a concurrent increase of de novo
Cer and decrease of anti-apoptotic Sph-1P and GlcCer. Not only, targeting Cer metabolism increased
chemosensitivity to Res in acute myeloid leukemia cells.
Kartal’s study [115] was also focused on the relationship between the sphingolipid pathway,
Res and human K562 chronic myeloid leukemia cells. A synergistic anti-proliferative effect was
observed with Res in combination with: (1) Cer-C8, a cell-permeable analog of natural Cer inducing
de novo generation; (2) PDMP, an inhibitor of GlcS; and (3) PF-543, a SphK1 inhibitor. Moreover,
they showed that Res triggers apoptosis through raising expression of longevity assurance genes
(LASS2, LASS4, LASS5, LASS6) correlated with down-regulation of GlcS and SphK 1.
Chow et al. [116] reported an abnormal accumulation of Cer via activation of SPT resulting in an
ER dilation/expansion and thus ER stress. ER stress is, indeed, firmly associated with cell apoptosis by
mechanisms involving direct activation of ER-associate caspases (3, 9 and 12) and CHOP, a common
downstream pro-apoptotic molecule of unfolded protein response.
Wang et al. [117] described two divergent mechanisms of Res in melanoma B16 cells. They showed
an inhibition of B16 cell growth via induction of mitochondrial apoptosis and contemporary inducing
protective autophagy through Cer accumulation and AKT/mTOR pathway inhibition. Interruption
of the autophagy program leads to an improvement of the efficacy of Res cytotoxicity and apoptosis.
It was the first study revealing that Res-induced accumulation of Cer conferred protection of B16 cells
against apoptosis inducing protective autophagy.
Another mechanism was proposed according to Mizutani et al. [118]. Inhibition in K562 (a human
leukemia cell line) and HTC116 (a human colon cancer cell line) by Res was correlated to up-regulation
of Cer and aSMase expression and down-regulation of Sph-1P. This study suggested a possible
relationship between Res-induced cell growth inhibition and the sphingolipid metabolism modulation.
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As previously mentioned, catechin and Res synergically inhibit SphK1 activity, via a novel
ERK/PLD-dependent mechanism in prostate cancer cells (C4-2B hormone-responsive and PC-3
hormone- refractory) acting as a possible anti-cancer effector [40].
According to Scarlatti et al. [119] activation of the de novo Cer synthesis by Res is the mechanism
underlying its growth inhibitory effect on the metastatic, drug-resistant and highly invasive breast
cancer cell line MDA-MB-231. This accumulation derives from both de novo Cer synthesis and SM
hydrolysis by activation respectively of SPT and nSMase.
Another work by Scarlatti et al. [120] presented that pretreatment with Res enhances tumor
cell killing and inhibits the clonogenic survival in resistant irradiated-DU145 prostate cancer cells,
synergistically affecting the cellular response to ionizing radiation. This event was mediated by an
increase in cellular de novo Cer levels.
Dolfini et al. [121] demonstrated that targeting Cer signaling with Res might offer a potential
strategy to prevent the growth of hormone-independent breast cancer. Res exerts a severe inhibitory
effect on the growth of MDA-MB-231 both in vitro and in vivo. It affects the aggregation properties
of MDA-MB-231 cells into multicellular tumor spheroids in association with induction of de novo
synthesis of Cer.
Minutolo et al. [122] showed that a synthesized derivative of Res
[5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol] is more effective in triggering apoptosis, coupled with
the induction of endogenous Cer in human cancer cells MDA-MB-231. Since the Res biological activity
in cancer cells is limited by its photosensitivity and metabolic instability, the authors replaced the
3,5-hydroxy groups with more stable methoxy groups, thus obtaining a compound with increased
anti-proliferative activity. Moreover, the stabilization of the stilbene double bond of Res by a
naphthalene ring increases the molecular rigidity. This dramatically improves the biological activity
via Cer-mediated pro-apoptotic mechanism coupled to cleavage of PARP.
3.13. Silibinin
Silibinin is the most active and major component (60–70%) of silymarin, a standardized extract
from the seeds of the milk thistle seeds (Silybum marianum). Other flavonolignans consist in silibinin,
isosilibinin, silychristin, isosilychristin and silydianin. Silibinin is a mixture of two diastereomers,
silybin A and silybin B, in approximately equimolar ratio [123].
It has been used in the prevention and treatment of viral hepatitis, cirrhosis caused by alcohol
abuse and liver damage caused by medications or industrial toxins, in traditional and modern medicine.
Silibinin effects are due to free radical trapping, prevention of lipid peroxidation, an increment
of proapoptotic protein (Bax, p53), a decrement of anti-apoptotic proteins (Bcl-2 and Bcl-xL) and
anti-cancer activity.
Boojara et al. [124] investigated the effects of four silibinin derivatives that is silybin A, silybin B,
3-O-galloyl-silybin A and 3-O-galloyl-silybin B on cell viability, caspase assessment, total Cer levels
and Cer-metabolizing enzyme in Hep G2 hepatocarcinoma cell line. Exposure to silibinin isomers
and gallate derivatives in human liver carcinoma cells resulted in increased Cer levels. Gallate
derivatives had a stronger ability in Cer elevation in comparison with silybin A and B. The activity of
aCDase, the enzyme involved in the catabolism of Cer to Sph, was markedly inhibited by silybin B,
3-O-galloyl-silybin A and 3-O-galloyl-silybin B. The activity of nSMase was increased by treatment
with silybin A, silybin B and 3-O-galloyl-silybin A whereas the activity of GlcS was inhibited by silibin
A, silibin B and 3-O-galloyl-silybin B (Figure 6A).
3.14. Xanthohumol
Xanthohumol (3′-[3,3-dimethyl allyl]-2′,4′,4-trihydroxy-6′-methoxychalcone) is the principal
prenylated chalcone of the female inflorescences of the hop plant (Humulus lupulus). It is the
main ingredient of beer and together with prenylflavonoids it is used to add bitterness and flavor.
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The naturally occurring chalcones are heat-degraded during the brewing process therefore relatively
high levels are due to a second addition of hops to the boiling wort.
Xanthohumol has been shown to elicit anti-inflammatory, antiangiogenic, anticancer, antibacterial,
antifungal, antimalarial and antiviral effects. It favorably influences also sleep disorders and
menopausal symptoms in women, acting as estrogen by its metabolites isoxanthohumol and
8-prenylnaringenin. According to Xuan et al. [125] xanthohumol stimulates aSMase in dendritic cells,
derived from mouse bone marrow, leading to Cer formation and caspase activation. The sequence
of events postulated was: (1) translocation of aSMase onto cell surface; (2) formation of Cer;
(3) autocatalysis of caspase 8; (4) activation of caspase 3; and (5) DNA fragmentation and proteolysis
of intracellular proteins (Figure 6B).
4. Conclusions
Cancer treatment and cancer prevention are a constant challenge for clinicians and the whole
scientific community. Nutrients on their own appear to offer a good strategy in prevention more
than in cancer therapy. However, chemotherapy has gradually transitioned from monotherapy to
multidrug therapy. It is believed that a combination of classical chemotherapy with nutrients and
especially with polyphenols dietary sources may improve efficacy and decreases negative side effects
of the antineoplastic drug. In this multifaceted scenario, sphingolipids play a pivotal role as bioactive
molecules, controlling several aspects of cancer from cell growth and proliferation to anti-cancer
therapeutics. Further research on the crosstalk between polyphenols and sphingolipids could lead to
better understand their reciprocal roles and to develop new therapeutic strategies against cancer.
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AIF apoptosis inducing factor
AKT protein kinase B
AP-1 activator protein 1
aSMase lysosomal acidic sphingomyelinase
ATF6 activating transcription factor-6
ATM ataxia-telangiectasia mutated kinase
ATR serine/threonine-protein kinase ATR or ataxia telangiectasia and Rad3-related protein
BAX apoptosis regulator BAX
BAX apoptosis regulator BAX
Bcl-2 B-cell lymphoma 2
Bcl-xL B-cell lymphoma-extra large
Bcl-xS B-cell lymphoma-xS
BCR/ABL Philadelphia chromosome
c-FOS cellular DNA-binding proteins encoded by the c-fos genes
CAPE caffeic acid phenethyl ester
CDase ceramidase
Cdc25C gene for M-phase inducer phosphatase 3
Cdk1 cyclin-dependent kinase 1
Cer ceramide
CERT ceramide transfer protein
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CERT ceramide transfer protein
cGMP cyclic guanosine monophosphate
Chk1/2 checkpoint kinase 12
CHOP C/EBP homology protein
CHOP transcription factor CCAAT-enhancer-binding protein homologous protein
COX cyclooxygenase
COX-2 cyclooxygenase 2
cPLA2 cytosolic phospholipases A2
CREB cAMP response element-binding protein
DHCD dihydroceramide desaturase
DHCer dihydroceramides
DHSph dihydrosphingosine or sphinganine
EGCG epigallocatechin-3-gallate
EGF epithelial growth factor
ELISA enzyme-linked immunosorbent assay
ENOX Ecto-NOX disulfide-thiol exchanger
ENSA electrophoretic mobility shift assay
ER estrogen receptor
ER endoplasmic reticulum
ERK extracellular signal regulated kinase
FACS fluorescence activated cell sorted
Fas first apoptosis signal receptor
FITC fluorescein isothiocyanate
GalCer galactosylceramide
GC/MS gas chromatography tandem mass spectrometry
GD3 ganglioside GD3 or disialosyllactosylceramide
GlcCer glucosylceramide
GlcS glucosylceramide synthase
GPR30 G protein-coupled receptor for estrogen




HNSCC head and neck squamous cell carcimona
HPLC high performance liquid chromatography
HPTLC high performance thin layer chromatography
I2PP2A protein phosphatase 2A inhibitor 2
IKK IκBα kinase
IκBα inhibitory subunit of NF-κB
JAK janus kinase
JNK c-Jun N-terminal kinase
KDSR 3-ketodihydrosphingosine reductase
LacCer lactosylcercamide
LASS longevity assurance genes
Lc3 GlcNAcβ1-3Galβ1-4Glcβ-Cer
LPS lipopolysaccharides
MAPK mitogen activated protein kinase
MPM-2 mitotic protein monoclonal 2
mTOR mammalian target of rapamycin
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NADH reduced form of Nicotinamide adenine dinucleotide
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
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NGF nerve growth factor
NGFR nerve growth factor receptor
nSMase neutral sphingomyelinase Mg-dependent
P-gp permeability glycoprotein
p38 MAPK p38 mitogen activated protein kinase
p53 tumor protein p53
p75NTR low-affinity nerve growth factor receptor or p75 neurotrophin receptor
PA phosphatidic acid
Par-4 prostate apoptosis response 4
PARP poly (ADP-ribose) polymerase
PDMP DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol
PI3K phosphatidylinositide 3-kinases
PKC/PKA protein kinase C/protein kinase A
PLC phospholipase C
PLD phospholipase D
PPAR peroxisome proliferator-activated receptors
PPE polyphenon E
Res resveratrol
ROS reactive oxygen species
S1PR1-5 sphingosine-1-phosphate receptors 1–5




SMS1/2 sphingomyelin synthase 1/2
Sph sphingosine
Sph-1P sphingosine-1-phosphate
SphK1/2 sphingosine kinase 1/2
SPL sphingosine-1-phosphate lyase
SPPase1/2 sphingosine-1-phosphate phosphatases 1/2
SPT serinepalmitoyl transferase
STAT signal transducer and activator of transcription protein
THDF 5,7,3′-trihydroxy-3,4′-dimethoxyflavone
THDF 5,7,3′-trihydroxy-3,4′-dimethoxyflavone
TLC thin layer chromatography
TLC thin layer chromatography
TNF tumor necrosis factor alpha
VDAC voltage-dependent anion-selective channel
VEGF vascular endothelial growth factor
XM462 Octanoic acid (1S,2S)-(2-hydroxy-1-hydroxymethyl-3-tridecylsulfanyl-propyl)-amide
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